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Abstract 
Through the act of breathing, internal thoracic and abdominal anatomy is in constant motion: this 
motion can result in thoracic-abdominal tumours moving up to 5 cm as the patient breathes. During 
radiation therapy imaging and treatment delivery there are two fundamental types of errors: the errors 
occurring during treatment preparation (systematic) and the errors occurring during treatment delivery 
(random) both these types of errors are exacerbated by irregular respiratory-motion. Breathing 
guidance interventions operate to minimise the deleterious impacts of irregular respiration in cancer 
radiation therapy. Breathing guidance refers to a biofeedback system which measures patient 
respiration in real-time and simultaneously provides feedback to the patient on how to adjust their 
breathing to achieve the desired objective of regular respiration. Such breathing guidance interventions 
have been demonstrated to improve breathing motion regularity of both external surrogates in addition 
to internal anatomy as well as the tumour itself. However, much of the breathing guidance intervention 
investigations have not directly quantified the impact of regular breathing on radiation treatment 
accuracy, nor has there been a systematic review of the literature to thoroughly identify the gaps to 
indicate what the future direction breathing guidance investigations should take. 
The overall aim of this thesis was to investigate the clinical feasibility of the audiovisual biofeedback 
breathing guidance intervention through translational research and potential commercial market 
acceptance.  
The first aim of this thesis was to critically appraise the literature in terms of the use of breathing 
guidance interventions in the fields of radiation oncology and radiology via systematic review. Radiology 
was also included in this systematic review because certain radiology imaging modalities such as MRI 
and PET/CT are being utilised in emerging hybrid radiation treatment technologies such as the MRI-linac 
in addition to the use of PET/CT in radiation treatment planning. A systematic review of the literature 
was conducted and found that of the 27 identified studies, 21 yielded statistically significant 
improvements from the use of breathing guidance. None of the studies were randomised, and no 
studies quantified the impact of breathing guidance interventions on 4DCT image quality, the primary 
imaging modality utilised to plan radiation therapy for highly mobile tumours. The largely positive 
results found in this systematic review indicate that further clinical studies are warranted and should be 
focused on (1) utilising training and multiple sessions to maximize patient compliance with the breathing 
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guidance system, and (2) further determining the clinical impact of breathing guidance interventions by 
investigating outcomes pertaining to treatment margins, toxicity, and patient outcomes.  
The second aim of this thesis was to quantify the impact of audiovisual biofeedback breathing guidance 
on 4DCT. This study utilised free breathing and audiovisual biofeedback lung cancer patient data from an 
MRI study to program the motion of a digital phantom prior to simulating 4DCT imaging. Audiovisual 
biofeedback demonstrated to significantly improved 4DCT image quality over free breathing. The results 
demonstrate that audiovisual biofeedback can be a beneficial intervention to improve 4DCT for cancer 
radiation therapy. 
The third aim of this thesis was to assess the impact of audiovisual biofeedback on patient breathing 
over a course of radiation therapy. This was performed by monitoring the breathing motion of an 
external motion surrogate and implanted radio-opaque markers of liver cancer patients over the course 
of stereotactic body radiation therapy (SBRT). This study was the first investigation to utilise a screening 
procedure in addition to being the first to utilise breathing guidance over the course of SBRT. The 
findings of this study demonstrated the effectiveness of the screening procedure in facilitating regular 
respiration over the course of SBRT in addition to audiovisual biofeedback being a valuable tool in 
producing consistent interfraction respiratory motion between CT sim and treatment delivery. 
The fourth aim of this thesis was to utilise the findings yielded by the above aims to design and 
implement a novel and comprehensive clinical trial investigating the use and impact of audiovisual 
biofeedback in radiation therapy. This fourth aim was achieved by performing a retrospective analysis of 
the previous audiovisual biofeedback 24 lung cancer patient study. The findings of this retrospective 
analysis were utilised to design and determine the statistics of the most comprehensive breathing 
guidance study to date: a randomised, stratified, multi-site, phase II clinical trial investigating audiovisual 
biofeedback over the course of lung cancer radiation therapy.  
The fifth aim of this thesis was to explore the next stages of the audiovisual biofeedback technology in 
terms of translating evidence into broader clinical use through the commercialisation process. This aim 
was achieved by investigating the radiation oncology market, current medical products available in 
respiratory monitoring and biofeedback in this market, assessing the intellectual property position of 
the audiovisual biofeedback in addition to determining the product-market fit of the audiovisual 
biofeedback technology.  
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Presentation of Thesis 
This thesis is presented as a combination of one systematic review and one published paper as their own 
chapters, with a published case report and study protocol forming subsections within chapters.  
Chapter 1 provides a background to cancer radiation therapy and the deleterious impact of irregular 
patient breathing on cancer radiation therapy procedures before introducing audiovisual biofeedback 
breathing guidance as an intervention to minimise these deleterious impacts. Some background on 
audiovisual biofeedback is also provided in addition to recent developments towards the audiovisual 
biofeedback system utilised in the investigations presented in this thesis.  
Chapter 2: ‘Breathing guidance in radiation oncology and radiology: A systematic review of patient and 
healthy volunteer studies.’ Published in Medical Physics 42(9): 5490-5509 (2015). 
Chapter 3: ‘The impact of breathing guidance and prospective gating during thoracic 4DCT imaging: an 
XCAT study utilizing lung cancer patient motion.’ Published in Physics in Medicine and Biology 61(17) 
6248-6501.   
Chapter 4: ‘Audiovisual biofeedback breathing guidance over a course of liver SBRT: A motion analysis of 
external and internal surrogates.’ A Case Report of the first patient recruited into this study, published in 
the Journal of Medical Imaging and Radiation Oncology 59(5) 654-656 (2015), is included in Appendix III. 
Chapter 5: ‘Designing and initialising a multi-institutional randomisation phase II audiovisual 
biofeedback clinical trial’ is presented in two parts: (1) retrospective analysis of previous lung cancer 
patient study, and (2) the design and initiation of the randomised clinical trial. The clinical trial’s study 
protocol was published in BMC cancer, 15(1) 526-533 (2015) and is included as a sub-section of Chapter 
5. 
Chapter 6: ‘Translating evidence into clinical practice through commercialisation’ details the 
investigation into the commercialisation pathway of the audiovisual biofeedback technology, how these 
insights advanced the design and functionalities of audiovisual biofeedback, and validation testing of 
these new additions.  
Chapter 7 provides the summary and conclusions of the work undertaken in this thesis in addition to 
future research directions  
xxvii 
 
    
Publications  
First author publications  
Sean Pollock, Danny Lee, Paul Keall, and Taeho Kim (2013) Audiovisual biofeedback improves motion 
prediction accuracy, Medical Physics, 40(4) 041705 
Sean Pollock, Ricky O’Brien, Kuldeep Makhija, Fiona Hegi-Johnson, Jane Ludbrook, Angela Rezo, Regina 
Tse, Thomas Eade, Roland Yeghiaian-Alvandi, Val Gebski, and Paul Keall (2015) Audiovisual biofeedback 
breathing guidance for lung cancer patients receiving radiotherapy: a multi-institutional phase II 
randomised clinical trial, BMC cancer, 15(1) 526-533 
Sean Pollock, Robyn Keall, and Paul Keall (2015) Breathing guidance in radiation oncology and radiology: 
A systematic review of patient and healthy volunteer studies, Medical Physics, 42(9) 5490-5509 
Sean Pollock, Regina Tse, Darren Martin, Lisa McLean, Gwi Cho, Robin Hill, Sheila Pickard, Paul Aston, 
Chen‐Yu Huang, Kuldeep Makhija, Ricky O'Brien, and Paul Keall (2015) First clinical implementation of 
audiovisual biofeedback in liver cancer stereotactic body radiation therapy, Journal of Medical Imaging 
and Radiation Oncology, 59(5) 654-656 
Sean Pollock, John Kipritidis, Danny Lee, Kinga Bernatowicz, and Paul Keall (2016) The impact of 
breathing guidance and prospective gating during thoracic 4DCT imaging: an XCAT study utilizing lung 
cancer patient motion, Physics in Medicine and Biology, 61(17) 6485-6501 
Co-author publications  
Taeho Kim, Sean Pollock, Danny Lee, Ricky O’Brien, and Paul Keall (2012) Audiovisual biofeedback 
improves diaphragm motion reproducibility in MRI, Medical Phyics, 39(11) 6921-6928 
Harry Steel, Sean Pollock, Danny Lee, Paul Keall, and Taeho Kim (2014) The internal–external respiratory 
motion correlation is unaffected by audiovisual biofeedback, Australasian Physical & Engineering 
Sciences in Medicine, 37(1) 97-102  
xxviii 
 
Danny Lee, Sean Pollock, Brendan Whelan, Paul Keall, and Taeho Kim (2014) Dynamic keyhole: A novel 
method to improve MR images in the presence of respiratory motion for real-time MRI, Medical Physics, 
41(7) 072304 
Enid M Eslick, Dale L Bailey, Benjamin Harris, John Kipritidis, Mark Stevens, Bob T Li, Elizabeth Bailey, 
Denis Gradinscak, Sean Pollock, Chris Htun, Robin Turner, Thomas Eade, Ali Aslani, Graeme Snowdon, 
and Paul Keall (2015) Measurement of preoperative lobar lung function with computed tomography 
ventilation imaging: progress towards rapid stratification of lung cancer lobectomy patients with 
abnormal lung function, European Journal of Cardio-Thoracic Surgery, ezv276 
Lee, Danny, Peter B. Greer, Joanna Ludbrook, Jameen Arm, Perry Hunter, Sean Pollock, Kuldeep 
Makhija, Ricky T. O'brien, Taeho Kim, and Paul Keall (2016) Audiovisual Biofeedback Improves Cine–
Magnetic Resonance Imaging Measured Lung Tumor Motion Consistency, International Journal of 
Radiation Oncology* Biology* Physics 94(3) 628-636.  
Jaewon Yang, Tokihiro Yamamoto, Sean Pollock, Jonathan Berger, Maximilian Diehn, Edward E. Graves, 
Billy W. Loo, and Paul J. Keall (2016) The impact of audiovisual biofeedback on 4D functional and 
anatomic imaging: Results of a lung cancer pilot study, Radiotherapy and Oncology 120(2) 267–272. 
Lee, Danny, Peter B. Greer, Sean Pollock, Taeho Kim, and Paul Keall (2016) Quantifying the accuracy of 
the tumor motion and area as a function of acceleration factor for the simulation of the dynamic 
keyhole magnetic resonance imaging method, Medical physics 43(5) 2639-2648. 
Publications under review 
Sean Pollock, Regina Tse, Darren Martin, Lisa McLean, Melissa Pham, David Tait, Reuben Estoesta, Grant 
Whittington, Jess Turley, Christopher Kearney, Gwi Cho, Robin Hill, Sheila Pickard, Paul Aston, Kuldeep 
Makhija, Ricky O’Brien, and Paul Keall (2016) The impact of audiovisual biofeedback on respiratory 
motion regularity and reproducibility in liver cancer SBRT, under review by Physics and Imaging in 
Radiation Oncology.   
xxix 
 
Presentations  
Oral Presentations  
August 2012 Enhancing respiratory motion prediction accuracy using audiovisual (AV) biofeedback.  
Presented at the American Association of Physicists in Medicine conference 
July 2013 Respiratory guidance for cancer patients: audiovisual biofeedback.  
Presented at the Central Clinical School Young Investigators Symposium 
Nov. 2013  A prospective clinical technology assessment of respiratory guidance: Audiovisual 
biofeedback for lung cancer patients.  
Presented at Postgraduate Cancer Research Symposium 
May 2014  Breathe Well – Guidance for Stable Patient Breathing.  
Presented at Sydney Genesis Startup Program Final 
August 2014  Audiovisual Biofeedback: Breathing guidance for lung cancer patients 
Presented at University of Sydney Open Day 3 Minute Thesis University Final 
October 2014  Breathe Well 
Presented at University of Sydney Union INCUBATE Demo Day  
Nov. 2014  Breathe Well - Breathing guidance to improve cancer radiation therapy 
Presented at Pearcey Foundation University Pitching Competition 
Nov. 2014  Breathe Well  
Presented at 1776 Challenge Cup  
May 2015  Entrepreneurial Journey of Breathe Well 
Presented as Keynote Speaker at Sydney Genesis Startup Program Final 
Nov. 2015  Breathing guidance during liver cancer SBRT: impact of audiovisual biofeedback on liver 
tumour motion 
Presented at the Engineering & Physical Sciences in Medicine conference 
xxx 
 
Nov. 2015  The impact of audiovisual biofeedback breathing guidance on thoracic 4D-CT: a digital 
phantom study 
Presented at the Engineering & Physical Sciences in Medicine conference 
Dec. 2015  Impact of breathing guidance and prospective gating on 4DCT image quality: a digital 
phantom study 
Presented at MedPhys15 
April 2016  Impact of breathing guidance and prospective gating on 4DCT image quality: a digital 
phantom study 
Presented at the European Society for Radiotherapy and Oncology conference 
Sept. 2016 Respiratory Gating in Radiation Therapy 
Presented as an invited speaker at ASTRO 2016 in the education session: “Is there a best 
way to manage respiratory motion?”  
Poster Presentations  
May 2013 Impact of audiovisual biofeedback on internal and external respiratory motion 
correlation. 
Presented at the International Conference of the use of Computers in Radiation Therapy 
conference 
August 2013 Respiratory guidance for lung cancer patients: an investigation of audiovisual 
biofeedback training and effectiveness. 
Presented at the American Association of Physicists in Medicine conference 
Sept. 2014: The AVIATOR trial: A multicentre phase II randomised trial of audio-visual investigation 
advancing thoracic radiotherapy. 
Presented at the Combined Scientific Meeting 
April 2015  Audiovisual biofeedback breathing training during thoracic 4DCT imaging: a digital 
phantom study. 
Presented at the European Society for Radiotherapy and Oncology conference 
July 2015  A Systematic Review of Breathing Guidance in Radiation Oncology and Radiology. 
xxxi 
 
Presented at the American Association of Physicists in Medicine conference 
July 2015  Audiovisual Biofeedback Reduces Image Artefacts in 4DCT: A Digital Phantom Study. 
Presented at the American Association of Physicists in Medicine conference 
April 2016  The first clinical implementation of audiovisual biofeedback in liver cancer SBRT. 
Presented at the European Society for Radiotherapy and Oncology conference 
xxxii 
 
Miscellaneous Achievements  
Dec. 2012  Awarded EPSM Student Scholarship 
May 2013  Awarded Best Poster Award at the International Conference of the use of Computers in 
Radiation Therapy conference 
Nov. 2013  Awarded Best Presentation for ‘Skin & lung cancers’ at the Postgraduate Cancer 
Research Symposium 
May 2014  Finalist at Sydney Genesis Startup Competition 
August 2014  Awarded the 99 Scholars runner-up prize at University of Sydney 3 Minute Thesis final 
Nov. 2014  NSW Pitching Competition Winner at the Pearcey Foundation University Pitching 
Competition 
July 2015  Awarded the Edith Mary Rose travel scholarship 
Nov. 2015  NSW Health Medical Device Commercialisation Training Program 2015 graduate – 
Distinction 
Sept. 2016 Invited speaker to 2016 ASTRO conference  
Awarded Postgraduate Research Support Scheme in 2013, 2014, and 2015.   
xxxiii 
 
List of Appendices 
I. Signed statements from the co-authors of the included published manuscripts included in the 
body of this thesis 
II. Documentation submitted to the human research ethics committees (HREC) for the two clinical 
trials presented Chapter 4 and Chapter 5. This includes the submitted protocols, patient 
information and consent forms, information brochure, patient and staff questionnaires, and 
toxicity report.  
III. Published Case Report of patient 1 recruited into the study detailed in Chapter 4. This Case 
Report was published in Journal of Medical Imaging and Radiation Oncology and was the 
journal’s Case of the Month for October 2015.  
IV. Documentation provided for study site credentialing for the clinical trial presented in Chapter 5. 
This includes audiovisual biofeedback quality assurance, credentialing checklist and instructions. 
V. User guide documentation provided to study sites participating in audiovisual biofeedback 
studies. User guide documentation includes instruction for audiovisual biofeedback software 
and/or Intel RealSense setup depending on the study setup.  
VI. Media reports on the audiovisual biofeedback commercialisation process   
VII. Videos recorded and produced over the course of this thesis  
a. Patient information video used in the clinical trials presented in Chapters 3 and 4 
b. Medical Device Commercialisation Program 2015 Showcase presentation 
c. Animated 3 Minute Thesis presentation: produced by 99 Scholars as a part of my 
runner-up prize  
d. Keynote Genesis Final Speech: detailing the courses taken and lessons learned over the 
commercialisation process  
 
CHAPTER 1 
 
Introduction 
 
  
1
CHAPTER 1 
Introduction 
1.1. Cancer Radiation Therapy  
External beam radiation therapy involves directing a beam of ionizing radiation at a tumour to cause 
double-strand breaks in the cancer cells’ DNA, causing cancer cell apoptosis.1, 2  Worldwide, there are 
12.4 million new cancer cases each year,3 of these, approximately 6.8 million (55%4 of 12.4 million) are 
recommended to be treated using radiation therapy. These patients are typically treated using linear 
accelerators (linacs) which target the tumour with high-energy x-rays, shown in Figure 1-1(a) and Figure 
1-1(b). An emerging form of high-precision external beam radiation therapy is proton therapy, shown in 
Figure 1-1(c). The use of linacs in radiation therapy is by far the most common form of radiation therapy 
with a total of 11,245 linacs worldwide,5 whereas there are only 43 proton therapy facilities worldwide.6 
  
Figure 1-1. (a) A Varian Clinac iX linac at the Abben Cancer Center.7 (b) Illustration of the production of a high-
energy x-ray beam in a linac.8 (c) Proton therapy treatment room at the ProCure Proton Therapy Center - Oklahoma 
City.9 
1.1.1. Cancer Radiation Therapy Workflow 
The typical workflow for cancer radiation therapy is shown in Figure 1-2. It begins with the computed 
tomography (CT) simulation in order to determine the location, size, shape, and motion of the tumour, 
in addition to identifying organs at risk of receiving potential radiation damage. The obtained CT 
simulation images are used to determine the appropriate radiation dose to be delivered to the tumour, 
while keeping the dose delivered to the surrounding organs at risk as low as reasonably possible. After 
the patient’s treatment has been planned, the patient is setup on the treatment couch as similarly as 
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possible to their position on the CT sim couch to have their radiation treatment delivered to the tumour 
site. Standard fractionation typically involves 30 fractions of radiation treatment,10 meaning that the 
patient comes in for radiation treatment on 30 separate days.  
 
Figure 1-2. The three main steps in the radiation therapy workflow. (a) Example of a CT simulation image of a lung 
cancer patient, adapted from Chen, et al. (2012).11 (b) Example of a CT simulation image with treatment plan, 
indicating different regions of different prescribed radiation dose about the tumour, adapted from Admiraal, et al. 
(2008).12 (c) 3D rendering of radiation treatment delivery, from Genesys Hurley Cancer Institute.13  
1.1.2. Lung and Liver Cancer Patients in Radiation Therapy 
Lung cancer is the leading cause of cancer-related deaths, with 1.6 million new cases each year 
accounting for 18% of all (cancer-related and non-cancer-related) deaths in 2008.14  There are 748 
thousand new liver cancer cases each year, and is the second most frequent cause of cancer death in 
males and sixth highest cause of cancers death in females.14 Radiotherapy is frequently used to treat 
lung and liver cancers, with a recommended radiotherapy utilization rate of 77% for lung cancers,15 and 
over 54% of USA radiotherapy centres treating their liver cancer patients with stereotactic body 
radiation therapy (SBRT).16 However, a complicating factor inherent to lung and liver tumours is that 
they are subject to respiratory-induced motion,17 largely due their proximity to the thoracic diaphragm. 
A strong correlation has been demonstrated between the thoracic diaphragm with both lung tumour18, 
19 and liver tumour motion,20 as shown in Figure 1-3. 
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 Figure 1-3.(a) Example of lung tumour and thoracic diaphragm motion, from Cerviño, et al. (2009).18 (b) Example of 
three-dimensions of liver tumour motion and thoracic diaphragm motion, from Yang, et al. (2014).20   
Lung and liver cancer patients were selected as the focus of this thesis for the investigations performed 
in this thesis due to the systematic review (detailed in chapter 2) which found that the most commonly 
researched patient cohort for breathing guidance interventions was lung cancer patients, followed by 
liver cancer patients. Therefore, for the translational research conducted in this thesis lung and liver 
cancer patients were considered to be the more ethical patient cohort to be tested with the 
intervention during treatment delivery, rather than a kidney or pancreas patient cohort, where 
acceptance and effectiveness of such an intervention is less certain at this time. 
1.2. Respiratory Motion in Radiation Therapy 
Through the act of breathing, internal thoracic and abdominal anatomy is in constant motion, with the 
largest magnitude of motion in the superior-inferior direction;21 22 this can result in thoracic-abdominal 
tumours moving up to 5 cm as the patient breathes.17 In order to ensure that the tumour is being 
irradiated at all times, treatment margins, shown in Figure 1-2(b), are expanded to encompass the entire 
range of motion of the tumour,23 illustrated in Figure 1-4.  
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 Figure 1-4. Gross tumour volume (GTV) 
moving up and down as the patient breathes; 
its total range of motion indicated by the 
internal gross tumour volume (IGTV). 
Expanded around this is the internal target 
volume (ITV), which encompasses the IGTV 
with an additional internal margin accounting 
for variations in size, shape, and position of 
the IGTV. The planning target volume (PTV) 
takes into account both uncertainties 
accounted for by the ITV in addition to setup 
uncertainties.24 
The larger the uncertainties in patient setup, and GTV position, shape, and size, the more the margins 
are expanded, which ensures that the tumour is being targeted throughout its entire range of motion; 
however, it also increases the dose to the healthy surrounding tissue.25 Given the observed variety of 
different tumour sizes and shapes, the resultant radiation beam needs to be shaped in such a way as to 
match the shape of the PTV. This is primarily achieved through the use of multi-leaf collimators (MLC),26-
28 and are shown in Figure 1-5. 
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 Figure 1-5. Phantom as a surrogate for 
a tumour with MLCs shown conforming 
to the shape of the tumour. Each 
individual MLC can move back and 
forth (as indicated by yellow arrows), 
such that all the MLCs can create and 
conform to a wide range of tumour 
shapes and sizes. Adapted from 
Cosgrove, et al. (1999).28  
The material of each MLC is of a high atomic number, typically a tungsten28 (atomic number: 74) alloy, 
allowing it to block part of the incident radiation beam, shaping it such that it conforms to the desired 
PTV. Each individual MLC can move independently of the others, allowing the MLCs to be able to create 
a wide variety of shapes and sizes.  
1.2.1. Respiratory Motion Management in Radiation Therapy 
In order to manage a constantly moving tumour, a number of techniques and technologies are available 
to reduce the deleterious impact respiratory motion can have on cancer radiation therapy. Such motion 
management strategies are recommended when tumour motion exceeds 5 mm.29  
1.2.1.1. Four Dimensional Computed Tomography (4DCT) 
4DCT is a type of medical imaging used for CT simulation to obtain not only three-dimensional 
information on tumour position and shape, but temporal information to also determine the tumour’s 
range of motion during respiration.30-33 During 4DCT imaging axial CT images are acquired at a number of 
couch positions as the patient is moved through the CT bore. At each couch position, axial CT images are 
acquired over the course of one respiratory cycle as monitored by a respiratory sensor (see chapter 
1.2.1.5.) before moving on to the next couch position; each CT image is tagged with a respiratory 
position.32 At the end of image acquisitions each couch position has an associated collection of CT 
images encompassing a cycle of respiration; these images are retrospectively sorted based on their 
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associated respiratory position.32 This creates a 3D CT that includes information over an entire 
respiratory cycle, generating the 4DCT. This method of 4DCT reconstruction is referred to as cine mode 
and represents the conventional reconstruction 4DCT method for many scanners.34, 35  
1.2.1.2. Breath Holds 
One technique to minimise the impact of respiratory motion is for the patient to hold their breath. By 
suspending respiration, respiratory-induced motion is minimised,36-38 negating much of the deleterious 
effects respiratory motion can have on cancer radiation therapy.39, 40  The type of breath hold most often 
performed in cancer radiation therapy is the deep inspiration breath hold,41-43 which for thoracic 
cancers, particularly breast cancer, has the additional benefit of further increasing the geometric 
distance between the heart and radiation beam thereby reducing cardiac and pulmonary dose.44-46 An 
example of a deep inspiration breath hold is shown in Figure 1-6.  
 
Figure 1-6. Cancer patient 
respiratory signal performing 
deep inspiration breath holds 
(DIBH) demonstrating the 
respiratory stability of breath 
holds compared to free 
breathing. From Nehmeh, et al. 
(2007).47 
Breath holds during radiation therapy treatment delivery typically have a duration of 20-30 seconds,48, 49 
however, many treatments require a beam-on time in the order or minutes,50, 51 not seconds. Further to 
this, many patients may not be able to sustain or tolerate multiple breath holds, especially lung cancer 
patients who have compromised lung function. Treatment times utilizing breath holds are also typically 
longer compared to free breathing; Mah, et al. (2000) noted that the average free breathing treatment 
time was 16 minutes, compared to 32 minutes for DIBH.52 It should be noted that treatment time here 
refers to patient setup in addition to the treatment delivery itself.  
1.2.1.3. Respiratory Gating 
Respiratory gating refers to triggering on the radiation beam only during specific phase- or 
displacement-based windows of the respiratory cycle,53, 54 windows in which respiratory motion is 
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minimal, typically at exhale which has demonstrated to be more reproducible than inhale.55 Respiratory 
gating requires measurement of the tumour position or the use of a surrogate whose respiratory signal 
is synchronised with the target motion.56 If the measurement or surrogate signal is integrated with the 
linear accelerator delivery, the beam on/off can be controlled, automating a gating procedure. Figure 1-
7 illustrates the rationale behind the respiratory gating procedure.  
 
Figure 1-7. A lung tumour moving in and out of the gating window (or interval) as the patient breathes. In this 
example, the gating window is set at exhale (50% of the respiratory cycle). Adapted from Kim, et al. (2008).57 
By only treating the tumour within a specific region, respiratory gating in radiation therapy reduces the 
margins shown in Figure 1-4 since it no longer needs to encompass the tumour’s entire range of 
motion.58-60 However, by interrupting the radiation beam each time the respiratory signal moves outside 
the gating window, treatment time of respiratory gating can exceed that compared to no gating. In 
addition to being utilised during free breathing, respiratory gating is also often used in breath hold 
treatments, with the gating window set at the desired breath hold amplitude level.61, 62     
1.2.1.4. Tumour Tracking 
Tumour tracking is an emerging technology to monitor and adapt to tumour motion in real-time during 
treatment delivery.63, 64 Tracking of the tumour typically involves either real-time imaging of the region 
of interest,65, 66 or implanted transponders about the tumour itself.63, 67 By following the motion of the 
tumour itself it is not necessary to expand the margins to encompass its entire range of motion, thereby 
reducing the size of the margins illustrated in Figure 1-4.67, 68 The impact of tracking, and not tracking, on 
delivered radiation dose to a prostate is shown in Figure 1-8. 
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Figure 1-8. Example of dose distributions from a prostate patient demonstrating higher agreement with the 
planned dose from the use of tracking compared to without tracking. From Colvill, et al. (2015).67 
Should the tumour move in such a way that was not accounted for in the treatment planning stage, it 
can lead to a deviation in radiation dose delivered from what was planned, as shown in Figure 1-8.    
Motion prediction is utilised in tumour tracking to overcome the inherent latency of the treatment and 
imaging system.69-71 Here, ‘latency’ refers to the time taken to register tumour position, speed of the 
MLCs, and the reaction time of the delivery system in addition to software limitations.72, 73 During this 
time the tumour may have moved to a different position. As such, there is a requirement for predicting 
tumour motion over timescales of the system latency which can range from 50 to several hundred 
milliseconds.70, 71  
1.2.1.5. Respiratory Sensors 
To perform much of the procedures detailed in chapter 1.2.1.1., chapter 1.2.1.2., chapter 1.2.1.3., and 
chapter 1.2.1.4., respiratory sensors are utilised to track and monitor patient respiration. An overview of 
the available sensors is given in the following subsections.  
1.2.1.5.1. Varian RPM 
The Varian real-time position management (RPM) system (Figure 1-9) is comprised of an infra-red (IR) 
camera and an external marker block with IR reflective dots. The marker block is positioned on the 
patient’s abdomen, mid-way between the umbilicus and xiphoid process, and its motion is tracked by 
the IR camera at a rate of 30 Hz in three dimensions, however, only the anterior-posterior motion is 
typically utilised for the respiratory signal. 
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 Figure 1-9. (a) Varian RPM system setup in a CT scanner also showing (i) the infra-red camera, and (ii) the marker 
block with two infra-red reflective markers. Adapted from Giraud & Houle (2013).64 (b) Screenshot of the Varian 
RPM software showing the more recent 6-dot reflective marker. 
The Varian RPM system provides a physiologically accurate respiratory signal used for gating 
procedures, such as during imaging31, 74, 75 and radiation treatment delivery.39, 58, 76  
1.2.1.5.2. Elekta ABC 
The Elekta Active Breathing Coordinator (ABC) (Figure 1-10), rather than monitoring respiratory motion, 
monitors patient lung volume via spirometry.77 The patient’s nose is clamped closed and they breathe 
through a tube measuring the volume of airflow. 
 
Figure 1-10. (a) Elekta ABC system setup in a treatment room.78 (b) Screenshot of the Elekta ABC software. 
The Elekta ABC can also restrict patient airflow at a particular level, such as mid ventilation or deep 
inspiration, by closing a valve, suspending the patient’s respiration. This can result in reproducible and 
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accurate gated breath holds,79, 80 however minor patient discomfort in using the Elekta ABC has been 
reported.81-83 
Elekta is the second major company which, together with Varian, make up 80% of the radiation oncology 
market.84  As such, the vast majority of respiratory sensors utilised in radiation therapy are either the 
Varian RPM or the Elekta ABC.  
1.2.1.5.3. AlignRT VisionRT 
The VisionRT AlignRT (Figure 1-11) is a markerless surface imaging motion sensor, utilizing stereo vision 
to produce 3D surface images of the patient.85  
 
Figure 1-11. VisionRT AlignRT camera and examples of surface images.86 
AlignRT is not only used for real-time respiratory motion monitoring,87 but also patient positioning, 
ensuring that patient position is reproducible between fractions by comparing the 3D patient surface 
between fractions.88  
1.2.1.5.4. Calypso 
The Calypso system (Figure 1-12) is a method of tumour tracking that is comprised of implanted 
transponder beacons which generate an electromagnetic signal that is detected in real-time by a panel 
array.89, 90 The Calypso system has been described as being “GPS for the body”.91  
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 Figure 1-12. (a) Calypso panel array in place in the treatment room.92 (b) Implanted transponder beacons 
generating an electromagnetic signal detected by the panel array.93   
Recently, the Calypso system has been developed to position the transponder beacons on the patient as 
an external marker for procedures where implanted markers are not necessary (e.g. breast cancer 
radiation therapy).94, 95  
1.2.1.6. Abdominal Compression 
Another technique to minimise the impact of respiratory motion is to physically limit the magnitude of 
abdominal and thoracic diaphragm motion via abdominal compression (Figure 1-13). By applying 
pressure to the patient’s abdomen, it physically restricts diaphragmatic motion,96 thereby restricting the 
motion of tumours proximal to the diaphragm.97 
  
Figure 1-13. A patient with a plate compressing their abdomen.98 
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1.3. Irregular Respiratory Motion in Radiation Therapy  
Typical patient breathing is often irregular in nature, e.g. inconsistent amplitude, period, and baseline 
drifts.73, 74 The techniques detailed in chapter 2.1., account for respiratory motion, however, the 
additional errors introduced by irregular respiratory motion are still present. An example of an irregular 
patient respiratory pattern is shown in Figure 1-14.  
 
Figure 1-14. Example of an 
irregular patient respiratory 
pattern. Demonstrating 
inconsistent amplitude, period, 
and baseline drifts (respiratory 
signal from data analysed in 
chapter 5).  
During radiation therapy imaging and treatment delivery there are two main sources of error: the errors 
that arise during treatment preparation and the errors that arise during treatment delivery.99-102 These 
errors have a number of components including patient positioning, anatomic variations, incorrect 
determination of the isocentre, and setup variations. For margin calculations, these errors can be 
broken up into systematic and random errors, with systematic errors representing errors arising during 
preparation and random errors arising during treatment delivery; both these types of errors are 
exacerbated by irregular respiratory-motion.34, 94, 103 Inconsistent respiratory motion also leads to 
variations in the ITV size over the course of patient treatment, leading to variations from what was 
planned for treatment.104 Figure 1-15 shows examples of ITV size variations over time.  
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 Figure 1-15. Variations of the volume of 
ITV over a fraction of treatment for 8 lung 
cancer patients. From St James, et al. 
(2012).104 
 
Subsequent sections chapter 1.3.1., chapter 1.3.2., and chapter 1.3.3. detail the deleterious impact 
irregular respiratory motion has on the motion management methods introduced in chapter 1.2.1.  
1.3.1. Four Dimensional Computer Tomography (4DCT) 
4DCT image artefacts have been reported in up to 90% of 4DCT images,34 compromising the accuracy of 
tumour delineation.105 These artefacts have been linked to factors such as respiratory motion velocity 
and irregularity.106-109  
 
Figure 1-16. (a) example of 
4DCT image artefacts, from 
Yamamoto, et al., (2008).34 
(b) Example of delineation 
errors of a lung tumour due 
to 4DCT image artefacts, 
from Persson, et al., 
(2010).105 
These artefacts arise when the respiratory signal varies considerably between couch positions, resulting 
in anatomic mismatches amongst the same tagged respiratory position (as described in chapter 1.1.1.), 
Figure 1-17 illustrates the variations of a respiratory signal over a number of different couch positions 
that would result in 4DCT image artefacts as shown in Figure 1-16. 
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 Figure 1-17. Example of an irregular 
respiratory trace (red signal) of a 
liver cancer patient. Beam on image 
acquisition times across the different 
couch positions indicated with the 
blue trace. From Szegedi, et al. 
(2012).110  
1.3.2. Respiratory Gating 
The rationale behind respiratory gating is that the tumour will occupy the same region in 3D space 
within the gating window for each breath. However, if patient breathing amplitude is inconsistent and 
there are baseline drifts, as shown in Figure 1-18, respiratory displacement and tumour position are 
inconsistent within these gating windows, leading to the radiation beam being triggered at 
inappropriate times. This increases the risk of underdose to the tumour and overdose to the 
surrounding healthy tissue.   
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 Figure 1-18. Examples of phase-based and displacement-based gating for a respiratory signal exhibiting a baseline 
drift. From George, et al., (2006).111 
1.3.3. Tumour Tracking 
Tumour tracking refers to monitoring the tumour itself (typically surrogates proximal to the tumour) 
during radiation treatment delivery. Tracking tumour motion during treatment delivery can further 
reduce the geometric uncertainties of tumour position that otherwise contribute to the expansion of 
treatment margins.112, 113 Calypso, described in chapter 1.2.1.5.4., is one such example of tumour 
tracking, monitoring the beacons implanted proximal to the tumour during radiation treatment delivery. 
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However, there is inherent system latency in tumour tracking procedures. The tumour position is 
determined through either implanted beacons or real-time imaging, and this information is then 
interpreted and relayed to the linac which adjusts its MLCs in response to this information. The time 
required to perform these steps can accumulate to up to several hundred milliseconds,72 during which 
time the tumour may have moved, potentially leading to incorrect targeting of the tumour. As such, 
prediction algorithms are utilised to overcome this system latency,102, 114, 115 however, the accuracy of 
these prediction algorithms are compromised when respiratory motion is irregular.73, 116-118 Figure 1-19 
demonstrates the reduction of prediction accuracy with in the presence of respiratory irregularities.  
 
Figure 1-19. Patient 
(blue) and predicted 
(purple) respiratory 
signals for (a) regular 
respiration, and (b) 
irregular respiration. 
Note when respiration 
is irregular, the error in 
prediction (yellow line) 
increases. Adapted 
from Murphy and 
Dieterich (2006).73 
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1.4. Breathing Guidance in Radiation Therapy 
Breathing guidance refers to a biofeedback system which measures patient respiration in real-time and 
simultaneously provides feedback to the patient on how to adjust their breathing to achieve the desired 
objective of either facilitating regular respiration or stable breath holds. Breathing guidance systems 
operate to minimise the deleterious impacts of irregular respiration outlined in chapter 1.3.1., chapter 
1.3.2., and chapter 1.3.3..  
1.4.1. Breathing Guidance Interventions 
Table 1-1 details the range breathing guidance interventions utilised to facilitate regular breathing 
available in the published literature. Such breathing guidance interventions have demonstrated to 
improve breathing motion regularity of both external surrogates such as the Varian RPM,111, 119, 120 in 
addition to internal anatomy121 as well as the lung tumour itself.122 However, much of the breathing 
guidance intervention investigations have not directly quantified the impact of regular breathing on 
radiation treatment accuracy. Despite imaging being performed in many of the studies presented in 
Table 1-1, the impact of breathing guidance on image quality has yet to be quantified. Further to this, 
there has not yet been a systematic review of the literature to thoroughly identify the gaps in the 
literature to indicate what the future direction of breathing guidance investigations should take. 
The rows shaded blue in Table 1-1 indicate the development of studies investigating the audiovisual 
biofeedback breathing guidance intervention. The audiovisual biofeedback system is the most 
investigated breathing guidance intervention of all the interventions presented in Table 1-1. 
 
Table 1-1. Published studies investigating breathing guidance interventions to facilitate regular 
breathing. Table details study authors and year, participants recruited into the study, the nature 
of visual and/or audio prompts used to guide patient breathing, whether imaging or treatment 
was performed and an image of the intervention’s display (if used).  
Study author (Year) Participants 
Visual 
prompt 
Audio 
prompt 
Imaging / 
Treatment 
Vedam123 & Kini76  
(2003) 
5 lung cancer 
patients 
Breathing 
signal & 
limits 
Verbal 
commands 
Fluoroscopy 
18
Neicu (2006)124 
5 healthy volunteers 
& 33 lung cancer 
patients 
Breathing 
signal & 
limits 
Verbal 
commands 
4D-CT & 
treatment 
simulation 
George 
(2006)111, 125 
24 lung cancer 
patients 
Breathing 
limits 
Ascending & 
descending 
tones 
None 
Chen126 
(2007) 
Phantom 
& 
8 healthy volunteers 
Cyclic moving 
pattern 
None 
IMRT delivered 
to phantom 
Lim120 
(2007) 
10 healthy 
volunteers 
Breathing 
signal & 
waveguide 
Verbal 
commands 
or tones 
None 
Haasbeek127 
(2008) 
22 lung  
cancer patients 
None 
Verbal 
commands 
 
4D-CT 
Persson128 
(2008) 
13 healthy 
volunteers 
None 
Verbal 
commands 
None 
Venkat119 
(2008) 
10 healthy 
volunteers 
Waveguide or 
bar-model 
Ascending & 
descending 
tones 
Venkat:  
None 
Linthout129 
(2009) 
25 lung & 
liver cancer patients 
Breathing 
signal & 
limits 
Verbal 
commands 
Treatment 
delivery 
Masselli130 
(2009) 
10 healthy 
volunteers & 
5 lung 
cancer patients 
Breathing 
limits 
None None 
Nakamura131 
(2009) 
6 lung 
cancer patients 
None 
Verbal 
commands 
Fluoroscopy 
Cerviño132 
(2009) 
15 healthy 
volunteers & 
5 breast  
cancer patients 
Breathing 
signal & 
limits. 
None None 
Park133 
(2011)  
10 healthy 
volunteers 
Breathing 
signal & 
waveguide 
Verbal 
commands 
Simulated IMRT 
plan 
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 1.4.2. Audiovisual Biofeedback  
Audiovisual biofeedback is an interactive is an interactive and personalised respiratory guide which 
utilises audio and visual prompts to facilitate regular patient respiratory motion, thereby reducing 
respiratory irregularities, which is advantageous towards improved medical image quality and radiation 
treatment delivery. An example of an audiovisual biofeedback system is shown in Figure 1-20. As the 
patient breathes a marker block positioned mid-way between the xyphoid process and umbilicus move 
in the anterior-posterior (AP) direction. This marker block is monitored at a rate of 30 Hz by the Varian 
Real-time Position Management (RPM) system.138 The AP motion information of the marker block, as 
tracked by the Varian RPM, is shown to the patient as a red ball moving vertically up and down on a 
display; anterior and posterior marker block motion on the patient’s abdomen corresponds to up and 
down motion of the red ball on the patient display, respectively.  
Kim,121 Pollock,134 & 
Steel135 
(2012-2014) 
15 healthy 
volunteers 
Waveguide & 
breathing 
limits 
Music which 
varies in 
speed 
MRI 
Damkjær136 
(2013) 
24 breast 
cancer patients 
Breathing 
limits 
Verbal 
commands 
CT 
Lu137 
(2014) 
13 lung & 
Liver cancer  
patients 
Breathing 
limits 
Ascending & 
descending 
tones 
4D-CT 
Lee122 
(2015) 
9 lung  
cancer patients 
Breathing 
limits 
Music which 
fades to 
silence 
MRI 
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 Figure 1-20. Feedback loop of audiovisual biofeedback, from the tracking of respiratory motion to the guiding 
interface shown to the patient.  
Also visible on the patient display is the inhale-exhale region indicated by two labelled black lines; there 
is also a blue wave moving from right-to-left across the patient display. It is the goal of the patient to 
adjust their breathing such that (1) the red ball traces the motion of the blue wave, and (2) keep the red 
ball within the inhale-exhale limits. The audio component was music which speeds up when the red ball 
deviates more than 15% from the blue guiding wave.  
 
Figure 1-21. Deleting outlier respiratory cycles to 
produce the resultant guiding wave. Blue cycles 
indicate each individual respiratory cycle, the red 
cycle indicates which of the respiratory cycles has 
been selected for possible deletion, and the green 
cycle indicates the resultant guiding wave.  
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This shape of this guiding wave is calculated from each patient’s own breathing pattern. As described by 
Venkat, et al.,119 a sample of respiratory cycles are acquired and a Fourier series fit is utilised to produce 
the resultant guiding wave. Should there be any outlier respiratory cycles amongst the collected ten, it is 
possible to delete them such that the resultant guiding wave is as indicative of the patient’s natural 
breathing as possible. This process is shown in Figure 1-21. There are also options to alter the guiding 
wave’s amplitude and period, if necessary.  
Once this guiding wave has been saved, it is loaded for the patient’s subsequent imaging and treatment 
sessions. This is to ensure that the patient is ideally reproducing the same respiratory motion for each 
fraction of treatment 
1.4.2.1. Development of audiovisual biofeedback 
While the use of audiovisual biofeedback has demonstrated positive results in previous cancer patient 
studies,76, 111, 123 the development of the software and guiding interface from one generation to the next 
was largely conducted on healthy volunteers and motion phantoms.119, 121, 139 When the updated version 
of the audiovisual biofeedback software was tested with cancer patients once again the results were 
less positive than those of previous findings,140 indicating that patient acceptance of the updated guiding 
interface had declined.  
The previous patient study utilizing the older version of audiovisual biofeedback software was 
conducted in 2004 at Virginia Commonwealth University (VCU);111, 125, 141 their setup is shown below in 
Figure 1-22. 
 
Figure 1-22. 
Audiovisual 
biofeedback system 
used in the VCU study. 
The next audiovisual biofeedback study to recruit cancer patients was conducted in 2012 at Stanford 
University;142, 143 their setup is shown below in Figure 1-23. 
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 Figure 1-23. 
Audiovisual 
biofeedback system 
used in the Stanford 
study. 
Table 1-2 summarises the differences between the two versions of audiovisual biofeedback used in 
these two studies, as well as differences in study design and conduct. 
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Table 1-2. Comparison of the nature and conduct of the two patient studies. 
 VCU, 2004 Stanford, 2012 
Guiding 
interface 
 
 
Visual 
component 
 Breathing surrogate (green bar) moving 
vertically between breathing limits.  
 Patient adjusts breathing to keep green 
bar within the breathing limits (blue 
area). 
 Breathing surrogate (red ball) moving 
vertically between breathing limits and 
moving guiding wave (blue wave).  
 Patient adjusts their breathing to keep 
the red ball within the breathing limits 
and trace the motion of the moving 
guiding wave 
Audio 
component 
 Ascending and descending tones for 
inhalation and exhalation, respectively 
 Music speeds up should the red ball 
deviate more than 15% from the guiding 
wave 
Study 
characteristics 
 
 Number of patients: 24 
 Average breathing session length: 4 
minutes 
 Number of breathing sessions: 5 
 Visual modality: Monitor screen  
 Imaging performed: none 
 Number of patients: 10 
 Average breathing session length: 19 
minutes 
 Number of breathing sessions: 1 
 Visual modality: display goggles  
 Imaging performed: 4D PET/CT 
Study 
results 
 Significantly positive.  
 Breathing regularity significantly 
improved due to breathing guidance. 
 Non-significant.  
 No overall improvement in breathing 
regularity.  
The main factors distinguishing these two studies were:  
(1) the audiovisual biofeedback system utilised in the Stanford study involved more audio and 
visual prompts than the one utilised in the VCU study 
(2) the length of time the patients were using audiovisual biofeedback (4 minutes in VCU study 
compared to 19 minutes in the Stanford study). This is due to the additional time required to 
perform 4D PET/CT imaging in the Stanford study 
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(3) the number of patients in each of the studies 
Points (1) and (2) directly relate to the patient using audiovisual biofeedback, and following a more 
complex audiovisual biofeedback for longer period of time may have led to higher patient fatigue and a 
decrease in patient compliance,144 as evidenced by the less regular breathing yielded in the Stanford 
study. A decrease in patient compliance means that in the Stanford study the audio prompt of the music 
speeding up would have been triggered more often making the audiovisual biofeedback session a more 
unpleasant experience.  
The use of the guiding wave in volunteer studies has produced significant improvements in breathing 
regularity,119, 121 in addition to image quality,139 and motion prediction accuracy.134 So rather than 
remove the guiding wave aspect of audiovisual biofeedback, an investigation into the nature of 
information delivered to the patient was undertaken. Audiovisual biofeedback utilises audio and visual 
information delivered to the patient which are designed to prompt them when their breathing has 
become irregular, in addition to also prompting them when their breathing has become regular again. 
Audiovisual biofeedback uses the audio prompts to inform the patient about the nature of their 
breathing; the music speeds up, and sounds unpleasant, to inform them that they have deviated from 
the guiding wave by over 15%. The music returns to a normal speed once the red ball is within 15% of 
the guiding wave again. To phrase this in terms of learning and behaviour, when a response (deviating 
from the guiding wave) is followed by an adverse stimulus (sped up, unpleasant music), this is a form of 
punishment, positive punishment, specifically.145 This is designed to be followed by a second set of 
response and stimulus; when a response (adjust breathing to follow guiding wave again) is followed by 
the removal of an adverse stimulus (unpleasant music), this is negative reinforcement.145, 146  
A number of studies have detailed the superior efficiency of learning by using positive reinforcement 
over punishment and negative reinforcement.146-149 Such considerations of superior learning methods 
were taken into account in redesigning the audio and visual components of a version of audiovisual 
biofeedback more easily tolerated by patients.  
The differences between the Stanford version and the updated University of Sydney version are outlined 
below in Table 1-3.  
Table 1-3. Comparison of the version of AV biofeedback used in the Stanford study and the latest University of 
Sydney version. 
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 Stanford, 2012 University of Sydney, 2013 
Guiding 
interface 
 
 
Visual 
component 
 Inhale-exhale limits 
 Guiding wave 
 Breathing motion surrogate: red ball 
 White background 
 Inhale-exhale region (blue area) 
 Guiding wave 
 Breathing motion surrogate: grey block, 
similar in appearance to RPM block  
 Blue background 
Audio 
component 
 Midi-files.  
 Speeds up when red ball deviates from 
guiding wave  
 Mp3-files.  
 Music fades to silence when grey block 
moves outside blue area 
Response 
 Deviating from the guiding wave 
 Returning to the guiding wave 
 Deviating from the blue area 
 Returning to the blue area 
Stimulus 
 Sped-up music introduced 
 Sped-up music removed 
 Music removed 
 Music re-introduced 
In the updated University of Sydney version, a response (deviating from the blue region) being followed 
by the removal of a positive stimulus (music) is referred to as response cost; then another response 
(returning to the blue region) is followed by the appearance of a positive stimulus (music), this is a form 
of positive reinforcement.145 The focus of the response and stimulus relationship was also shifted from 
following the guiding wave in the Stanford version to staying within the blue area in the University of 
Sydney version. This is because controlling breathing amplitude is considered more clinically beneficial 
compared to controlling breathing period.21, 107, 150, 151 The breathing surrogate used in the visual 
component was changed from a red ball to the image of an RPM marker block (the real marker block 
can be seen on the subject’s abdomen in Figure 1-23). This was done to better inform the patient of the 
source of breathing motion being displayed to them. The colour scheme was also altered to appear 
mainly blue due to the reinforcing and positive emotions studies have found it to be associated with.152, 
153 The colour scheme was also altered in order to reducing eye-strain compared to the white 
background present in the Stanford version to assist making prolonged breathing sessions more 
tolerable. The current generation of audiovisual biofeedback utilised in the studies presented in this 
thesis is shown in Figure 1-24. 
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 Figure 1-24. Updated audiovisual biofeedback system utilizing the most recent version of the guiding interface.  
For the updated version of audiovisual biofeedback, visible on the patient display is the inhale-exhale 
region indicated by the blue area in addition to the white guiding wave moving from right-to-left across 
the patient display. It is the goal of the patient to adjust their breathing such that (1) keep the grey block 
within the blue area, and (2) trace the motion of the guiding wave. The audio component is classical 
music which fades to silence should the grey block move outside the blue area.   
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1.5. Summary of literature review and unmet areas of research  
Radiation therapy is a valuable and cost-effective method of cancer treatment. However, when the 
tumour target is highly mobile, as is the case with abdominal and thoracic cancers largely due to 
breathing motion, additional motion management measures are utilised to counter the additional 
margins and potential treatment inaccuracies introduced by these moving tumour targets. Further to 
this, irregular breathing motion has a deleterious impact on cancer radiation therapy, exacerbating 
systematic and random errors in addition to reducing the effectiveness of motion management 
strategies and technologies. To further complicate the situation, in the case of abdominal tumours, pre-
treatment and 4DCT imaging is incapable of discriminating the tumour from the soft tissue. 
One method to minimise breathing motion irregularities are breathing guidance interventions. These 
interventions refer to a biofeedback system which measures patient respiration in real-time and 
simultaneously provides feedback to the patient on how to adjust their breathing to achieve the desired 
objective of stable and regular respiration. The most thoroughly researched breathing guidance 
intervention to date, audiovisual biofeedback, has demonstrated to improve breathing regularity of 
motion surrogates, internal anatomy, and the lung tumour itself, but has yet to be utilised during patient 
radiation treatment nor has its impact of medical image quality been quantified. The gap in the 
literature lies in patient radiation therapy and imaging studies, however, a systematic review has yet to 
be performed to more conclusively indicate this direction of investigation.  
1.5.1. Aims of this project 
The aims of this thesis are:  
1. To critically appraise the literature in terms of the use of breathing guidance interventions in the 
fields of radiation oncology and radiology via systematic review  
2. To quantify the impact of audiovisual biofeedback breathing guidance on 4DCT, the primary 
imaging modality utilised to plan radiation therapy for highly mobile tumours  
3. To assess the impact of audiovisual biofeedback on patient breathing over a course of radiation 
therapy  
4. To utilise the findings of the above aims to design and implement a novel and comprehensive 
clinical trial investigating the use and impact of audiovisual biofeedback in radiation therapy  
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5. To explore the next stages of audiovisual biofeedback in terms of translating evidence into 
broader clinical use through the commercialisation process 
1.5.2. Presentation of thesis  
This thesis is presented as a combination of one systematic review and one published paper as their own 
chapters, with a published case report and study protocol forming subsections within chapters. The 
chapter presentation of this thesis will largely follow the aims detailed above in chapter 1.5.1., with each 
results chapter addressing one of the aims, following them sequentially. Chapter 1 (this chapter) 
provides a background to cancer radiation therapy, and the deleterious impact of irregular patient 
breathing on cancer radiation therapy procedures before introducing audiovisual biofeedback breathing 
guidance as an intervention to minimise these deleterious impacts. Some background on audiovisual 
biofeedback is also provided in addition to recent developments towards the audiovisual biofeedback 
system utilised in the investigations presented in this thesis.  
Chapter 2 reports on the systematic review into the use of breathing guidance interventions in the fields 
of radiation oncology and radiology. Radiology was also included in this systematic review because 
certain radiology imaging modalities such as MRI and PET/CT are being utilised in emerging hybrid 
radiation treatment technologies such as the MRI-linac154 in addition to the use of PET/CT in radiation 
treatment planning.155 This systematic review was published in Medical Physics. Chapter 2 addresses 
aim 1, detailed in chapter 1.5.1.. 
Chapter 3 reports, quantitatively, on the impact of audiovisual biofeedback on 4DCT image quality. This 
study utilised lung cancer patient data from an MRI study to program the motion of a digital phantom 
prior to simulating 4DCT imaging. The 4DCTs were analysed utilising a range of image quality metrics in 
addition to noting the treatment time and imaging dose. This chapter also tests and compares the 
impact of prospective respiratory gating on 4DCT image quality. These results were published as a paper 
in Physics in Medicine and Biology. Chapter 3 addresses aim 2, detailed in chapter 1.5.1.. 
Chapter 4 reports on the impact of audiovisual biofeedback on breathing motion of an external motion 
surrogate and implanted radio-opaque markers of liver cancer patients over the course of stereotactic 
body radiation therapy (SBRT). Breathing motion was analysed in terms of the consistency of breathing 
displacement and period, the correlation between internal and external breathing signals, and the 
agreements of breathing motion between 4DCT and each treatment fraction. This study also utilised a 
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screening procedure; after patients were recruited into the study, a screening procedure was performed 
to determine which breathing condition would be utilised over their course of SBRT, free breathing or 
audiovisual biofeedback. This was the first investigation to utilise a screening procedure in addition to 
being the first to utilise breathing guidance over the course of SBRT. A case report, reporting on the first 
patient recruited into this study, was published The Journal of Medical Imaging and Radiation Oncology 
and is included as a subsection of Chapter 3’s results. Chapter 4 addresses aim 3, detailed in chapter 
1.5.1.. 
Chapter 5 reports on a retrospective analysis of the previous audiovisual biofeedback lung cancer 
patient study, the findings of which were utilised to design and determine the statistics of the most 
comprehensive breathing guidance study to date: a randomised, stratified, multi-site, phase II clinical 
trial investigating audiovisual biofeedback over the course of lung cancer radiation therapy. Chapter 5 is 
presented in two parts: (1) retrospective analysis of previous lung cancer patient study, and (2) the 
design and initiation of the randomised clinical trial. The clinical trial’s study protocol was published in 
BMC Cancer and is included in as a subsection of Chapter 5’s Methods section reporting on the design of 
the clinical trial. Chapter 5 addresses aim 4, detailed in chapter 1.5.1.. 
Chapter 6 builds upon the findings of the translational research presented in Chapters 3, 4, and 5 by 
reporting on the commercial pathway of the audiovisual biofeedback technology. Chapter 6 reports on 
the radiation oncology market, existing technologies, the value proposition that audiovisual biofeedback 
can contribute to this market, and the milestones to achieve to move this technology forward. Chapter 6 
also details how these commercial insights impact the design and function of the audiovisual 
biofeedback technology and the validation testing that has been conducted around this. Chapter 6 
addresses aim 5, detailed in chapter 1.5.1.. 
Chapter 7 summarises and provides conclusions of the research reported on in Chapters 2 – 6 in 
addition to providing details on future work.     
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CHAPTER 2 
 
Breathing guidance in radiation oncology and radiology: A 
systematic review of patient and healthy volunteer studies 
 
This chapter contains the review paper titled “Breathing guidance in radiation oncology and 
radiology: A systematic review of patient and healthy volunteer studies” which has been published 
in Medical Physics (2015; 42(9) 5490-5509) 
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Purpose: The advent of image-guided radiation therapy has led to dramatic improvements in the
accuracy of treatment delivery in radiotherapy. Such advancements have highlighted the deleterious
impact tumor motion can have on both image quality and radiation treatment delivery. One approach
to reducing tumor motion irregularities is the use of breathing guidance systems during imaging and
treatment. These systems aim to facilitate regular respiratory motion which in turn improves image
quality and radiation treatment accuracy. A review of such research has yet to be performed; it was
therefore their aim to perform a systematic review of breathing guidance interventions within the
fields of radiation oncology and radiology.
Methods: From August 1–14, 2014, the following online databases were searched: Medline, Embase,
PubMed, and Web of Science. Results of these searches were filtered in accordance to a set of
eligibility criteria. The search, filtration, and analysis of articles were conducted in accordance
with preferred reporting items for systematic reviews and meta-analyses. Reference lists of included
articles, and repeat authors of included articles, were hand-searched.
Results: The systematic search yielded a total of 480 articles, which were filtered down to 27 relevant
articles in accordance to the eligibility criteria. These 27 articles detailed the intervention of breathing
guidance strategies in controlled studies assessing its impact on such outcomes as breathing regularity,
image quality, target coverage, and treatment margins, recruiting either healthy adult volunteers or
patients with thoracic or abdominal lesions. In 21/27 studies, significant (p< 0.05) improvements
from the use of breathing guidance were observed.
Conclusions: There is a trend toward the number of breathing guidance studies increasing with
time, indicating a growing clinical interest. The results found here indicate that further clinical
studies are warranted that quantify the clinical impact of breathing guidance, along with the
health technology assessment to determine the advantages and disadvantages of breathing guidance.
C 2015 Author(s). All article content, except where otherwise noted, is licensed under a Creative
Commons Attribution 3.0 Unported License. [http://dx.doi.org/10.1118/1.4928488]
Key words: motion management, breathing guidance, systematic review, radiation oncology,
radiology
1. INTRODUCTION
The advent of image-guided radiation therapy (IGRT) has
led to dramatic improvements in the accuracy of treatment
delivery in radiotherapy, with the reduction of both random
and systematic uncertainties.1–6 While IGRT has improved the
accuracy of radiotherapy by utilizing information about tumor
motion and positioning throughout a patient’s treatment, it
has also shed light on the deleterious impact tumor motion
can have on both image quality and radiation treatment deliv-
ery.2,4,7–10 Anatomic motion due to breathing in the thoracic
and abdominal regions is of great concern due to their prox-
imity to the thoracic diaphragm, where respiratory-induced
motion can be up to 5 cm.11 In addition, heightened patient
anxiety levels during imaging and treatment,12,13 can result in
increasingly irregular breathing, leading to erratic breathing
motion of both internal anatomy and the tumor itself.8,14,15
The widespread utilization of IGRT has led to the investiga-
tion of an increasing number of methods to address breathing
motion and therefore tumor and organ movement and the resul-
tant uncertainties they cause. A number of image reconstruc-
tion methods and tracking systems have been developed to
ameliorate these uncertainties.16–19 However, such techniques
can be expensive and do not directly manage the problem of
irregular breathing motion. Addressing irregular tumor motion
directly at the source by managing the patients’ breathing
has been of increasing interest in recent times, with several
breathing guidance techniques being developed from simple
buzzer signals to interactive guiding interfaces to facilitate
regular and predictable tumor motion.
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F. 1. Left: Examples of 4D-CT image artifacts due to irregular breathing [Reprinted with permission from Yamamoto et al., “Retrospective analysis of artifacts
in four-dimensional CT images of 50 abdominal and thoracic radiotherapy patients,” Int. J. Radiat. Oncol., Biol., Phys. 72(4), 1250–1258 (2008). Copyright
2008 by Elsevier]. Right: Example of irregular respiratory-induced tumor motion during treatment setup and delivery [Adapted with permission from Worm
et al., “Variations in magnitude and directionality of respiratory target motion throughout full treatment courses of stereotactic body radiotherapy for tumors in
the liver,” Acta Oncol. 52, 1437–1444 (2013). Copyright 2013 by Informa Healthcare].
1.A. Irregular breathing in radiation oncology
and radiology
The deleterious impact of irregular motion during image
acquisition has been well documented for across a range of
medical imaging modalities.8,14,20–28 During radiation treat-
ment, there are two fundamental types of errors: the errors
occurring during treatment preparation (systematic) and the er-
rors occurring during treatment delivery (random);5,29–31 both
these types of errors are exacerbated by irregular breathing
motion.9,10,27
Systematic errors typically arise from errors in the images
used to plan the patient’s treatment; Fig. 1 demonstrates the
irregular tumor motion and errors present in images due to such
irregular breathing motion.
Random errors typically arise from variations in target posi-
tion throughout the patient’s treatment. Irregular breathing
leads to larger variations in target position not only during
treatment but also between treatments,9,10 as shown in Fig. 2.
To account for irregular breathing motions’ exacerbation
of systematic and random errors, the treatment volume is
expanded;32 increasing radiation dose to the healthy surround-
ing tissue thus increasing the risk of post-treatment radia-
tion complications such as radiation pneumonitis.33–39 Such
complications occur in over 60% of lung cancer patients after
treatment, with 47% developing at least grade 2 pneumonitis
requiring clinical intervention.34 Such clinical interventions
involve the prescription of anti-inflammatory pharmaceuticals
thereby increasing healthcare costs for that patient’s course
of treatment.36,40 To combat the increase of these systematic
and random errors, a number of strategies directly engaging
with the patient have been investigated to minimize the
irregularity of patient breathing motion. These breathing
guidance strategies have the advantage of being noninvasive,
requiring minimal modifications to existing facilities and
protocols.
Given the relatively recent widespread interest in such
breathing guidance strategies, a review of such research has yet
to be performed. It was therefore our aim to perform the first
systematic review of breathing guidance intervention strat-
egies within the fields of radiation oncology and radiology.
2. METHODS
This systematic review follows the preferred reporting
items for systematic reviews and meta-analyses (PRISMA)-
statement reporting standard.41 Table I presents our research
questions in the patients, intervention, comparison, outcome,
study design (PICOS) approach; given the relatively recent
F. 2. Example of interfraction breathing variations [Adapted with permission from Shah et al., “Real-time tumor tracking in the lung using an electromagnetic
tracking system,” Int. J. Radiat. Oncol., Biol., Phys. 86, 477–483 (2013). Copyright 2013 by Elsevier].
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T I. PICOS approach to the systematic review following the PRISMA statement.
P—patients/participants • Cancer patients with tumors affected by breathing motion (e.g., thoracic and
abdominal tumors) receiving radiotherapy and/or medical imaging
• Healthy volunteers participating as surrogates for the above patient population
I—intervention Breathing guidance—technologies which monitor patient breathing and provide
feedback to the patient informing them on how to adjust their own breathing in real
time on their own accord
C—comparison No breathing guidance of the same breathing type (i.e., nonguided breath-holds for
breath-hold studies and free breathing for breathing guidance studies)
O—outcome Regularity of breathing signal and anatomic/tumor motion, medical image quality,
radiation treatment margins and coverage, medical imaging, and radiation treatment
times
S—study design Quantitative and controlled prospective or retrospective trials
interest in such breathing guidance strategies, healthy volun-
teer studies were also considered in addition to patient
studies.
Once eligible articles were identified, they were filtered
in accordance to the selection criteria. The objective of the
selection criteria was to acquire scientific articles describ-
ing in sufficient detail a breathing guide intervention’s utili-
zation toward some aspect of abdominal or thoracic radi-
ology and radiotherapy application. Articles were extracted
by two authors using an electronic (Microsoft  2010)
pro forma specifying the identified articles. Where there was
disagreement between the reviewers, discussion was under-
taken among all authors until consensus was reached.
2.A. Selection criteria
Articles were included if they satisfied the following inclu-
sion criteria:
(1) Quantitatively evaluate the intervention of breathing
guidance relevant to the practice of either medical
imaging or thoracic/abdominal radiotherapy (prospec-
tive or retrospective).
(2) Participants were human over the age of 18 (retrospec-
tive data were from adult human study).
(3) Reported in the English language.
(4) Published in a peer-reviewed journal between the years
1994–2014.
(5) Had a control group for the same breathing type:
• For guided breathing studies, control group per-
formed unguided free breathing.
• For guided breath-hold studies, control group per-
formed unguided breath-holds.
Articles which excluded, even if satisfying the above inclu-
sion criteria, if they
(1) did not have a control group comparing intervention
to no intervention for the same breathing type (free
breathing or breath-hold),
(2) lacked a statement of statistical significance,
(3) did not describe, or reference to an article, in sufficient
detail of the breathing guidance intervention,
(4) was not a scientific paper (e.g., conference abstract,
conference proceeding, book, patent).
2.B. Search strategy
From August 1–14, 2014, the following online databases
were searched: Medline, Embase, PubMed, and Web of Sci-
ence. The search for articles initially included the fields of
radiation oncology and radiology using the terms: (radiation
therapy OR radiotherapy OR imaging). These search results
were then refined toward breathing guidance by using the
terms: (respiration OR breathing) AND (audio OR visual)
AND (guidance OR training OR feedback OR biofeedback).
The findings from the above mentioned databases in addi-
tion to articles identified through hand searching of their refer-
ence lists and cross-referencing for previously unidentified
articles which met the inclusion criteria. These articles were
exported to a citation manager, Endnote X5 where duplicate
articles were also removed. The process tree for attaining the
search strategies results in shown in Fig. 3. After duplication
and filtering through the selection criteria, five articles iden-
tified by this hand searching method made it into the final 27
articles.
Information extracted from each included article included
(1) purpose of intervention (breath-holds, regular breathing);
(2) study participants [healthy volunteers and/or patients, num-
ber recruited, disease type (if patients)]; (3) nature of audio
prompt (verbal, tones, music); (4) nature of visual prompt
(breathing limits, guiding-wave, etc.); (5) imaging performed
(if any); (6) treatment performed (if any); (7) main findings
of intervention strategy compared to control group; (8) visual
display of intervention (if any).
2.C. Analysis of articles
Due to the diverse applications and results used to deter-
mine the efficacy of breathing guidance strategies, a meta-
analysis was not performed; however, the main findings from
each of these articles were organized in terms of statistical
significance: achieving positive significant results, nonsignif-
icant results, or negative results.
Quality assessment scoring of the identified and included
articles was also performed in accordance with the Standard
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F. 3. Search strategy results. Screening and eligibility based on inclusion and exclusion criteria.
Quality Assessment Criteria for Evaluating Primary Research
Papers From a Variety of Fields.42 Quality assessment score is
given based on 14 questions about the article, the reviewers
award yes (2 points), partial (1 point), and no (0 points) or
not applicable (N/A—question not counted in score). Over-
all, a score out of 28 (or less if N/A is chosen) is found
and then converted to a percentage. Articles were scored by
two authors, and when discrepancies arose in the scores allo-
cated, a discussion was then undertaken until a consensus was
reached.
3. RESULTS
Twenty-seven articles were included as a part of this sys-
tematic review as shown in Fig. 3. After duplication and filter-
ing through the selection criteria, four articles identified by
this hand searching method made it into the final 27 articles.
Tables II–V detail the development of such strategies over
the past 20 yr, in addition to the quality assessment score of
each article. The average quality assessment score was 79%
(range: 54%–95%). Figure 4 also illustrates the timeline of
these studies.
Table VI is an assembly of these 27 articles’ findings and
whether their results were significantly positive, negative, or
nonsignificant. It should be noted that the number of outcomes
exceeds the number of identified articles because most articles
investigated more than one outcome.
4. DISCUSSION
Findings from the 27 identified articles yielded a diverse
range of breathing guidance intervention strategies being uti-
lized on a range of different cancer types. Breathing guid-
ance strategies ranged from buzzer signals to customized,
interactive guides. Of the 27 included articles in this system-
atic review, 21 yielded at least one statistically significant
positive outcome from the use of breathing guidance, with a
further 2 articles reporting nonsignificant improvements (or
not reporting the significance of improvements) from the use
of breathing guidance and 4 articles reporting at least one
statistically significant negative result. Of the four studies that
yielded negative results, three investigated audio-only guid-
ance, which resulted in larger breathing motion amplitudes,
an undesirable trait in most radiation oncology and radiology
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T II. Details of radiology breathing guidance studies.
Study author
(Year)
Purpose of
intervention Participants Visual prompt
Audio
prompt
Imaging/
treatment
Breathing
motion sensor
Quality assessment
score (%) Display
Wang (1995)
(Ref. 43)
Breath-holds 11 healthy
volunteers
None Buzzer
tone
MRI Bellows belt 54 No display used
Locklin
(2007)
(Ref. 44)
Breath-holds 16 cancer
patients
Breathing signal None CT Bellows belt 75
Okada (2009)
(Ref. 45)
Regular breathing
and breath-holds
13 healthy
volunteers
Breathing signal None MRI MRI navigator
echo
88
Jhooti (2011)
(Ref. 46)
Regular breathing 10 healthy
volunteers
Video game-type
interface
None MRI MRI navigator
echo
79
procedures.22,62,70–75 Of the findings assembled in Table VI, 63
were positive statistically significant, 82 were nonsignificant
(or significance not reported), and 7 were negative statistically
significant. It should be noted that of the 82 nonsignificant (or
significance not reported) results, 35 noted improvements from
the use of breathing guidance, 12 of which were reported to be
nonsignificant, and 23 did not report the significance.
Of the 27 identified articles, 12 were healthy volunteer
studies and 12 were patient studies, with 3 studies recruiting
both healthy volunteers and patients; the most investigated
cancer type was lung cancer (12 studies), followed by breast
(2 studies) and liver cancer (2 studies). Of the breathing guid-
ance intervention strategies, most were designed to facili-
tate regular breathing (21 articles); 4 articles detailed breath-
hold guidance, 1 study investigated both regular breathing and
breath-hold guidance, and 1 study investigated quasibreath-
hold breathing guidance where each exhale was extended to
3, 5, or 7 s. Medical imaging was performed in 15 studies, and
radiation treatment was performed (or simulated) in 4 studies.
Given these numbers, and as evident from Table VI, there are
areas of breathing guidance which require more investigation.
For example, research into the impact of breathing guidance
on radiation treatment margins and target coverage is limited
and largely inconclusive, with all results thus far being nonsig-
nificant. Further investigation into this area would be valuable
as such findings would also give insight into the impact of
breathing guidance strategies on patient outcomes. Further
to this, of the 27 identified articles, none were randomized
studies, indicating that future study designs should incorporate
randomization.
Twenty of the 27 identified articles did not explicitly control
for confounding; however, the authors of this review paper
did not consider this to bias their results. Of the 27 articles,
none declared any conflicts of interest; however, two articles
acknowledged at least partial funding from either Phillips
(Lu et al.)69 or VisionRT (Cerviño et al.),63 and two articles
acknowledged research agreements with either Varian Medical
Systems (Persson et al.)57 or Phillips Medical Systems [Lock-
lin et al. (2007)]. However, these articles received positive
quality assessment scores, as such the authors of this review
paper did not consider the results presented in these articles to
be biased.
4.A. Breathing guidance for breath-holds
Breath-holds are a well-documented and frequently uti-
lized strategy for minimizing anatomic motion during imaging
and treatment.43,63,68,76–84 To further improve the efficacy and
reproducibility of breath-holds, measures have been taken to
provide guidance to the patient to maintain breath-hold stabil-
ity.43,44,68,85 Wang utilized a buzzer signal to prompt patients
to perform their breath-hold; such simple additions in this
MR imaging study resulted in improved consistency of breath-
holds resulting in achieving their goal of improving image
quality.43 Locklin investigated a more-comprehensive guid-
ance system by showing the patient their own breathing signal
as well as the intended breath-hold level.44 These studies also
resulted in improved image quality and intrafraction motion
management.
Breathing guidance has also been developed for deep-
inspiration breath-holds (DIBH).63,68 DIBH is often performed
by the patient in left breast cancer radiotherapy to minimize the
radiation damage to the lung and heart.79,80,82,83,86 Given the
increased difficulty in achieving deep-inspiration and main-
taining it for the adequate duration of imaging and treatment,
DIBH an attractive technique to implement with a breathing-
guidance strategy. The use of breathing guidance for DIBH
improved the consistency of breath-holds as demonstrated by
Cerviño, leading to an increased sparing of organs at risk in
breast radiation therapy, as demonstrated by Damkjær.63,68
4.B. Breathing guidance for regular breathing
While breath-holds have positively impacted imaging and
radiotherapy, they can be taxing on the patient who often
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T III. Metrics and results of radiology breathing guidance studies.
Study author (Year) Metric(s) used Result(s)
Wang (1995) (Ref. 43) Standard deviation of superior–inferior (SI)
position of cardiac structures
• Without breathing guidance: Standard deviation of right coronary
artery SI position was 2.0 mma
• Breathing guidance: Standard deviation of right coronary artery SI
position was 0.9 mma
Slice misregistration • Without breathing guidance: The total number of slices was 35
• Breathing guidance: The total number of slices was 19, much less
than no breathing guidanceb
• Total number of breath-holds needed reduced by almost a factor of
2b
Improving image quality • With breathing guidance, there were less missing cardiac struc-
turesb
• Image quality improved in six (of eight) subjects whose image
quality was evaluated by a radiologist and a physicista
Locklin (2007) (Ref. 44) Standard error of the mean (SEM) of
breath-hold position readings
• With breathing guidance:
◦ SEM reduced for inspiratory breath-holds (p = 0.0693)c
◦ SEM reduced for expiratory breath-holds (p = 0.0083)d
◦ SEM reduced for midbreath breath-holds (p = 0.053)c
Okada (2009) (Ref. 45)
Five point grading system of image quality
by assessors
• Worse scores were observed for breathing guidance compared to
free breathing (p < 0.05)d
◦ Of the 15 coronary artery segments that were scored, 5 were
scored significantly worse for breathing guidance
◦ Of the 15 coronary artery segments that were scored, none were
scored significantly better for breathing guidance
Scan time • Free breathing: Mean scan time was 10.0±2.2 min
• Breathing guidance: Mean scan time was 10.0±2.5 min, no signif-
icant difference compared to free breathingc
Jhooti (2011) (Ref. 46) Respiratory efficiency (the minimum time
required to acquire a full dataset within a
5 mm range of respiratory motion)
• Free breathing: Respiratory efficiency was 45%
• Breathing guidance: Respiratory efficiency was 56%, significantly
improved over free breathing (p = 0.006)d
Scan time • Free breathing: Scan time was 7 min 44 s
• Breathing guidance: Scan time was 5 min 43 s, significantly shorter
than free breathing (p = 0.026)d
Image quality • No different in image qualityc
aNo p-value, no statement of significance.
bNo p-value, but significance stated.
cP ≥ 0.05 (nonsignificant).
dP < 0.05 (significant).
has compromised respiratory function and are typically not
feasible beyond 20 s. As such, techniques to dynamically
control breathing during imaging and treatment have been
developed to, rather than immobilize the tumor, minimize the
irregular motion of the tumor, which would otherwise compro-
mise the accuracy of radiation targeting7,8,14,22,87 and image
quality.8,14,21,22,24–27
Prompts used to guide patient toward regular breathing
have undergone considerable development and refinement
over the years as detailed in Tables II–V. Audio-only guid-
ance typically appeared in the form of verbal instructions
or tones,50–52,56,57,62 and while the regularity of breathing
was improved, it also increased the amplitude of breathing
motion.48,56,57,62 Increased tumor motion, even if it is regular,
is undesirable in a patient’s treatment planning and deliv-
ery.22,62,70–75 Visual guidance has garnered positive results not
only over free breathing44,63 but also over audio-only guid-
ance.47,48,50,62,68,81 However, utilizing both audio and visual
guiding prompts together has yielded the most significant
improvements over free breathing.47,48,50–52,58,60,64–66,69 Both
audio and visual guiding prompts have led to significant
improvements over audio-only and visual-only guidance as
well.50,60 On top of this, as noted by Venkat, utilising audio
and visual prompts together poses no increase in the patient’s
cognitive load, i.e., it does not require additional concentration
for the patient to incorporate two different sensory forms of
guidance at once.58
The guiding prompts of breathing guidance have developed
from a buzzer sounding to provide a queue for breath-holds,
to a patient display presenting breathing-surrogates superim-
posed with a guiding interface. Additional constraints have
been added to the visual prompts to further manage respiration,
such as the displaying of inhale and exhale limits,47,48,50,60
a waveguide with fixed period and amplitude for the
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T IV. Details of radiation oncology breathing guidance studies.
Study author (Year)
Purpose of
intervention Participants Visual prompt Audio prompt
Imaging/
treatment
Breathing motion
sensor
Quality
assessment
score (%) Display
Vedam and Kini
(2003) (Refs. 47
and 48)
Regular breathing Five lung cancer
patients
Breathing signal
and limits
Verbal commands Fluoroscopy
Real-time position
management system
(RPM)
Vedam: 73
Kini: 55
Neicu (2006)
(Ref. 49)
Regular breathing 5 healthy volunteers
and 33 lung cancer
patients
Breathing signal
and limits
Verbal commands 4D-CT and
treatment simulation
RPM 68
George (2006)
(Refs. 50 and 51)
and An (2013)
(Ref. 52)a
Regular breathing 24 lung cancer
patients
Breathing limits
Ascending and
descending tones
None RPM George (a): 91
George (b): 95
An: 55
Chen (2007)
(Ref. 53)
Regular breathing Phantom and eight
healthy volunteers
Cyclic moving
pattern
None IMRT delivered to
phantom
RPM 59
Lim (2007)
(Ref. 54)
Regular breathing Ten healthy
volunteers
Breathing signal
and waveguide
Verbal commands or
tones
None Respiratory
monitoring mask with
thermocouple
77
Vedam (2007)
(Ref. 55)
Regular breathing 90 lung cancer
patients
Breathing signal
and limits
Verbal commands CT RPM 82
Haasbeek (2008)
(Ref. 56)
Regular breathing 22 lung cancer
patients
None Verbal commands 4D-CT RPM 77 No display used
Persson (2008)
(Ref. 57)
Regular breathing 13 healthy volunteers None Verbal commands None RPM 91 No display used
Venkat (2008) and
Yang (2012)
(Refs. 58 and 59)a
Regular breathing Ten healthy
volunteers
Waveguide or
bar-model
Ascending and
descending tones
Venkat: None RPM Venkat: 77
Yang: PET Phantom
programmed with
RPM motion
Yang: 86
Linthout (2009)
(Ref. 60)
Regular breathing 25 lung and liver
cancer patients
Breathing signal
and limits
Verbal commands Treatment delivery ExacTrac 82
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T IV. (Continued).
Study author (Year)
Purpose of
intervention Participants Visual prompt Audio prompt
Imaging/
treatment
Breathing motion
sensor
Quality
assessment
score (%) Display
Masselli (2009)
(Ref. 61)
Regular breathing Ten healthy
volunteers and five
lung cancer patients
Breathing limits None None Pneumatic strain
gauge
73
Nakamura (2009)
(Ref. 62)
Regular breathing Six lung cancer
patients
None Verbal commands Fluoroscopy RPM 91 No display used
Cerviño (2009)
(Ref. 63)
Deep inspiration
breath-holds
15 healthy volunteers
and 5 breast cancer
patients
Breathing signal
and limits.
None None GateCT-RT 91
Park (2011)
(Ref. 64)
Quasibreath-hold Ten healthy
volunteers
Breathing signal
and waveguide
Verbal commands Simulated IMRT
plan
Infrared-based stereo
camera
82
Kim, Pollock, and
Steel (2012–2014)
(Refs. 65–67)
Regular breathing 15 healthy volunteers
Waveguide and
breathing limits
Music which varies
in speed
MRI
RPM (abdominal
motion) and MRI
(thoracic diaphragm
motion)
Kim: 95
Pollock: 86
Steel: 82
Damkjær (2013)
(Ref. 68)
Deep inspiration
breath-holds
24 breast cancer
patients
Breathing limits Verbal commands CT RPM 91
Lu (2014) (Ref. 69) Regular breathing 13 lung and liver
cancer patients
Breathing limits Ascending and
descending tones
4D-CT RPM and active
breathing coordinator
83
aRetrospective analysis.
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T V. Metrics and results of radiation oncology breathing guidance studies.
Study author
(Year) Metric(s) used Result(s)
Vedam and Kini
(2003) (Refs. 47
and 48)
Standard deviation of thoracic diaphragm
motion
• Free breathing: Standard deviation of 0.36 cm
• Audio guidance: Standard deviation of 0.71 cm, higher than free breathinga
• Visual guidance: Standard deviation of 0.47 cm, comparable to free breathinga
Measure of ability to predict diaphragm
motion (standard deviation of relative
position between actual and predicted
motion traces)
• Free breathing: Standard deviation of 0.09 cm
• Audio guidance: Standard deviation of 0.09 cm
• Visual guidance: Standard deviation of 0.11 cm
• Breathing guidance comparable to free breathinga
Vedam: Relationship between respiratory
signal and diaphragm motion
• Strong linear relationship between respiratory signal and diaphragm motion (p < 0.001) over all sessions, regardless of the type of breathing guidance
or whether it was used at all (p = 0.19)
Kini: Average and standard deviation in
breathing period
• Audio breathing guidance: Reproducible breathing frequency compared to free breathinga
• Visual breathing guidance: Further improved reproducibility in breathing frequency compared to free breathinga
Kini: Average and standard deviation in
breathing range of motion
• Audio guidance: Higher variations and magnitude in breathing range of motion compared to free breathinga
• Visual guidance: Lower variations in breathing range of motion compared to audio guidanceb
Neicu (2006)
(Ref. 49)
User acceptance of breathing guidance • All five healthy volunteers were able to follow audio-visual breathing guidance
• Of the 33 lung cancer patients:
◦ 10 could follow audio-visual breathing guidance
◦ 13 could follow only audio breathing guidance
◦ 4 were not able to follow breathing guidance
◦ 6 had naturally regular breathing, so breathing guidance was deemed unnecessary
SMART duty cycle • Lung cancer patients:
◦ Free breathing: Only 3 patients had duty cycles higher than 60%
◦ Audio-visual breathing guidance: Most patients had duty cycles around 80% or larger, and all patients had duty cycles higher than 60%a
◦ Audio breathing guidance: 5 patients had duty cycles higher than 80%, and higher than 60% for 7 patientsa
Duty cycles for simulated amplitude
gating
• Healthy volunteers:
◦ Simulated amplitude gating:
 Free breathing: Average duty cycle was 32%
 Audio-visual breathing guidance: Average duty cycle was 36%, an improvement over free breathinga
 Audio breathing guidance: With the exception of patients 6, 8, and 11, breathing guidance reduced intrasession variations in period from about
23% to 11%a
◦ Simulated hybrid amplitude/phase gating:
 Free breathing: Average duty cycle was 21%
 Breathing guidance: Average duty cycle was 32%, an improvement over free breathinga
• Lung cancer patients:
◦ Simulated amplitude gating and hybrid amplitude/phase gating:
 Audio-visual breathing guidance: Four patients demonstrated good improvements over free breathing, one patient demonstrated worse results with
breathing guidance, and the rest of the patient demonstrated similar results to free breathinga
 Audio breathing guidance: Six patients demonstrated slight improvements over free breathing, one patient demonstrated worse results, and the
rest of the patient demonstrated similar result to free breathinga
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T V. (Continued).
Study author
(Year) Metric(s) used Result(s)
Intrasession breathing amplitude
variations
• Healthy volunteers:
◦ Breathing guidance reduced intrasession standard deviations in amplitude by a factor of 3a
◦ Baseline drift almost entirely removed from the use of breathing guidancea
• Lung cancer patients:
◦ Audio-visual breathing guidance:
 Breathing guidance did not have much difference to free breathing for intrasession variations in amplitudea
 Breathing guidance typically increases breathing amplitudea
Intrasession breathing period variations • Healthy volunteers:
◦ Breathing guidance reduced intrasession standard deviations in period by a factor of 2a
• Lung cancer patients:
◦ Audio-visual breathing guidance:
 Breathing guidance reduced intrasession variations in period by about 12%a
 Breathing guidance typically increases breathing perioda
◦ Audio breathing guidance:
 With the exception of patients 6, 8, and 11, breathing guidance reduced intrasession variations in period from about 23% to 11%a
 Breathing guidance typically increases breathing perioda
Intrasession breathing end-of-inhale and
end-of-exhale variations
• Healthy volunteers:
◦ Breathing guidance reduced standard deviations of the end-of-inhale and end-of-exhale positions, normalized to the average amplitude, by a factor
of 2–3a
• Lung cancer patients:
◦ Audio-visual breathing guidance:
 With the exception of patient 6, breathing guidance reduced standard deviations of end-of-exhale positions by a factor of 2.5a
 Breathing guidance produced mixed results for the standard deviations of end-of-inhale positionsa
Intersession breathing variations • Healthy volunteers:
◦ Intersession standard deviations of amplitude and period for breathing guidance were about 3 times smaller than free breathinga
George (2006)
and An (2013)
(Refs. 50–52)c
George (a): Residual breathing motion
(standard deviation of displacement)
within a duty cycle at inhale and exhale
for phase-based gating
• Gating at inhale with 40% duty cycle:
◦ Free breathing: Mean residual motion was 0.47 cm
◦ Audio breathing guidance: Mean residual motion was 0.47 cm, no significant difference to free breathinga
◦ Audio-visual breathing guidance: Mean residual motion was 0.36 cm, significantly improved over free breathing and audio guidanceb
• Gating at exhale with 40% duty cycle:
◦ Free breathing: Mean residual motion was 0.32 cm
◦ Audio breathing guidance: Mean residual motion was 0.31 cm, no significant difference to free breathinga
◦ Audio-visual breathing guidance: Mean residual motion was 0.27 cm, significantly improved over free breathing and audio guidanceb
• Duty cycles of 30% and 50% were also tested and demonstrated similar results
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Study author
(Year) Metric(s) used Result(s)
George (a): Residual breathing motion
(standard deviation of displacement)
within a duty cycle at inhale and exhale
for displacement-based gating
• Gating at inhale with 40% duty cycle:
◦ Free breathing: Mean residual motion was 0.42 cm
◦ Audio breathing guidance: Mean residual motion was 0.44 cm, no significant difference to free breathinga
◦ Audio-visual breathing guidance: Mean residual motion was 0.31 cm, significantly improved over free breathing and audio guidanceb
• Gating at exhale with 40% duty cycle:
◦ Free breathing: Mean residual motion was 0.27 cm
◦ Audio breathing guidance: Mean residual motion was 0.27 cm, no significant difference to free breathinga
◦ Audio-visual breathing guidance: Mean residual motion was 0.21 cm, significantly improved over free breathing and audio guidanceb
• Duty cycles of 30% and 50% were also tested and demonstrated similar results
George (b): Relationship between
patient, tumor, and treatment variables
with breathing residual motion
• Inhale based gating:
◦ Correlation between residual motion and visual training displacement (p < 0.05)d
◦ Correlation between residual motion and breathing guidance types (p < 0.05)d
• A number of other correlations were investigated; however, they were independent from breathing guidance (e.g., Karnofsky performance status and
dose-per-fraction) and therefore were not included in these results
An: Breathing reproducibility of internal
motion (variation of range of motion in
the first session compared to the
subsequent four sessions)
• Free breathing: Breathing reproducibility of range of motion decreased by 28.5%±27.9%
• Audio-visual breathing guidance: Breathing reproducibility of range of motion improved by 21.4%±20.7%, significantly more reproducible than
free breathing (p < 0.05)d
An: CTV coverage • Free breathing: CTV coverage decreased by 7.0%
• Audio-visual guidance: CTV coverage improved by 20.2%, an improvement over free breathinga
Chen (2007)
(Ref. 53)
Mean percent error in breathing • Free breathing: Mean percent error was 21%
• Breathing guidance: Mean percent error was 1.8%, considerably less than free breathinga
Intrapatient breathing standard deviation • Intrapatient standard deviations decreased with breathing guidanceb
Lim (2007)
(Ref. 54)
Standard deviation of breathing
amplitudes
• Free breathing: Standard deviation of amplitudes was 0.0029 (arbitrary units)
• Breathing guidance: Standard deviation of amplitudes was 0.00139 (arbitrary unites), significantly improved over free breathing (p = 0.029)d
Standard deviation of breathing periods • Breathing guidance reduced standard deviation of periods from 0.359 to 0.202 s (p = 0.002)d
Vedam (2007)
(Ref. 55)
Difference between simulated and
delivery gate threshold determined by
using the mean displacement from within
the phase interval
• Gating phase interval of 40%–60%:
◦ Free breathing: Mean difference was 0.14
◦ Breathing guidance: Mean difference was 0.08, significantly improved compared to free breathingd
• Gating phase interval of 30%–70%:
◦ Free breathing: Mean difference was 0.08
◦ Breathing guidance: Mean difference was 0.04, significantly improved compared to free breathingd
• The above improvements due to breathing guidance had p-values between 0.01 and 0.02
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(Year) Metric(s) used Result(s)
Difference between simulated and
delivery gate threshold determined by
using the maximum of average
displacements from within the selected
phase
• Gating phase interval of 40%–60%:
◦ Free breathing: Mean difference was 0.18
◦ Breathing guidance: Mean difference was 0.11, significantly improved compared to free breathingd
• Gating phase interval of 30%–70%:
◦ Free breathing: Mean difference was 0.17
◦ Breathing guidance: Mean difference was 0.11, significantly improved compared to free breathingd
• The above improvements due to breathing guidance had p-values between 0.01 and 0.02
Haasbeek
(2008) (Ref. 56)
Lung volume • End-inspiration lung volume:
◦ Audio breathing guidance increased lung volume by 415 ml (10.2%) compared to free breathing (p = 0.001)d
• End-expiration lung volume:
◦ Audio breathing guidance increased lung volume by 131 ml (2.9%) compared to free breathing (p = 0.08)e
• Between inspiration and expiration lung volume:
◦ Audio breathing guidance increased lung volume by 671 ml (19.2%) compared to free breathing (p < 0.001)d
Displacement of internal target volume
(ITV)
• Free breathing: Mean displacement of 3D ITV center of mass was 9.2±8.3 (range: 0–27 mm)
• Breathing guidance: Mean displacement of 3D ITV center of mass was 13.0±12.9 (range: 0–46 mm), significantly larger compared to free breathing
(p = 0.008)d
Persson (2008)
(Ref. 57)
Breathing amplitude • Compared to free breathing, more volunteers had larger breathing amplitudes (p values between <0.0001 and 0.0237):d
◦ 7 of 12 volunteers (and 6 of 12) had significantly larger amplitude for type 1 (and type 2) audio guidance
◦ 2 of 12 (and 2 of 12) volunteers had significantly lower amplitude for type 1 (and type 2) audio guidance
Standard deviation of breathing
amplitude intrafractionally
• No significant difference in the standard deviation of the breathing amplitude distribution between guidance and free breathinge
Venkat (2008)
and Yang (2012)
(Refs. 58 and
59)c
Venkat: Root mean square (RMS)
variations in breathing motion
displacement
• Free breathing: Mean RMS variation in displacement was 0.16 cm
• Bar-model breathing guidance: Mean RMS variation in displacement was 0.10 cm, 40% more regular than free breathing (p = 0.005)d
• Wave-model breathing guidance: Mean RMS variation in displacement was 0.08 cm, 55% more regular than free breathing, and significantly more
regular than bar-model breathing guidance (p = 0.006)d
Venkat: RMS variations in breathing
motion period
• Free breathing: Mean RMS variation in period was 0.77 s
• Bar-model breathing guidance: Mean RMS variation in period was 0.33 s, 50% more regular than free breathing (p = 0.002)d
• Wave-model breathing guidance: Mean RMS variation in period was 0.2 s, 75% more regular than free breathing and significantly more regular than
bar-model breathing guidance (p = 0.005)d
Yang: Motion blurring (quantified by
target size)
• Free breathing: Average increase in target diameter was 1.3±2.2 mm
• Breathing guidance: Average increase in target diameter was 0.6±1.6 mm, a significant improvement in target size compared to free breathing
(p < 0.001)d
Yang: Dice coefficient • Free breathing: Average Dice coefficient was 0.88±0.10
• Breathing guidance: Average Dice coefficient was 0.90±0.07, a significant improvement compared to free breathing (p < 0.001)d
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Study author
(Year) Metric(s) used Result(s)
Yang: Recovery coefficient • For all targets, breathing guidance had consistently higher recovery coefficients than free breathinga
• Target size had a greater impact on recovery coefficient values than breathing motiona
• For the largest target:
◦ Free breathing: Recovery coefficient was 0.97±0.04
◦ Breathing guidance: Recovery coefficient was 1.00±0.04
• For the smallest target:
◦ Free breathing: Recovery coefficient was 0.36±0.05
◦ Breathing guidance: Recovery coefficient was 0.39±0.03
Linthout (2009)
(Ref. 60)
Delivery time of gated treatment • Free breathing: 1.7±0.6 min/100 MU
• Visual breathing guidance: 1.4±0.4 min/100 MU, a nonsignificant reduction in delivery time compared to free breathing (p = 0.249)e
• Audio-visual breathing guidance: 0.9±0.2 min/100 MU, a significant reduction in delivery time compared to free breathing (p = 0.004)d and a
significant reduction in treatment time compared to visual breathing guidance (p = 0.008)d
Masselli (2009)
(Ref. 61)
Baseline shift • Removal of baseline drifta
Average amplitude • Healthy volunteers:
◦ Free breathing: Average amplitude was 10±2 mm
◦ Breathing guidance: Average amplitude was 6±1 mm, lower compared to free breathingb
• Lung cancer patients:
◦ Free breathing: Average amplitude was 8±2 mm
◦ Breathing guidance: Average amplitude was 5±1 mm, lower compared to free breathingb
Variability of breathing amplitude • No significant difference in standard deviation of amplitudee
Average breathing frequency • Healthy volunteers:
◦ Free breathing: Breathing frequency was 17 breaths/min
◦ Breathing guidance: Breathing frequency was 37 breaths/min, more than free breathingb
• Lung cancer patients:
◦ Free breathing: Breathing frequency was 15 breaths/min
◦ Breathing guidance: Breathing frequency was 45 breaths/min, more than free breathingb
Nakamura
(2009) (Ref. 62)
Mean SI tumor displacement • Free breathing: Mean SI tumor displacement was 10.4 mm
• Breathing guidance: Mean SI tumor displacement was 23.0 mm, a significant increase compared to free breathing (p < 0.01)d
Mismatches between SI lung tumor
position and abdominal position
• Free breathing: The average position mismatch was 1.70 mm
• Breathing guidance: The average position mismatch was 2.09 mm
◦ Compared to free breathing, SI lung tumor position mismatches became larger in 75% of sessions with breathing guidance (p = 0.01)d
Correlation between abdominal
displacement and lung tumor motion
• Free breathing: Correlation coefficients ranged from 0.89 to 0.97
• Breathing guidance: Correlation coefficients ranged from 0.93 to 0.99, significantly improved compared to free breathing (p < 0.01)d
Cerviño (2009)
(Ref. 63)
Reproducibility of breath-holds:
Maximum difference between difference
breath-hold levels
• Without guidance: Average reproducibility was 2.1 mm
• Breathing guidance: Average reproducibility was 0.5 mm, significantly improved compared to free breathing (p < 0.001)d
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Stability of breath-holds: Maximum of
the amplitude change between initial and
end time points of a breath hold
• Without guidance: Average stability was 1.5 mm
• Breathing guidance: Average stability was 0.7 mm, significantly improved compared to free breathing (p < 0.01)d
Park (2011)
(Ref. 64)
Simulated treatment time • Free breathing: Average treatment time was 530.4±9.0 s
• Quasibreath-hold with 3 s exhale (QBH3) guidance: Average treatment time was 466.8±26.5 s, significantly lower than free breathing (p < 0.001)d
• QBH5 guidance: Average treatment time was 452.3±29.9 s, significantly lower than free breathing (p < 0.001)d
• QBH7 guidance: Average treatment time was 430.8±8.3 s, significantly lower than free breathing (p < 0.001)d
Mean absolute error (MAE) between the
guiding wave and measured breathing
signal
• Free breathing: Average MAE was 0.9±0.7 s
• QBH3 guidance: Average MAE was 0.8±0.6 s, lower than free breathing (p = 0.497)e
• QBH5 guidance: Average MAE was 0.7±0.6 s, significantly lower than free breathing (p = 0.013)d
• QBH7 guidance: Average MAE was 0.6±0.7 s, significantly lower than free breathing (p = 0.021)d
Mean absolute deviation (MAD) of the
measured breathing signal
• Free breathing: Average MAD was 0.7±0.7 s
• QBH3 guidance: Average MAD was 0.5±0.5 s, motion variations lower than free breathing (p = 0.144)e
• QBH5 guidance: Average MAD was 0.5±0.4 s, motion variations significantly lower than free breathing (p = 0.006)d
• QBH7 guidance: Average MAD was 0.5±0.6 s, motion variations significantly lower than free breathing (p = 0.029)d
Kim, Pollock,
and Steel
(2012–2014)
(Refs. 65–67)
Kim: Root mean square error (RMSE) of
breathing motion displacement
• Abdominal breathing motion:
◦ Free breathing: Average RMSE in displacement was 1.3 mm
◦ Breathing guidance: Average RMSE in displacement was 0.7 mm, 46% more regular than free breathing (p < 0.0001)d
• Thoracic diaphragm breathing motion:
◦ Free breathing: Average RMSE in displacement was 2.6 mm
◦ Breathing guidance: Average RMSE in displacement was 1.6 mm, 38% more regular than free breathing (p < 0.0001)d
Kim: RMSE of breathing period • Abdominal breathing motion:
◦ Free breathing: Average RMSE in period was 1.6 s
◦ Breathing guidance: Average RMSE in period was 0.3 s, 81% more regular than free breathing (p < 0.0001)d
• Thoracic diaphragm breathing motion:
◦ Free breathing: Average RMSE in period was 1.7 s
◦ Breathing guidance: Average RMSE in period was 0.3 s, 82% more regular than free breathing (p < 0.0001)d
Kim: Spectral power dispersion metric
(SPDM) of thoracic diaphragm breathing
motion
• Free breathing: Average SPDM was 2.1
• Breathing guidance: SPDM was 0.7, 67% more regular than free breathing (p = 0.005)d
Kim: Baseline drift of breathing motion • Abdominal breathing motion:
◦ Free breathing: Average baseline drift was 0.21 mm/min
◦ Breathing guidance: Average baseline drift was 0.05 mm/min, 75% more regular than free breathing (p < 0.0001)d
• Thoracic diaphragm breathing motion:
◦ Free breathing: Average baseline drift was 1.6 mm/min
◦ Breathing guidance: Average baseline drift was 0.9 mm/min, 44% more regular than free breathing (p = 0.012)d
M
edicalPhysics,Vol.42,N
o.9,Septem
ber2015
54
5504
Pollock,Keall,and
Keall:System
atic
review
ofbreathing
guidance
studies
5504
T V. (Continued).
Study author
(Year) Metric(s) used Result(s)
Kim: Breathing regularity difference
from breathing session 1 to breathing
session 2
• Abdominal breathing motion:
◦ RMSEAV/RMSEFB in displacement:
 Breathing session 1: 0.700
 Breathing session 2: 0.509, a larger discrepancy between free breathing and breathing guidance regularity (p = 0.053)e
◦ RMSEAV/RMSEFB in period:
 Breathing session 1: 0.386
 Breathing session 2: 0.237, a larger discrepancy between free breathing and breathing guidance regularity (p = 0.093)e
◦ Baseline driftAV/baseline driftFB:
 Breathing session 1: 0.904
 Breathing session 2: 1.684, a larger discrepancy between free breathing and breathing guidance regularity (p = 0.230)e
• Thoracic diaphragm breathing motion:
◦ RMSEAV/RMSEFB in displacement:
 Breathing session 1: 0.875
 Breathing session 2: 0.639, a larger discrepancy between free breathing and breathing guidance regularity (p = 0.170)e
◦ RMSEAV/RMSEFB in period:
 Breathing session 1: 0.426
 Breathing session 2: 0.269, a larger discrepancy between free breathing and breathing guidance regularity (p = 0.212)e
◦ Baseline driftAV/baseline driftFB:
 Breathing session 1: 1.426
 Breathing session 2: 0.926, a larger discrepancy between free breathing and breathing guidance regularity (p = 0.212)e
Pollock: RMSE between breathing signal
and predicted breathing position
• Abdominal breathing motion:
◦ Free breathing: Average RMSE was 1.4±1.0 mm
◦ Breathing guidance: Average RMSE was 1.0±0.8 mm, 26% more accurate than free breathing (p < 0.001)d
• Thoracic diaphragm breathing motion:
◦ Free breathing: Average RMSE was 2.8±2.1 mm
◦ Breathing guidance: Average RMSE was 2.0±1.4 mm, 29% more accurate than free breathing (p < 0.001)d
Steel: Correlation between abdominal
and thoracic diaphragm breathing motion
• Free breathing: Average correlation was 0.96±0.02
• Breathing guidance: Average correlation was 0.96±0.03, no significant difference to free breathing (p = 0.88)e
Steel: Correlation between RMSE in
displacement and abdomen–diaphragm
correlation
• Free breathing: Minimal correlation between RMSE values and motion correlation values (R = 0.079)
• Breathing guidance: Minimal correlation between RMSE values and motion correlation values (R =−0.33)
Steel: Correlation between SPDM and
abdomen–diaphragm correlation
• Free breathing: Weak correlation between SPDM values and motion correlation values (R =−0.0633)
• Breathing guidance: Weak correlation between SPDM values and motion correlation values (R =−0.0471)
Damkjær (2013)
(Ref. 68)
Mean inspiration level • Unguided: Mean inspiration level was 16.6±1.66 mm
• Guided breath-holds: Mean inspiration level was 20.5±0.38 mm, a significant increase compared to unguided (p < 0.002)d
Mean dose to CTV (Dmean,CTV) • Unguided: Mean Dmean,CTV was 50.1 Gy
• Guided breath-holds: Mean Dmean,CTV was 50.0 Gy, a nonsignificant difference compared to unguided (p > 0.05)e
Relative volume receiving more than
95% of the prescribed dose (V95%,CTV)
• Unguided: Mean V95%,CTV was 93.9%
• Guided breath-holds: Mean V95%,CTV was 92.6%, a nonsignificant difference compared to unguided (p > 0.05)e
If internal mammary nodes (IMN) were
included in the target volume, relative
volume receiving 90% of the prescribed
dose (V90%,IMN)
• IMN included in target area for 19 of 24 patients
• Unguided: Mean V90%,IMN was 70.6%
• Guided breath-holds: Mean V90%,IMN was 76.1%, a nonsignificant difference compared to unguided (p > 0.05)e
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Volume receiving more than 107% of the
prescribed dose (V107%,body)
• Unguided: Mean V107%,body was 7.3 cm3
• Guided breath-holds: Mean V107%,body was 7.3 cm3, a nonsignificant difference compared unguided (p > 0.05)e
Absolute volume of the left lung
(Vleftlung)
• Unguided: Mean Vleftlung was 1982 cm3
• Guided breath-holds: Mean Vleftlung was 2286 cm3, 11% larger than unguided (p < 0.0004)d
Relative volume of the lung receiving 20
Gy or more (V20Gy, leftlung)
• Unguided: Mean V20Gy, leftlung was 29.6%
• Guided breath-holds: Mean V20Gy, leftlung was 27.1%, a 9% decrease in lung dose compared to unguided (p < 0.002)d
Maximum dose to the left anterior
descending coronary artery (LAD)
(Dmax,LAD)
• Unguided: Mean Dmax,LAD was 16.1 Gy
• Guided breath-holds: Mean Dmax,LAD was 16.1 Gy, a nonsignificant difference compared to unguided (p > 0.05)e
Mean dose to the heart (Dmean,heart) • Unguided: Mean Dmean,heart was 2.41 Gy
• Guided breath-holds: Mean Dmean,heart was 2.49 Gy, a nonsignificant difference compared to unguided (p > 0.05)e
Volume of heart receiving more than 25
Gy (V25Gy,heart)
• Unguided: Mean V25Gy,heart was 0.8%
• Guided breath-holds: Mean V25Gy,heart was 0.7%, a nonsignificant difference compared to unguided (p > 0.05)e
Lu (2014)
(Ref. 69)
Volume ratio between two methods of
ITVs generation: ITV10 and ITVMIP
• Free breathing: ITV10/ITVMIP was 1.19
• Breathing guidance with RPM: ITV10/ITVMIP was 1.21
• Breathing guidance with ABC: ITV10/ITVMIP was 1.19
• No significant impact of breathing guidance (p > 0.05)e
Centroid difference between ITV10 and
ITVMIP
• Free breathing: Centroid difference between ITV10 and ITVMIP was 1.9 mm
• Breathing guidance with RPM: Centroid difference between ITV10 and ITVMIP was 1.7 mm
• Breathing guidance with ABC: Centroid difference between ITV10 and ITVMIP was 2.3 mm
• No significant impact of breathing guidance (p > 0.05)e
Overlap between ITV10 and ITVMIP
quantified by Dice coefficient
• Free breathing: Dice coefficient was 0.87
• Breathing guidance with RPM: Dice coefficient was 0.88
• Breathing guidance with ABC: Dice coefficient was 0.86
• No significant impact of breathing guidance (p > 0.05)e
RMS difference between surfaces of
ITV10 and ITVMIP
• Free breathing: RMS distance was 2.7 mm
• Breathing guidance with RPM: RMS distance was 2.6 mm
• Breathing guidance with ABC: RMS distance was 3.0 mm
• No significant impact of breathing guidance (p > 0.05)e
Correlation coefficient between the best
cosine fit and the original breathing
signal
• Free breathing: Correlation coefficient was 0.66
• Breathing guidance with RPM: Correlation coefficient was 0.72, a nonsignificant difference compared to free breathinge
• Breathing guidance with ABC: Correlation coefficient was 0.77, significantly more regular than free breathing (p < 0.05)d
Power dominant frequency (PDF) of
breathing signal
• Free breathing: The PDF was 0.04
• Breathing guidance with RPM: The PDF was 0.08, significantly more regular than free breathing (p < 0.05)d
• Breathing guidance with ABC: The PDF was 0.08, significantly more regular than free breathing (p < 0.05)d
aNo p-value, no statement of significance.
bNo p-value, but significance stated.
cRetrospective analysis.
dP < 0.05 (significant).
eP ≥ 0.05 (nonsignificant).
M
edicalPhysics,Vol.42,N
o.9,Septem
ber2015
56
5506 Pollock, Keall, and Keall: Systematic review of breathing guidance studies 5506
F. 4. Timeline of the number of breathing guidance studies (top) and the study publications (bottom) from 1995 to 2014, detailed in Tables II–V.
patient to match their own breathing to,54 and combinations
thereof.58,64,65
In addition to the nature of guiding prompts utilized, study
design has also factored into influencing patient acceptance
and compliance with the breathing guidance intervention.
Studies in which patients used breathing guidance multi-
ple times demonstrated improved breathing consistency with
time.50,58,65 Hence, to achieve optimal compliance with breath-
ing guidance, patient training and repeated sessions are of
importance to bolster their familiarity with the system; such
elements have been absent in previous patient studies which
yielded nonsignificant results.69,88,89
While this systematic review yielded 27 articles, it should
be noted that some articles that were in contention required
considerable discussion between the authors to conclude on
their exclusion from the final selection. The main factor influ-
encing the decision to exclude these articles was the control
group criterion; while several studies investigated a breathing
guidance intervention strategy, the control group was not of
the same breathing type (see inclusion criterion 5).81,84–86,89–92
While the search undertaken and review of articles by the
authors was performed as objectively as possible, it should
be noted that two of the authors of this systematic review,
Sean Pollock and Paul Keall, are either first- or co-authors of
3 and 9 of the 27 included articles, respectively, investigating
the breathing guidance intervention: audiovisual biofeedback.
Their familiarity with breathing guidance strategies led to the
identification that a gap in the literature existed in that a review
of such research had yet to be performed; however, uninten-
tional bias may have permeated this review toward audiovisual
biofeedback. To minimize this bias, co-author Robyn Keall was
invited to review and screen the identified 319 (see Fig. 3);
where there was disagreement between reviewers, a discussion
was undertaken among all authors until consensus was reached.
While 21 of the 27 included articles reported at least one
statistically significant positive finding from the use of breath-
ing guidance interventions, bias should also be noted that pap-
ers reporting on positive results are more likely to be published
than papers with negative results.93,94 This notes the systemic
bias in scientific reporting and the possibility that negative
results on breathing guidance may not have been published.
The largely positive results found in this systematic review
indicate that further clinical studies are warranted and should
be focused on (1) utilizing training and multiple sessions to
maximize patient compliance with the breathing guidance sys-
tem, and (2) further determining the clinical impact of breath-
ing guidance interventions by investigating outcomes pertain-
ing to treatment margins, toxicity, and patient outcomes. Such
factors are being explored in ongoing and upcoming studies,
with some preliminary results presented thus far.95–97
T VI. Number of study outcomes investigated and their statistical significance (references in brackets).
Positive results Nonsignificant resultsa Negative results
Breathing regularity and tumor motion 27/60 (Refs. 48, 52–54, 58, 61, 64,
65, and 69)
28/60 (Refs. 48, 49, 53, 56, 57, 61,
64, 65, and 69)
5/60 (Refs. 56, 57, and 62)
Breath-hold stability and reproducibility 3/6 (Refs. 44, 63, and 68) 3/6 (Refs. 43 and 44)
Gating efficiency 17/42 (Refs. 46, 50, and 55) 25/42 (Refs. 47, 49, and 50)
Image quality 3/7 (Refs. 43 and 59) 3/7 (Refs. 43, 46, and 59) 1/7 (Ref. 45)
Reduced margins 8/8 (Ref. 69)
Reduced dose to healthy tissue 2/6 (Ref. 68) 4/6 (Ref. 68)
Improved target coverage 4/4 (Refs. 52 and 68)
Reduced treatment/imaging time 6/8 (Refs. 43, 46, 60, and 64) 2/8 (Refs. 45 and 60)
Otherb 5/11 (Refs. 51, 62, and 66) 5/11 (Refs. 47 and 67) 1/11 (Ref. 62)
Total 63 82 7
aOr significance of results not stated.
bMotion correlation, motion prediction, and correlation with disease type.
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5. CONCLUSION
A systematic review of breathing guidance intervention
strategies in radiotherapy and radiology has been performed
and 27 studies were identified. In 21 studies, statistically
significant improvements from the use of breathing guid-
ance were observed. No studies observed worse breathing
consistency with guidance; however, audio-only guidance,
while facilitating regular breathing, also increased respira-
tory amplitude which is undesirable in most circumstances.
Studies that have repeated breathing guidance across mul-
tiple sessions have observed an improvement in participant
compliance from one session to the next, emphasizing the
importance of patient practice and training. Such insights are
valuable in designing breathing guidance studies in terms
of both guiding prompts used and patient familiarity with
the intervention to maximize the effectiveness of the inter-
vention. The largely positive results found here indicate that
further clinical studies are warranted to further assess and
quantify the clinical impact of breathing guidance, along with
the health technology assessment to determine the advan-
tages and disadvantages of the use of breathing guidance
strategies.
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Abstract
Two interventions to overcome the deleterious impact irregular breathing has 
on thoracic-abdominal 4D computed tomography (4DCT) are (1) facilitating 
regular breathing using audiovisual biofeedback (AVB), and (2) prospective 
respiratory gating of the 4DCT scan based on the real-time respiratory motion. 
The purpose of this study was to compare the impact of AVB and gating on 
4DCT imaging using the 4D eXtended cardiac torso (XCAT) phantom driven 
by patient breathing patterns.
We obtained simultaneous measurements of chest and abdominal walls, 
thoracic diaphragm, and tumor motion from 6 lung cancer patients under two 
breathing conditions: (1) AVB, and (2) free breathing. The XCAT phantom 
was used to simulate 4DCT acquisitions in cine and respiratory gated 
modes. 4DCT image quality was quantified by artefact detection (NCCdiff), 
mean square error (MSE), and Dice similarity coefficient of lung and tumor 
volumes (DSClung, DSCtumor). 4DCT acquisition times and imaging dose were 
recorded.
In cine mode, AVB improved NCCdiff, MSE, DSClung, and DSCtumor 
by 20% ( p  =  0.008), 23% ( p  <  0.001), 0.5% ( p  <  0.001), and 4.0% 
( p  <  0.003), respectively. In respiratory gated mode, AVB improved NCCdiff, 
MSE, and DSClung by 29% ( p  <  0.001), 34% ( p  <  0.001), 0.4% ( p  <  0.001), 
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respectively. AVB increased the cine acquisitions by 15 s and reduced 
respiratory gated acquisitions by 31 s. AVB increased imaging dose in cine 
mode by 10%.
This was the first study to quantify the impact of breathing guidance and 
respiratory gating on 4DCT imaging. With the exception of DSCtumor in 
respiratory gated mode, AVB significantly improved 4DCT image analysis 
metrics in both cine and respiratory gated modes over free breathing. The 
results demonstrate that AVB and respiratory-gating can be beneficial 
interventions to improve 4DCT for cancer radiation therapy, with the biggest 
gains achieved when these interventions are used simultaneously.
Keywords: 4DCT, thoracic imaging, breathing guidance, respiratory gating
(Some figures may appear in colour only in the online journal)
1. Introduction
4D computed tomography (4DCT) is an imaging modality frequently utilized to incorporate 
breathing motion in the treatment planning stage of radiotherapy (Ford et al 2003, Vedam et al 
2003, Keall 2004, Pan et al 2004). However, image artefacts have been reported in up to 90% 
of 4DCT images (Yamamoto et al 2008), compromising the accuracy of tumor delineation 
(Persson et al 2010). These artifacts have been linked to irregular breathing (Mutaf et al 2007, 
Clements et al 2013, Zhang et al 2013). An additional problem is inconsistent inter-fraction 
breathing motion, where the tumor motion observed during 4DCT treatment planning is not 
consistent with the motion observed during treatment delivery (Ge et al 2012), resulting in an 
increase in the irradiated healthy tissue (Schmidt et al 2013). The radiation treatment volume 
itself is often expanded to account for these additional errors (Roman et al 2012), increasing 
the radiation dose to the healthy surrounding tissue, thus further increasing the risk of post-
treatment radiation toxicities (Rancati et al 2003, Matsuo et al 2012, Wang et al 2013, Scotti 
et al 2014).
To reduce the errors associated with irregular breathing motion, the patient breathing guid-
ance system, audiovisual biofeedback (AVB) has been utilized to facilitate regular and con-
sistent respiratory-motion (George et al 2006, Venkat et al 2008, Masselli et al 2009, Kim 
et al 2012, Pollock et al 2015a, 2015b) to improve image quality (Yang et al 2012, Cossmann 
2012), imaging and treatment time (Jhooti et al 2011, Park et al 2011, Cossmann 2012), and 
treatment accuracy (Chen et al 2007). However, the assessment of patient breathing guidance 
on 4DCT image quality has yet to be quantified. A study by Cossmann (2012) noted that the 
more consistent breathing motion as provided by breathing guidance improved the quality of 
4DCT images (Cossmann 2012), but this improvement was not quantified. Another study by 
Lu et al (2014) investigated the impact of breathing guidance on the match between ITVMIP 
(internal target volume generated by contouring in the maximum intensity projection scan) 
and ITV10 (ITV generated by combining the gross tumor volumes contoured over the 10 
phases of a 4DCT) (Lu et al 2014); however, no analysis of image quality was performed.
A second method to reduce irregular breathing motion artefacts is prospective gating, which 
limits the 4DCT ‘beam-on’ time to regular breathing, defined in terms of real-time displace-
ment, velocity and/or phase criteria. A number of experimental and simulation studies have 
suggested a potential improvement to 4DCT image quality using real-time prospective gating, 
at some cost to acquisition time (Keall et al 2007, Langner and Keall 2010, Bernatowicz et al 
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2015). Bernatowicz et al (2015) simulated prospective gated 4DCT acquisition for 8 patients, 
using the realistic 4D eXtended cardiac-torso (XCAT) deformable digital human phantom 
(Segars et al 2010, Bond et al 2012) synchronized to measured tumor motion patterns (Mishra 
et al 2012). They found prospective respiratory gated 4DCT reduced the mean square error 
(MSE) difference between reconstructed and ground truth thoracic 4DCT images as much as 
46% on average, but with an average acquisition time 84% longer than cine mode. Computer-
controlled prospective gated 4DCT has yet to be implemented clinically, in part because the 
anticipated increase in acquisition time may be considered a disadvantage in busy hospital 
environments. Meanwhile the XCAT has been utilized in a number of simulation studies to 
quantify the impact of breathing motion on image quality (Cai et al 2011, Rong et al 2012, 
Bernatowicz et al 2015) and on treatment delivery (Ecclestone et al 2013, Koybasi et al 2014).
The goal of this study is to perform the first comparisons of AVB and prospective gating 
technologies in view of their impacts on 4DCT image analysis metrics and acquisition time. 
This is also the first study to investigate the impact of breathing guidance on 4DCT image 
analysis metrics directly. As in the Bernatowicz study, this work employs the 4D XCAT but 
with an added emphasis on realistic patient motion. This is achieved by incorporating not only 
tumor motion, but also simultaneous measurements of chest wall, abdominal wall, and tho-
racic diaphragm motion. This data is derived from a study by Lee et al (2016) who performed 
magnetic resonance imaging (MRI) on lung cancer patients whilst they breathed both with and 
without the aid of AVB (Lee et al 2016). The Lee et al (2016) study extracted lung tumor and 
thoracic diaphragm motion information from the 2D MR images as well as monitoring exter-
nal breathing motion from the real-time position management (RPM) system and the Siemens 
physiological measurement unit (PMU) chest belt.
By programming the 4D XCAT with separate internal and external breathing motion 
patterns, we aim to perform realistic comparisons of 4DCT imaging across two breathing 
conditions (AVB and free breathing) and two acquisition modes (cine mode and prospective 
respiratory gating). We hypothesize that the more regular breathing motion as provided by 
AVB will result in improved 4DCT image analysis metrics over free breathing, and that the 
largest improvement in image analysis metrics will come from the use of both AVB and res-
piratory gating interventions. Other metrics, such as acquisition time, could be more depend-
ent on couch-stay time than motion regularity, particularly in cine mode.
2. Method and materials
To simulate 4DCT imaging as realistically as possible, the XCAT digital phantom was pro-
grammed with both the internal and external motion information in addition to lung tumor size 
and position information obtained in the Lee et al (2016) MRI study (Lee et al 2016).
2.1. Breathing motion data
Breathing guidance utilized by the 10 lung cancer patients in the Lee et al (2016) study was 
the AVB system, as developed by Venkat et al (2008). Lee et al (2016) analyzed the lung 
tumor motion regularity of these 10 lung cancer patients and found that AVB significantly 
improved the regularity of lung tumor motion period and displacement by 73% and 34%, 
respectively (Lee et al 2016).
10 non-small cell lung cancer (NSCLC) patients underwent two MR imaging sessions, 
the second session occurring 3–6 weeks after the first. Each session involved imaging the 
patient under two breathing conditions: (1) with AVB, and (2) free breathing. Sagittal MR 
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images yielded 2D lung tumor motion (superior–inferior (SI) and anterior–posterior (AP)). 
Tumor motion was extracted from the centroid of the segmented tumor, tumor segmentation 
was performed by a region-growing algorithm (Lee et al 2016). External breathing motion of 
chest motion and abdominal motion was also monitored during MR imaging. Chest motion 
was monitored by the Siemens PMU belt, and abdominal motion was monitored by the Varian 
RPM system. Figure 1 illustrates the motion utilized to program the motion of the XCAT 
phantom.
XCAT programmable motion inputs include chest AP motion, thoracic diaphragm SI 
motion, tumor AP, SI and left–right (LR) motion. Other XCAT inputs include tumor posi-
tion within the lung and tumor volume. External motion utilized was the chest displacement 
information from PMU belt. PMU belt motion was used to program the XCAT chest motion, 
while diaphragm SI motion, and tumor SI and AP motion was used to program the XCAT 
internal motion. XCAT tumor LR motion was disabled as it could not be obtained from the 
sagittal MR images. RPM phase information was used for 4DCT binning. It should be noted 
that chest motion from the PMU belt was originally normalized and without units. To obtain 
absolute chest displacement, the PMU motion data was rescaled to have one quarter of the AP 
motion range of the corresponding RPM signal. This is in accordance with findings presented 
by Kaneko and Horie (2012).
The inclusion criteria for this study was that free breathing tumor motion be greater than 
0.5 cm as stated in the management of respiratory motion in radiation oncology report of 
AAPM Task Group 76 (Keall 2006). This inclusion criteria made 6 patients across 10 MRI 
sessions eligible for simulation in this study.
Figure 1. (a) External and (b) internal respiratory motion utilized to program the 
motion of the XCAT phantom. Sagittal MR image shown with segmented lung tumor.
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Table 1 details the patient characteristics included in this study, the mean age of patients 
was 66 years (range: 54–79) with 3 male and 3 female.
2.2. Simulation of 4DCT acquisition using XCAT
Our method for simulating 4DCT acquisitions proceeds similar to the retrospective method 
used by Bernatowicz et al (2015). Briefly, for each simulation the first 60 s of RPM displace-
ment/phase data are analyzed to determine the average breathing period TAvg, as well as the 
mean (DMean) and std. dev. (DSD) of displacement in each of 10 phase bins. The subsequent 
RPM data is then analyzed to derive a schedule of couch shifts and kilovoltage (kV) image 
acquisitions, used to extract axial slices from the 4D XCAT programmed with the measured 
patient motion. Figure 2 details the workflow of this study.
In these simulations, the cine mode uses a constant kV imaging frequency corresponding 
to a gantry rotation time of 0.3 s, and a constant couch-shift frequency corresponding to a cine 
duration of TAvg +1 s for each of 30 couch positions. The CT slice acquisition time was deter-
mined by multiplying a typical 0.5 s gantry rotation time by a factor of approximately 220/360 
(accounting for the angular span required for a single complete reconstruction) resulting in a 
0.3 s acquisition time for each CT slice. Cine mode represents the conventional reconstruc-
tion 4DCT method for many scanners (Yamamoto et al 2008, Langner and Keall 2010). The 
respiratory gated mode is similar to the cine mode, except that kV acquisition is triggered 
only when the real-time respiratory motion falls within a phase-specific displacement gat-
ing window DMean  ±  DSD. The respiratory gated mode disallows duplicate kV acquisitions 
at the same couch position/phase bin and allows early couch shifts once all 10 phase bins are 
acquired. The gated mode allows a maximum couch stay of 2500 s at any one couch position, 
but this limit was never exceeded in any of the simulations. For each kV imaging timepoint, 
we generate an instantaneous 3D XCAT volume, and extract 4 axial slices (spaced 2.5 mm 
apart) corresponding to the given couch position. The simulation method does not include a 
forward/backprojection step (i.e. the simulated CT slices are not reconstructed from a simu-
lated sinogram, rather they are extracted directly from the XCAT volume). This is appropriate 
as our focus is on motion-induced anatomic discontinuities, rather than image blur.
Table 1. Patient tumor motion information, peak-to-peak amplitude is given in brackets.
Patient
Session 
number
Tumor 
volume  
(cm3)
Tumor motion range from 
MRI (max–min)
Tumor motion range from 
MRI (max–min)
Free breathing  
(peak-to-peak amplitude) 
(cm)
AVB  
(peak-to-peak amplitude) 
(cm)
1 1 21 0.8 (0.7) 0.7 (0.5)
2 15 0.7 (0.5) 0.9 (0.4)
2 1 19 0.6 (0.2) 0.7 (0.3)
2 7 0.8 (0.3) 0.6 (0.4)
3 1 29 0.6 (0.2) 0.5 (0.2)
4 1 19 1.9 (1.0) 2.1 (1.6)
2 20 2.2 (1.4) 2.9 (2.0)
5 1 73 0.7 (0.2) 0.6 (0.3)
2 58 0.9 (0.2) 0.3 (0.2)
6 2 46 0.5 (0.2) 0.4 (0.2)
Average (range) 55 (7–73) 1.0 (0.5) (0.5–2.2 (0.2–1.4)) 1.0 (0.6) (0.3–2.9 (0.2–2.0))
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For the case of perfect 4D sampling (i.e. no duplicate or missing phase/couch combina-
tions), each simulation will nominally produce 1200 axial slices that are binned into 10 res-
piratory phase bins. We also generate a set of ‘Ground truth’ 4D phase images, which give 
the average of all instantaneous XCAT volumes generated for each phase bin. These motion-
blurred images represent the ‘average’ anatomic geometry during beam-on time. We note that 
while our simulation of the respiratory gated acquisition was performed retrospectively, the 
kV triggering is nevertheless based on measured, real-time RPM phase/displacement data as 
would be the case for a clinical implementation of this gating method.
2.3. Image analysis metrics
Image quality was quantified by (1) an automated method of assessing the presence of image 
artefacts (Cui et  al 2012), (2) MSE intensity difference between the simulated 4DCT and 
ground images (Bernatowicz et al 2015), and (3) the dice similarity coefficient (DSC) between 
simulated 4DCT and ground truth images (Bernatowicz et al 2015).
Respiratory related 4DCT image artefacts were assessed utilizing a method developed by 
Cui et al (2012). Specifically, for each 4DCT phase image we calculate the normalized cross 
correlation (NCC) of pixel values between each pair of adjacent axial slices:
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In equation (1), i specifies the phase bin, z specifies the axial slice and x, y refer to the pixel 
location in the transverse plane. An NCC value closer to 1 indicates better agreement in pixel 
values between adjacent slices, conversely a value closer to 0 indicates poor agreement. Unlike 
the DSC metric, the NCC values are calculated in the absence of any tumor intensification. 
We then obtain an artefact rating, NCCdifff which accounts for the sum of differences in NCC 
values at couch transition points across each reconstructed 4DCT phase image:
Figure 2. Workflow of study from driving XCAT motion to simulating and analyzing 
4DCTs. Purple boxes indicate workflow and metrics utilizing the ground truth images. 
Blue boxes indicate workflow and metrics that did not utilize the ground truth.
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Where nbound represents the slice index for the transition between the nth and n 1 th( )+  couch 
position. Here, a value of NCCdiff closer to 0 indicates smaller differences in the NCC values 
between adjacent axial slice pairs across the image, and hence fewer anatomic discontinuities.
We note that NCCdiff should not be interpreted as an absolute artefact ‘count’ as it may 
also capture information about non-artefactual anatomic discontinuities. For example, a slice 
pair straddling the diaphragm edge will likely exhibit a poorer NCC value than for slice pairs 
where both slices are just above or just below the edge. Since all 4DCT reconstructions have 
the same geometry at exhale (aside from the tumor), and thus similar contributions to NCCdiff 
from non-artefact discontinuities, we interpret NCCdiff as an artefact ‘rating’ or ‘quality factor’.
DSC between simulated and ground truth images was assessed in terms of lung volume 
(DSClung) and lung tumor volume (DSCtumor). To more easily evaluate the tumor volume, the 
tumor volume was intensified by a factor of 10, as per the method described by Bernatowicz 
et al (2015). The intensity values of tumor voxels was multiplied by a factor of 10 to aid in 
segmentation; this modification of the tumor intensities was performed only for the DSCtumor 
analysis so does not affect the NCC or MSE values.
These image analysis metrics were compared across the two breathing conditions (AVB 
and free breathing) for the two 4DCT acquisition modes (cine and respiratory gated) using the 
Student’s t-test. 4DCT imaging dose and acquisition times were also recorded across the two 
breathing conditions and two reconstruction methods. It should be noted that the image dose 
estimate is based on the number of acquired slices; results presented here will be in number of 
slices as a surrogate for imaging dose.
2.4. Correlation between image analysis metrics and respiratory motion
The correlation between the image analysis metrics and lung tumor motion regularity in addi-
tion to acquisition time and lung tumor motion regularity was assessed using the Pearson’s 
correlation coefficient (R), and a p-value for testing the hypothesis of no correlation. Pearson’s 
correlation coefficient has been utilized as the correlation test in previous internal–external 
respiratory motion studies (Ionascu et al 2007, Steel et al 2014). Respiratory motion regular-
ity was quantified by the root mean square error (RMSE) in displacement (Venkat et al 2008) 
of the respiratory signal of chest motion during beam-on time only. A lower value of RMSE 
is indicative of more regular motion. We investigated the potential dependence of imaging 
time on displacement RMSE for both cine and respiratory gated acquisition modes. For the 
respiratory-gated mode it seems intuitive that highly irregular breathing could affect the scan 
time. For cine mode the connection between displacement RMSE and scan time is more sub-
tle; since in our study the cine mode uses a ‘patient specific’ cine duration set at one breath-
ing period (TAvg)  +  1 s, it follows that irregularities in the breathing period (or alternately, 
displacement) could affect the cine mode scan times as well.
3. Results
3.1. Reconstructed 4DCT Images of XCAT Phantom
Figure 3 illustrates the original MRI and 4DCTs for Patient 4, whose resultant NCCdiff value 
in cine mode was the median.
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The ground truth images in figure 3 also demonstrate some blurring, particularly around 
the thoracic diaphragm. This blurring arises because the ground truth was constructed from a 
range of anatomic positions during beam-on time.
3.2. 4DCT Image Analysis Metrics
NCCdiff, MSE, DSClung, and DSCtumor values were generated for each 4DCT respiratory bin, 
as such, 10 metric values were generate for each simulated 4DCT. The results for these met-
rics are shown in figure 4; average values and their statistical significance are shown in table 2.
Merging the data from the AVB and free breathing conditions, cine mode yielded mean 
NCCdiff, MSE, DSClung, and DSCtumor values of 0.099, 9.4  ×  10−7, 0.980, and 0.889 respec-
tively. Respiratory gating improved the NCCdiff, MSE, DSClung, and DSCtumor values by 36% 
( p  <  0.001), 42% ( p  <  0.001), 0.7% ( p  <  0.001), and 2.3% ( p  =  0.01), over cine mode 
respectively. With the exception of DSCtumor, the largest improvements were obtained when 
utilizing both AVB and respiratory gating together, which improved NCCdiff, MSE, DSClung, 
and DSCtumor values by 52% ( p  <  0.001), 59% ( p  <  0.001), 1.2% ( p  <  0.001), and 3.5% 
( p  =  0.01), respectively, compared to cine mode 4DCT under free breathing. For the DSC 
values, this translates to an additional 38 cm3 of correctly imaged lung volume and an addi-
tional 0.9 cm3 of correctly imaged tumor volume. While we cannot guarantee that the volumes 
encompassed by these respective contours are imaged correctly, from a treatment planning 
perspective the impact of modified contours on the dose-volume calculations may still be sig-
nificant. A surprising result here is that the use of AVB and respiratory gating yielded inferior 
(though non-significant) DSCtumor values compared to AVB with cine mode in addition to free 
breathing with respiratory gating.
3.3. Image dose and acquisition time
Figure 5 shows the mean  ±  standard deviation 4DCT acquisition times and imaging dose 
across cine mode and respiratory gated mode for AVB and free breathing patients. Number of 
slices acquired is given as a surrogate for imaging dose.
Figure 3. Left to right: Original MR image (tumor outlined in blue), simulated inhale 
phase images for cine ground truth 4DCT, cine mode 4DCT and respiratory gated 
(Resp. Gated) ground truth 4DCT, and Resp. Gated 4DCT in the sagittal (top) and 
coronal (bottom) planes for Patient 4. *Coronal MR images acquired at different times 
to sagittal MR images, only data from sagittal MR images was used to program XCAT 
motion. Coronal MR image is shown here to demonstrate anatomic comparison to 
reconstructed 4DCT coronal images.
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Merging the data from the AVB and free breathing conditions, cine mode yielded a 
(mean  ±  STD) acquisition time of 227  ±  23 s, 31% faster than respiratory gated mode which 
had an acquisition time of 328  ±  89 s. Interestingly, the impact of AVB on acquisition times 
was opposite between the two acquisition modes. In cine mode, AVB increased the average 
imaging time by 15 s compared to free breathing ( p  =  0.02); whereas in respiratory gated 
mode, AVB reduced the average imaging time by 31 s compared to free breathing ( p  =  0.41). 
In cine mode, AVB increased the estimated average imaging dose by 10% compared to free 
breathing ( p  =  0.05); whereas the respiratory gated mode always acquired 1200 slices by con-
struction as this represents the ideal 4D sampling for this simulation (10 phase bins with 120 
slices each). It should be noted that the number of slices in respiratory gated mode was 1200 
by construction, as 1200 slices represents the ideal dose for this simulation.
3.4. Correlation between image analysis metrics and respiratory motion
Table 3 compares values of the displacement RMSE during beam-on time for different breath-
ing conditions and acquisition modes.
Figure 4. Image analysis metrics, from left to right: NCCdiff, MSE, DSClung, and 
DSCtumor for both cine and respiratory gated (Resp. Gated) reconstruction modes. AVB 
shown as blue boxes, solid lines. Free breathing shown as red boxes, dashed lines. The 
data plotted are each of the 10 respiratory phase bins for each patient. The horizontal 
edges of each box represent the 25th, 50th and 75th percentile values. Whiskers 
represent other points extending out to 1.5 times the interquartile range. Any points 
beyond the whiskers (‘+’) are considered outliers.
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For each combination of breathing condition and acquisition mode, the RMSE values are 
different owing to the different acquisition timing.
Figure 6 shows the variation of the image analysis metrics (NCCdiff, MSE, DSClung, and 
DSCtumor) and acquisition time as a function of the RMSE values, separated according to 
breathing condition and acquisition mode. For any given acquisition mode, AVB produced a 
smaller range of RMSE values compared to free breathing. For each panel of figure 6, table 4 
shows the Pearson’s correlation coefficient irrespective of breathing condition.
4. Discussion
This was the first study to quantify the impact of AVB breathing guidance on 4DCT image 
analysis metrics. As shown in tables 2 and 3, with the exception of DSCtumor in respiratory 
gated mode, AVB significantly improved 4DCT image analysis metrics across both acquisition 
Table 2. Average AVB and free breathing image analysis metrics values for cine and 
respiratory gated 4DCT reconstruction methods.
NCCdiff
Free breathing AVB
Improvement due 
to AVB
Cine 0.111 0.089 20% ( p  =  0.008)
Respiratory gated 0.075 0.053 29% ( p  <  0.001)
Improvement due to  
resp. gated
32% ( p  <  0.001) 40% ( p  =  0.001)
MSE
Free breathing AVB Improvement due  
to AVB
Cine 10.6  ×  10−7 8.2  ×  10−7 23% ( p  <  0.001)
Respiratory gated 6.5  ×  10−7 4.3  ×  10−7 34% ( p  <  0.001)
Improvement due to 
resp. gated
39% ( p  <  0.001) 47% ( p  <  0.001)
DSClung
Free breathing AVB Improvement due  
to AVB
Cine 0.978 0.982 0.5% ( p  <  0.001)
Respiratory gated 0.986 0.989 0.4% ( p  <  0.001)
Improvement due to  
resp. gated
0.8% ( p  <  0.001) 0.7% ( p  <  0.001)
DSCtumor
Free breathing AVB Improvement due  
to AVB
Cine 0.871 0.907 4.0% ( p  =  0.003)
Respiratory gated 0.917 0.901 −1.6% ( p  =  0.20)
Improvement due to 
resp. gated
5.2% ( p  <  0.001) −0.6% ( p  =  0.63)
Note. Values presented here represent the average of all respiratory phase bins across all patients.
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modes. The impact to DSC values, while mostly significant, were small (<1%); whereas the 
magnitude of the impact of AVB to NCCdiff and MSE was considerably larger. Compared to 
conventional free breathing 4DCT in cine mode, the addition of both AVB and respiratory 
gated mode improved DSClung, NCCdiff, and MSE by 1.2% ( p  <  0.001), 52% ( p  <  0.001), 
and 59% ( p  <  0.001), respectively. As illustrated by figure 4, respiratory gated mode yielded 
better 4DCT image analysis metrics over cine mode, which is consistent with the findings of 
previous investigations (Langner and Keall 2010, Bernatowicz et al 2015). Bernatowicz et al 
(2015) reported slight, but significant, improvements in lung errors of 0.4% due to respira-
tory gated mode compared to cine mode (Bernatowicz et al 2015); comparable to the 0.7% 
improvement of respiratory gated mode over cine mode demonstrated here.
As shown in table 4, motion regularity (RMSE) during beam-on time significantly corre-
lated with DSClung, NCCdiff, and MSE in cine and respiratory gated acquisition modes, in addi-
tion to significantly correlating with acquisition time in respiratory gated mode. It is important 
to note that other factors beyond RMSE in displacement will impact image analysis metrics 
and acquisition time. For instance, the average period increased from 4.3 s under free breath-
ing to 4.8 s using AVB. Thus the use of AVB lead to increased cine duration time (TAvg  +  1 s) 
explaining why AVB produced longer cine acquisition times and increased imaging dose com-
pared to free breathing in figure 5. It should be noted that will not be the case for clinical 4DCT 
Figure 5. 4DCT acquisition times (left) and imaging dose (right) with number of slices 
as a surrogate for dose, for AVB (blue) and free breathing (red) patients for both cine 
mode and respiratory gated mode.
Table 3. Mean  ±  STD RMSE in displacement during beam-on time for AVB and free 
breathing for the two acquisition modes.
RMSE in displacement (cm)
Free breathing AVB
Improvement 
due to AVB
Cine 0.91  ±  0.99 0.61  ±  0.28 33% ( p  =  0.30)
Respiratory gated 0.52  ±  0.58 0.30  ±  0.14 42% ( p  =  0.23)
Improvement due to 
Resp. Gated
43% ( p  =  0.02) 51% ( p  <  0.001)
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protocols using a fixed cine-duration time (as opposed to the patient specific cine duration of 
TAvg  +  1 s). In respiratory gated mode, AVB reduced acquisition times as a result of improved 
motion regularity, which has been shown to improve gating efficiency in previous studies 
(George et al 2006, Linthout et al 2009, Lee et al 2014). Also, each simulation will nominally 
Figure 6. From top to bottom: NCCdif, MSE, DSClung, DSCtumor, and acquisition time 
verses RMSE in displacement for bean-on time for AVB (blue) and free breathing (red) 
patients for both cine mode (left) and respiratory gated mode (right).
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produce 1200 axial slices that are binned into 10 respiratory phase bins and respiratory gating 
is optimized to produce exactly 1200 axial slices, which is why the mean  ±  standard devia-
tion number of slices for respiratory gating are 1200  ±  0 for both AVB and free breathing, as 
shown in figure 5.
Furthermore, while DSCtumor was the only image analysis metric not to significantly cor-
relate with motion regularity, it was found that DSCtumor did significantly correlate with the 
tumor motion range values (given in table 1) for both cine mode (r  =  −0.79, p  <  0.001) and 
respiratory gated mode (r  =  −0.86, p  <  0.001). Given that the average peak-to-peak ampl-
itude of free breathing was 0.5 cm and 0.6 cm for AVB, this may explain why an improvement 
was not observed for AVB in respiratory gated mode. Further to this, 4DCT gating and binning 
is based on the signal of an external surrogate and not the motion of the tumor itself.
This study builds upon previous investigations which assessed the impact of breathing 
guidance interventions on medical image quality. Yang et al (2012) found that AVB reduced 
motion blurring and improved Dice coefficient of the tumor in PET images of a thoracic 
phantom (Yang et al 2012). Jhooti et al (2011) and Lee et al (2014) observed a reduction in 
MRI scan time from the use of breathing guidance with only the Lee et al (2014) study not-
ing an improvement in image quality. Importantly, table 4 indicates that respiratory motion 
regularity (RMSE in displacement) during beam-on time may be a useful metric for predicting 
quantitative aspects of 4DCT image analysis metrics. It would be interesting to test how well 
RMSE correlates with other clinically relevant measures of 4DCT image quality (e.g. absolute 
artefact counts).
A limitation of this study, as evident from figure 3, is that the anatomy of the XCAT dig-
ital phantom did not exactly match that of the original MR images. Differences in tumor 
shape, organ shapes, and organ volumes between the XCAT and MRI scans may be observed. 
Despite these differences, the XCAT represents a population averaged anatomy, based on vis-
ible human data from the National Library of Medicine (Segars et al 2010, National Library of 
Medicine), so these results should be relevant to a large percentage of the adult (male) popula-
tion receiving 4DCT scans. An additional limitation is that our 4DCT simulations assumed 
x-ray collimation of 4  ×  2.5 mm at the detectors, whereas newer scanners might have 8×, 
16  ×  , or more which would decrease the number of couch transition regions where breathing-
induced image discontinuities might occur. In other words, our simulations may overestimate 
the impact of AVB or respiratory gating for wide field of view 4DCT scanners. This study 
Table 4. Pearson’s correlation coefficient values (r) and their p-values for the 
correlations between respiratory motion regularity (RMSE) and image analysis metrics 
irrespective of breathing condition.
Correlation between RMSE and r value p-value
Cine NCCdiff 0.89 <0.001
MSE 0.91 <0.001
DSClung −0.92 <0.001
DSCtumor −0.23 0.32
Acquisition time −0.29 0.21
Respiratory gated NCCdiff 0.91 <0.001
MSE 0.68 <0.001
DSClung −0.91 <0.001
DSCtumor −0.30 0.19
Acquisition time 0.46 0.04
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attempted to adapt the XCAT simulations to the MRI acquisition as much as possible by uti-
lizing the several elements of the MRI patient data: tumor motion, diaphragm motion, chest 
motion, abdominal motion, tumor volume, and tumor position. Despite this, diseased lung can 
exhibit localised variations in the motion field that are not so easily modelled using XCAT. 
For tumors in the vicinity of emphysematous or fibrotic regions, the measured motion may 
appear different compared to the XCAT motion which assumes smoothly varying motion 
over the lung. Further to this, the MRI data utilized in this study had an acquisition time of 
approximately 158 s, shorter than the time needed to complete a 4DCT simulation. As such, 
the motion traces were repeated until the 4DCT image acquisition was complete; the discon-
tinuity between these repeated motion segments is not ideal.
Additionally, a limitation of our RMSE calculation is that we generated a ‘mean’ cycle 
based on only 10 phase bins, as opposed to a much larger number (e.g. 360) in other studies 
(Venkat et al 2008, Pollock et al 2015c). This seemed appropriate due to the instantaneous 
nature of the simulated beam-on events which leads to a sparse amount of displacement data 
during beam on time, resulting in a larger magnitude of RMSE results compared to previous 
investigations.
The results presented here support our hypothesis that AVB resulted in improved 4DCT 
image analysis metrics over free breathing. The respiratory gated mode resulted in improved 
4DCT image analysis metrics over cine mode, however, acquisition time was faster in cine 
mode compared to the respiratory gated mode. This study indicates that respiratory gated 
mode can benefit from AVB not only in terms of improved image analysis metrics, but also in 
reduced acquisition times compared to free breathing. AVB and respiratory gated mode rep-
resent two emerging techniques to improve the quality of 4DCT images, producing the best 
image analysis metrics when used simultaneously.
5. Conclusion
This was the first study to compare the impacts of AVB breathing guidance, and prospective 
respiratory gated acquisition on 4DCT image analysis metrics compared to free breathing cine 
mode 4DCT. Compared to free breathing, AVB was demonstrated to significantly improve the 
image analysis metrics of both cine and respiratory gated modes of 4DCT acquisition, and 
can reduce the amount of time needed to acquire a respiratory gated 4DCT scan. Meanwhile, 
respiratory-gating consistently yielded better image analysis metrics over cine mode irrespec-
tive of the breathing condition. The results presented here demonstrate both AVB and the 
respiratory gated acquisition mode as potential tools to implement in CT simulation for can-
cer radiation therapy. Statistically significant improvements in image analysis metrics can 
be realized for a small increase in time when AVB and respiratory gated mode are utilized 
simultaneously.
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 CHAPTER 4 
Audiovisual biofeedback breathing guidance over a course of liver 
SBRT: A motion analysis of external and internal surrogates 
4.1. Introduction 
Stereotactic body radiotherapy (SBRT) is a high-precision, high-dose irradiation of a lesion in a small 
number of fractions.1 SBRT has been incorporated into the treatment of liver cancer due to its 
demonstrated effectiveness in clinical studies as well as improving survival rate2, 3 with over 54% of 
liver cancer patients being treated with SBRT in America.4 Liver tumours are considered highly 
mobile due to their proximity to the thoracic diaphragm. When this breathing motion is irregular, it 
exacerbates systematic and random errors,5-7 compromising the quality of radiation therapy;6, 8-11 
which is a particular concern for such hypofractionated treatments as SBRT.  
To counter this exacerbation of systematic and random errors due to irregular breathing 
motion a number of breathing guidance strategies have been investigated to engage with the 
patient to facilitate stable and regular breathing.12-15 Such breathing guidance strategies have also 
been investigated with liver cancer patients with demonstrated benefits.16, 17 A study by Linthout et 
al. (2009) investigated the use of breathing guidance during lung and liver cancer SBRT and found 
that audio-visual breathing guidance significantly reduced gated treatment times by 17%.16 The 
audiovisual biofeedback system, developed by Venkat et al.,14 has demonstrated to significantly 
improve breathing regularity for both external motion surrogates and internal anatomic motion.13, 14 
A volunteer study by Kim, et al. found that audiovisual biofeedback significantly improved the 
regularity of thoracic diaphragm breathing motion.13 An MRI lung cancer patient study by Lee, et al. 
found that audiovisual biofeedback significantly improves the regularity of lung tumour motion.18 
However, based on a recently performed systematic review on breathing guidance interventions, 
provided in chapter 2., only 2 of the 27 identified articles recruited liver cancer patients.15 Despite 
being highly mobile tumours being treated increasingly with hypofractionated treatments, a gap in 
the literature exists in terms of investigating the use of breathing guidance with liver cancer patients 
during radiation treatment.  
This study was the first to implement a screening procedure prior to CT simulation to ensure 
that the most regular breathing condition (free breathing or audiovisual biofeedback) was utilised 
throughout the patient’s treatment. The primary objective of this clinical trial was to evaluate the 
improvement in the reproducibility of respiratory-related motion for liver cancer patients with the 
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 audiovisual biofeedback system. The reproducibility of respiratory motion was evaluated both 
intrafractionally and interfractionally for both external and internal surrogates. Secondary objectives 
include assessing the proportion of patient for whom audiovisual biofeedback improved respiratory 
motion regularity, evaluation of the correlation between internal fiducial marker and external 
marker motion, and an evaluation of the patient and operator experience with the audiovisual 
biofeedback system though a survey will be performed. A direct comparison between free breathing 
and audiovisual biofeedback was performed during the screening procedure when each patient 
underwent both breathing conditions. An unpaired comparison between free breathing and 
audiovisual biofeedback patients was then performed for subsequent CT sim and treatment sessions 
when each patient exclusively utilised either free breathing or audiovisual biofeedback breathing 
conditions.  
Presented here are the findings of subsequent liver cancer patients recruited into the study.  
4.2. Method 
The ethics, governance, legal, and regulatory processes were completed prior to the initiation of the 
clinical trial. The clinical trial was registered with the Australian New Zealand Clinical Trials Registry 
(ANZCTR), trial ID: ACTRN12613000110785. The protocol accepted by ethics is provided in Appendix 
II.  
4.2.1. Patient information 
The eligibility criteria for patients to be recruited in this study are as follows:  
 Liver cancer patients, either primary hepatocellular carcinoma or liver metastases, eligible 
for stereotactic radiotherapy 
 Older than 18 years old 
 No gender or ethnic restrictions  
 Radio-opaque markers implanted (fiducials and/or surgical clips previously implanted in the 
liver) 
 Able to give written informed consent and willingness to participate and comply with the 
study  
 No pregnant/lactating women  
Table 4-1 details the information of patients recruited into this study.  
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 Table 4-1. Patient and treatment information. 
Age Sex Prescribed dose Number of 
fractions 
Tumour surrogate 
65 M 36 Gy 6 Surgical clips 
75 M 36 Gy 6 Fiducial markers 
59 M 36 Gy 6 Surgical clips 
53 M 48 Gy 6 Surgical clips 
58 M 48 Gy 6 Fiducial markers 
4.2.2. Audiovisual Biofeedback 
The audiovisual biofeedback system, developed by Venkat et al,14 and described in chapter 1.4.2. 
utilises audio and visual prompts to guide the patient to facilitate regular breathing. The real-time 
breathing signal is from the Real-time Position Management system (RPM, Varian Medical Systems, 
Palo Alto, USA). The setup of audiovisual biofeedback in the linac and CT sim rooms is shown below 
in Figure 4-1. The  audiovisual biofeedback equipment setup was the same in both rooms, with the 
system being mounted to the patient table.  
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The use of audiovisual biofeedback required the addition of a patient display in each of the rooms 
with the controlling software being operated by a radiation therapist in the control room. The 
patient display was held over the patient’s head at a comfortable distance by a goose-neck clamp 
which was mounted to the patient couch by a c-clamp. Gantry clearance from the patient display & 
clamp was checked each day in the linac room. Real-time breathing signal was acquired from the 
RPM system; the RPM infra-red camera was mounted on the ceiling of each room.  
4.2.3. Study Protocol & Workflow 
After the patient consented to participating in the study they underwent a screening procedure to 
determine which breathing condition will be utilised in their imaging and treatment, either (1) free 
breathing, or (2) audiovisual biofeedback. After the screening procedure, either free breathing or 
 
 
Figure 4-1. Study setup in Linac (top) and CT sim (bottom) rooms 
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 audiovisual biofeedback would be utilised in their 4D-CT imaging and subsequent course of SBRT. 
Study workflow is shown in Figure 4-2.  
The study progressed much the same as per current liver SBRT standard of care with the addition of 
an audiovisual biofeedback screening procedure prior to the CT sim and then the implementation of 
audiovisual biofeedback during treatment planning and treatment delivery should that be the 
resultant decision yielded from the screening procedure.  
4.2.3.1. Screening Procedure 
A screening procedure was performed to ensure that the most regular breathing condition was 
utilised throughout the patient’s subsequent treatment planning and treatment delivery, either (1) 
free breathing, or (2) audiovisual biofeedback. A training session was performed to familiarise the 
patient with audiovisual biofeedback. The training session involved a brief information video 
describing the audiovisual biofeedback system and how to follow it, followed by a one minute 
practice session using the audiovisual biofeedback system. After the training session, breathing 
motion was monitored for 4 minutes for each of the breathing conditions (1) free breathing and (2) 
audiovisual biofeedback. At the 2 minute mark, CBCT images were acquired. Determining which 
breathing condition would be selected was based on the regularity of the 4 minutes of external 
breathing motion (regularity quantified by the root mean square error (RMSE) in displacement);14 
the lower the RMSE value, the more regular the breathing motion. Decisions were made in situ using 
 
Figure 4-2. General flowchart of the study from 
screening procedure to treatment 
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 an ‘Analyse Respiratory Session’ function within the audiovisual biofeedback software. Workflow of 
the screening procedure is shown in Figure 4-3. The breathing condition that was performed first, 
audiovisual biofeedback or free breathing, alternated between patients.  
 
Figure 4-3. Workflow of the screening procedure. 4 
minutes of breathing was recorded from the Varian 
RPM, with a CBCT acquired at the 2 minute mark, 
providing 1 minute of internal motion information. 
The audiovisual biofeedback training included an 
information video and 1 minute practice with 
audiovisual biofeedback to determine whether any 
modifications to the guiding wave were necessary.    
4.2.3.2. Treatment Planning and Treatment Delivery 
Treatment planning and treatment delivery proceeded as per the currently implemented clinical 
liver SBRT protocol with the addition of the audiovisual biofeedback setup, as shown in Figure 4-1, 
should that be the resultant decision from the screening procedure.  
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Figure 4-4. Workflow of treatment planning and 
treatment delivery. Only the RPM signal was acquired 
during 4DCT imaging. During radiation treatment, pre-
treatment CBCTs are acquired before treatment 
delivery. Hence, during actual treatment delivery, only 
external RPM signal was acquired. For each patient, 
one CT sim session was performed and 6 treatment 
fractions were performed.  
As evident from Figure 4-4, during radiation treatment, internal breathing motion was acquired in 
the pre-treatment CBCTs, not during treatment delivery. In reporting the radiation treatment 
results, the external RPM breathing signal during treatment delivery is reported on, and the internal 
breathing signal from the CBCTs during pre-treatment are reported on.    
4.2.3.3. Data Analysis 
To satisfy the primary and secondary objectives, intrafraction and interfraction breathing motion 
was assessed in addition to the internal-external motion correlation, and reporting on the survey 
results. External breathing motion was extracted from the RPM text files. Internal breathing motion 
of implanted radio-opaque markers was extracted from the CBCT projections images utilising a 
method developed by Poulsen, et al,19, 20 and illustrated in Figure 4-5. 
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Figure 4-5. (a) CBCT projection image with marker to be tracked circled in red. (b) Segmented marker 
highlighted in red square, with the marker being tracked as it moves. (c) Motion of the tracked fiducial marker. 
Data analysis was performed for the screening procedure and SBRT treatment separately. The screening 
procedure allowed a direct comparison between free breathing and audiovisual biofeedback for all patients as 
they underwent both breathing conditions in the screening procedure. Whereas for the CT sim and treatment 
delivery the patient underwent these procedures under one breathing condition only.  
It should be noted that while Figure 4-5  illustrates the one dimensional superior-inferior breathing 
motion of the implanted radio-opaque marker, the method developed by Poulsen, et al19, 20 obtains 
three dimensional information of the marker. The method developed by Poulsen, et al19, 20 utilises 
the two dimensional rotating coordinate system from the CBCT images to estimate the 3D marker 
trajectory. Figure 4-5 illustrates the superior-inferior motion as this is the dominant direction of 
breathing motion due to its proximity to the thoracic diaphragm, and is what was analysed in the 
results section.     
4.2.3.3.1. Breathing Motion Regularity 
External and internal breathing motion were analysed by assessing the regularity of breathing 
motion, quantified as the root mean square error (RMSE) of displacement and period.13-15, 21, 22  
RMSE was calculated was described by equations 1 and 2. For a breathing pattern comprised of 
𝑛 individual breathing cycles, where each cycle in the phase domain can be written as  𝑋 =
{𝑥1, 𝑥2, … , 𝑥360} and the average waveform of these cycles can be written as 𝑌 = {𝑦1, 𝑦2, … , 𝑦360}, 
the RMSE in displacement is calculated as:  
𝑅𝑀𝑆𝐸 𝑖𝑛 𝑑𝑖𝑠𝑝𝑙𝑎𝑐𝑒𝑚𝑒𝑛𝑡 =  
∑ √∑
(𝑥𝑖−𝑦𝑖)
2
360𝑖=1…360𝐴𝑙𝑙 𝐶𝑦𝑐𝑙𝑒𝑠
𝑛
  (1) 
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 The period of each of the 𝑛 breathing cycles, in seconds, can be written as 𝑃 = {𝑝1, 𝑝2, … , 𝑝𝑛}, with 
the period of the average waveform expressed as 𝑃𝑒𝑟𝑖𝑜𝑑𝑚𝑒𝑎𝑛, the RMSE in period is calculated as: 
𝑅𝑀𝑆𝐸 𝑖𝑛 𝑝𝑒𝑟𝑖𝑜𝑑 =  √
∑ (𝑝𝑖−𝑃𝑒𝑟𝑖𝑜𝑑𝑚𝑒𝑎𝑛)2𝑖=1…𝑛
𝑛
 (2) 
4.2.3.3.2. Interfraction Motion Consistency  
External respiratory displacement data was also sorted into phase bins from 0% to 90% in 10% 
increments, as per standard for 4DCT imaging.23-25 The mean difference of the displacement in each 
phase bin was compared for each fraction of treatment to the CT sim, normalised by CT sim 
amplitude, to determine the relative difference between what was planned to motion during 
treatment, as illustrated by Figure 4-6.  
 
Figure 4-6. Relative difference 
between CT bins and treatment 
bins averaged over all treatment 
fractions (𝑛 = 6, 𝐹𝑥1, … , 𝐹𝑥6). 
𝐴𝑚𝑝𝐶𝑇 refers to the peak-to-
peak amplitude of CT sim 
motion. 
4.2.3.3.3. Internal-External Motion Correlation 
The internal-external motion correlation was assessed using the Pearson’s correlation coefficient (r), 
which has been utilised as the correlation test in previous intern-external respiratory motion 
studies.26, 27 The Pearson’s correlation coefficient was selected as the statistical test of choice 
because: (1) Pearsons’ correlation coefficient is a common test for bivariate data,28 (2) a 
scatterplot of the internal-external displacements was plotted to visually inspect the relationship 
between the two datasets; the relationship clearly appeared to be linear and therefore adequately 
described by Pearson’s correlation coefficient,28 and (3)  also from the visual inspection of the 
scatterplot, no outlier data was evident (which the Pearson’s correlation coefficient is sensitive to), 
and therefore Pearson’s correlation coefficient was still an adequate test.28 Motion utilised here was 
from the pre-treatment external and internal breathing motion as indicated in Figure 4-3. It should 
be noted that the external breathing motion from the Varian RPM was not saved during CBCT 
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 imaging for Patient 1, as such, only Patients 2 – 5 are reported on for the internal-external 
correlation results.  
4.2.3.3.4. Patient and staff survey 
An evaluation of the patient and radiation therapist experience with the audiovisual biofeedback 
was also assessed though a survey, which can be found in Appendix II. Radiation therapists 
completed the survey because they were the hospital staff responsible for setting up and 
audiovisual biofeedback hardware and operating the audiovisual biofeedback software during the 
study. Surveys were taken by all patients and radiation therapists immediately after the Screening 
Procedure, and once more on the final fraction of treatment for those patients who had been 
utilising audiovisual biofeedback during treatment. These surveys involved responding to questions 
on a scale of 0 to 5 (required), in addition to inviting further comments (optional).   
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 4.3. Results 
A Case Report published in the Journal of Medical Imaging and Radiation Oncology (see Appendix III) 
details the first patient recruited into the study. 
4.3.1. Screening Procedure 
The screening procedure yielded the decision to utilise audiovisual biofeedback over a course of 
SBRT with 3 of the 5 recruited liver cancer patients; hence, 2 patients underwent SBRT free 
breathing. Figure 4-7 compares the individual patient breathing cycles for free breathing and 
audiovisual biofeedback. Breathing condition outcome of the screening procedure highlighted in 
green.  
Patient Free Breathing Audiovisual Biofeedback 
1 
 
RMSE in displacement = 0.31 cm 
  
RMSE in displacement = 0.26 cm 
2 
 
RMSE in displacement = 0.18 cm 
 
RMSE in displacement = 0.07 cm 
3 
 
RMSE in displacement = 0.18 cm 
 
RMSE in displacement = 0.19 cm 
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 4 
 
RMSE in displacement = 0.15 cm 
 
RMSE in displacement = 0.10 cm 
5 
 
RMSE in displacement = 0.05 cm 
 
RMSE in displacement = 0.15 cm 
Figure 4-7. Patient breathing cycles for free breathing (left) and audiovisual biofeedback (right). Solid blue 
lines are each individual breathing cycle, dashed red lines are the average of all breathing cycles. Plots 
outlined in green indicate the breathing condition that yielded more regular breathing in the screening 
procedure. 
The average RMSE in displacement values across all patients in the screening procedure are given in 
Table 4-2.  
Table 4-2. Screening procedure average ± STD RMSE values for audiovisual biofeedback and free breathing 
across all patients for external and internal breathing motion. 
RMSE in Displacement 
 Free breathing (cm) 
Audiovisual 
biofeedback (cm) 
Improvement due to  
audiovisual biofeedback 
External motion 0.17 ± 0.09 0.15 ±  0.08 11% (p = 0.6) 
Internal motion 0.14 ± 0.06 0.18 ±  0.07 -24% (p = 0.2) 
RMSE in period 
 Free breathing (s) 
Audiovisual 
biofeedback (s) 
Improvement due to  
audiovisual biofeedback 
External motion 0.85 ±  0.46 0.56 ± 0.22 34% (p = 0.2) 
Internal motion 0.62 ±  0.32 0.42 ±  0.09 33% (p = 0.2) 
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 Audiovisual biofeedback improved the regularity of external breathing period for 4 patients, and 
improved the regularity of internal breathing period for 3 patients, these 3 patients then utilised 
audiovisual biofeedback for their subsequent CT sim and treatment deliverry procedures.  
4.3.2. CT sim and Treatment Delivery 
For the 5 recruited liver cancer patients, 3 utilised audiovisual biofeedback and 2 were free 
breathing during their CT sim and 6 treatment fractions. Data presented here is organised into each 
individual patient’s course of SBRT (CT sim → fraction 6) in the figures, and mean ± standard 
deviation values for all audiovisual biofeedback and free breathing patients, respectively. For the 
data presented as boxplots, the horizontal edges of each box represent the 25th, 50th and 75th 
percentile values (bottom, middle, and top lines of box, respectively). Whiskers represent other 
points extending out to 1.5 times the interquartile range. Any points beyond the whiskers (‘+’) are 
considered outliers. 
4.3.2.1. Motion Regularity 
Intrafraction motion regularity of displacement was quantified by equation (1). The screening 
procedure identified the most regular breathing condition, either free breathing or audiovisual 
biofeedback, for each patient. Over their courses of SBRT, Patients 1, 2, and 4 utilised audiovisual 
biofeedback, and Patients 3 and 5 were free breathing, based on the decision made in the screening 
procedure. Figure 4-8 shows the RMSE in displacement results of external and internal breathing 
motion across the course of the SBRT. Internal breathing motion was acquired from CBCT projection 
images, and as such, internal motion was acquired for fractions of treatment only, and not from the 
CT sim session.    
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Figure 4-8. Average RMSE in displacement values for each patient over the course of SBRT from CT sim to 
fraction 6 for (a) external motion, and (b) internal motion. Free breathing patients shown as red, audiovisual 
biofeedback patients shown as blue. 
Intrafraction motion regularity of period was quantified by equation (2). Figure 4-9 shows the RMSE 
in period results of external and internal breathing motion across the course of the SBRT.  
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Figure 4-9. Average RMSE in period values for each patient over the course of SBRT from CT sim to fraction 6 
for (a) external motion, and (b) internal motion. Free breathing patients shown as red, audiovisual biofeedback 
patients shown as blue. 
Table 4-3. Average ± STD RMSE values for audiovisual biofeedback and free breathing for all patients across 
all treatment fractions for external and internal breathing motion. 
RMSE in Displacement (cm) 
 Free breathing 
Audiovisual 
biofeedback 
Improvement due to  
audiovisual biofeedback 
External motion 0.13 ± 0.06 0.13 ± 0.07 
-2% (p = 0.9)  
(no improvement) 
Internal motion 0.16 ± 0.08 0.17 ± 0.05 
-8% (p = 0.7) 
(no improvement) 
RMSE in period (seconds) 
 Free breathing 
Audiovisual 
biofeedback 
Improvement due to  
audiovisual biofeedback  
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 External motion 0.66 ± 0.19 0.47 ± 0.19 28% (p = 0.01) 
Internal motion 0.59 ± 0.29 0.46 ± 0.15 23% (p = 0.2) 
In terms of RMSE in displacement, audiovisual biofeedback and free breathing patients 
demonstrated comparable breathing motion regularity. For external breathing motion, Patient 2 
(audiovisual biofeedback) demonstrated the most regular breathing over their course of SBRT with 
an average RMSE in displacement of 0.11 cm; the next most regular breathing was Patient 4 
(audiovisual biofeedback) with an RMSE  in displacement of 0.11 cm, followed by Patient 5 (free 
breathing) with an RMSE in displacement of 0.12 cm, followed by Patient 3 (free breathing) with an 
RMSE in displacement of 0.15 cm, followed by Patient 1 (audiovisual biofeedback) with an RMSE in 
displacement of 0.19 cm. For internal breathing motion, Patient 5 (free breathing) demonstrated the 
most regular breathing over their course of SBRT with an average RMSE in displacement of 0.08 cm; 
the next most regular breathing was Patient 4 (audiovisual biofeedback) with an RMSE  in 
displacement of 0.15 cm, followed by Patient 2 (audiovisual biofeedback) with an RMSE in 
displacement of 0.16 cm, followed by Patient 3 (free breathing) with an RMSE in displacement of 
0.21 cm, followed by Patient 1 (audiovisual biofeedback) with an RMSE in displacement of 0.22 cm. 
4.3.2.2. External Interfraction Motion Consistency 
Interfraction motion consistency is described by Figure 4-6, the breathing signal was organised into 
10 phase bins, from 0% to 90% in 10% increments. The phase bins from CT sim were compared to 
the phase bins from each treatment fraction. Figure 4-10 shows the breathing signals from the CT 
sim and each treatment fraction organised into 10 phase bins for patients 1 to 5 for the CT sim and 
each fraction of treatment.  
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Figure 4-10. Breathing displacements organised into 10 phase bins for breathing motion during CT sim (black 
line, filled markers), and each fraction of treatment (coloured line, hollow markers) for free breathing (red) and 
audiovisual biofeedback (blue) patients. 
The difference of each fraction of treatment to the CT sim are shown in Figure-14.  
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Figure 4-11. Average (a) relative difference, and (b) absolute difference between CT sim phase bins and the 
each  fraction of treatment phase bins. Free breathing patients shown as red, audiovisual biofeedback patients 
shown as blue. 
Table 4-4. Average ± STD Inter-fraction motion consistency values for audiovisual biofeedback and free 
breathing. 
Relative Difference 
 Free breathing 
Audiovisual 
biofeedback 
Improvement due to  
audiovisual biofeedback 
Inter-fraction motion 
consistency (%) 
22.0 ± 16.3 14.9 ± 10.0 32% (p < 0.001) 
Absolute Difference 
 Free breathing 
Audiovisual 
biofeedback 
Improvement due to  
audiovisual biofeedback 
Inter-fraction motion 
consistency (cm) 
0.15 ± 0.10 0.14 ± 0.13 4% (p = 0.6) 
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 In terms of relative difference, Patient 2 (audiovisual biofeedback) demonstrated the most 
consistent interfraction motion with an average relative difference of 12% over their course of SBRT. 
Patient 1 (audiovisual biofeedback) demonstrated the next most consistent interfraction motion 
with an average relative difference of 14%, followed by Patient 5 (free breathing) with an average 
relative difference of 18%, followed by Patient 4 (audiovisual biofeedback) with an average relative 
difference of 19%, followed by Patient 3 (free breathing) with an average relative difference of 25%. 
In terms of absolute difference, Patient 2 (audiovisual biofeedback) demonstrated the most 
consistent interfraction motion with an average absolute difference of 0.07 cm over their course of 
SBRT. Patient 4 (audiovisual biofeedback) demonstrated the next most consistent interfraction 
motion with an average absolute difference of 0.07 cm, followed by Patient 3 (free breathing) with 
an average absolute difference of 0.14 cm, followed by Patient 5 (free breathing) with an average 
absolute difference of 0.15 cm, followed by Patient 1 (audiovisual biofeedback) with an average 
absolute difference of 0.27 cm.    
As shown in Figure 4-11(b), for two patients audiovisual biofeedback largely produced sub-
millimetre interfraction motion consistency. While Patient 1 demonstrated low inter-fraction motion 
consistency in terms of relative difference, it had a considerably larger inter-fraction motion 
consistency in terms of the absolute difference. This is because Patient 1 had the largest amplitude 
of the 5 patients (see Figure 4-10), and therefore, by normalising the respiratory signal by its 
amplitude, the larger absolute differences (in cm) corresponded to a lower relative difference.  
4.3.2.3. Internal-External Motion Correlation 
Examples of the median R value for each patient are shown in Figure 4-12. 
Table 4-5. Median R values for patients 2 to 5 and their corresponding breathing signals and correlation 
plots.  
Patient Breathing signals Correlation plot r 
2 (AV) 
  
0.96 
98
 3 (FB) 
  
0.84 
4 (AV) 
  
0.93 
5 (FB) 
  
0.96 
In the screening procedure a stronger r-value was yielded for two audiovisual biofeedback patients, 
and stronger for free breathing for the other two patients. It should be noted that Patient 1 was not 
included in this analysis due to external motion data loss during CBCT imaging.  Figure 4-12 shows 
the Pearson’s correlation coefficient (r) values for the internal-external motion correlation across 
each patient’s course of SBRT and Table 4-6 provides the average values for the two breathing 
conditions over the entire course of SBRT. 
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Figure 4-12. R values for free breathing 
(red) and audiovisual biofeedback (blue) 
across all CBCT imaging sessions (decision 
procedure and pre-treatment imaging). 
 
 
 
 
 
Table 4-6. Average ± STD R values for all patients’ course of SBRT for Audiovisual 
biofeedback and free breathing. 
 Free breathing 
Audiovisual 
biofeedback 
Improvement due to  
audiovisual biofeedback 
R 0.89 ± 0.08 0.93 ± 0.04 4% (p = 0.14) 
4.3.2.4. Patient and Staff Survey 
Audiovisual biofeedback surveys were taken by patients and radiation therapists on the patient’s 
first and last use of audiovisual biofeedback, on the screening procedure and on the final fraction of 
treatment. The survey was taken a second time on the final fraction of treatment only for the 
patients and radiation therapists who utilised audiovisual biofeedback during their course of 
treatment. All patients completed the survey on the screening procedure. Table 4-7 and Table 4-8 
details the questions and average scores given by the patients and radiation therapists, respectively.  
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 Table 4-7. Questions and average responses from all patients 
Question Response options Average patient response 
Do you feel your breathing was more 
consistent using audiovisual 
biofeedback?  
0 (no) , moderately (3), to 5 (yes)  3.75 
Was the training session that you had 
prior to this session helpful?  
0 (no) , moderately (3), to 5 (yes)  4.67 
Did you feel physically comfortable 
with the audiovisual biofeedback 
system?  
0 (no) , moderately (3), to 5 (yes)  4.5 
Did you feel the audiovisual 
biofeedback visual guide (white curve) 
was too fast or too slow?  
0 (too slow) , just right (3), to 5 (too 
fast)  
3.13 
Did you feel the audiovisual 
biofeedback visual guide (white curve) 
was too shallow or deep?  
0 (too shallow) , just right (3), to 5 
(too deep)  
2.38 
Did you like having the music?  0 (no) , moderately (3), to 5 (yes)  3.14 
Did the music help you breathe more 
consistently?  
0 (no) , moderately (3), to 5 (yes)  2.33 
Did you feel anxious during the 
session?  
0 (no) , moderately (3), to 5 (yes)  1.25 
Table 4-7 demonstrates the importance of the training session performed in assisting patients 
becoming familiar and comfortable with the audiovisual biofeedback system. Further to this, the 
survey also demonstrates that the audiovisual biofeedback system was comfortable for the patient 
to use and did not make the patient anxious, with patients reporting a low level of anxiety. Patients 
reported that the speed and amplitude of the guiding wave were almost ‘just right’, with one 
patient commenting that the guiding wave was a little slow, and another noting that it was a little 
fast, and another patient noting that it seemed a little fast at one time and a little slow at another.     
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Table 4-8. Questions and average responses from radiation therapists 
Question Response options Average patient response 
Do you think that the training session 
was useful for the patient?   
0 (no) , moderately (3), to 5 (yes)  4 
Do you think that audiovisual 
biofeedback helped your patient to 
breathe more regularly? 
0 (no) , moderately (3), to 5 (yes)  4.25 
Was the audiovisual biofeedback 
system easy to setup?  
0 (no) , moderately (3), to 5 (yes)  3.75 
Was the audiovisual biofeedback 
system easy to operate?   
0 (too slow) , just right (3), to 5 (too 
fast)  
4 
Would you recommend the audiovisual 
biofeedback guidance to your 
colleagues at other centres in similar 
treatment?   
0 (no) , 3 (moderately), to 5 (yes)  3.25 
Responses from the radiation therapists support the importance of an audiovisual biofeedback 
training session. Radiation therapists also reported to be confident in audiovisual biofeedback 
facilitating regular patient breathing. In addition to providing scores, radiation therapists also 
commented that the multiple components involved in setting up audiovisual biofeedback could be 
cumbersome, initially. Radiation therapists also commented that they would hold off recommending 
audiovisual biofeedback to colleagues until the results from the clinical trial were disseminated and 
whether such results demonstrated clinical improvements.  
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 4.4. Discussion 
This was the first investigation into the use of breathing guidance during a course of liver SBRT 
employing an initial screening procedure to ensure the most regular breathing condition is utilised 
for each patient. For the five patients recruited into this study, the findings from the screening 
procedure yielded the decision to utilise audiovisual biofeedback during treatment planning and 
treatment delivery for 3 of the 5 patients.  
Over the course of SBRT treatment, there was no significant difference in the average 
breathing regularity between free breathing and audiovisual biofeedback patients. The mean RMSE 
in displacement of the external RPM motion for audiovisual biofeedback patients in this study was 
0.13 cm, comparable to the findings of a lung cancer patient audiovisual biofeedback study, which 
obtained average RMSE in displacement values of 0.14 cm for audiovisual biofeedback patients 
(results presented in chapter 5.). Whereas the free breathing patients in this study yielded an 
average RMSE in displacement values of 0.12 cm, considerably lower than the RMSE values obtained 
in a previous cancer patient study (0.20 cm, see chapter 5.), and either comparable to or lower than 
RMSE values yielded in healthy volunteer studies (0.13 cm13 and 0.16 cm14). This suggests that the 
screening procedure initially performed is an effective method of producing regular breathing over 
the subsequent course of SBRT, either by providing audiovisual biofeedback guidance or by 
identifying naturally regular free breathing patients.  
While no significant difference in terms of breathing regularity was observed between free 
breathing and audiovisual biofeedback patients, a significant improvement in interfraction motion 
consistency was observed from the use of audiovisual biofeedback, with 32% more agreement 
between respiratory motion during each treatment fraction and CT sim. This demonstrates that 
audiovisual biofeedback could be a useful tool in maintaining consistent interfraction breathing 
motion, minimising the deviation in respiratory motion from what was planned in CT sim to each 
fraction of treatment. While internal radio-opaque marker motion was not obtained during 
treatment delivery, the Pearson’s correlation coefficient (r) results indicate a significant correlation 
between internal and external respiratory motion. Further to this, audiovisual biofeedback 
produced a 4% improvement (p = 0.14) in Pearson’s correlation coefficient (r) values over free 
breathing. Previous studies have found that audiovisual biofeedback does not impact the correlation 
between internal and external respiratory motion in healthy volunteers; a study by Steel, et al., 
(2014) found that the correlation between external RPM motion and thoracic diaphragm motion 
was 0.96 for both free breathing and audiovisual biofeedback.26 However, recent preliminary 
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 findings by Lee, et al., (2015) from a lung cancer patient study indicate that audiovisual biofeedback 
does improve the correlation between external surrogates and internal tumour motion over free 
breathing.29 Lee, et al., (2015) found the correlation between abdominal to thoracic diaphragm 
motion to be 0.91 and 0.95 for free breathing and audiovisual biofeedback, respectively. The 
findings reported in this chapter here appear consistent with those of Lee, et al., (2015), with the 
average correlation between external RPM and implanted radio-opaque marker motion being 0.89 
and 0.93 for free breathing and audiovisual biofeedback, respectively. This indicates that audiovisual 
biofeedback could be a useful tool in facilitating a more robust correlation between external 
respiratory surrogates and abdominal or thoracic tumours. However, further investigation is 
required to determine the factors responsible for the improvement in this correlation. Additionally, 
utilising more direct measurements of the tumour by the audiovisual biofeedback system, such as 
ultrasound or MR Navigator signal,30, 31 would yield a stronger correlation between audiovisual 
biofeedback signal and the tumour.       
Survey results also demonstrated that patients were comfortable using audiovisual biofeedback, 
both in terms of physical comfort and patients reporting near ‘just right’ responses in terms of speed 
(i.e. period) and amplitude of the guiding wave. Further to this, both patients and radiation 
therapists indicated the importance of the training session to help familiarise the patient with 
audiovisual biofeedback. 
The results presented here demonstrate the effectiveness of an initial screening procedure 
in facilitating regular breathing over the course of liver cancer SBRT by either providing audiovisual 
biofeedback breathing guidance or identifying naturally regular free breathing. Further to this, this 
study indicates that audiovisual biofeedback can improve the agreement between respiratory 
motion during CT sim and during treatment delivery.  
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 4.5. Conclusion 
This was the first clinical implementation of audiovisual biofeedback utilising a screening procedure 
to ensure regular breathing is produced during the subsequent course of liver SBRT. This screening 
procedure yielded the decision to utilise audiovisual biofeedback over a course of SBRT in 3 / 5 
patients recruited into this study, with the other 2 patients receiving their SBRT under free breathing 
conditions. These 5 liver cancer patients demonstrated regular breathing over the course of their 
SBRT regardless of whether they used audiovisual biofeedback or free breathing, with RMSE values 
comparable to previous audiovisual biofeedback cancer patient studies, and considerably lower than 
free breathing patients in previous studies. These 5 liver cancer patients demonstrated regular 
breathing over the course of their SBRT regardless of whether they used audiovisual biofeedback or 
free breathing. While respiratory regularity was comparable between the two breathing conditions, 
audiovisual biofeedback did improve the interfraction motion consistency over free breathing; 
significantly improving the agreement between CT sim and treatment fraction respiratory motion.  
Audiovisual biofeedback also improved the internal-external respiratory motion correlation, 
however these results were non-significant. These findings demonstrate the effectiveness of the 
screening procedure in facilitating regular respiration over the course of SBRT in addition to 
audiovisual biofeedback being a potentially valuable tool in producing consistent respiratory motion 
between CT sim and treatment delivery. However, a study with a larger patient cohort is necessary 
to investigate this further. 
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CHAPTER 5 
 
Designing and initialising a multi-insitutional randomisation phase 
II audiovisual biofeedback clinical trial 
 
This chapter contains the study protocol titled “Audiovisual biofeedback breathing guidance for 
lung cancer patients receiving radiotherapy: a multi-institutional phase II randomised clinical trial” 
which has been published in BMC Cancer (2015; 15(1) 526-533) 
  
109
CHAPTER 5 
Designing and initialising a multi-institutional randomisation phase II 
audiovisual biofeedback clinical trial 
As evident in chapter 2, to date, there have not been any randomised clinical trials testing breathing 
guidance interventions. Studies to date have largely demonstrated the proof of principle that 
breathing guidance improves the regularity and stability of respiratory motion. This chapter will 
focus on the design and initiation of a multi-site, randomised audiovisual biofeedback clinical trial. 
This chapter is presented in two parts: 5.1. retrospective analysis of a previous lung cancer patient 
audiovisual biofeedback study, and 5.2. the design and initiation of the randomised clinical trial. The 
aim of chapter 5.1. was to yield estimates of clinically relevant outcomes based on a retrospective 
analysis of a previous lung cancer patient audiovisual biofeedback investigation. The aim of chapter 
5.2. was to take the insights obtained in chapter 5.1. to design and then initiate a randomised 
audiovisual biofeedback clinical trial.    
5.1. Retrospective Analysis 
The previous audiovisual biofeedback study that recruited lung cancer patients was conducted at 
Virginia Commonwealth University by George, et al. (2003 – 2004).1-3 This study recruited a total of 
24 lung cancer patients who breathed both with and without audiovisual biofeedback across 5 
sessions, with each session being performed on a different date. The George, et al. study was also 
the largest audiovisual biofeedback study, to date. Given that there were no completed audiovisual 
biofeedback clinical trials, clinical insights to go into designing a randomised clinical trial needed to 
be estimated based on previous investigations. Considering that the George, et al. study was the 
largest audiovisual biofeedback lung cancer study, the George, et al., study data,1-3 was employed to 
estimate clinically relevant outcomes to determine the design and statistical considerations of a 
randomised audiovisual biofeedback clinical trial.  
5.1.1. Introduction 
As noted in chapter 1.3., for highly mobile tumors, such as those in the thoracic and abdominal 
regions,4,5 unstable and irregular breathing motion has a deleterious impact on the accuracy of 
medical imaging and radiation therapy.6-9 During radiation treatment there are two fundamental 
types of errors: the errors occurring during treatment preparation (systematic) and the errors 
occurring during treatment delivery (random); both these types of errors are exacerbated by 
irregular breathing-motion.  
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As noted in chapter 3 and chapter 4, the use of interactive breathing guidance interventions to 
engage with the patient, informing the patient in real-time on how to adjust their breathing to 
achieve stable and regular breathing motion, is one such technique to reduce systematic and 
random errors. The breathing guidance system audiovisual biofeedback,10 has demonstrated to 
facilitate regular anatomic motion10,11 and regular tumour motion,12,13 in addition to achieving 
improved medical image quality,14 imaging time,15 and gating efficiency.1 In studies that involved 
participants utilizing breathing guidance across multiple sessions on different dates, a trend that the 
participant exhibited increasingly regular breathing with increased usage of the breathing guidance 
intervention has been observed. A study by Kim, et al., (2012) performed MR imaging on 15 healthy 
volunteers over two days, spaced approximately one week apart, and observed that the breathing 
motion of the abdominal wall and the thoracic diaphragm was, on average, more regular on the 
second day.11 A study by Cossmann, et al., (2012), recruiting breast cancer patients and observed a 
decrease in treatment duration over 16 fractions from the use of breathing guidance in examples of 
two patients’ course of radiotherapy.16 A study performed by Venkat, et al. (2008), tested two 
different types of breathing guidance on 10 healthy volunteers performing a total of three breathing 
sessions over three different days. A trend towards more regular breathing with time was observed 
for one of the types of breathing guidance tested, but not for the other.10 However, the relationship 
between free breathing and audiovisual biofeedback guided breathing interfractionally has yet to be 
assessed. Given the observations of previous studies, should a training effect be determined to be a 
non-stochastic process, this would have valuable implications for achieving higher patient 
compliance with breathing guidance thereby further minimizing irregularities present in breathing 
motion. This would also give insights into optimising this training effect to achieve more regular 
breathing motion earlier in the patient’s course of treatment.  
Further to this, the impact of audiovisual biofeedback on systematic and random errors has also yet 
to be assessed. An audiovisual biofeedback study by Lu, et al, (2014) investigated the impact of 
breathing guidance on the match between ITVMIP (internal target volume generated by contouring in 
the maximum intensity projection scan) and ITV10 (ITV generated by combining the gross tumor 
volumes contoured over the 10 phases of a 4D-CT), however, this study did not assess the impact of 
audiovisual biofeedback on margin size.  
A study by George, et al. (2006), investigated the impact of audiovisual biofeedback on respiratory 
gating efficiency across five days of breathing sessions. George, et al., (2006) assessed the standard 
deviation of breathing motion within a gating window and found that audiovisual biofeedback 
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improved gating efficiency over free breathing and audio-only guidance, however this study did not 
assess the contribution of this to systematic or random errors.  
To address this gap in the literature, a retrospective analysis of the George data was performed to 
investigate the impact of audiovisual biofeedback breathing guidance on interfraction breathing 
regularity in addition to the respiratory-components of systematic and random errors, and the 
combination of these errors using the van Herk margin calculation. It should be noted that the 
George, et al., (2006) data is the respiratory signal from the real-time position management (RPM) 
external surrogate, and as such, a number of limitations of this methodology are prevalent. The 
calculation of systematic and random errors assume no other sources of error are present, so this 
represents a lower bound estimate of errors. It additionally includes the assumption that the RPM 
motion is similar to the tumour motion, which is a reasonable assumption in some circumstances, if 
the tumour is located in the lower lobe of the lung for example, but may not be an accurate 
surrogate for upper lobe tumours.17 However, given that a clinical evaluation of audiovisual 
biofeedback has not yet been performed, such an approximation is the best available option. 
George, et al., (2006) data was utilised as the five days of breathing sessions is representative of a 
hypofractionated course of radiotherapy.18 
5.1.2. Methods 
331 four minute breathing signals were acquired from 24 lung cancer patients in the George, et al., 
(2006) study.1,2 Patients participated in five breathing sessions performed on five different days. In 
each of the sessions three breathing conditions were tested for 4 minutes each: (1) free breathing 
(no guidance), (2) audio breathing guidance, and (3) audiovisual biofeedback breathing guidance. For 
the purpose of this study we only considered free breathing and audiovisual biofeedback breathing 
sessions. Of the 24 lung cancer patients recruited, 3 did not complete all five breathing sessions. 
Henceforth, each breathing session will be referred to as a fraction.  
5.1.2.1. Breathing motion Analysis 
Breathing motion was analysed in terms of average breathing peak-to-peak amplitude and breathing 
regularity. The root mean square error (RMSE) of breathing displacement and period was used to 
quantify breathing regularity.10,11 A lower value of RMSE is indicative of more regular motion. RMSE 
values were organised into the five separate breathing sessions to assess the trend of breathing 
regularity interfractionally.    
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5.1.2.2. Phase-based gating analysis for inhale, exhale and static beam 
Phase-based gating was utilized. An example phase and displacement signal is shown below. 
 
Figure 5-1. Top: Anterior-posterior (AP) breathing motion. Bottom: Phase of the top breathing motion. 
Peak exhale corresponds to 𝑃ℎ𝑎𝑠𝑒 =  𝜋 and peak inhale corresponds to 𝑃ℎ𝑎𝑠𝑒 =  0, 2𝜋. A gating 
window of 40% is typical for radiation therapy. So for exhale, a 40% gating window refers to the 
breathing signal within Phase =  𝜋 ± 20% =  (1.9 → 4.4). For inhale, a 40% gating window refers to 
the breathing signal within Phase =  {
0 + 20%
2𝜋 − 20%
=  
(0 → 1.3)
(5.0 → 2𝜋)
. 
A static beam refers to a gating window of 100%, i.e. the entire breathing signal from Phase = 0 →
2𝜋. Figure 5-2 illustrates these gating windows by highlighting them on the same respiratory signal 
illustrated in Figure 5-1.  
 
Figure 5-2. The same respiratory signal as displayed in Figure 5-1, with phase-based gating at exhale indicated 
in black, and phase-based gating at inhale indicated in red. 
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5.1.2.3. Margin Calculation 
The systematic error (Σ) is the error between the anatomy at the time of set-up and the anatomy 
during treatment. A breathing signal with displacement 𝑋 = {𝑥1, … , 𝑥𝑛} can be expressed between 
times 𝑡1 and 𝑡2 as 𝑋𝑡1
𝑡2 = {𝑥𝑡1 , … , 𝑥𝑡2}, where 𝑡1 and 𝑡2 are in seconds. Assuming a setup time of 15 
seconds, the systematic error for each fraction can be described as the difference in mean 
displacement between setup (first 15 seconds) and delivery (from 15 seconds to end of fraction (240 
seconds)):  
Σ𝑓 =  𝑋15
240̅̅ ̅̅ ̅̅ −  𝑋𝑜
15̅̅ ̅̅ ̅ (1) 
For each patient, the systematic error across all 𝑓 fractions can be expressed as:  
Σ𝑝𝑡 =  
1
𝑓
∑ Σ𝑓
𝑓
1   (2) 
The random error (σ) is the error during treatment, the random error for each fraction can be 
expressed as the standard deviation during treatment delivery (from 15 seconds to end of fraction (4 
minutes)): 
𝜎𝑓 = 𝑆𝐷(𝑋15
240)  (3) 
For each patient, the random error across all 𝑓 fractions can be expressed as:  
𝜎𝑝𝑡 =  
1
𝑓
∑ 𝜎𝑓
𝑓
1   (4) 
Systematic and random errors are used to estimate margin size using the van Herk formula:  
2.5Σ𝑝𝑡 +  0.7𝜎𝑝𝑡   (5) 
The van Herk formula was used to calculate the respiratory component of margins for static beam, 
exhale phase-based gating, and inhale phase-based gating. Free breathing and audiovisual 
biofeedback results were compared using a paired two-tailed Student’s t-test.  
5.1.2.4. Correlation between margins and breathing regularity 
The correlation between the calculated margins and respiratory motion regularity was assessed 
using the Pearson’s correlation coefficient (r), and a p-value for testing the hypothesis of no 
correlation. Respiratory motion regularity was quantified by the mean root mean square error 
(RMSE) in displacement for each lung cancer patient as described in chapter 5.1.2.1. 
5.1.3. Results 
5.1.3.1. Interfraction Breathing Regularity  
Figure 5-3 demonstrates the change in RMSE in displacement values over the five study days 
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 Figure 5-3. Mean RMSE 
values for each study 
session for audiovisual 
biofeedback (AVB, blue) 
and free breathing (red) 
Mean ± standard deviation (STD) RMSE values across the five study days, in addition to how 
significant the improvement in breathing regularity was on each study day, are given in Table 5-1.  
Table 5-1. Mean ± STD breathing regularity (RMSE in displacement, in cm) values for each study session performed 
across five days.   
 Session 1 Session 2 Session 3 Session 4 Session 5 All Sessions 
Free breathing 0.17 ± 0.06 0.18 ± 0.07 0.20 ± 0.07 0.22 ± 0.12 0.21 ± 0.08 0.20 ± 0.08 
Audiovisual 
biofeedback 
0.16 ± 0.08 0.15 ± 0.07 0.15 ± 0.08 0.12 ± 0.05 0.13 ± 0.07 0.14 ± 0.07 
Reduction due to 
audiovisual 
biofeedback 
6% 
(p = 0.48) 
19% 
(p = 0.04) 
28% 
(p = 0.003) 
43% 
(p < 0.001) 
40% 
(p < 0.001) 
28% 
(p < 0.001) 
While the improvement in breathing regularity was not significant on the patients’ first breathing 
session, by the second day of the study the improvement in breathing regularity was significant, 
reaching peak disparity between audiovisual biofeedback and free breathing on day 4. The Pearson’s 
correlation coefficient (r) between session day and RMSE value for audiovisual biofeedback was 
found to be -0.93 (p = 0.02), and 0.92 (p = 0.02) for free breathing. Further to this, the correlation 
between time and RMSE was found to be significant for audiovisual biofeedback with r = -0.93 (p = 
0.02). 
5.1.3.2. Margin Calculation 
Results of the respiratory components of the van Herk margin calculation for static beam, exhale 
phase-based gating (exhale gated), and inhale phase-based gating (inhale gated) are shown in Figure 
5-4 and given in Table 5-2.  
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 Figure 5-4. Margin calculations for all 24 lung cancer patients for audiovisual biofeedback (AVB, blue) and free 
breathing (red) for static beam, exhale gated, and inhale gated. 
Table 5-2. Margin calculations (in cm) based on the respiratory components of patient breathing motion for static 
beam, and phase-based gating with a duty cycle of 40% for exhale and inhale.  
 Static beam Exhale Inhale 
Free breathing 
0.75 ± 0.38 
(range: 0.30 – 1.99) 
0.51 ± 0.35 
(range: 0.18 – 1.66) 
0.73 ± 0.46 
(range: 0.30 – 2.12) 
Audiovisual biofeedback 
0.45 ± 0.19 
(range: 0.19 – 0.89) 
0.09 ± 0.67 
(range: 0.09 – 0.67) 
0.34 ± 0.20 
(range: 0.13 – 0.78) 
Margin reduction due to 
audiovisual biofeedback 
40% 
(p = 0.0006) 
48% 
(p = 0.002) 
54% 
(p = 0.0003) 
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Audiovisual biofeedback reduced the calculated margin size for 20 out of 24 patients for static 
beam, 19 out of 24 for exhale gating, and 21 out of 24 patients for inhale gating. Further to this, 14, 
22, and 19 out of 24 lung cancer patients had margins less than 5 mm for audiovisual biofeedback 
for static beam, exhale gated, and inhale gated margins respectively; while only 5, 14, and 9 lung 
cancer patients had margins less than 5 mm for free breathing for static beam, exhale gated, and 
inhale gated margins respectively.   
5.1.3.3. Correlation between margins and breathing regularity 
Figure 5-5 shows the calculated margins as a function of RMSE in displacement values. Table 5-3 
shows the Pearson’s correlation coefficient (r) irrespective of breathing condition. 
 
Figure 5-5. Calculated margins as a function of RMSE in displacement for (from left to right) static beam, 
exhale gated, and inhale gated. Audiovisual biofeedback (AVB) indicated as blue circles, and free breathing 
indicated a red squares.   
Table 5-3. Pearson’s correlation coefficient (r) values and their respective p-values for the 
correlation between respiratory motion regularity (RMSE) and calculated margins for static 
beam, exhale gated, and inhale gated. 
 r p-value 
Static beam 0.59 < 0.001 
Exhale gated 0.41 0.004 
Inhale gated 0.58 < 0.001 
Figure 5-5 and Table 5-3 demonstrate a significant correlation between calculated margin and 
respiratory motion regularity.  
5.1.4. Discussion 
This retrospective analysis of the George, et al.1,2 data has yielded the clinically relevant insights 
pertaining to the impact of audiovisual biofeedback on both training effect in addition to calculated 
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treatment margins. The original study by George et al., monitored the breathing of 24 lung cancer 
patients across five sessions performed over five separate days and observed an improvement in the 
standard deviation of breathing motion within a gating window, but observed no trend of this with 
respect to time.1 In this study, the George et al. data was analysed utilising a metric of motion 
regularity (RMSE),10-12 rather than a metric for gating efficiency, to determine the interfraction 
relationship between breathing regularity and time. Further to this, the respiratory-components of 
systematic and random errors were analysed utilising the van Herk margin calculation.19  
On day 1 of the study, there was no significant difference in terms of breathing regularity 
between audiovisual biofeedback and free breathing (6% improvement, p = 0.48). However, by day 2 
a significant difference between audiovisual biofeedback and free breathing was observed, with 
audiovisual reaching peak regularity by day 4, significantly more regular than free breathing (43% 
improvement, p < 0.001). The correlation between time and RMSE was found to be significant for 
audiovisual biofeedback with r = -0.93 (p = 0.02). Interestingly, the correlation between time and 
RMSE was also found to be significant for free breathing, too, with r = 0.92 (p = 0.03). The main 
difference between these two relationships is that the trend for audiovisual biofeedback is for RMSE 
to decrease with time, whereas RMSE increased with time for free breathing. The decrease in RMSE 
(i.e. increasing regularity) for audiovisual biofeedback is evidence for a training effect, with patients’ 
familiarity and compliance with breathing guidance increasing with time. This increase in RMSE for 
free breathing may have had to do with their ongoing radiation treatment which was being 
performed in parallel with this study, with potential radiation toxicities compromising their 
respiratory function as evident as their decreasing free breathing regularity. However, as radiation 
toxicities were not reported in the George, et al., investigation, this hypothesis is difficult to test.  
Audiovisual biofeedback also facilitated an improvement in margin reduction, significantly 
improving static beam, exhale gated, and inhale gated margins by 40%, 48%, and 54% respectively. 
Furthermore, a significant correlation between breathing regularity (RMSE) and margin size was 
observed, providing evidence that breathing motion regularity can significantly impact clinically 
relevant outcomes. Audiovisual biofeedback achieved a margin size of less than 5 mm for 14, 22, and 
19 out of 24 lung cancer patients for static, exhale gated, and inhale gated margins respectively; 
whereas free breathing achieved this for much few patients, with 5, 14, and 9 out of 24 lung cancer 
patients had margins less than 5 mm for static, exhale gated, and inhale gated margins respectively.   
However, the margin calculation performed is not a direct measure of treatment margins, as 
it only takes into account the respiratory components of systematic and random errors of an 
external respiratory surrogates signal and assumes no other radiotherapy errors. Furthermore, the 
respiratory signal utilised in these margin calculations was from an external surrogate, the real-time 
118
position management (RPM) system. It should be noted that there are several other factors that 
impact margin size that are independent of respiratory motion. So the results presented here should 
not be interpreted as the impact of audiovisual biofeedback on the PTV margin size, rather, the 
reduction of what the respiratory component contributes to systematic and random errors in 
radiation therapy.    
This was the first study to investigate the impact of audiovisual biofeedback on systematic 
and random errors in radiation therapy in addition to the first study to investigate the training effect 
of audiovisual biofeedback. The results presented here provide valuable insights in terms of patient 
training and clinical outcomes to contribute to the design of a randomised audiovisual biofeedback 
clinical trial.   
119
5.2. Clinical Trial Design and Initiation 
Based on the findings from chapter 2, a randomised clinical trial investigating breathing guidance 
interventions has yet to be performed, further to this, investigations to date have all be single-
institution studies. Using the findings presented in chapter 5.1. to drive the design and statistical 
considerations of a randomised clinical trial.    
5.2.1. Introduction 
The precision of radiotherapy can be reduced due to respiratory-related tumour motion, particularly 
for tumours in the thoracic region, leading to increased irradiation of healthy surrounding tissues, 
resulting in a significant increase in radiation-related toxicity.20-22 This is further exacerbated when 
respiration is irregular in nature.23,24 A 1Gy increase in tumour dose results in a 4% improvement in 
survival,20 however, a 0.5 cm range of tumour motion can cause a 4% variation in radiation dose22 
which leads to an increase in mean dose to healthy surrounding tissues resulting in an increase in 
risk of pneumonitis and radiation toxicity.21,25  
Breathing guidance is one such technique which specifically aims to facilitate regular patient 
breathing by showing the patient how to adjust their breathing in real-time. One such breathing 
guidance system is the audiovisual biofeedback system, developed by Venkat, et al.10 
Audiovisual biofeedback is a real-time, interactive and personalised respiratory guide designed to 
facilitate regular patient breathing. However, the findings of a recent literature search, presented in 
chapter 2, yielded that a randomised clinical trial with any breathing guidance intervention has not 
yet been performed. To fill the gap in the literature, we have designed a multi-institutional, phase II, 
randomised clinical trial to thoroughly assess the clinical impact of the audiovisual biofeedback 
breathing guidance system. Based on previous findings and the results presented in chapter 5.1.3., 
we hypothesise that audiovisual biofeedback will significantly improve breathing regularity and 
reduce medical imaging errors for lung cancer patients undergoing imaging and treatment 
procedures during radiotherapy.  
5.2.2. Study Design 
The statistical considerations for this study are largely based on the analysis performed in chapter 
5.1. utilising the data from a study conducted at Virginia Commonwealth University (VCU) on 24 lung 
cancer patients.1,2 26 patients were recruited for the VCU study, however, 2 patients dropped out 
due to not being treated with radiotherapy or rapid worsening of disease, and so their data was not 
collected. A clinically significant different in clinical improvement due to audiovisual biofeedback has 
been determined to be a margin calculation of less than 5 mm. Irregular breathing causes larger 
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systematic errors (Σ) from motion artefacts and variations between the planned and treated 
anatomy as well as random day to day variations (σ) in the treated anatomy (see chapter 5.1.3.). To 
combine systematic and random errors and estimate the margin contribution due to breathing 
irregularity we will use the van Herk method26: margin = 2.5Σ + 0.7σ (as described in chapter 
5.1.2.3.). From this calculation, there were 14/24 patients with margins <5 mm with audiovisual 
biofeedback, while only 5/24 for free breathing in the static beam case. The limitations of this 
margin analysis have been outlined in chapter 5.1.4. in that the margin calculation performed is not 
a direct measure of treatment margins, as it only takes into account the respiratory components of 
systematic and random errors of an external respiratory surrogates signal and assumes no other 
radiotherapy errors. But given that a clinical evaluation of audiovisual biofeedback has not yet been 
performed, such an approximation is the best available option.  
In this proposed study, we would like to increase the proportion of patients with reduced 
margins calculated using the van Herk method. This will be achieved in an exploratory phase II 
randomised clinical trial examining the potential impact of the audiovisual biofeedback system in 
facilitating regular breathing in lung cancer patients receiving radiation therapy for the treatment of 
lung cancer. Without this system, it is conservatively estimated that approximately 40% of patients 
experience regular breathing (margin component below 5mm). Increasing this proportion to 60% 
using the audiovisual biofeedback system would be clinically worthwhile. Based on Simon’s design,27 
a sample size of 50 patients receiving the audiovisual biofeedback system will have at least 80% 
power with 95% confidence to rule out a regular rate of 40% in favour of a 60% rate. To minimise 
patient selection bias and provide an estimate of regular breathing from a contemporary control, the 
proposed design will be a randomized phase II with 50 patients receiving the intervention and 25 
patients receiving the standard of care (no biofeedback intervention). Patients will be randomised in 
a 2:1 ratio, with 2/3 of the patients being recruited into the audiovisual biofeedback (intervention) 
arm and 1/3 in the free breathing (control) arm as shown in Figure 5-3 in chapter 5.2.3. 2:1 
randomisation is appropriate as within the interventional arm there is a screening procedure where 
only patients whose breathing is more regular with audiovisual biofeedback use this system for their 
imaging and treatment procedures (Figure 5-3 in chapter 5.2.3.).  Patients will be stratified by 
treating institution and for treatment intent (palliative vs. radical) to ensure similar balance in the 
arms across the sites. As the study is not powered for formal comparisons between the groups, 
estimates of the proportion of patients which do not experience irregular breathing will provide 
information as to whether further investigation is warranted. 
Assuming a contamination and dropout rate of no more than 10%, this study will require that 
75+8=83 patients be recruited (the 10% value was based on the 2/26 patient drop-out rate in the 
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VCU study). The estimated patient numbers are conservative because they are derived from the 24-
lung cancer patient VCU study which used a cruder breathing training system that what will be used 
in this study. Further to this, from the results presented in chapter 5.1.3.1., a training effect is 
evident with patients using audiovisual biofeedback, with their breathing becoming increasingly 
regular with time. With this in mind, additional measures of patient training will be incorporated into 
this clinical trial to expedite this training effect, implementing a brief practice period and a patient 
information video to further familiarise the patient with the audiovisual biofeedback system. 
Providing lengthy training sessions for each patient is not feasible in a busy department, therefore 
the training session was designed to fit within a reasonable amount of time such that the patient 
could be informed and introduced to audiovisual biofeedback in a time-efficient manner. Over-
training the patient through lengthy information and practice sessions that are clinically impractical 
may bias the results to have more audiovisual biofeedback patients in the intervention arm, 
compromising the secondary objective (see subsequent section 5.2.3. Study Protocol) of determining 
the indications and contra-indications for the use of audiovisual biofeedback.  
Patients at each institution will be treated per department protocol with no additional 
constraints on dose, fractionation, immobilisation or image guided procedures.  
5.2.3. Study Protocol 
The ethics, governance, legal, and regulatory processes were completed prior to the initiation of the 
clinical trial. The clinical trial was registered with the Australian New Zealand Clinical Trials Registry 
(ANZCTR), trial ID: ACTRN12613001177741. Documentation approved by the Hunter New England 
Human Research Ethics Committee is presented in Appendix II.  
This study’s protocol was published in BioMed Central Cancer. 
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randomised clinical trial 
 
Sean Pollock1*, Ricky O’Brien1, Kuldeep Makhija1, Fiona Hegi-Johnson2, Jane Ludbrook3, Angela Rezo4, 
Regina Tse5, Thomas Eade6, Roland Yeghiaian-Alvandi7,8, Val Gebski9   and  Paul J Keall1 
 
 
 
Abstract 
 
Background: There is a clear link between  irregular breathing  and errors in medical imaging and radiation 
treatment.  The audiovisual biofeedback  system is an advanced form of respiratory guidance that has previously 
demonstrated to facilitate regular patient breathing. The clinical benefits of audiovisual biofeedback will be 
investigated in an upcoming  multi-institutional,  randomised, and stratified clinical trial recruiting a total of 75 lung 
cancer patients undergoing  radiation therapy. 
Methods/Design: To comprehensively  perform  a clinical evaluation of the audiovisual biofeedback  system, a multi-
institutional  study will be performed. Our methodological  framework will be based on the widely used Technology  
Acceptance  Model, which  gives qualitative  scales for two specific variables, perceived usefulness and perceived  
ease of use, which are fundamental  determinants  for user acceptance. A total of 75 lung cancer patients will be 
recruited  across seven radiation  oncology  departments  across Australia. Patients will be randomised in a 
2:1 ratio, with 2/3 of the patients being recruited into the intervention arm and 1/3 in the control  arm. 2:1 
randomisation  is appropriate  as within the interventional arm there is a screening procedure where only patients 
whose breathing is more regular with audiovisual biofeedback will continue to use this system for their imaging 
and treatment procedures. Patients within the intervention arm whose free breathing is more regular than 
audiovisual biofeedback in the screen procedure  will remain in the intervention arm of the study but their imaging 
and treatment procedures will be performed without audiovisual biofeedback. Patients will also be stratified by 
treating institution and for treatment intent (palliative vs. radical) to ensure similar balance in the arms across the 
sites. Patients and hospital staff operating the audiovisual biofeedback system will complete questionnaires to 
assess their experience with audiovisual biofeedback. The objectives of this clinical trial is to assess the impact of 
audiovisual biofeedback on breathing motion, the patient experience and clinical confidence in the system, clinical 
workflow, treatment margins, and toxicity outcomes. 
(Continued on next page) 
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(Continued from previous page) 
Discussion: This clinical trial marks an important  milestone in breathing guidance studies as it will be the first 
randomised, controlled trial providing the most comprehensive evaluation of the clinical impact of breathing 
guidance on cancer radiation therapy to date. This study is powered  to determine the impact of AV biofeedback 
on breathing regularity and medical image quality. Objectives  such as determining the indications and contra- 
indications for the use of AV biofeedback, evaluation  of patient experience, radiation toxicity occurrence and 
severity, and clinician confidence will shed light on the design of future  phase III clinical trials. 
Trial registration: This trial has been registered with the Australian New Zealand Clinical Trials Registry (ANZCTR), 
its trial ID is ACTRN12613001177741. 
 
Keywords: Breathing guidance, Motion management, Randomised, Stratified, Phase II clinical trial, Lung cancer, 
Radiotherapy 
 
 
Background 
The precision of radiotherapy can be reduced due to 
respiratory-related tumour  motion,  particularly  for  tu- 
mours in the thoracic region, leading to increased ir- 
radiation  of healthy surrounding tissues, resulting in a 
significant  increase  in  radiation-related toxicity  [1–3]. 
This is further  exacerbated  when respiration is irregular 
in  nature   (deep/shallow   breaths,   baseline  shifts,  sus- 
pended  breathing,  etc.) [4, 5]. A 1Gy increase in tumour 
dose results  in a 4 % improvement in survival, [6] how- 
ever, a 0.5 cm range  of tumour motion  can cause a 4 ~ 
5 % variation  in radiation  dose [7] which leads to an 
in- crease   in  mean   dose  to  healthy   surrounding  
tissues resulting  in an increase in risk of pneumonitis 
and radi- ation toxicity [8, 9]. 
Techniques such as respiratory  gating, breath-holds and 
tumour tracking are clinically useful for tumour motion 
management [10, 4, 11]. However, irregular respiration can 
reduce the efficiency of such motion management tech- 
niques, [12, 13] irregular respiration also causes motion  ar- 
tefacts and anatomic  errors in medical imaging [14–19]. 
Breathing guidance is one such technique  which spe- 
cifically aims  to  produce   regular  patient   breathing   by 
showing  the  patient   how  to  adjust  their  breathing   in 
real-time.  One such breathing  guidance system is the au- 
diovisual (AV) biofeedback  system (shown  in Fig. 1), de- 
veloped by Venkat, et al [13]. 
AV biofeedback  is a real-time,  interactive  and  persona- 
lised respiratory  guide designed to facilitate regular patient 
breathing.  Table 1 outlines  the findings from previous AV 
biofeedback investigations. 
However, none of the studies presented in Table 1 were 
randomised trials, in addition  to this, the findings of a re- 
cent  literature   search  yielded  that  a randomised clinical 
trial with any breathing  guidance  intervention has not yet 
been performed.  To fill the gap in the literature,  we have 
designed  a multi-institutional,  phase  II, randomised clin- 
ical trial to thoroughly  assess the clinical impact of the AV 
biofeedback breathing  guidance system. Based on previous 
findings, we hypothesise  that  AV biofeedback  will signifi- 
cantly improve breathing regularity and reduce medical 
imaging  errors  for  lung  cancer  patients  undergoing im- 
aging and treatment procedures during radiotherapy. 
This trial has been registered with the Australian New 
Zealand  Clinical  Trials  Registry (ANZCTR),  its trial  ID 
is ACTRN12613001177741. 
 
Methods/Design 
This study aims to assess the clinical impact of AV biofeed- 
back by recruiting  75 lung cancer patients  across seven ra- 
diation  oncology  departments.  What  follows is an outline 
of the AV biofeedback setup, primary and secondary objec- 
tives, participant selection criteria, the study workflow, and 
statistical considerations for our study design. 
 
 
 
Fig. 1 AV biofeedback system (left). Display goggles and real-time position management  (RPM) marker block  on the abdomen shown. The 
visual display (right), as seen by the patient, of the AV biofeedback guiding  interface shows the waveguide (white curve) and a marker position 
(grey marker) in real time 
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Table 1 Details of previous AV biofeedback  investigations 
Investigation  author (Year) Participants Findings 
George [23] (2006) 24 lung cancer patients • Residual breathing  motion within a gating  window improved 
 
Venkat [13] (2008) 10 healthy volunteers • Waveguide breathing guidance produced more regular breathing             
__________________________________________________than bar-model guidance and free breathing 
Yang [22] (2012) Phantom study • 4D  PET image quality improved 
 
An [36] (2013) Retrospective  analysis 
___________________________of George (2006) data 
• CTV coverage  improved 
• Internal  motion variation improved 
 
Kim, [21] Pollock, [37] & 
Steel [38] (2012–2014) 
15 healthy volunteers • Kim (2012): Breathing  regularity  of thoracic diaphragm and abdominal wall improved 
 • Pollock  (2013): Accuracy  of kernel density estimation motion prediction improved 
 
• Steel (2014): Strong correlation  between  internal and external anatomic  motion 
for both AV biofeedback and free breathing 
Lee [24] (2014) 5 healthy volunteers • Improved  3D MR image quality 
• Reduced  gated  MRI scan time 
Lu [39] (2014) 13 lung & liver cancer patients • Breathing regularity improved 
• ITVMIP underestimated  ITV10 
Lee [40] (2014) 7 lung cancer patients • Improved intrafraction lung tumour motion consistency 
• Improved interfraction lung tumour motion consistency 
 
 
 
Research Ethics Committee 
The protocol for this clinical trial has been reviewed and 
approved by the Hunter New England Human Research 
Ethics Committee (HREC). This  Human  Research  Ethics 
Committee is constituted and operates  in accordance  with 
the   National   Health   and   Medical   Research   Council’s 
‘National  Statement on  Ethical  Conduct   in  Human   Re- 
search (2007)’ (National Statement) and the ‘CPMP/ICH 
Note of Guidance  on Good Clinical Practice’. The Hunter 
new England HREC has also been accredited  by the New 
South Wales Department of Health as a lead HREC under 
the single ethical and scientific review. A report on the 
progress of this clinical trial is required  to be submitted 
annually to the Hunter New England HREC. 
 
 
Audiovisual biofeedback system 
The  AV biofeedback  system,  as shown  in Fig. 1, utilises 
the Real-time Position  Management system (RPM, Varian 
Medical Systems, Palo Alto, USA) to track  the motion  of 
an external  marker  positioned  on the  patient’s  abdomen. 
This real-time  respiratory-motion is used by the AV bio- 
feedback software  to calculate  an average cycle of respir- 
ation  (using  a Fourier  series  fit from  10 obtained 
respiratory  cycles). This average cycle is used as the wave- 
guide  (white  curve  in  Fig. 1)  which  continually   moves 
from right-to-left across the visual display and acts as part 
of the visual prompt for AV biofeedback. Also on the vis- 
ual  display  is  a  grey  marker   moving  vertically  up-and- 
down  corresponding to  the  anterior-posterior motion  of 
the marker  block positioned  on the patent’s  abdomen.  It is 
the  goal for the  patient  to keep the  marker  block within 
inhale-exhale  limits (presented as the blue region in Fig. 1) 
and  match  the  grey marker  block  over  the  white  wave- 
guide.  The  audio  component of AV biofeedback  is clas- 
sical  music  playing  to  the  patient;  the  music  fades  to 
silence  should  the  marker  block  move  outside  the  blue 
area breathing  limits. AV biofeedback  has been shown  to 
be compatible  in a number of imaging and treatment mo- 
dalities, [20–22] as well as utilising  different  types of pa- 
tient   displays  [23,  21,  24].  There   are  two  options   for 
patient display in this study: video goggles, or a screen 
mounted to  the  couch.  Which  patient  display  option  is 
utilised  in this  study  will depend  on  what  is available at 
each institution. 
Figure  2 illustrates  the  schematic  of the  AV biofeed- 
back study setup,  from  the RPM camera  monitoring pa- 
tient  breathing  motion,  to the AV biofeedback  computer 
receiving the RPM signal and extending  the AV biofeed- 
back guiding interface  to the patient  display. 
 
 
Objectives 
This  clinical  trial  will  recruit   75  lung  cancer  patients 
across  7 radiation  oncology departments testing  the  fol- 
lowing objectives: 
Primary  objective: In  a prospective  multi-institutional 
randomised clinical trial we will test  the  hypothesis  that 
AV biofeedback will significantly improve breathing 
regularity  and  reduce  medical  imaging  errors  for  lung 
cancer patients  undergoing imaging and treatment pro- 
cedures  during  radiotherapy. 
Secondary  objectives  will involve  patient-specific and 
department-specific objectives: 
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Fig. 2 Audiovisual biofeedback study setup schematic 
 
 
Patient-specific  objectives are to evaluate the impact  of 
AV biofeedback by: 
 
1) Quantifying the proportion of patients for whom 
breathing  is more regular with AV biofeedback, 
2) Quantifying the variability in breathing  motion 
throughout a course of treatment, 
3) Quantifying the improvement in image quality with 
AV biofeedback, 
4) Evaluating the patient experience through  a 
perception  of care survey, 
5) Developing indications and contra-indications for 
the use of AV biofeedback, 
6) Quantifying the differences in image-guided radio- 
therapy (IGRT) shifts during treatment, and 
7) Recording toxicity outcomes  for up to 12 months 
after treatment has been completed. 
 
Department-specific objectives are to evaluate  the  im- 
pact of AV biofeedback  on clinical testing  by: 
 
1) Quantifying any practice changes (e.g. margin 
reduction), 
2) Quantifying the impact on workflow using the AV 
biofeedback device through  time-motion studies, 
3) Evaluating the operator  and clinician confidence in 
the AV biofeedback device’s reliability and clinical 
efficacy through  a technology-impact survey, 
4) Quantifying the system robustness  through 
hardware  and software fault reporting,  and 
5) Performing system quality assurance, sharing the 
results through  web-based uploads and provide 
feedback for QA improvement. 
Our methodological  framework will be based on the 
widely used Technology Acceptance Model (TAM) 
[25, 26]. The TAM gives qualitative scales for two 
specific variables, perceived usefulness and perceived 
ease of use, which are fundamental  determinants for 
user acceptance. 
Study participant selection criteria 
This study will recruit  patients  with cancer of the lung 
receiving  external  beam  radiation   therapy.  Patients  fit- 
ting  the  eligibility criteria  (see below)  will be identified 
and introduced to this study by their treating  physicians, 
who will participate as investigators  in this study. The 
eligibility criteria are as follows: 
 
1) Lung cancer patients 
i.  No restrictions  to type of external beam radiation 
therapy being received 
ii. Primary or secondary cancer 
2) >18 years old 
3) No gender or ethnic restrictions 
4) An ECOG score in the range of 0 to 2 
5) Able to give written  informed consent  and 
willingness to participate  and comply with the study 
6) No pregnant  / lactating woman 
 
Study workflow 
Once informed  consent  has been obtained,  the patient  will 
be randomised into  either  the intervention or control  arm 
of the study. For patients  randomised into the intervention 
arm,   prior   to   their   planning   and   treatment  they   will 
undergo  a breathing  decision session during which they will 
breathe  both with and without  the guidance of AV biofeed- 
back. Preceding  each breathing  session will be a training 
session to familiarise the patient with the AV biofeedback 
system. After the breathing  decision session has been com- 
pleted, the most reproducible breathing  condition (AV bio- 
feedback or free breathing)  will be determined in situ by an 
‘Analyse Respiratory  Session’ function  within  the  AV bio- 
feedback software. It will be the most reproducible breath- 
ing condition  that  will continue to be used throughout the 
rest of that particular  patient’s  planning  and treatment. The 
flowchart for this study is shown in Fig. 3. 
For  all  patients,   each  follow-up  visitation  they  have 
with their treating  physician for the first 12 months  after 
their  treatment has finished, their  treating  physician  will 
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Fig. 3 Study flowchart 
 
 
complete   a  toxicity   report   to   satisfy  the   Secondary 
Patient-Specific    Objective   7:  Recording   toxicity   out- 
comes for up to 12 months  after treatment has been 
completed   by reporting   the  occurrence and  severity  of 
any radiation  toxicities. 
 
Patient randomisation 
This trial is stratified,  hence,  study group  random  alloca- 
tion will be determined by minimisation [27, 28]. Patients 
will be stratified  by treating  institution and  for treatment 
intent  (palliative  vs. radical)  and  minimisation consider- 
ably reduces the imbalance of these stratification  factors 
across the control and intervention groups of the study. 
Patients  will be randomised in a 2:1 ratio, 2 out  of 3 pa- 
tients  will be randomised into the AV biofeedback  (inter- 
vention)  arm  and  1 out  of 3 will be randomised into  the 
free breathing  (control) arm as illustrated  by Fig. 3. 
 
Sample size and power calculation 
The  statistical  considerations  for  this  study  are  largely 
based on a previous study conducted at Virginia Com- 
monwealth  University (VCU) on 24 lung cancer  patients 
[23, 29]. Prior to this multi-institutional clinical trial, the 
VCU study was the largest AV biofeedback  investigation, 
recruiting  a total of 26 lung cancer patients, however, 2 
patients dropped out due to not being treated with 
radiotherapy or rapid  worsening  of disease, and  so their 
data was not collected. In the VCU study 109 breathing 
sessions  were  performed  comparing  AV biofeedback  to 
free  breathing,   of  which,  87  sessions  (80  %) demon- 
strated more regular breathing  with AV biofeedback. 
Framing  this is in a more  clinical relevant  way: irregular 
breathing   motion  exacerbates  the  systematic  errors  (Σ) 
arising  from  motion  image  artefacts  and  variations  be- 
tween  the  planned  and  treated  anatomy,  as well as ran- 
dom  errors  (σ) from  day-to-day  variations  in the treated 
anatomy  [30, 15, 31]. To  combine  systematic  and  ran- 
dom  errors  and estimate  the margin  contribution due to 
breathing  irregularity  we will use  the  van Herk  method 
[32]: margin = 2.5Σ + 0.7σ, incorporating the  respiratory 
components of systematic  and  random  errors.  A clinic- 
ally significant difference in clinical improvement due to 
AV biofeedback  has been determined to be a margin  cal- 
culation  of less than  5 mm. This magnitude of reduction 
was  elected  as  clinically  significant  because  this  is  the 
same magnitude  of displacement attributed to contribut- 
ing to  significant  artefacts  and  errors  during  radiother- 
apy procedures as detailed  in AAPM Task Group  76 [4]. 
From  this van Herk  calculation,  in the VCU study there 
were 14/24 patients  with margins <5 mm with AV bio- 
feedback, while only 5/24 for free breathing. 
In this proposed  study, to get a more  accurate  indica- 
tion  of the  proportion of patients  with reduced  margins 
calculated  using the van Herk method  we have designed 
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an  exploratory   phase  II  randomised  study  examining 
the potential impact of an AV biofeedback system in 
regulating  breathing  in patients  receiving  radiation 
therapy  for the  treatment of lung  cancer.  Without the 
AV  biofeedback  system,  it  is  conservatively  estimated 
that  approximately   40  % of  patients   naturally  exhibit 
regular breathing  (margin  component below 5 mm). In- 
creasing  this proportion to 60 % using the  AV biofeed- 
back system would be clinically worthwhile. Based on 
Simon’s design, [33] a sample size of 50 patients  receiv- 
ing the  AV biofeedback  system  will have at least  80 
% power  with  95 % confidence  to  rule  out  a regular  
rate of 40 % in favour  of a 60 % rate.  To  minimise  
patient selection   bias   and   provide   an   estimate    of   
regular breathing  from a contemporary control, the 
proposed design will be a randomised phase II with a 
50 patients receiving the intervention and 25 receiving 
current standard of care.  Patients  will be  randomised 
in  a 2:1 ratio,  with  2/3 of the  patients  being  recruited  
into  the AV biofeedback (intervention) arm and 1/3 in 
the free breathing  (control)  arm  as illustrated  by Fig. 3. 
2:1 ran- domisation is appropriate as within  the  
interventional arm  there  is a screening  procedure 
where only patients whose  breathing  is more  regular  
with  AV biofeedback 
use this system  for their  imaging  and  treatment proce- 
dures.  Patients  will be stratified  by treating  institution 
and for treatment intent  (palliative vs. radical) to ensure 
similar balance in the arms across the sites. As the study 
is  not  powered   for  formal  comparisons  between   the 
groups, estimates  of the proportion of patients  which do 
not experience  irregular  breathing  will provide informa- 
tion as to whether  further  investigation  is warranted. 
Assuming  a  contamination  and  dropout  rate  of  no 
more  than  10 %, this study will require  that  75 + 8 = 83 
patients  be recruited  (the  10 % value was based  on the 
2/26 patient  drop-out rate in the VCU study).  
Patients  at each  institution will be treated  per  depart- 
ment protocol  with no additional constraints on dose, 
fractionation, immobilisation or image guided procedures. 
Results will be adjusted for institution (using a fixed effect) 
to account  for differences between institutions. 
 
Data analysis 
The primary objective is to assess the impact of AV 
biofeedback  on  breathing  regularity  and  image  errors; 
the section that follows details the metrics  to be utilised 
for the primary  objective. 
Breathing  motion  regularity  is quantified  as the  root 
mean  square  error  (RMSE) in displacement and  period 
[13, 21, 24, 34]. A breathing  signal is separated  into its 
individual  cycles  and  an  ‘average’  waveform  is  calcu- 
lated using a Fourier series fit. Figure 4 illustrates an 
example  breathing  trace,  its separation  into  cycles, and 
its average waveform. 
RMSE will be calculated  as detailed  by Venkat,  et al., 
(2008),[13] but will be outlined  here for clarity. For a 
breathing  pattern comprised  of n individual breathing 
cycles,  where  each  cycle  in  the  phase  domain   can  be 
written  as X = {x1,  x2, …, x360} and the average waveform 
of these  cycles can be written  as Y = {y1, y2, …, y360},  the 
RMSE in displacement is calculated  as: 
 
The period of each of the n breathing  cycles, in seconds, 
can be written  as P = {p1, p2, …, pn}, with the period of the 
average waveform  expressed  as Periodmean,  the  RMSE in 
period is calculated as: 
 
The impact  of AV biofeedback  on 4D-CT  image qual- 
ity will utilise an automated method  of image artefact 
identification   developed  by Cui,  et  al., (2012),  [35] but 
will be outlined  here for clarity. The method  is based on 
.
Fig. 4 Example of breathing motion  trace (left) then separated into individual cycles with the average waveform shown as the red dashed curve (right) 
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the similarity between edge slices at adjacent  couch posi- 
tions  A and  B; the  edge  similarity  between  slice A and 
slice B is expressed  by the normalised  correlation coeffi- 
cient  (NCC). Deviations  from  standard NCC, represent- 
ing  normal   anatomical   changes   between   edge   slices, 
signify  the  presence   of  an  image  artefact.  Cui,  et  al., 
(2012)  reported   good  agreement   of  their  method   with 
the assessment  of two observers. 
 
Discussion 
This clinical trial marks an important milestone  in breath- 
ing guidance studies as it will be the first randomised, con- 
trolled  trial providing  the most  comprehensive evaluation 
of the clinical impact of breathing  guidance  on cancer 
radiation therapy to date. Based on the structure of 
previous investigations and taking into consideration the 
increase in scope of this study, the authors have designed 
a multi-institutional, randomised, phase II, stratified 
clinical trial to test the hypothesis that audiovisual 
biofeedback breathing guidance will significantly 
improve breathing regularity and reduce medical 
imaging errors for lung cacner patients undergoing 
imaging and treatment procedures during radiotherapy. 
While patients will be stratified by treating institution 
and for treatment intent, the study is not powered for 
formal comparisons between these stratified groups; 
estimates from the current proposed study of the 
proportion of patients which do not experience irregular 
breathing will provide information as to whether further 
investigation is warranted. Further to this, objectives 
such as determining the indications and contra-
indications for the use of audiovisual biofeedback, 
evaluation of patient experience, radiation toxicity 
occurrence and severity, and clinician confidence will 
shed light on the design of future phase III clinical trials. 
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 5.2.4. Institution Credentialing 
For an institute to become fully credentialed to recruit patients in this clinical trial it is required to:  
1) Receive ethics approval from a Human Research Ethics Committee (HREC) 
2) Receive ethics approval from Local Health District (LHD) 
3) Receive a receipt notification from the  Therapeutic Goods Administration (TGA) for the 
Clinical Trial Notification (CTN) 
4) Perform audiovisual biofeedback daily and monthly quality assurance (QA) in CT sim and 
linac rooms  
5) Perform clinical trial workflow, imaging, and data acquisition in CT sim and linac rooms with 
a motion phantom 
6) Perform clinical trial workflow and data acquisition in CT sim and linac rooms with a 
volunteer 
7) Transfer de-identified data from institution’s radiation oncology department to University of 
Sydney  
Points 4) through 7) need to be performed by investigators affiliated with the participating 
institution without input or assistance from investigators from the University of Sydney. This is to 
ensure that each institution can perform the clinical trial unsupervised, as it is not feasible for a 
University investigator to be present at all participating institutions during the study.   
Table 5-4 details the progress of each participating institution towards full credentialing.  
Nepean Cancer Centre has yet to commence training and credentialing due to not having a Varian 
RPM system available. Alternative motion sensors solutions are being explored; however, the 
absence of a current solution has limited the amount of progress of this institution towards 
credentialing.    
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 Table 5-4. Audiovisual biofeedback details for each of the seven participating institutions. 
Institution 
HREC 
approval 
LHD approval TGA approval QA performed 
Phantom tests 
performed 
Volunteer tests 
performed 
Data transfer Credentialed 
Patient 
recruited 
Calvary Mater 
Hospital, 
Newcastle 
Complete Complete Complete Complete Complete Complete Complete Yes 
Yes 
(April 11th, 
2016) 
Canberra Hospital Complete Complete Complete Complete Complete Complete Complete Yes No 
Royal North 
Shore Hospital 
Complete Complete Complete Complete Complete Complete To be done No No 
Gosford Hospital Complete Complete To be done Complete Complete Complete To be done No No 
Westmead 
Hospital 
Complete Complete To be done Complete Complete To be done To be done No No 
Chris O’Brien 
Lifehouse 
To be done To be done To be done Complete Complete Complete To be done No No 
Nepean Cancer 
Centre 
Complete To be done To be done To be done To be done To be done To be done No No 
 
 
  
132
 5.2.4.1. Investigator Training 
In order to be able to conduct the workflow of the clinical trial unsupervised, training was provided 
by University of Sydney investigators to institution investigators. This training involved:  
1) Clinical trial information presentation 
2) Performing daily and monthly QA under supervision  
3) Performing clinical trial workflow with phantom under supervision  
Documentation utilised to perform this investigator training is given in Appendix II. 
5.2.4.2. Credentialed Institutions 
Once investigator training was completed, investigators at each institution performed the 
credentialing procedures; the credentialing form used for this clinical trial can be found in Appendix 
IV. Table 5-5 illustrates the credentialing performed at the clinical trial study institutions.  
Table 5-5. Photo evidence of credentialing and training performed at each of the clinical trial’s participating 
institutions. Evidence of hospital staff training prior to credentialing is indicated with “training purposes”.   
Calvary Mater 
Hospital, 
Newcastle 
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 Canberra Hospital 
 
Royal North Shore 
Hospital 
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 Gosford Hospital 
 
Westmead 
Hospital 
 
Chris O’Brien 
Lifehouse 
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 Nepean Cancer 
Centre 
Training and credentialing to be performed once motion sensor solution is 
implemented. 
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 5.2.5. Discussion 
This clinical trial marks an important milestone in breathing guidance studies as it will be the first 
randomised, controlled trial providing the most comprehensive evaluation of a breathing guidance 
intervention on cancer radiation therapy to date. Based on the structure of previous investigations, 
as detailed in chapter 5.1. and taking into consideration the increased in scope of this study, a multi-
institutional, randomised, phase II, stratified clinical trial has been designed to test the hypothesis 
that audiovisual biofeedback breathing guidance will significantly improve breathing regularity and 
reduce medical imaging errors for lung cancer patients undergoing imaging and treatment 
procedures during radiotherapy. While patients will be stratified by treating institution and for 
treatment intent, the study is not powered for formal comparisons between the these stratified 
groups; estimates from the current proposed study of the proportion of patients which do not 
experience irregular breathing will provide information as to whether further investigation is 
warranted. Further to this, objectives such as determining the indications and contra-indications for 
the use of audiovisual biofeedback, evaluation of patient experience, radiation toxicity occurrence 
and severity, and clinician confidence will shed light on the design of future phase III clinical trials.   
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 5.3. Conclusion 
Through a retrospective analysis of a previous lung cancer patient audiovisual biofeedback study, 
valuable insights into patient training and the clinical impact of audiovisual biofeedback on radiation 
therapy were obtained to be utilised in the design of a randomised, phase II audiovisual biofeedback 
clinical trial.  Such a clinical trial marks an important milestone in breathing guidance studies as it will 
be the first randomised, controlled trial providing the most comprehensive evaluation of the clinical 
impact of breathing guidance on cancer radiation therapy to date. Objectives such as determining 
the indications and contraindications for the use of audiovisual biofeedback, evaluation of patient 
experience, radiation toxicity occurrence and severity, and clinician confidence will shed light on the 
design of future phase III clinical trials. 
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CHAPTER 6 
Translating evidence into clinical practice through commercialisation 
Translational research refers to translating research findings into medical practice, to enable broader 
implementation of a medical intervention outside the confines of a clinical trial to general clinical 
use. For audiovisual biofeedback, a medical device which has demonstrated benefits in proof-of-
principle studies1-4 has also further demonstrated more clinically relevant benefits in the 
translational research conducted and detailed in chapter 3, chapter 4, and chapter 5. Further to this, 
there is also granted patent protection5 underpinning the audiovisual biofeedback technology. One 
such method to translate evidence into clinical practice is through commercialisation; this 
commercialisation process was explored in-house.  
What follows is an analysis of the radiation oncology market in which the audiovisual biofeedback 
medical device will exist, the commercialisation process of audiovisual biofeedback, and how 
insights from these processes further developed the audiovisual biofeedback technology. The goal of 
the commercialisation process was to determine the feasibility of an audiovisual biofeedback 
medical product, to enable broader implementation of audiovisual biofeedback outside the confines 
of clinical trials in order to be used by more radiation oncology departments with more patients 
receiving radiation therapy.   
6.1. Radiation Oncology Market 
6.1.1. Global Market 
Cancer radiotherapy is a market which generates US$5.5 billion per annum worldwide and is 
growing 8% each year.6 Worldwide there are 7879 radiotherapy centres housing 11239 linear 
accelerators, 2275 Cobalt-60 therapy machines, and 7168 CT scanners and simulators for 
radiotherapy treatment planning.7  The largest markets in the world are the United States of 
America (USA), China, and Japan with 2736, 1118, and 792 radiotherapy centres, respectively. 
Western Europe is also a large market with 1050 radiotherapy centres. Australia is home to 71 
radiotherapy centres with 168 linear accelerators.8  
Two major companies operate in the cancer radiotherapy market, with a combined 80% market 
share for the companies Varian and Elekta. Figure 6-1 illustrates the major companies’ market share 
in cancer radiotherapy.9 
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 Figure 6-1. Cancer radiotherapy companies and their market share. 
*Tomotherapy, Brainlab, IBA, Still River Systems, ViewRay. 
It should be noted that Siemens has since left the cancer radiotherapy linear accelerator market.10 
6.1.2. Regulatory Bodies 
In cancer radiotherapy, regulatory bodies are responsible for assuring the safety, efficacy, and 
security of medical devices utilised for patient treatment. The Australian regulatory body is the 
Therapeutic Goods Administration (TGA), which follows a similar structure to the regulatory body of 
the European Economic Area, the Conformité Européenne (CE). The Food and Drug Administration 
(FDA) is the governing body over the world’s single largest cancer radiotherapy market: the USA.    
Medical devices are typically ranked according to classifications which indicate their risk and 
required controls. Risk is determined by the medical devices’ intended use, the probability of harm 
from the use of the device and the severity of that harm; the level of risk is determined by the 
medical device’s manufacturer. For consistency, the classifications will be outlined here in 
accordance with the Australian TGA, since this is where the audiovisual biofeedback technology is 
based and operates under. The TGA medical devices categories are detailed in Table 6-1.11  
Table 6-1. Medical device classifications, in order of lowest risk to highest risk. 
Classification Level of risk 
Class I Low risk medical device. 
Class I (measuring / supplied sterile) Low – medium risk medical device. 
Class IIa Low – medium risk medical device. 
Class IIb Medium – high risk medical device. 
Class III High risk medical device. 
Active Implantable Medical Devices (AIMD) High risk medical device. 
With increasing risk of the medical devices’ classification come increasing regulatory requirements 
for the medical device to satisfy, as illustrated by Figure 6-2.   
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 Figure 6-2. Risk of 
medical device verses 
regulatory 
requirements. Adapted 
from  Australian 
regulatory guidelines 
for medical devices 
(ARGMD) Version 
1.1.12 
6.1.3. Cancer Radiotherapy Customers  
Who and what constitute a customer can be divided into three main customer segments: Users, 
Choosers, and Payers.13 There can be overlap between these categories in the radiotherapy market, 
and it is important to map out the decision making process towards a medical device being 
purchased, as there may be different value propositions desired by the different customer segments.  
Users are considered those who directly interact with the medical device itself. In cancer 
radiotherapy the users are typically the patients, radiotherapists, and medical physicist. The patients 
are the end recipient of the medical device designed to form part of the radiation treatment 
process. Radiotherapists are responsible for the setup and operation of medical devices involved in 
each patient’s treatment. Medical physicists are responsible for conducting the quality assurance for 
the medical devices involved in the patients’ radiation treatment.  
Choosers are those who strongly influence the decision of whether or not to acquire new 
equipment. In cancer radiotherapy the users are primarily the department heads (chief physicist, 
chief radiotherapist) and radiation oncologists. Department heads coordinate the activities of their 
respective staff (either medical physicists or radiotherapists); they will not typically use the medical 
devices themselves and operate in more of a managerial role. Radiation oncologists prescribe the 
radiation treatment for the patient and will often be there to oversee the treatment delivery 
process. Choosers will often attend conferences and training days to identify new techniques to 
implement. While Choosers are the key decision makers, they often strongly rely on the hospital 
Users involved in executing the patient treatments such as the radiotherapists and medical 
physicists.  
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Payers are those responsible for the monetary purchase of the medical device. In cancer 
radiotherapy, Payers are often not involved in the patient’s treatment, and occupy more of a 
hospital administrative role indented from the patient’s treatment. In cancer radiotherapy, the 
Payer is typically the radiation oncology department, and unlike the Users and Choosers, is the only 
customer responsible for the monetary purchase of the medical device.    
6.1.4. Existing respiratory motion management interventions 
Table 6-2 below lists respiratory motion management medical devices currently available on the 
cancer radiotherapy market, their primary functionalities, their class of medical device, and their 
price. As indicated in chapter 2,14 of the medical devices presented in Table 6-2 the Varian Real-time 
Position Management (RPM) system has been the most prominently utilised medical device in 
cancer radiotherapy respiratory motion management research.  
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 Table 6-2. Cancer radiotherapy respiratory motion management medical devices currently available.  
Proposed audiovisual biofeedback medical device also included for comparison.  
Medical device 
Monitors patient  
breathing 
Synchronises 
with treatment 
/ imaging 
Breathing 
guidance 
biofeedback 
Does not 
touch the 
patient 
Key components 
Class of 
Medical 
device 
Price 
(Australian 
dollars) 
Varian Real-time Position 
Management (RPM)15 
 
 
Infra-red (IR) 
camera 
   
1. IR camera 
2. Marker block 
Class IIb $62,000 * 
Elekta Active Breathing 
Coordinator (ABC)16 
 
 
Spirometer 
 ‡  
1. Mouthpiece 
2. Spirometer tube 
3. Nose plug 
Class IIb $80,000 * 
QFix SpiroDynr’X (SDX)17 
 
 
Spirometer 
 
 
Breathing signal 
and target 
 
1. Mouthpiece 
2. Spirometer tube 
3. Nose plug 
4. Video goggles 
Class IIb $104,000 † 
VisionRT AlignRT18 
    
1. Camera Class IIb $200,000 * 
146
 Optical surface 
tracking 
Medspira19 
 
 
Chest belt 
 
 
Light-up display 
panel 
 
1. Patient display 
2. Chest belt 
Class I $32,000 † 
Calypso20 
 
 
Beacon 
   
1. Beacon 
2. Panel 
Class IIb $800,000 * 
Audiovisual Biofeedback 
 
  ‖   
1. All-in-one unit Class I $50,000 
* Information obtained from customer interviews  
† Information obtained from vendors 
‡ Reflective mirrored prism-goggles are available to view monitor display across room 
‖ Integration with the CT scanner and linac to facilitate CT sorting and beam holds respectively is a desirable feature of the AVB system, but is not planned for the initial 
product release 
  
  
147
6.2. Commercialising Audiovisual Biofeedback   
The following programs, shown in Figure 6-3 were utilised to explore and develop audiovisual 
biofeedback’s commercialisation pathway: the University of Sydney offered Genesis21 and Incubate22 
startup accelerator programs, and NSW Health’s Medical Device Commercialisation Training 
Program (MDCTP).23 
   
 
 
 
Figure 6-3. Left to right: the University of Sydney Genesis, Incubate, and NSW Health MDCTP startup 
accelerator programs.  
The general approach for each of these programs was that of a startup company, typically defined by 
the search for the right business model,24 which is achieved by talking to customers, investigating 
regulatory affairs, and determining the product-market fit.25 For the purposes of these programs, the 
current research setup described in chapter 4 and chapter 5 was considered a research prototype, 
with the details of what the final medical product would be becoming more and more apparent 
through the progression through each of these commercialisation programs and with increasing 
customer engagement.  
6.2.1. Value Proposition of Audiovisual Biofeedback 
The first step is to determine what the value proposition of the medical device is. Determining what 
value the device creates for the proposed customers, what customer pains does it alleviate and what 
desired gains does it create for the customer? For audiovisual biofeedback, the proposed value 
propositions are the following:  
1) Patient-customised breathing guidance biofeedback  
o Breathing guidance negates the errors arising from breathing motion irregularities 
as detailed in chapter 2, chapter 3, and chapter 4. 
o Personalised guide adds an additional element of personalised healthcare appealing 
to both the patient and their physicians 
2) All-in-one motion sensor, patient display medical device unit 
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o By having all required components for the device housed in a single unit, this 
reduces the needed setup and calibration times compared to existing medical 
devices presented in Table 6-2 
3) Active patient involvement in assisting accurate radiation treatment 
o Patient is no longer a passive participant in their treatment 
o Patient empowered in helping improve their own treatment  
The value propositions described above were used to develop the concept for the final audiovisual 
biofeedback medical device, highlighted in Figure 6-4. 
  
Figure 6-4. Audiovisual biofeedback product concept design, highlighted on the CT couch on the left, and 
components indicated on the right. Images curtesy of DESIGN + INDUSTRY Sydney.26 
Prior to conducting customer interviews the initial value propositions are effectively hypotheses on 
what we think customers want. In order to effectively conduct customer interviews, the customers 
for audiovisual biofeedback need to be identified and mapped out.  
6.2.2. Customer Segments for Audiovisual Biofeedback 
As described above, customers are not only the ones responsible for the monetary purchase of the 
medical device but also the conceptual purchase of the device. The majority of those that will 
interact with the medical device, the radiotherapists, the medical physicists, the radiation 
oncologists, may not be responsible for the actual monetary purchase of the device, but are 
instrumental in recommending its use and acquisition.  Table 6-3 details the Users, Choosers, and 
Payers and their interaction with the audiovisual biofeedback medical device.  
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Table 6-3. Details of the Users, Choosers, and Payers of the audiovisual biofeedback medical device.  
User 
Patient. The cancer patient will directly interact with the audiovisual biofeedback device. The 
medical device will monitor their breathing and the patient will then follow the guiding 
prompts. The patient is understandably anxious about their treatment.  
Radiotherapist. Radiotherapists prepare the treatment rooms for each patient’s treatment, so 
they will be responsible for setting up the audiovisual biofeedback device prior to the patient’s 
arrival, controlling the software during treatment, and packing it away once the treatment is 
over. 
Medical Physicist. Medical physicists perform quality assurance tests on the audiovisual 
biofeedback device, assuring that the hardware and software components will perform robustly 
during patient treatment. 
Chooser 
Radiation Oncologist. The radiation oncologists will not directly interact with the audiovisual 
biofeedback medical device, but are crucial in recommending its use. Radiation oncologists are 
key decision makes in adopting new techniques and technologies. 
Department Head. Similar to the radiation oncologists, department heads are crucial in 
recommending the acquisition of audiovisual biofeedback. However, while radiation oncologists 
will be more motivated by clinical benefits of the medical device, the department head will also 
have more focus on the cost-benefits of the medical device. 
Payer 
Radiation oncology department. Typically from a capital budget, the radiation oncology 
department will represent the final stage of approving and paying for a purchase recommended 
by the radiation oncologist and/or department head.  
The typical decision making process, highlighting the users, choosers, and payers in a radiation 
oncology department, is illustrated in Figure 6-5. 
 
Figure 6-5. Typical decision making process in a radiation oncology department. 
Each of the customer segments presented in Table 6-3 and Figure 6-5 prioritise the value 
propositions of audiovisual biofeedback differently. To best align the value propositions of 
audiovisual biofeedback with its customer segments, customer interviews are required to determine 
whether there is a product-market fit for the medical device. It should be noted that the 
relationships in a multi-disciplinary radiation oncology department are far more complex than 
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linearly indicated in Figure 6-5, with each indicated segment having influence over the others. For 
example, a radiation oncologist will defer to the judgement of the radiation therapist as they are the 
ones conducting the patient treatments every day; or a department head heeding the advice of 
medical physics on the technical feasibility of medical equipment.     
6.2.2.1. Customer Interviews 
A total of 106 customer interviews were conducted; interviewees ranged from hospital staff, medical 
companies and vendors, cancer patients, and business and startup mentors. Table 6-4 details the 
number of interviews and interviewees. 
Table 6-4. Total number of interviews conducted. 
Hospital Staff 73 
Radiotherapists 30 
Medical Physicist 12 
Radiation Oncologists 12 
Department Heads 11 
Other* 8 
Companies/ vendors 15 
Cancer patients 6 
Business/startup mentors 12 
*Radiologists, technicians, scientists 
32 interviews were conducted during the Incubate accelerator program, and 74 were conducted 
during the MDCTP.  
An online survey was conducted during Incubate interviews determining how important regular 
respiratory motion and the importance of the use of audiovisual biofeedback was in the facilitation 
of this. The questions provided in the online survey and the overall responses are given in Table 6-5. 
Table 6-5. Responses to interview questions conducted in the Sydney Incubate program. 
(1) How important do you consider 
regular and stable patient 
breathing-motion to be during 
imaging and/or radiation 
treatment? 
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(2) How useful would audiovisual 
biofeedback be for patients' 
imaging and/or treatment? 
 
 
(3) How likely is it that you would 
recommend audiovisual 
biofeedback’s use in patient 
imaging and/or radiation 
treatment 
 
(4) How useful would breath-hold 
guidance be for patients' imaging 
and/or treatment? 
 
(5) Which function do you consider 
more useful: standard breath 
holds (SBH) or deep-inspiration 
breath holds (DIBH)? 
 
(6) How likely is it that you would 
recommend audiovisual 
biofeedback to a colleague?  
(7) For which patients / conditions 
do you consider audiovisual 
biofeedback to be useful? 
(Multiple answers possible)  
Lung cancer 87% 
Liver cancer 73% 
Breast cancer 60% 
Stress/anxiety 53% 
Kidney cancer 40% 
Pancreas cancer 33% 
Hypertension 27% 
Pneumonitis 20% 
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Interviews conducted throughout the MDCTP, rather than focusing on what customers thought 
about audiovisual biofeedback, focused on what customers thought about what they currently 
implemented in cancer radiotherapy. Information gathered from these interviews provided insights 
into what the customers’ main frustrations and desired improvements were and whether the value 
propositions offered by audiovisual biofeedback aligned with, or could be adapted to, addressing 
these problems encountered by customers. Also, given the interest expressed from previous 
interviews in breath hold guidance, MDCTP interviews also perused this functionality of audiovisual 
biofeedback.  
From the 74 interviews conducted in the MDCTP, Table 6-6 details the main frustrations and desires 
expressed by cancer radiotherapy hospital staff.  
Table 6-6. Key insights from hospital staff on current medical devices used in cancer radiotherapy. 
Radiation Oncologists Medical Physicists Radiotherapists 
Reproducibility of medical device 
Extra time is needed to implement 
new technologies 
Poor patient communication 
Cost-effectiveness of medical 
device 
Software interface of current 
medical devices (see Table 6-2) 
often frustrating to use 
Poor patient compliance 
A total of 37 Australian radiation oncology departments (52% of the Australian market) participated 
in these interviews. Clinically in Australia, there are no hospitals with a solution to facilitate regular 
patient breathing, and there are 20 hospitals that are not performing DIBH with their breast cancer 
patients. A key element of the commercialisation process is establishing a product-market fit, 
ensuring the product offering matches your customers’ wants and needs, pivoting if need be to 
ensure that it does. A key element that customers communicated during the interview process is 
that there is a strong desire for biofeedback methods for deep inspiration breath holds with breast 
cancer patients. As such, DIBH for breast cancer patients was also considered in the 
commercialisation process.  
Patients who were interviewed indicated that had there been an option for them to help assist with 
improving their radiation therapy, they would have wanted to contribute.  
Customer interviews yielded that there is not an equivalent breathing guidance solution on the 
market to audiovisual biofeedback, and that the key insights from hospital staff highlighted the need 
for an effective and simple to use solution to maximise communication efficiency between patients 
and radiotherapists and minimise setup time. This higher efficiency would lead to faster treatments 
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times per patient, allowing more patients to be treated per day, increasing the cost-effectiveness of 
the medical device.  
6.2.3. Regulatory Approval 
While audiovisual biofeedback does monitor patient breathing motion, but these measurements are 
not used to diagnose, prescribe, or guide treatment, and as such audiovisual biofeedback is 
considered a non-measuring device. For the cancer radiotherapy procedures it will be used for, 
audiovisual biofeedback is not required to be kept sterile. Therefore, audiovisual biofeedback is a 
Class I medical device. Table 6-7 details the regulatory requirements of audiovisual biofeedback for 
the regulatory bodies TGA, CE, and FDA.  
Table 6-7. Regulatory approval classification and details for the regulatory bodies of Australia, the USA, and 
Europe. 
 Australia Europe USA 
Regulatory Admin TGA CE FDA 
Classification Class I Class I Class I 
Quality 
Management 
System 
Not needed27 Not needed28 Not likely needed29 
Risk Analysis Low risk30 Low risk31 No risk analysis needed32 
Regulatory body 
intervention 
Incidence reporting to 
TGA33 
Notify local government 
authorities of adverse event34 
Incidence reporting to FDA35 
It should be noted that should audiovisual biofeedback be synchronised with the radiation 
treatment beam, this would increase the class of medical device to Class IIb, because then the 
measurements taken by audiovisual biofeedback are being used to guide treatment.  
6.2.4. Intellectual Property & Freedom to Operate 
Current intellectual property (IP) is primarily in the form of United States patent US 7955270 B2 
protecting the methodology of producing a customised patient-specific interface for biofeedback 
breathing guidance.5  
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 Figure 6-6. US 7955270 B2 figures demonstrating the audiovisual biofeedback setup (left) and guiding interface 
(right).5  
This patent protects the world’s single largest radiation oncology market, the United States of 
America, which is also where the largest radiation oncology company, Varian, is based. Personalised 
medicine is becoming increasingly of interest,36, 37 so producing a customised patient-specific 
breathing guide to further tailor radiation treatment to the patient is one of audiovisual 
biofeedback’s competitive advantages. This patent details claims pertaining to a respiratory audio-
visual biofeedback device for medical imaging and radiotherapy treatment procedures incorporating 
a target position and the patient’s position and presenting them in such a way such that the 
difference between the target position and patient position is readily apparent. Subsequent claims 
relate back to this core claim further incorporating elements of learning patient breathing and 
producing target position via mathematical algorithms. This protects the audiovisual biofeedback IP 
by protecting the use of audio and visual prompts to guide patient respiration, in addition to 
producing a customised guiding interface by learning the patient breathing through mathematical 
algorithms. 
Table 6-8 details the findings of a freedom to operate search, detailing similar patents to patent US 
7955270 B2 protecting audiovisual biofeedback and their relative risk to US 7955270 B2. For 
reference, audiovisual biofeedback’s patent US 7955270 B2 was filed on 04/10/2006 and granted on 
07/06/2011. 
Table 6-8. Findings of freedom to operate search.  
Patent Summary of claims Relative risk of IP 
Patent number: US 6,937,696 
B1 
Title: Method and system for 
predictive physiological gating 
Filed: 26/06/2001 
 Method of detecting / estimating 
regular cycles of physiological 
activity 
 Gating of radiation treatment based 
on the phase of physiological 
Low.  
Patient guidance / feedback not 
considered. 
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Date of patent: 30/08/2005 activity  
Patent number: US 7,393,329 
B1 
Title: Method and apparatus for 
delivering radiation therapy 
during suspended ventilation 
Filed: 22/05/1998 
Date of patent: 01/07/2008 
 Apparatus: ventilator controlling 
inhalation and exhalation 
 Valves in ventilator shut to suspend 
patient breathing 
 Display apparatus of lung volume 
and target 
 Apparatus of mirror-glasses to view 
display 
Low-Medium.  
Apparatus described is decidedly 
different from audiovisual 
biofeedback.  
Claims detailing a ‘target’ and 
‘display’ relate it back to lung 
volume and mirror-glasses. 
Infringement between 
audiovisual biofeedback and this 
unlikely.   
Patent number: US 7,869,562 
Title: Automatic patient 
positioning system 
Filed: 18/03/2009 
Date of patent: 11/01/2011 
 3D optical imaging system for 
positioning patient relative to 
radiographic equipment 
 3D optical system produces 
positional signal 
 Used to reposition the couch 
relative to various scanners 
Low.  
Filing date is later than 
audiovisual biofeedback’s.  
audiovisual biofeedback utilises 
a 1D signal, this was focussed on 
3D 
No details regarding displaying 
signal to patient  
Patent number: US 7,769,430 
B2 
Title: Patient visual instruction 
techniques for synchronising 
breathing with a medical 
procedure 
Filed: 30/09/2004 
Date of patent: 03/08/2010 
 Continuation of ‘US 6,937,696 B13’ 
 Informing patients of the 
relationship between an action 
performed by the patient and a 
target result to be achieved 
 Focus on synchronisation with 
radiation source and medical device. 
High.  
Has earlier filing date than 
audiovisual biofeedback’s. 
Details relationship between 
patient position and the desired 
target position.  
Details synchronisation with 
‘radiation source’ and ‘medical 
device’.  
Patent number: US 8,619,945 
B2 
Title: Prediction-based breathing 
control apparatus for radiation 
therapy 
Filed: 20/09/2011 
Date of patent: 31/12/2013 
 Method of radiation delivery based 
by determining a future treatment 
opportunity 
 Past observed motion is used to 
predict future positions 
Low.  
Details using the breathing signal 
to predict future position for the 
radiation beam to fire upon.  
No details on providing feedback 
to the patient or breath holds.  
Patent number: US 8,781,558 
B2 
 Ventilator used to generate 
respiratory manoeuvres 
Medium.  
Patent specific to ventilation 
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Title: System and method of 
radiation dose targeting through 
ventilator controlled anatomical 
positioning 
Filed: 07/11/2011 
Date of patent: 15/07/2014 
 Closed loop with imaging / 
treatment machines  
 
methods (spirometry), however, 
feedback to patient is mentioned 
in one of the claims.  
audiovisual biofeedback has 
earlier filing date. 
Patent number: US 
2006/0129044 A1 
Title: Device for monitoring 
anatomical imaging unit or a 
radiotherapy unit 
Filed: 22/04/2002 
Date of patent: 15/06/2006 
 Representing ventilator level of 
their suspended ventilator level for 
inhalation and exhalation  
 Two valves: rest valve, triggering 
valve  
Medium.  
Has earlier filing date than 
audiovisual biofeedback. But 
pertains to ventilation, i.e. 
measuring airflow, not anatomic 
motion.  
Potential conflict of ‘suspended 
breathing’ claims.  
Patent number: US 
2013/0211261 A1 
Title: Motion compensation and 
patient feedback in medical 
imaging systems 
Filed: May 7, 2010 
Date of patent: 15/08/2013 
 An optical motion sensing system  
 This was confusingly worded… 
 Generate feedback data, providing 
audio and visual feedback indicative 
of the anatomic structure 
Medium-High.  
Details of the feedback motion 
sensor descriptions seem to 
infringe on audiovisual 
biofeedback patent claims.  
audiovisual biofeedback’s patent 
predates this one. 
Patent number: US 
2013/0261424 A1 
Title: System for inducing 
respiration using biofeedback 
principle 
Filed: 08/03/2013 
Date of patent: 03/10/2013 
 A system for processing a 
biofeedback-treated, respiration-
induced signal image using the 
biofeedback principle.  
 Claims focussed on image 
processing for segmenting an 
observed image into regions and 
extracting signal from there 
Medium.  
While biofeedback is detailed in 
the application, the claims 
pertain to image processing.  
Potential conflict for how certain 
motion sensors can operate.   
From the results of the freedom to operate search, there is one patent (US 7,769,430 B2) with an 
earlier priority date that poses a high risk to audiovisual biofeedback’s IP. However, Varian, which 
owns patent US 7,769,430 B2, did not extend this patent to protect the Australian market. 
Therefore, audiovisual biofeedback has freedom to operate in the Australian market, with a 
potential risk of patent infringement in the American market.  
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6.2.5. Reimbursement 
In order to be eligible for insurance reimbursement a medical device, under the Australian Medicare 
system, needs:  
 TGA approval 
 To lodge an application to Medical Services Advisory Committee (MSAC) 
o To demonstrate health benefit and economic benefit in terms of quality adjusted life 
years (QALYs) and incremental cost-effectiveness ratio (ICER), respectively. 
The Medicare Benefits Schedule (MBS) doesn’t usually make reference to the specific equipment 
used, it typically just refers to the service provided; radiation Oncology – General has the MBS Note 
T2.1.38 However, there are exceptions should the medical device demonstrate a certain level of 
health benefits and cost-effectiveness. For example, gold fiducial markers implanted in the prostate 
for use in radiotherapy has the MBS item number 37217.39 
Audiovisual biofeedback needs to demonstrate a certain level of health and economic benefits 
before it can be listed on the MBS for reimbursement. Outcomes of ongoing and future clinical trials 
will provide evidence as to whether this is achievable; otherwise, the radiation oncology department 
will be the sole payer of the device. 
6.2.6. Market Analysis and Business Model 
Based on the price of similar medical devices shown in Table 6-2, the revenue stream of the 
audiovisual biofeedback medical device is a capital cost of $50,000 for the audiovisual biofeedback 
product was determined to be both competitive and conducive to generate positive cash flow once 
making sales. Further to this, similar medical devices also include a service cost of 20% to cover staff 
training, installation, system breakages, and maintenance. As such, there will also be an annual 
service charge of an additional 20% ($10,000) for audiovisual biofeedback.  
6.2.6.1. Audiovisual Biofeedback Market    
The market for audiovisual biofeedback will be considered from three perspectives: the total 
addressable market, served available market, and the target market.24 The total addressable market 
refers to monetary value representative of if everyone who could purchase the medical device did 
purchase the medical device. The served available market represents those customers in the total 
addressable market that can be feasibly reached through an available sales channel. The target 
market represents the medical device’s first customers.  
Audiovisual biofeedback would be used on CT scanners and simulators in addition to linacs; as 
detailed in chapter 6.1.1., there are 11244 linacs and 7169 CT scanners and simulators worldwide,7 
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therefore there are a total of 18413 facilities where audiovisual biofeedback can be used, 
representing a total addressable market size of $1,104,780,000. Note that each purchase takes into 
account the capital cost of $50,000 in addition to the first years’ service cost ($10,000).  
Since it is more likely that our serviceable markets are Australia, the USA, and Europe, where there 
are 6523 linacs and 2818 CT scanners and simulators,7 this represents a served available market size 
of $560,460,000.  
The first sales of audiovisual biofeedback will likely be made in Australia, as that is where both the 
technology and the team behind it are based. The first customers will most likely be those hospitals 
who currently no not perform breathing guidance for both regular breathing and DIBH. As detailed 
in chapter 6.2.2.1., this is represented by 20 hospitals. Each Australian hospital will have one CT 
scanner or simulator, and has an average of 2.3 linacs per radiation oncology department.7 Taking 2 
linacs per department as a conservative estimate, audiovisual biofeedback’s first customers 
comprise of 40 linacs and 20 CT scanners and simulators, representing a target market of 
$3,600,000.  
6.2.6.2. Business Model Canvas  
A business model canvas, shown in Figure 6-7, is a tool to identify and plan out the main aspects of a 
company, a startup company is typically defined as the search for the business model outlining not 
only their first customers, but a scalable business.24   
 
Figure 6-7. A blank business model canvas.40 
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The value proposition, customer segments, and revenue streams have already been described. The 
order in which to approach each component of the business model canvas is as follows: (1) 
Customer segments, (2) Value proposition, (3) Customer relationships, (4) Channels, (5) Revenue 
streams, (6) Key resources, (7) Key activities, (8) Key partners, (9) Cost structure.40 When the value 
proposition aligns with the customer segments, this is referred to a product market fit.25  
Customer relationships outline the different types of relationships the business has with its 
customer segments. These could be how first contact is made with customers and how the 
relationship is sustained once the customer acquires the medical device. Channels describe how the 
medical device and the value it delivers is provided to the customer segments.   
Key resources describes business’ infrastructure and what resources of are crucial for the business’ 
success. This can involve the team itself executing the business plan and IP protection.  Similarly, key 
activities describe what needs to be done for the business to succeed; these activities can be 
broadening IP protection, fund raising, and regulatory approval. Key partnerships describe those 
outside your business who can assist in adding value to your business. Examples of key partners 
include clinical trial partners, manufacturing partners, and distribution partners. 
Once components (1) through (8) on the business model canvas are well understood will reveal how 
much each of these components will cost. If the cost structure is appropriately less than the revenue 
stream, then there is a viable business model. 
Initially, the business model canvas for audiovisual biofeedback was filled in with assumptions about 
what we thought its model model should be. Over time, the business model canvas for audiovisual 
biofeedback was continuously refined over the 106 performed customer and mentor interviews. 
Figure 6-8 details the current business model canvas for audiovisual biofeedback after all the 
customer interviews.  
Through the customer interviews, the decision making process for acquiring new equipment of 
radiation oncology departments was determined, as such, key relationships with customers and the 
channel to customers was determined to best utilise existing relationships through clinical trials, 
demonstrate the technology at hospital research meetings, providing the technology to customers 
via distributions channels provided by the manufacturers.  
Also throughout the interview process, component providers, designers, and manufacturers were 
identified and enganged to produce the final audiovisual biofeedback product.41-43 The audiovisual 
biofeedback product concept design shown in Figure 6-4 is a result of these engagements.  
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This business model canvas details the not only audiovisual biofeedback’s first customers (the target 
market) but is scalable and so describes customers for when audiovisual biofeedback enters the 
international market (the served available market).  
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 Figure 6-8. Business model canvas for audiovisual biofeedback. 
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6.2.6.3. Cost-effectiveness of audiovisual biofeedback  
In addition to determining a product-market fit, a key element to be demonstrated by medical 
devices is the cost-effectiveness, especially for it to be eligible for insurance reimbursement, as 
detailed in chapter  6.2.5.. The primary health benefit of audiovisual biofeedback  will present itself 
in terms of reducing the occurance and severity of radiation toxicities, and therefore, the primary 
cost-effectiveness of audiovisual biofeedback will be in terms of reducing the costs associated with 
managing these toxicities.  
As shown in Table 6-5, the patients for whom audiovisual biofeedback was considered most useful 
were lung, liver, and breast cancer patients; lung and breast cancer are also the two most common 
forms of cancer. The most common radiation toxicities for such patients include esophagitis, 
pneumonitis, pulmonary fibrosis, and cardiovascular complications such as ischemic heart disease. 
For the purpose of this analysis, cost-effectiveness for lung cancer patients was considered from the 
perspective of regular breathing audiovisual biofeedback, and cost-effectiveness for breast cancer 
patients was considered from the perspective of deep inspiration breath hold (DIBH) audiovisual 
biofeedback. Table 6-9 details the costs involved in managing radiation toxicities. 
Table 6-9. Costs involved in managing radiation toxicities. Values given are 
in Australian dollars.  
Cardiac toxicities 
Event Cost 
Coronary Artery Grafts-Bypass surgery $38,10044 
Insertion of a Cardiac Stent $7,80044 
Coronary Angiogram $9,10044 
Pulmonary toxicities 
Esophagitis $1,754.2445 
Pneumonitis $5,672.5245 
Pulmonary fibrosis $1,502.6145 
Miscellaneous costs 
Hospital bed per day $325.9146 
Economic cost of one sick day $37547 
Table 6-10 details the occurrence and length of recovery for lung and breast cancer patients with 
such aforementioned toxicities. It has been reported that for patients presenting with cardiac 
toxicities 1/3rd of these patients require an angiogram and stents and 10% are treated with coronary 
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artery bypass surgery.48  Based on this and the values presented in Table 6-9, the average cost of 
cardiac toxicities per patient was calculated to be $9,443.33.  
Table 6-10. Occurance and recovery time of raidation toxicities for free breathing lung 
and breast cancer patients.  
Breast cancer patients 
Occurrence of serious cardiac event 
(no radiotherapy) 
19.2%49 
Increase of risk due to the use of radiotherapy 43%50  
Relationship between risk of cardiac event and 
radiation dose to the heart 
Increases by 7.4% with each Gy of 
mean heart dose51 
Hospital days after surgery 
(see Table 6-9) 
Up to 852 
Sick days after surgery 
Up to 2 months52 
(40 business days)  
Risk of pneumonitis 14%50 
Lung cancer patients 
Risk of esophagitis 31.6%45 
Risk of pneumonitis 30%45 
Risk of pulmonary fibrosis 8.3%45 
Relationship between risk of pulmonary toxicity 
and radiation dose to the lungs 
Increases by 10% from an increase 
of 4.5% in mean lung dose53 
Relationship between treatment margin size and 
dose to the lungs 
23% reduction in PTV (~0.29cm) 
corresponds to 10% reduction in 
mean lung dose54 
Based on the information presented in Table 6-10, radiotherapy increases the risk of a serious 
cardiac event by 43%, from 19.2% to 27.5%, for free breathing breast cancer patients. Further to 
this, for free breathing breast cancer patients receiving radiotherapy, the risk of a cardiac event 
increases by 7.4% with each Gy delivered to the heart. In addition to this, also taking into account 
the information presented in Table 6-9, the cost of an 8 days stay at the hospital equates to 
$2,607.28 and 40 sick days equates to $15,000. However, this would only be applicable to the 
43.33% of patients requiring cardiac procedures (detailed in Table 6-9, 10% of patient receiving 
bypass surgery, 1/3rd receiving angiogram and stents), resulting in an average hospital stay and sick 
day cost of $7,629.82.  
Pulmonary toxicities do not typically require surgery, as such, there are negligible additional days 
spent at the hospital and days spent home from work for the patient. Also, a 4.5% reduction in mean 
164
lung dose corresponds to a 10% decrease in pulmonary toxicity, corresponding to approximately a 
2.22% increase in toxicity risk with each percent increase in mean lung dose.  
Table 6-11 details the benefits of providing DIBH to breast and regular breathing for lung cancer 
patients.   
Table 6-11. Impact of DIBH and audiovisual biofeedback on mean dose and treatment 
margins.   
Impact of DIBH on mean heart dose  
Mean heart dose is reduced by 
2.5Gy55 
Impact of DIBH on mean lung dose 
Mean ipsilateral lung dose is 
reduced by 1 Gy56   
Impact of regular breathing on margin size  
Audiovisual biofeedback reduced 
margin size by 0.30 cm (see 
chapter 5.)* 
* Assuming no other errors 
Hence, based on the information presented in Tables 6-9 to 6-11, for breast cancer patients:  
 DIBH reduced mean heart dose by 2.5 Gy (Table 6-11), and therefore reduces the risk of a 
serious cardiac event by 2.5 × 7.4% = 18.5% (Table 6-10), reducing the risk of a cardiac event 
from 27.5% to 22.4% 
 DIBH reduced mean lung dose by 1 Gy, which as stated earlier, corresponds to a 2.22% 
decrease in toxicity risk, resulting in a decrease in risk of pneumonitis from 14% to 11.78%. 
 Audiovisual biofeedback reduced margins by 0.30 cm (Table 6-11), comparable to the 0.29 
cm reduction achieving a 10% reduction in mean lung dose (Table 6-10), which corresponds 
to a 10 × 2.22 = 22.2% reduction in risk of pulmonary toxicity. Reducing the risk of 
esophagitis from 31.6% to 24.6%, pneumonitis from 30% to 23.34%, and pulmonary fibrosis 
from 8.3% to 6.5%.  
The cost-effectiveness was determined to be the difference between the cost of managing toxicities 
(free breathing) and the cost of managing toxicities (DIBH/regular breathing) for breast and lung 
cancer patients. The cost of managing toxicities was determined to be:  
𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑠𝑡 =  [𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠] × [𝑅𝑖𝑠𝑘 𝑜𝑓 𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦] × [𝑀𝑜𝑛𝑒𝑡𝑎𝑟𝑦 𝑐𝑜𝑠𝑡 𝑜𝑓 𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦] (1) 
Where, in Australia, only left-sided breast cancer patients are considered since DIBH is not typically 
performed for right-sided breast cancer patients:  
𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑠𝑡𝑓𝑟𝑒𝑒 𝑏𝑟𝑒𝑎𝑡ℎ𝑖𝑛𝑔
= ([7090] × [27.46%] × [$9443.33 + $7629.82])𝑐𝑎𝑟𝑑𝑖𝑎𝑐
+ ([7090] × [14%] × [$5,672.52])𝑝𝑛𝑒𝑢𝑚𝑜𝑛𝑖𝑡𝑖𝑠 = $38,870,504  
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𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑠𝑡𝐷𝐼𝐵𝐻 = ([7090] × [22.38%] × [$9443.33 + $7629.82])𝑐𝑎𝑟𝑑𝑖𝑎𝑐
+ ([7090] × [11.78%] × [5,672.52])𝑝𝑛𝑒𝑢𝑚𝑜𝑛𝑖𝑡𝑖𝑠 = $31,828,389  
Yielding a cost-effectiveness of $7,042,000 from the use of DIBH for breast cancer patients, or $993 
per patient. Globally, this translates to cost-effectiveness of $844,000,000 each year. 
For lung cancer patients treated with radiotherapy in Australia each year:  
𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑠𝑡𝑓𝑟𝑒𝑒 𝑏𝑟𝑒𝑎𝑡ℎ𝑖𝑛𝑔
=  ([5000] × [31.60%] × [$1754.24])𝑒𝑠𝑜𝑝ℎ𝑎𝑔𝑖𝑡𝑖𝑠
+ ([5000] × [30%] × [$5672.52])𝑝𝑛𝑒𝑢𝑚𝑜𝑛𝑖𝑡𝑖𝑠
+  ([5000] × [8.60%] × [$1502.61])𝑓𝑖𝑏𝑟𝑜𝑠𝑖𝑠 = $11,926,602  
𝑇𝑜𝑡𝑎𝑙 𝐶𝑜𝑠𝑡𝑟𝑒𝑔𝑢𝑙𝑎𝑟
=  ([5000] × [24.85%] × [$1754.24])𝑒𝑠𝑜𝑝ℎ𝑎𝑔𝑖𝑡𝑖𝑠  
+ ([5000] × [23.34] × [$5672.52])𝑝𝑛𝑒𝑢𝑚𝑜𝑛𝑖𝑡𝑖𝑠
+  ([5000] × [6.46%] × [$1502.61])𝑓𝑖𝑏𝑟𝑜𝑠𝑖𝑠 = $9,284,817  
Yielding a cost-effectiveness of $2,640,000 from the facilitation of regular breathing from audiovisual 
biofeedback for lung cancer patients, or $528 per patient. Globally, this translates to cost-
effectiveness of $475,000,000 each year. 
The use of audiovisual biofeedback for both DIBH and regular breathing stands to reduce the 
Australian health-care associated costs of lung and breast cancer patients’ radiotherapy by a 
combined $9,684,000, and $1,319,000,000 worldwide.   
Further to this, a typical radiation oncology department will treat 100 lung cancer patients and 100 
breast cancer patients each year. After purchasing audiovisual biofeedback for $50,000 (see Table 6-
2), the cost savings from the use of audiovisual biofeedback will make up for the cost of the device 
itself after 66 lung and breast cancer patients have been treated (within 8 months).   
6.2.7. Market Capture Strategy and Future Projections  
In keeping with a lean startup approach, the Australian go-to-market strategy is direct distribution, 
starting in NSW and moving across Australia, leveraging the existing NSW-focused clinical trials 
detailed in chapter 4 and chapter 5. Direct distribution refers to directly delivering the product to 
customers personally rather than through contracted distributors. Direct distribution is lower cost 
than going through a contracted distributor but also limits the company to a low volume of sales; 
however given the high gross margin of the product allows the company to be sustainable 
throughout early low-volume customer sales. The proximity to our customer base through direct 
distribution will enable close company-customer feedback and interaction, with rapid product 
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improvement to meet user needs. As of August 2016, two NSW radiotherapy centres have signed an 
intent-to-purchase letter to secure the audiovisual biofeedback device once it becomes TGA-
approved. Early adopters in Australia will help us establish a viable business model, determine its 
multipliers and generate funds for international growth. Contracted distributors will be engaged for 
international sales and service. Figure 6-9 illustrates projected sales revenue and company growth in 
terms of full time equivalent (FTE) employees over the next 3 years until end of financial year (EOFY) 
2018/2019.    
Figure 6-9. Projections of sales revenue (blue) and number of FTE employees (red) by EOFY 2018/19. 
Projections indicate revenue from sales to be $4.8M by EOFY 2018/19, with 11 new jobs created by 
EOFY 2018/19. Assumptions made in regards to the projections illustrated in Figure 6-10 include:  
 TGA approval and first sales in Australia in November, 2016  
 FDA approval and first sales  in the USA in November, 2017 
 New employees are recruited when (i) an additional 20 products are in service, and (ii) 
company demonstrates continuous growth 3 months in a row 
 Direct sales implemented in Australia, distributor channels utilised in the USA with a 40% 
distributor margin.    
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6.3. Feeding Customer Insights back into research approach 
From the interviews conducted, both with hospital staff currently using audiovisual biofeedback for 
the clinical trials described in chapter 3 and chapter 4 and with hospital stuff who have never used 
audiovisual biofeedback, a number of insights were garnered in terms of what desired features for 
the audiovisual biofeedback system in addition to currently used motion management technologies 
(see chapter 1.2.1.5.).   
6.3.1. Development of the audiovisual biofeedback hardware  
From the insights garnered by talking with radiation oncology hospital staff, the most cumbersome 
element of the current research setup of the audiovisual biofeedback system is interfacing with and 
receiving the respiratory signal from the Varian RPM motion sensor. This requires:  
1) “Enabling Serial Protocol” in the RPM software to enable the real-time output of respiratory 
information  
2) Installing the required cable drivers on the research computer with audiovisual biofeedback 
installed  
Various firewalls and limitations to internet access can greatly inhibit the two critical steps detailed 
above which are necessary to simply adequately connect the research computer with audiovisual 
biofeedback installed to the Varian RPM. Once connectivity between audiovisual biofeedback and 
the RPM is enabled, there is still the need to connect all the components together; the schematic 
shown in Figure 6-10(a) is from a clinical trial workflow guide (included in Appendix IV) illustrates the 
current audiovisual biofeedback setup. Figure 6-10(b) illustrates the schematic setup of a condensed 
audiovisual biofeedback system setup, housing the motion sensor, patient display, and software in a 
single unit.  
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 Figure 6-10. Audiovisual biofeedback system components and connectivity, with (a) the current research setup 
and (b) the proposed condensed setup on the right. 
6.3.1.1. Development of stand-alone motion sensor 
The first major hurdle to house the necessary audiovisual biofeedback components in a single unit 
was to identify and test a physiologically-accurate respiratory sensor alternative to the current 
sensor: the Varian RPM.  
6.3.1.1.1. Microsoft Kinect 
One such respiratory sensor was the Microsoft Kinect, which monitors respiratory motion as a depth 
sensor.57, 58 Figure 6-11 illustrates the Microsoft Kinect operating as a depth sensor.  
 
Figure 6-11. Screenshot of the Microsoft Kinect’s motion tracking software developed in-house, demonstrating 
(a) depth image, (b) optical image, (c) depth signal of the determined region of interest, and (d) the Microsoft 
Kinect interfaced with the audiovisual biofeedback software.  
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Figure 6-12 demonstrates a volunteer Microsoft Kinect test performed at the Seattle Cancer Care 
Alliance Proton Therapy Center on August 7th, 2015.  
 
Figure 6-12. Volunteer testing with the Microsoft Kinect and the Elekta ABC. (a) Volunteer test setup. (b) 
Screenshot of the Microsoft Kinect depth sensor tracking volunteer abdominal respiratory motion.  
As shown in Figure 6-12, an Elekta ABC (see chapter 1.2.1.5.2.) was also used in this volunteer 
testing; the signals of the Elekta ABC and the Microsoft Kinect were compared, as shown in Figure 6-
13. Correlation between the two respiratory signals was assessed using Pearson’s correlation 
coefficient (r).  
 
Figure 6-13. (a) Respiratory signals obtained from the Microsoft Kinect (blue) and Elekta ABC (red); two exhale 
breath holds were performed. (b) Correlation plot between the Microsoft Kinect and Elekta ABC respiratory 
signals.  
Validation tests of the Microsoft Kinect were also performed with the AlignRT (see chapter 
1.2.1.5.3.); volunteer setup shown in Figure 6-14, performed July 22nd at the University of Texas 
SouthWestern.  
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 Figure 6-14. (a) Volunteer test setup in the CT sim room with the Kinect mounted on a tripod fixed to the end of 
the patient couch. (b) Depth image, optical image, and respiratory signal from the region of interest on the 
volunteer’s abdomen. (c) Schematic of the setup with distance from Microsoft Kinect to monitored region of 
interest included. 
The region of interest monitored by the Microsoft Kinect was created to be as close as possible to 
the region being tracked by the ceiling-mounted AlignRT, shown in Figure 6-15.  
 
Figure 6-15. (a) Ceiling-mounted AlignRT 
monitoring volunteer abdominal motion. 
(b) Screenshot of AlignRT software, pink 
region indicates registered abdominal 
surface, green region indicates the area of 
the abdominal surface being tracked.   
The signals of the AlignRT and the Microsoft Kinect were compared, as shown in Figure 6-16. 
Correlation between the two respiratory signals was assessed using Spearman's rank correlation 
coefficient (rho).  
 
Figure 6-16. (a) Respiratory signals obtained from the Microsoft Kinect (blue) and AlignRT (red). (b) Correlation 
plot between the Microsoft Kinect and AlignRT respiratory signals.  
While the correlation between the Microsoft Kinect and AlignRT was considerably higher than that 
between the Microsoft Kinect and the Elekta ABC, as evident from Figure 6-14(b) and Figure 6-16(a), 
more noise was evident in the Microsoft Kinect signal in the AlignRT tests. This was largely due to 
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the greater distance between the Microsoft Kinect and the region being monitored in the AlignRT 
test compared to the Elekta ABC test, where the Microsoft Kinect was directly next to the volunteer 
as shown in Figure 6-12(a). Microsoft reports that the Microsoft Kinect depth sensor range is from 
80 cm to 400 cm;59 however, studies have reported depth sensor ranges of 75 cm to 250 cm.60  
6.3.1.1.2. Intel RealSense 
Another depth sensor that was identified was the Intel RealSense,61 which can also be utilised as a 
depth sensor.62, 63 Figure 6-17 illustrates the Intel RealSense operating as a depth sensor. The 
operational distance of the Intel RealSense depth sensor is 20cm to 120 cm.61  
 
Figure 6-17. (a) Setup with a motion phantom as a surrogate for respiratory motion with the Intel RealSense 
positioned above the phantom by a table frame. (b) Screenshot of Intel RealSense motion depth sensor 
software, highlighting the region of interest and its corresponding respiratory motion signal. (c) It’s possible to 
switch the depth image display with an optical image display.  
Volunteer testing was performed at the University of Sydney on January 14th, 2016. The Varian RPM 
system (see chapter 1.2.1.5.1.) was also used to compare the respiratory signals of the two motion 
sensors. The setup for this test is shown in Figure 6-18. The region being monitored was selected to 
be the surface of the RPM marker block, therefore, the two respiratory signals should have the same 
amplitude.  
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 Figure 6-18. (a) Volunteer study setup indicating the position of the Intel RealSense, Varian RPM, and RPM 
marker block. (b) Optical view of the Intel RealSense, indicating that the region of interest being monitored was 
the anterior surface of the RPM marker block.  
The signals of the Varian RPM and the Intel RealSense were compared; the sampling frequency of 
the Varian RPM was found to be 29.9 ± 1.2 Hz, the sampling frequency of the Intel RealSense was 
found to be 23.5 ± 7.4 Hz. Figure 6-19 shows the respiratory signals and correlation between the 
Varian RPM and Intel RealSense.  
 
Figure 6-19. (a) Respiratory signals obtained from the Intel RealSense (blue) and Varian RPM (red). (b) 
Correlation plot between the Intel RealSense and Varian RPM respiratory signals.  
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6.3.1.2. Logistics of single unit audiovisual biofeedback 
A wooden prototype frame was built to test the logistics of dimensions for how future audiovisual 
biofeedback systems would fit in imaging and treatment rooms; this frame is shown in Figure 6-20. 
 
Figure 6-20. (a) Wooden frame prototype, (b) in the CT sim bore, and (c) on the treatment couch. 
Measurements were taken in order to ensure the frame will fit within the CT imaging bore as well as 
avoiding any potential collisions with the linac’s gantry. The dimensions for the frame are illustrated 
in Figure 6-21.  
 
Figure 6-21. Dimensions and design considerations for the audiovisual biofeedback frame to be positioned on 
the linac treatment couch without risk of gantry collision. Image provided by Design + Industry Sydney.26 
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As shown in Figure 6-21, the minimum distance between the subject and the frame is 22 cm, as 
such, it will be required of the motion sensor to produce a physiologically accurate signal for 
distances as low as 22 cm. This eliminates the Microsoft Kinect as a viable motion sensor as the 
minimum achievable distance for the Microsoft Kinect is 75 cm.60 The Intel RealSense achieves the 
desired distance from frame to subject by having an operational distance of 20cm to 120 cm,61 and 
the distance from the Intel RealSense sensor to the region being monitored, as shown in Figure 6-18, 
was 25 cm. Further to this, the Intel RealSense achieved a strong correlation with the clinically 
implemented Varian RPM system.  
6.3.2. Development of Audiovisual Biofeedback for Deep Inspiration Breath 
Holds 
While audiovisual biofeedback has been utilised to facilitate regular respiration and anatomic 
motion,1-4 inhale and exhale breath holds,64, 65 and quasi-breath holds,66 it has yet to be utilised to 
assist with deep inspiration breath holds (DIBH). Further to this, many of the interviewees described 
respiratory guidance biofeedback for DIBH to be a highly desirable feature.  
6.3.2.1. Deep Inspiration Breath Holds for Breast Cancer Radiation Therapy 
DIBH is performed with breast cancer patients because by taking a deep breath in, lung volume 
increases and the heart position moves inferiorly in the thorax, this reduces the pulmonary and 
cardiac dose during radiation therapy,56, 67, 68 illustrated by Figure 6-22. 
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 Figure 6-22. Axial and sagittal CT 
scans of a breast cancer patient 
free breathing: (a) and (b), and 
performing DIBH: (c) and (d). PTV 
indicated as the green area, and 
boost PTV indicated by the orange 
area. Adapted from Hayden, et al. 
(2012).69 
As shown in Figure 6-22(a), for the free breathing case the heart is proximal to the PTV and boost 
PTV areas in addition to partially being in the path of the planned tangential radiation beam. 
Whereas, as shown in Figure 6-22(c), the heart is now more distal to the PTV and boost PTV areas in 
addition to being outside of the planned tangential radiation beam. Figure 6-22(d) demonstrates the 
heart in a more inferior position during DIBH compared to free breathing.  
Previous findings have demonstrated the advantages of treating their left-sided breast cancer 
patients with DIBH over free breathing.56, 70, 71 The Vikström, et al. (2011) study noted a reduction in 
mean heart dose of 54% from the use of DIBH compared to free breathing (from 3.7 Gy to 1.7 Gy 
with DIBH). Vikström, et al. (2011) also found that the ipsilateral lung volume receiving at least 20 Gy 
(V20) was reduced by 18%.56 
Further to this, utilising visual feedback to assist patients perform DIBH has demonstrated to further 
improve upon unguided DIBH procedures.72, 73 Cerviño noted an improvement in breath hold 
reproducibility and stability of 76% and 53%, respectively from the use of visual feedback DIBH 
compared to DIBH without feedback. Figure 6-23 illustrates examples of DIBH from the use of DIBH 
with visual feedback and DIBH without feedback.  
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 Figure 6-23. Examples of DIBHs 
performed by a volunteer. The first 
four DIBHs (red, solid lines) are 
without visual feedback, the second 
four (blue, dashed lines) are with 
visual feedback. Adapted from 
Cerviño, et al. (2009).73  
 
Figure 6-23 demonstrates that through the use of visual feedback, volunteers were able to 
reproduce the same DIBH each time in addition to sustaining a stable breath-hold level compared to 
DIBH without visual feedback, where DIBH amplitude varied in addition to the respiratory signal 
drifting downwards mid-breath hold. Damkjær, et al. (2013) compared gated breath holds to DIBH 
with visual feedback and found that V20 was significantly reduced by 9% from the use of visual 
feedback.72  
6.3.2.2. Audiovisual biofeedback for Deep Inspiration Breath Holds 
Given the positive findings of both DIBH over free breathing and the use of visual feedback in 
assisting patients perform DIBH over DIBH with no feedback in addition to customer interview 
feedback, the functionalities of audiovisual biofeedback have been extended to assist patients to 
perform DIBH. In the Damkjær, et al. (2013) study, they extended the display of the Varian RPM to 
show the patient their respiration and the gating window to hold their breath at. Audiovisual 
biofeedback will utilise an automated method of producing a customised breath hold guide for each 
patient. Table 6-12 details the main differences between the two methods.  
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Table 6-12. Comparison of DIBH used in Damkjær, et al. (2013) study to the proposed audiovisual biofeedback 
DIBH. 
 Damkjær, et al. (2013) DIBH72 Audiovisual Biofeedback DIBH 
Visual display 
Before DIBH 
  
During DIBH 
  
Breath hold level Set manually Automatically detected and loaded 
Miscellaneous 
 Synchronised with Varian 
RPM gating 
 Save and load patient-specific 
breath hold guides  
 Breath hold countdown shown 
to patient 
 Markerless  
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6.4. Conclusion 
Given the proof of principle research detailed in chapter 1.4.2. and chapter 2., the translational 
research conducted and detailed in chapter 3., chapter 4., and chapter 5., and the granted patent 
protection5 underpinning the audiovisual biofeedback technology, this positions audiovisual 
biofeedback towards the commercialisation pathway. This commercialisation pathway was explored 
utilising a variety of commercialisation accelerator programs paired with extensive customer 
interviews to map out the market, regulatory, and intellectual property landscape of the audiovisual 
biofeedback technology and search for the best business model to address the customer’s unmet 
need, ultimately yielding commitments from NSW radiotherapy centres to purchase the audiovisual 
biofeedback device. Extensive customer engagement also yielded the expansion of audiovisual 
biofeedback functionalities to deep inspiration breath holds for use with breast cancer patients. 
Learnings from these customer interviews were then applied back into the research component to 
further develop the audiovisual biofeedback technology and functionalities. Further to this, the cost-
effectiveness of audiovisual biofeedback for both lung and breast cancer patients can potentially 
reduce the health-care burden by almost $10 million a year in Australia alone, and over $1.3 billion 
worldwide.      
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 CHAPTER 7 
Summary, Conclusions, and Future Work 
7.1. Summary and Conclusions  
This thesis has identified the gaps in the literature by performing the first systematic review of 
breathing guidance interventions in radiation treatment and imaging procedures (chapter 2), and 
then utilised these insights to perform experiments and design clinical trials to address these gaps in 
the literature. By initiating the first randomised, phase II clinical trial for a breathing guidance 
intervention, this thesis also explored the next steps in determining the pathway to broaden the 
audiovisual biofeedback’s use beyond the current limited number of hospitals under clinical trial 
conditions to widespread clinical implementation through commercialisation.   
This thesis has given evidence that audiovisual biofeedback significantly improves 4DCT image 
quality (chapter 3), interfraction motion consistency with liver cancer patients (chapter 4), and the 
respiratory-components of treatment margin calculation (chapter 5.1.). There was also an observed 
training effect where audiovisual biofeedback became more regular interfractionally which 
demonstrated a significant correlation between time and RMSE values (chapter 5.1.). These insights 
went towards the design and workflow of the largest respiratory guidance intervention investigation 
study, to date (chapter 5.2.), which recruited its first patient on April 11th, 2016. This clinical trial 
demonstrates a number of firsts for respiratory guidance investigations: it is the first (1) 
randomised, (2) multi-site, (3) stratified, (4) phase II, (5) lung cancer radiotherapy audiovisual 
biofeedback clinical trial.  
With the proof of principle of respiratory guidance interventions explored (chapter 1, chapter 2), 
and the more clinically relevant metrics of 4DCT image quality (chapter 3), interfraction consistency 
(chapter 4), and margin size (chapter 5.1.), coupled with its patent protection, warranted the 
exploration of the commercialisation of the audiovisual biofeedback technology in order for cancer 
patients to benefit from this technology. This was done through an extensive evaluation of the 
radiation oncology field and over one hundred interviews to determine the product-market fit of 
audiovisual biofeedback.  
The culminations of these findings demonstrate the clinical benefit of the audiovisual biofeedback 
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 respiratory guidance system, and the need to make breathing guidance systems more widely 
available to patients.  
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 7.2. Future Work 
While a number of the results presented in this thesis address the gaps in the literature as detailed 
in chapter 1 in addition to the systematic review presented in chapter 2, as detailed in chapter 2 
there still areas of research to fill these gaps further. As detailed in Table VI in chapter 2, prospective 
studies focussing on the impact of breathing guidance on radiation dose to healthy tissue, tumour 
tracking, target coverage, and treatment margins would be valuable future work. Further to this, as 
noted in chapter 4, it is recommended that the clinical impact of audiovisual biofeedback on liver 
cancer patients is evaluated with a larger patient cohort.    
In addition to future studies further addressing the identified gaps in the literature, future 
work of audiovisual biofeedback will also pertain to building upon the results presented in this 
thesis. Building upon the results in chapter 3 with a prospective 4DCT patient study, for example. 
The clinical trials detailed in chapter 4 and chapter 5 will provide insight into the design of a phase III 
audiovisual biofeedback clinical trial. Clinical studies will also need to be conducted to test the 
hardware and software updates detailed in chapter 6. In the subsequent sections, such studies that 
are being prepared to build upon this thesis are detailed.   
7.2.1. Audiovisual biofeedback with tumour tracking 
Further to this, a clinical trial tracking and adapting to prostate motion during cancer radiation 
therapy in real-time utilising multi-leaf collimator (MLC) tracking1-3 and the Calypso electromagnetic 
transponder tracking system4-6 was recently completed at Northern Sydney Cancer Centre, Royal 
North Shore Hospital. This clinical trial demonstrated that utilising tracking significantly improved 
the agreement between delivered and planned doses compared to no tracking.7  
Given the positive findings from this prostate tracking clinical trial, a follow up tumour tracking 
clinical trial recruiting lung cancer patients has been developed. However, the system latency of the 
tumour tracking software and hardware has been demonstrated to be 350 ms.8 The use of the 
Calypso transponders will also provide further insights into the correlation between external 
respiratory surrogates and internal respiratory motion.   
7.2.2. Audiovisual biofeedback during breast cancer DIBH 
The audiovisual biofeedback setup with the Intel RealSense described in chapter 6.3.1.1.2., coupled 
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 with the functionality for DIBH, as described in chapter 6.3.2.2., will be utilised in an upcoming 
breast cancer patient clinical trial to be performed at Royal North Shore Hospital. This study will 
recruit a total of 40 breast cancer patients and its primary objective is to test the efficacy of 
audiovisual biofeedback to assist DIBH during breast cancer radiotherapy compared with the current 
treatment standard, the Varian RPM. The primary hypothesis is that accuracy of audiovisual 
biofeedback is non-inferior to the RPM system.  
7.2.3. Audiovisual biofeedback during proton therapy  
The audiovisual biofeedback setup with the Intel RealSense described in chapter 6.3.1.1.2., has been 
provided to the University of Washington, Seattle, to be used to guide regular respiration during 
lung cancer patient proton therapy. This study represents a landmark in the field as it will be the 
first study to investigate the use of a breathing guidance intervention over the course of proton 
therapy. It was noted by Figure 1-15 in chapter 1.3. (shown here for clarity) that the size of the ITV 
can vary not only over the course of treatment but also during treatment delivery. The University of 
Washington will be testing the hypothesis that audiovisual biofeedback will reduce the variations in 
ITV size, compared to free breathing, over the course of lung cancer patient proton therapy. Interest 
was also indicated for the use of audiovisual biofeedback for guided exhale breath holds for liver 
cancer patients receiving proton therapy.   
 
Figure 1-15. Variations of the volume of 
ITV over a fraction of treatment for 8 
lung cancer patients. From St James, et 
al. (2012).9 
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Summary 
Study Title:  Investigation of respiratory-related tumour motion in 
liver cancer patients undergoing stereotactic body 
radiotherapy treatment (SBRT) using audiovisual (AV) 
biofeedback.   
Protocol version:  V4.0 
Objectives Primary objective: Evaluate the improvement in 
reproducibility of respiratory-related tumour motion (via 
fiducial maker surrogacy) for liver cancer patients with 
the AV biofeedback respiratory guidance system. 
 Secondary objectives: Assess the potential clinical 
benefit of AV biofeedback. 
 Analysis of obtained data will involve: 
 (1) Based on the respiratory motion analysis, the 
proportion of patients with improved reproducibility 
of respiratory motion from AV biofeedback will be 
obtained 
 (2) Quantification of the improvement in dose 
distributions and treatment margins with and without 
AV biofeedback by reconstructing the delivered 
dose using a method developed for liver SBRT 
 (3) Quantification of the reduction in 4D CT errors 
with and without AV biofeedback by programming 
the Quasar phantom with the AV biofeedback and 
free breathing respiratory traces 
 (4) Reconstruction of cone beam CT (CBCT) images 
into 4D CBCT using the respiratory signal and 
comparing the image quality with and without AV 
biofeedback 
 (5) Evaluation of the correlation between internal 
fiducial marker and external marker motion. 
 (6) An evaluation of the patient and operator 
experience with the AV biofeedback system through 
a questionnaire will also be performed. 
  
Study design The reproducibility (i.e. the consistency of respiratory 
amplitude and period) of liver fiducial-marker motion 
due to respiration will be assessed with AV biofeedback 
and for free breathing using CBCT imaging.  To improve 
the image quality and radiation targeting for the patient, 
all subsequent imaging and treatment sessions will use 
the most reproducible breathing condition, AV or free 
breathing.     
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 Planned sample size  
 This study will involve the participation of 30 liver 
cancer patients.  
 
 Selection criteria  
 The following patients are eligible for this study: 
 1) Liver cancer patients, either primary 
hepatocellular carcinoma or liver metastases, 
eligible for stereotactic radiotherapy.  
 2) >18 years old 
 3) No gender or ethnic restrictions 
 4) Radio-opaque markers implanted (fiducials and/or 
surgical clips previously implanted in the liver) 
 5) Able to give written informed consent and 
willingness to participate and comply with the study 
 6) No pregnant / lactating woman 
   
Study procedure The AV biofeedback system is simple and easy to 
implement. It is comprised of a screen or AV goggles 
that the patient views to receive their audio and visual 
guiding prompts. As a part of their clinical treatment 
plan, the patients will already be having 18 CBCT scans; 
by participating in this study, they will have only two 
additional CBCT scans.  
 Eligible patients that have agreed to participate in the 
study and have given informed consent will undergo 
routine radiotherapy planning in preparation for their 
SBRT treatment. During the planning procedure, as part 
of this study, the following will also be performed in 
addition to standard procedure: Two additional CBCT 
scans will be obtained, one while the patient undergoes 
AV biofeedback and the other with the patient during 
free breathing.  The reproducibility of liver tumour 
motion due to respiration will be assessed with AV 
biofeedback and for free breathing using cone beam CT 
imaging.  To improve the image quality and radiation 
targeting for the patient, all subsequent imaging and 
treatment sessions will be undertaken with the best and 
most reproducible breathing condition, either AV 
feedback or free breathing (signed off by radiation 
oncologist, see Figure 14: Proposed Patient Report).  
 
 Patient time commitment  
 Each session will take a total of 1 hour inclusive of 
setting and packing up the AV biofeedback system in 
addition to the CBCT scans, but it may be completed in 
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less time than this. After each initial study session 
(during planning) the patient will be asked to complete a 
questionnaire regarding the AV biofeedback system; 
each questionnaire is designed to only take 2 minutes to 
complete. In the event that AV biofeedback is the more 
reproducible breathing condition, it will be continued to 
be used as a part of their treatment in the remainder of 
their 18 CBCT scans and treatment. Should AV 
biofeedback remain in the patient’s treatment, a single 
follow-up questionnaire will be performed towards the 
end of their treatment to gauge any change in opinion 
towards the AV biofeedback system.  
  
 Data analysis 
 For each patient the acquired internal motion (from 
CBCT images) and respiratory data (from the TGA-
approved real-time position management (RPM) system) 
will be analysed in order to quantify the clinical impact 
of AV biofeedback through the following measurements:  
 1) Quantify the proportion of patients for whom 
respiration is more regular with the guidance of AV 
biofeedback.  
 2) Quantify the respiratory reproducibility with AV 
biofeedback and free breathing. Respiratory results 
will be evaluated using the root mean squared error 
(RMSE) method and compared using statistical 
analysis methods such as the Student t-test.  
 3) Quantify the improvement in treatment margins 
and dose distributions with and without AV 
biofeedback by reconstructing the delivered dose 
using a method developed for liver SBRT. 
 4) Quantify the reduction in 4D CT errors 
with/without AV biofeedback by programming the 
Quasar phantom with the AV and free-breathing 
respiratory traces. 
 5) Reconstruct the CBCT into the 4D CBCT using 
the respiratory signal and compare the image quality 
with and without AV biofeedback.  
 (6) The correlation between internal and external 
motion  
 
Estimate the clinical benefit To estimate the improvement in treatment margins and 
dose distributions, dose reconstruction using the method 
of Poulsen et al (Med Phys 2012)
1,2
will be performed 
using the tumour motion extracted from AV 
biofeedback-guided CBCT images and free breathing 
CBCT images. Using radiobiological response models 
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from QUANTEC (Quantitative Analysis of Normal 
Tissue Effects in the Clinic) we will assess the impact of 
the change in radiation dose delivered to healthy tissues 
with and without AV biofeedback respiratory guidance. 
 4D CBCT image quality will also be investigated. CBCT 
images will be reconstructed into 4D CBCT using the 
obtained respiratory signals and the image quality will be 
compared for with and without AV biofeedback.    
Statistical considerations According to preliminary results from 15 healthy human 
subjects, assuming a type I error rate of 5%, 80% power 
and a moderate effect size of 0.34σ for the paired 
differences between free breathing and AV biofeedback, 
a sample size of 30 patients will be required. If we 
assume that the standard deviations of these differences 
in the patient population will be approximately double 
that of the healthy volunteers then the minimal detectable 
difference will be 0.068, (σ = 0.2). 
  
Duration of the Study 2 years 
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1.BACKGROUND 
In Australia, 115,000 cancer patients are newly diagnosed each year and 40% of cancer 
patients receive radiotherapy as part of their treatment plan
3
 with radiotherapy being an 
effective anti-cancer treatment by delivering high-energy radiation directly to tumours to 
destroy cancer cells.
4
 Stereotactic body radiotherapy (SBRT) in particular has recently been 
incorporated into the treatment of liver cancer due to its demonstrated effectiveness in 
clinical studies as well as improving survival rate,
5,6
 with over 54% of American liver cancer 
patients being treated with SBRT.
7
 SBRT is a high-precision, high-dose irradiation of a lesion 
in a small number of fractions (typically 1 – 6).8In 2008, there were 1304 new cases of liver 
cancer diagnosis across Australia,
9
 with NSW having a higher rate of diagnosis than the 
national average.
9,10
 Liver tumours are considered highly mobile due to their proximity to the 
thoracic diaphragm, which is a dominant factor in inducing respiratory motion in the thoracic 
and abdominal regions.
11,12
 
Such respiratory motion reduces the precision of radiation therapy resulting in poor radiation 
targeting and tumour control.
12,13
 A key problem to be solved in this study is inadequate 
respiratory-related tumour motion management, especially for irregular respiratory-related 
tumour motion which further negatively affects the clinical outcome.
14,15
 A 1Gy increase in 
tumour dose results in a 4% improvement in survival,
16
 however, a 0.5cm tumour motion 
leads to a 4~5% variation in radiation dose
17
 which can lead to an increase in mean dose to 
healthy surrounding tissues. In previous reports, tumours subject to respiratory motion have 
been shown to move up to 5 cm,
12
 and rotate up to 45° during respiration.
18
 Given that 
average liver motion in the superior-inferior (SI) direction has been shown to be 9 ± 5 mm,
19
 
this can exacerbate the variation in radiation dose by up to 10%, leading to a further  increase 
in mean radiation dose to the healthy liver tissue.  
During radiotherapy, in order to irradiate the tumour at all times, the treatment volume must 
be increased to cover the entire range of tumour motion; this increases the dose delivered to 
the surrounding healthy tissue.
16,17,20,21
 Without respiratory motion management, patients can 
receive an underdose of radiation to the tumour and overdose to the surrounding healthy 
tissues, which can lead to cancer recurrence and severe radiation side effects. For example: a 
1Gy increase in mean lung dose results in on average a 1% reduction in pulmonary function
22
 
and a 2% increase in risk of pneumonitis(28% of patients were suspected of having radiation 
pneumonitis in a previous study).
20,23
We hypothesise that the more reproducible respiratory 
motion as a result of AV biofeedback will result in reduced treatment margins leading to 
improved radiation sparing of the surrounding healthy tissue. 
Techniques such as respiratory gating, breath-holds and tumour tracking are clinically useful 
for tumour motion management;
24-26
 abdominal compression is also used to reduce the 
magnitude of liver tumour motion.
27
 However, irregular respiration (such as deep/shallow 
breaths, baseline shifts, inconsistent amplitude, etc) can reduce the efficiency of such motion 
techniques
28,29
 as well as causing motion artefacts and anatomic errors in medical imaging.
30-
35
 
Respiratory guidance is one such technique which specifically aims to produce regular 
patient breathing. At the forefront of respiratory guidance is the audiovisual (AV) 
biofeedback system. The AV biofeedback system (Figure 1) developed by Venkat, et al
29
 is 
one such management technique to minimise irregular respiration. AV biofeedback uses a 
non-invasive external marker to measure abdominal motion and guides the patient to produce 
regular respiration. This system has demonstrated a reduction in average cycle-to-cycle 
variations in respiratory amplitude and period by up to 50% and 70% respectively,
29
 which 
has also shown to be beneficial in improving motion reproducibility for respiratory-gated 
radiotherapy
36
 in addition to reducing blurring artefacts in 4D PET
37
 and CT.
38
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Figure 1. AV biofeedback system. AV goggles (left) and screen (right) setups; marker block on the abdomen 
shown (IR camera not shown, see section 5.1: Study Equipment). The visual display (centre) as seen by the 
subject (sans arrows) of the AV biofeedback system shows the guiding wave (white curve) and a marker position 
(marker image) in real time.   
 
Additionally, this system can be employed for real-time tumour tracking and respiratory 
gating. In this case, tumour motion can be indirectly managed by regularising respiratory 
motion based on the correlation between the external abdominal position and the internal 
tumour position during regular breathing.
39,40
 
Despite the positive results of AV biofeedback studies to date, the participants have thus far 
been healthy volunteers, which are sufficient when investigating tumour surrogates. 
However, to determine the true clinical value of the AV biofeedback system a study 
involving the monitoring of tumours themselves needs to be undertaken; that is the purpose 
of this study. 
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2.PRELIMINARY RESULTS 
2.1. IRREGULAR RESPIRATION LEADS TO MEDICAL IMAGE AND ANATOMIC ERRORS 
There is a clear link between respiratory irregularity and anatomic errors on 4D CT images.
30-
35
 The irregularity of breathing is shown in Figure 2; the impact of this irregularity on 
medical images is shown in Figure 3. 
Figure 2.  Example lung tumour motion (superior-inferior) with time showing the variation in breathing period, 
shape, magnitude and baseline position.  From Suh et al.
12 
 
 
Figure 3.  Irregular breathing causes four different types of errors in 4D CT images: 46 of 50 patients had 
scans with an on average 11mm error.  From Yamamoto et al.
31
 
 
210
   
Liver tumour motion using audiovisual biofeedback 
Version 4.0, 29/06/2015 
13 
2.2. LIMITATIONS OF PRIOR STUDIES OF BREATHING TRAINING IN RADIATION ONCOLOGY 
To address the problem of respiratory irregularity, various methods of patient respiratory 
guidance have been applied by other groups, as summarised in Table 1.  However there are a 
number of limitations: none of the studies used audio biofeedback, only a single measurement 
point was used for the respiratory signal and none of these systems are commercially 
available.  Despite these limitations, improvements in the respiratory signal reproducibility 
was observed, indicating the potential for breathing training to improve image quality and 
radiation targeting. 
This will be the first study to implement AV biofeedback in liver cancer patients undergoing 
radiation therapy. 
Table 1.  Summary of breathing training studies in radiation oncology 
Author, year Sensor Subjects Comments 
Wang 1995
41 Bellows belt 6 Audio prompt for breath-hold MRI 
Wang 1995
42 MR navigator 6 Visual prompt for multiple breath-hold MRIs 
Wong 1999
24 Flow monitor 12 Immobilizing breathing motion 
Vedam 2003
28 RPM 5 
Visual motion wave with two motion limits (inhale 
and exhale limits) 
George 2005,
43
 
2006
36,44 
RPM 24 
Visual motion bar with two motion limits with audio 
instruction 
Lim 2007
45 Thermocouple 10 
Visual guidance with audio prompt.  Baseline drift not 
observed using the thermocouple 
Locklin 2007
46 Bellows belt 16 Visual biofeedback only for breath-hold CT scans 
Ono 2011
47 Accelerometer Phantom Used cheap, available equipment.  No patient studies. 
 
This study will involve the recruitment of 30 participants, which is considerably greater than 
the participants involved in the vast majority of previous respiratory guidance studies as 
shown in Table 1. Such a number of participants in this study would make it the most 
comprehensive AV biofeedback study to date. The inclusion of more participants would also 
produce more accurate and significant results.  
Unlike previous studies that tested the effect of AV biofeedback on respiration,
29
 CT image 
quality,
38
 or treatment margins, such studies involved the participation of healthy 
volunteers,
28
 this study involves the recruitment and imaging of cancer patients.  
 
2.3. RESPIRATORY REPRODUCIBILITY 
Respiratory reproducibility refers to how consistent a breathing signal’s amplitude and period 
are. The commonly used quantification of respiratory reproducibility used throughout the 
literature is the root mean square error (RMSE).
5,29,48
 A low value of RMSE is indicative of a 
highly reproducibly respiratory signal. Figure 4(c & f) exemplifies the difference in 
respiratory reproducibility; the respiratory signal shown in Figure 4f would have a much 
lower RMSE value (in both amplitude and period) that the signal presented in Figure 4c, and 
is therefore the more reproducible signal of the two. Even though the two respiratory signals 
presented in Figure 4c & f have similar ranges of motion, a lower value of RMSE has been 
demonstrated to result in reduced treatment margins. A previous study found that the 
superior-inferior (SI) margins were reduced from 1.1cm to 0.8cm by implementing 
respiratory guidance.
28
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2.4. AV BIOFEEDBACK SYSTEM COMBINED WITH MRI AND CT 
Recently, Kim et al. (2012) reported the feasibility of respiratory motion management with 
15 healthy human subjects using the AV biofeedback system combined with a 3 Tesla 
MRI.
48-50
 These studies demonstrated a reduction of motion artefacts and improvement of 
organ motion reproducibility in MRI using the AV biofeedback system in conjunction with 
the real-time position management (RPM) external position management system from Varian 
Medical Systems. This study demonstrated that using the AV biofeedback system could 
improve the reproducibility of internal structure’s (in this case: the thoracic diaphragm) 
respiratory motion. By using the AV biofeedback system, diaphragm motion reproducibility 
was significantly improved (Figure 4). Average RMSE in diaphragm displacement of 15 
healthy human subjects was reduced from 2.7 mm with free breathing to 1.6 mm with AV 
biofeedback (p-value < 0.05). Additionally, the average RMSE in the diaphragm motion 
period was reduced from 1.84 s with free breathing to 0.34 s with AV biofeedback (p-value < 
0.05). However, a limitation of this study was that the participants were healthy volunteers, 
not cancer patients, as such the true clinical viability was difficult to achieve.  
While the thoracic diaphragm has been demonstrated to be an accurate tumour surrogate,
39,40
 
fiducial markers are frequently used clinically due to their increased proximity to the tumour 
(compared to the diaphragm) and are therefore a highly accurate tumour surrogate.
51,52
 
  
In addition to MRI, AV biofeedback has also been implemented in imaging studies utilising 
PET
37
 and CT.
38,46
 AV biofeedback has the advantage of being compatible with a range of 
imaging modalities, as such, implementation with the CBCT imaging modality will be very 
straight-forward and the improvements to image quality are expected to be consistent with 
the previously mentioned AV biofeedback imaging studies. This study is a continuation from 
the Kim’s 2012 MRI study, as the fast MR pulse sequence utilised in that study (fast gradient 
 
Figure4. (a, d) ROI (region of interest) boxes on coronal images in Study 6. (b, e) 1D signal profile of the 
ROI over 512 images. Outline of diaphragm shown (red line). (c, f) Diaphragm motion cycles (blue) and 
average curve (red) shown in phase domain. By using the AV biofeedback system the diaphragm motion 
reproducibility has been significantly improved. 
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echo: fGRE) would have comparable image quality to images obtained using CBCT. The 
advancement from Kim’s study to this one is the recruitment of liver cancer patients in 
addition to monitoring a more accurate tumour surrogate: fiducial markers implanted within 
the liver. 
 
2.5. ASSESSMENT OF THE BENEFIT OF REDUCING TUMOUR MARGINS 
Additional margins about the tumour are generally measured as the CTV-to-PTV margins: 
where CTV is the clinical target volume (approximation of the tumour volume) and PTV is 
the planning target volume (the CTV with additional margins to account for tumour motion 
and geometric uncertainties). 
A liver cancer study by Molinelli, et al (2008) found that the reduction of CTV-to-PTV 
margins of liver tumours resulted in both dose escalation to the tumour (higher dose to the 
tumour: more effective in eliminating the tumour) as well as improved sparing of the healthy 
liver tissue (reducing post-treatment complications and improving long-term survival rate).
53
 
Molinelli’s study found that a reduction of the CTV-to-PTV margin by 50% resulted in a 
further sparing of health liver tissue by up to 47% (average: 26%).  
Therefore, if imaging can be improved to reduce geometric uncertainties in addition to 
improving motion management techniques to compensate tumour motion more accurately, 
then the CTV-to-PTV margins can be further reduced resulting in more efficient dose 
delivery to the tumour itself while improving the sparing of the surrounding healthy tissue. 
AV biofeedback is proposed to improve both these aspects.  
Treatment margins for liver SBRT patients at the Chris O’Brien Lifehouse Department of 
Radiation Oncology are determined by internal target volume (ITV). ITV is defined as the 
CTV plus a margin to account for uncertainties in shape, size and position of the CTV, much 
like the PTV, although the ITV is typically a tighter margin than the PTV.    
  
213
   
Liver tumour motion using audiovisual biofeedback 
Version 4.0, 29/06/2015 
16 
 
3.STUDY OBJECTIVES AND AIMS 
Liver tumour motion management using AV biofeedback will be investigated using fiducial 
markers as a surrogate and test the hypothesis that the more regular respiration as 
produced by AV biofeedback will result in more reproducible liver tumour motion 
which will have numerous clinical advantages. To test this we will conduct a 30 liver 
cancer patient clinical using CBCT and correlative outcomes study with the following 
objectives: 
 
3.1. PRIMARY AIM: 
Evaluate improvement in the reproducibility of respiratory-related tumour motion for 
liver cancer patients with the AV biofeedback system: We propose a study involving 30 
liver cancer patients. Each patient will undergo a CBCT scan during which two breathing 
conditions will be tested: (1) with AV biofeedback and (2) without AV biofeedback (free 
breathing) in order to assess tumour motion reproducibility. Respiratory motion of an 
external marker and internal fiducial markers (and/or surgical clips) will be assessed via a 
respiratory displacement and frequency analysis. 
 
3.2. SECONDARY AIM: 
Assess the potential clinical benefit of AV biofeedback: Analysis of obtained data will 
involve:  
(1) Based in the respiratory motion analysis, the proportion of patients benefitting from 
AV biofeedback will be obtained. 
(2) Quantification of the improvement in dose distributions and treatment margins with 
and without AV biofeedback by reconstructing the delivered dose using a method 
developed for liver SBRT.  
(3)  Quantification of the reduction in 4D CT errors with/without AV biofeedback by 
programming the Quasar phantom with the audiovisual and free-breathing traces.  
(4) Reconstruction of CBCT images into 4D CBCT using the respiratory signal and 
compare the image quality with/without AV biofeedback. 
(5) Evaluation of the correlation between internal fiducial marker and external marker 
motion.  
(6) An evaluation of the patient and operator experience with the AV biofeedback 
system though a questionnaire will be performed. 
The methods of achieving these aims will be further detailed in section 5.3: Investigation 
Plan. 
To achieve these objectives the following data will be collected: 
 External breathing motion data from RPM & AV biofeedback computers: 
 CBCT projection & image data: 
 Patient and staff surveys 
 4DCT images 
 Free breathing CTs 
 Patient treatment plan  
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4.PARTICIPANT SECTION 
This study is specifically aimed at liver cancer patients.  Patients fitting the eligibility criteria 
(see below) will be identified and introduced to this study by their treating physician who will 
participate as a principal investigator in this study.  
 
4.1. INCLUSION CRITERIA 
1)  Liver cancer patients, either primary hepatocellular carcinoma or liver metastases, 
eligible for stereotactic radiotherapy 
2) > 18 years old 
3) No gender or ethnic restrictions 
4) Radio-opaque markers implanted (fiducials and/or surgical clips previously implanted 
in the liver) 
5) Ability to give written informed consent and willingness to participate and comply 
with the study 
 
4.2. EXCLUSION CRITERIA 
1) Pregnant/ lactating women  
2) <18 years old.  
3) Prior radiotherapy treatment to the liver 
4) Life expectancy less than 6 months 
5) Non-liver cancer patients 
 
4.3. NUMBER OF PARTICIPANTS 
30 liver cancer patients. As shown in Table 1, 30 participants are considerably greater than 
the participants involved in the vast majority of previous respiratory guidance studies. Such a 
number of participants in this study would make it the most comprehensive AV biofeedback 
study to date. The inclusion of more participants would also produce more accurate and 
significant results.  
 
4.4. NUMBER OF CENTRES 
This study will be conducted solely at Chris O’Brien Lifehouse Department of Radiation 
Oncology, Sydney. 
 
4.5. DURATION 
The expected duration of the study is 2 years.  Estimated time of first recruitment is early 
2014. The study recruitment phase and data analysis phase will be done concurrently; 
analysis of data for each patient can commence once CBCT scans have been acquired for that 
patient. Overall analysis will commence after last patient recruitment.  
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5.STUDY OUTLINE 
The data required for the study: external and internal respiratory signals in addition to the 
CBCT scans, will be collected before and during treatment. All patients will receive the same 
CBCT scans. 
Each CBCT study (inclusive of setting up and packing away the AV biofeedback system in 
addition to CBCT scan time) will be completed within a 1 hour timeframe on a single day as 
per SBRT clinical trial protocol. Once informed consent has been obtained, the principal 
investigator will schedule a time for the study.  
 
5.1. STUDY EQUIPMENT 
The additional hardware needed for this study is comprised of the AV goggles or screen. The 
CBCT images will be acquired using a Novalis Tx linear-accelerator (linac). In the data 
analysis stage of the study, further equipment and software will be used, both of which are 
frequently used in quality assurance tests and treatment planning.  
 
5.1.1. AV BIOFEEDBACK 
In this study the audio and visual prompts of the AV biofeedback system will be delivered to 
the patient via easy to wear and light-weight goggles, shown in Figure 5, or a screen, shown 
in Figure 6. The screen to be used is the Google Nexus tablet computer.  
 
 
Figure 5. The AV goggles (left) and being worn by a volunteer (right). 
The patients will view a high resolution built-in monitor for the visual component in addition 
to hearing the audio component via built-in speakers.  
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Figure 6. The screen (Google Nexus tablet computer) in a linac (left) and CT (right) room. 
The Google Nexus tablet has built-in speakers as well as a 3.5mm headphone jack if the 
patient would rather wear headphones.  
The respiratory motion information will be acquired using the RPM system (Figure 7), which 
is comprised of an infrared (IR) camera tracking the motion of a marker block at a rate of 30 
Hz (real-time). 
 
Figure 7. The RPM system: an IR camera tracking the marker block at a rate of 30 Hz. 
 
AV biofeedback is a non-invasive, interactive respiratory guide designed to guide the patient 
towards regular respiration in the most comfortable way possible. 
 
5.1.2. NOVALIS LINEAR ACCELERATOR 
For the CBCT scans, a TGA-approved, fully clinical, routine SBRT treatment unit at Chris 
O’Brien : Novalis Tx Linear Accelerator (Figure 8) will be used. As a part of their SBRT 
treatment plan, each patient will already be receiving 18 CBCT scans. By participating in this 
study, each patient will receive two additional CBCT scans with an addition piece of 
equipment: the AV goggles (Figure 5) or screen (Figure 6), in order to test the AV 
biofeedback system.  
 
Figure 8.The Novalis Tx Linear Accelerator. 
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5.1.3. QUASAR PHANTOM 
In the data analysis stage of the study, the reduction in 4D CT errors with/without AV 
biofeedback will be quantified by programming the Quasar phantom (Figure 9) with the AV 
and free-breathing traces.  
 
Figure 9. The Quasar phantom.  
The Quasar phantom is a breathing simulator and is frequently used in quality assurance tests 
on radiotherapy systems. By programming the Quasar with an acquired patient respiratory 
signal we are able to study the effect of AV biofeedback on 4D CT image quality without 
giving additional dose to the patient.  
 
5.1.4. ECLIPSE FOR DOSE RECONSTRUCTION 
The impact of AV biofeedback on dose distribution will be assessed using the Varian 
treatment planning software: Eclipse. In a method developed by Poulsen et al (Med Phys, 
2012)
1,2
 the respiratory motion will be incorporated into treatment plans. Dose distributions 
and dose volume histograms (DVH) will be acquired through this method to assess the 
impact of AV biofeedback on the patients’ treatment plan. Examples of dose distributions 
acquired in the Poulsen (Med Phys, 2012)
2
 study are shown in Figure 10. Also computed by 
the Eclipse software are the DVHs which are a mathematical tool frequently used in 
radiotherapy to determine the adequacy of a treatment plan. DVHs graphically describe dose 
distributions across a target volume in addition to organs at risk. A DVH from Poulsen, et 
al’s (Med Phys, 2012) study is shown in Figure 11.  
The Eclipse dose reconstruction software is available is both the Radiation Oncology 
Department at Chris O’Brien Lifehouse as well as the University of Sydney.  
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Figure 10. Calculated (left side of each pair) and measured (right side) 2D dos distributions for a conformal 
field delivered to a static target and to a moving target with and without dynamic multi-leaf collimator (DMLC) 
tracking. 
 
 
 
 
Figure 11. A DVH from Poulsen’s study (Med Phys 2012). It is describing how much of the tumour itself (GTV: 
Gross Tumour Volume) is receiving what percentage of radiation dose.  
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5.2. STUDY FLOW CHART 
The study flow chart is shown in Figure 12. Details of the investigation plan will be 
described in section 5.3. 
 
Figure 12.  Data acquisition procedure for the 30 cancer patients in the CBCT AV biofeedback study. Each 
study will involve the patient breathing both with and without the guidance of AV biofeedback. 
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5.3. INVESTIGATION PLAN 
The study will progress much the same as per the currently implemented clinical liver SBRT 
protocol with the addition of an AV biofeedback training session prior to the scans and then 
the implementation of AV biofeedback during a CBCT scan at the treatment planning stage, a 
second CBCT scan will also be taken without the implementation of AV biofeedback. 
Should fiducial marker motion be more than 10 mm, abdominal compression may be used. 
Our AV biofeedback system is shown schematically in Figure 13. The real-time (30 Hz) 
respiratory data is input into the respiratory motion management system to determine a 
patient’s respiratory-related motion pattern (waveguide). Two CBCT scans will be taken 
during the study under two different breathing conditions: (1) with AV biofeedback and (2) 
without AV biofeedback (free breathing). To improve the image quality and radiation 
targeting for the patient, all subsequent imaging and treatment sessions will use the most 
reproducible breathing condition: free breathing or AV biofeedback.  
 
 
During each patient’s CBCT scans they will breathe under two conditions: (1) with AV 
biofeedback and (2) without AV biofeedback (free breathing). To improve the image quality 
and radiation targeting for the patient, all subsequent imaging and treatment sessions will use 
the most reproducible breathing condition, free breathing or AV biofeedback.  
Numbers 1 – 5 on the study flow chart (Figure 12) indicate the progression of the study plan:  
1) Patient order selection: Non-randomised. Patients will alternate between what 
breathing condition is implemented first in their study: AV biofeedback or free 
breathing. 
2) Use external (RPM signal) and internal marker signals for respiratory signals.  
Respiratory data analysis; respiratory reproducibility will be quantified by 
RMSE (in displacement and period). 
3) Patient report: proposed report shown in Figure 14.  
4) Patient/Radiation Therapist (RT) questionnaire: to gauge the level of acceptance of 
AV biofeedback from both the patient and clinician. (See section 10.2. Questionnaire) 
5) Respiratory Data Analysis. For each patient, the acquired internal motion and 
external respiratory data will be analysed in order to quantify the clinical impact of 
AV biofeedback through four criteria: 
 
 
Figure 13.  Schematic AV biofeedback system to be used in this study. Not shown: abdominal compression to be 
utilised if tumour has range of motion larger than 10mm. Shown here is the use of the screen to show patients 
the visual display, however, the use of goggles are also available (see Figures 1 & 5).  
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i) Quantify the fraction of patients for whom breathing is more regular 
(reproducibility calculated in point 2) with AV biofeedback and proceed to 
simulation and treatment.  
ii) Quantify the improvement in dose distributions and DVHs with and 
without AV biofeedback by reconstructing the delivered dose using the dose 
reconstruction method of Poulsen et al (Med Phys, 2012).
1,2
 This dose 
reconstruction method incorporates the motion information of the target and is 
compatible with a number of treatment planning systems including Eclipse, 
Varian Systems.  
iii) Quantify the reduction in 4D CT errors with/without AV biofeedback by 
programming the Quasar phantom with the AV and free-breathing traces. 
iv) Reconstruct the CBCT into 4D CBCT using the respiratory signal and 
compare the image quality with and without AV biofeedback.  
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Figure 14. Proposed Patient Report, V1.0.  
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Criteria 
    
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CBCT Scans     
Study Analyses     
Review of Study 
Progression 
    
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    
 
5.4. STUDY PROCEDURE RISKS 
Considering that patients are receiving standard oncology treatments, which they are subject 
to regardless of participation in this study, their treating physician will be counselling them 
on the risk of their appropriate treatments. Studies have found that the risks of major and 
minor complications as a result of the implantation of fiducial markers are 5% and 17.3%, 
respectively,
54
 and that very few patients have mild side effects lasting more than 2 weeks.
55
 
However, it should be emphasised that patients will undergo fiducial marker implantation as 
per clinical SBRT protocol, not as a result of participating in this study.  
For the procedures pertaining to this study, the risks to the patient are low: this research study 
involves exposure to a very small amount of radiation from the CBCT scans (which are done 
multiple times routinely as a part of SBRT treatment). As part of everyday living, everyone is 
exposed to naturally occurring background radiation and receives a dose of about 2 to 3 
millisieverts (mSv) each year. This study will involve the addition of two additional CBCTs:  
the upper-range estimate of effective dose from this study is about 16.4 mSv (8.2 mSv per 
CBCT scan).
56
 At this dose level, the risk is low. The dose from this study is comparable to 
that received from routine diagnostic x-ray and nuclear medicine procedures. 
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The RPM and AV biofeedback systems do not involve any invasive procedures or ionising 
radiation and are of no risk to the patients.  
 
5.5. RECRUITMENT AND SCREENING 
Patients fitting the eligibility criteria will be identified and introduced to this study by the 
treating physician who will participate as a principal investigator in this study.  
 
5.6. ENROLMENT PROCEDURE AND INFORMED CONSENT PROCESS 
The patients will be given ample time to completely read the informed consent form as well 
as ask any questions that they may have.
57,58
 The patients will be contacted by the principal 
investigator with regards to their decision in partaking in the study. Patients that agree to 
partake in the study will be asked to sign an informed consent form at their next hospital visit. 
The participant will receive a study enrolment number and this will be documented in the 
participant’s medical record and on all study documents. Patients who agree to participate 
will be contacted by principal investigator to organise times for to the study scans to be 
conducted.   
 
5.7. INFORMED CONSENT PROCESS 
The principal investigator will be obtaining informed consent from patients after consulting 
with their physician prior to commencing the study.  
 
5.8. RANDOMISATION PROCEDURE 
There is no randomisation procedure in this study.  
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6.SAFETY 
6.1. ADVERSE EVENT REPORTING 
6.1.1. CLINICAL TRIALS AND ADVERSE EVENT REPORTING 
The principal investigator and sub investigators will report adverse events to the Radiation 
Safety Officer on site and to the Human Research Ethics Committee and the Research 
Governance Officer within 72 hours of the event occurring unless immediate notification is 
required. 
 
6.1.2. ADVERSE EVENT 
The AV biofeedback system is not invasive and is not expected to cause any adverse event. 
The goggles used for AV biofeedback are easy to put on and are comfortable to wear. The 
Google Nexus tablet computer also to be used as the screen for is held above the patient by a 
tablet-holder clamped on to the treatment couch; the screen is held at a comfortable distance 
from to patient and is anticipated to be a more comfortable option over the goggles. For the 
audio component, there is volume control on the goggles and tablet themselves for built-in 
speakers. The other procedures performed (fiducial marker/surgical clips, CBCT scans) are 
standard/routinely performed for SBRT treatment therefore no adverse effect is anticipated 
by the participation in this study 
The risks associated with the acquisition of radiological scans are outlined in the risk Section 
5.4. (No known side effects). 
 
6.1.3. SERIOUS ADVERSE EVENT (SAE) 
We do not anticipate any serious adverse events as a result of the procedures pertaining to 
this study. 
 
6.1.4. DEVICES EVENTS 
Standard imaging protocols and full clinical, treatment and imaging software will be used in 
the acquisition of imaging scans in this study. We do not anticipate that any adverse event 
will occur as a result of AV biofeedback as the addition equipment needed to implement AV 
biofeedback: the goggles, are lightweight and easy to wear (and take off), in addition to the 
screen and tablet-holder are is easy to clamp to and remove from the treatment couch. 
Accidental protocol breaches will be reported to the hospital’s Radiation Safety Committee. 
 
6.2. SERIOUS ADVERSE EVENT REPORTING 
The principal investigator and sub investigators will report adverse events to the Radiation 
Safety Officer on site and to the Human Research Ethics Committee and the Research 
Governance Officer within 72 hours of the event occurring unless immediate notification is 
required. 
 
6.3. DATA SAFETY AND MONITORING BOARD 
The imaging modalities that are used in this study are approved for clinical practice, therefore 
this study we will not nominate a separate Data and Safety Monitoring Board.  
Our steering committee (investigators and sub investigators including consumer 
representatives) will meet monthly to monitor the conduct of the study and assess progress. In 
addition, the principal and majority of sub investigators will maintain weekly contact via 
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email and face-face or teleconference meetings in order to facilitate implementation of the 
study and provide quality assurance to all aspects of the study. The principal investigator will 
be on-site to personally conduct, oversee, and supervise all of the activities. 
 
6.4. EARLY TERMINATION 
We do not anticipate any reason for early termination of the study. 
  
227
   
Liver tumour motion using audiovisual biofeedback 
Version 4.0, 29/06/2015 
30 
 
7.BLINDING AND UNBLINDING 
There is no blinding in this study.   
  
228
   
Liver tumour motion using audiovisual biofeedback 
Version 4.0, 29/06/2015 
31 
 
8.STATISTICAL CONSIDERATIONS 
8.1. SAMPLE SIZE, POWER CALCULATION AND ANALYSIS PLAN  
According to preliminary results from 15 healthy human subjects, assuming a type I error rate 
of 5%, 80% power and a moderate effect size of 0.34σ for the paired differences between free 
breathing and AV biofeedback, a sample size of 30 patients will be required. If we assume 
that the standard deviations of these differences in the patient population will be 
approximately double that of the healthy volunteers then the minimal detectable difference 
will be 0.068, (σ = 0.2). 
For the primary objective, tumour motion reproducibility with and without AV biofeedback 
will be quantified. Results will be evaluated using the RMSE method and compared using 
statistical analysis methods such as the Student t-test. The possible changes in treatment 
planning will be evaluated qualitatively by visual inspection of dose distribution and 
quantitatively by analysing dose-volume metrics derived from dose-volume histograms 
(DVHs) as described by Poulsen et al.
1,2
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9.CONFIDENTIALITY AND STORAGE AND ARCHIVING OF STUDY       
DOCUMENTS 
Collected data, as itemised on page 16, will be collected from the subjects. After acquisition 
the CBCT data will be de-identified, however, patient data could be made re-identifiable to 
obtain additional clinical information for the data analysis stage of the project, but only by the 
principal investigator. De-identified data will be stored on a secure, password protected 
backed up database that will be created, much the same to what we have designed for our 
previous studies. A separate key of the subject study number and their medical record number 
will be securely stored by the principal investigator to allow re-identification if necessary. 
Only the principal investigator will have the ability to re-identify subjects. All other 
investigators will only have access to the de-identified data. The data will be stored for 15 
years as per clinical trial guidelines. 
 The location of data storage will be in the University of Sydney’s Medical Foundation 
Building. Access to the building requires swipe card access; therefore, the general public has 
no access to it. In addition to this, the lab rooms within the Medical Foundation Building 
require a key to enter it. 
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10.DISCLOSURE OF CONFLICT OF INTEREST 
Audiovisual biofeedback is being developed towards commercialisation. This has led to the 
incorporation of a company, Respiratory Innovations Pty Ltd, by University of Sydney 
investigators Prof. Paul Keall, Mr. Kuldeep Makhija, and Mr. Sean Pollock. No financial 
support is provided by Respiratory Innovations to any of the investigators or to the 
investigation itself; however, Paul Keall, Kuldeep Makhija, and Sean Pollock are 
shareholders in Respiratory Innovations.  
No patient data will be used for promotion for Respiratory Innovations outside of what is 
publically available, e.g. presentations or publications.  
11.APPENDIX 
11.1. LIST OF ABBREVIATIONS 
- AV Biofeedback: Audiovisual biofeedback 
The respiratory guidance system to be testing in this study composing of screen or 
goggles and motion tracking  
- FB: Free Breathing 
 The respiratory condition during which AV biofeedback will not be used 
- RMSE: Root mean square error. 
Metric to quantify the reproducibility of a respiratory signal. A lower value is 
indicative of a more reproducible signal.  
- CBCT: Cone beam computed tomography 
 Medical imaging modality to be used to monitor fiducial marker motion 
- RPM: Real-time position management 
Infra-red tracking camera and marker block used to obtain the external 
respiratory signal for the real-time input for AV biofeedback 
- SBRT: Stereotactic body radiotherapy 
Cancer radiation treatment which involves the high-precision delivery of high-
dose radiation to a localised area in a small number of treatment fractions.  
- DVH: Dose volume histogram  
Mathematical representation of three-dimensional dose distributions in a two-
dimensional graph.  
- mSv: milli Sieverts  
 Sieverts are the SI unit of equivalent absorbed radiation dose 
- TGA: Therapeutic Goods Administration 
- GTV: Gross Tumour Volume 
 GTV is the physical volume of the tumour 
- CTV: Clinical Target Volume 
 CTV is the approximation of tumour volume (given imaging uncertainties) 
- PTV: Planning Target Volume 
PTV is the CTV with additional margins to account for variations in size, shape 
and position of the tumour. 
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11.2. QUESTIONNAIRE  
Audiovisual (AV) Biofeedback Survey 
 
Goal: To evaluate your experience with the audiovisual (AV) biofeedback guidance 
system and identify any areas where development is needed to improve the AV 
biofeedback experience.   
 
 
Patient status 
Disease and stage: Body-mass index: 
Lung function: or Height/Weight: 
Immobilisation: Cognitive ability: 
Treatment schedule: Heart rate/ blood pressure: 
Performance status:  
 
 
Date:  
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Audiovisual (AV) Biofeedback Patient Survey  
 
Goal: To evaluate your experience with the audiovisual (AV) biofeedback guidance 
system and identify any areas where you feel development is needed to improve the 
AV biofeedback experience.   
 
Introduction: In medical imaging and radiotherapy, irregular breathing negatively 
impacts image quality, in addition to inaccurate tumour targeting. AV biofeedback 
provides respiratory guidance to produce consistent respiratory motion. AV 
biofeedback will help to improve the quality of imaging scans in addition to the 
accuracy of radiotherapy treatment. 
 
Timing: After initial simulation session and within last week of treatment 
 
Demographics  
 
Age range: Impeded eyesight: y / n 
Sex: Impeded hearing:  y / n  
Height: Highest level of education: 
Weight: Frequency of computer use: 
 Anxiety level: 
     1 (not at all anxious) – 10 (very anxious)  
(1) Do you feel your breathing was more 
consistent using the AV biofeedback? 
No  Moderately  Yes 
1 2 3 4 5 
Comment: 
 
 
 
(2) Was the training session that you had 
prior to this session helpful? 
No  Moderately  Yes 
1 2 3 4 5 
Comment: 
 
 
 
(3) Did you feel physically comfortable with 
the AV biofeedback system? 
No  Moderately  Yes 
1 2 3 4 5 
Comment: 
 
 
 
(4) Did you feel the AV biofeedback visual Too slow  Just right  Too fast 
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guide (blue curve) was too slow or fast? 1 2 3 4 5 
Comment: 
 
 
 
 
(5) Did you feel the AV biofeedback visual 
guide (blue curve) was too shallow or deep? 
Too shallow  Just right  Too deep 
1 2 3 4 5 
Comment: 
 
 
 
(6) Did you like having the music? 
 
No  Moderately  Yes 
1 2 3 4 5 
Comment: 
 
 
 
(7) Did the music help you breathe more 
consistently? 
 
No  Moderately  Yes 
1 2 3 4 5 
Comment: 
 
 
 
(8) Did you feel anxious during the session? 
 
No  Moderately  Yes 
1 2 3 4 5 
Comment: 
 
 
 
 (9) Do you have any comments or suggestions either on your experience or how we 
can improve the AV Biofeedback system?  
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Audiovisual (AV) Biofeedback Radiotherapist Survey  
 
Goal: To quantify the user acceptance of audiovisual (AV) biofeedback and identify 
areas to improve the user AV biofeedback experience.   
 
Introduction: In medical imaging and radiotherapy, variations in cycle-to-cycle 
breathing results in imaging artefacts, leading to inaccurate radiation beam coverage 
and tumour targeting. AV biofeedback guides patients to produce regular respiratory 
motion using an AV device combined with a respiratory monitoring system. The AV 
biofeedback system will help to improve the quality of scans and the accuracy of 
radiotherapy treatment for patients. 
 
Timing: After initial simulation session and within last week of treatment for each 
patient 
 
Demographics  
Position: 
Years of experience: 
 
(1) Do you think that the training session was 
useful for the patient? 
No  Moderately  Yes 
1 2 3 4 5 
Comment: 
 
 
(2) Do you think the AV biofeedback system 
helped your patient to breathe more 
regularly? 
 
No  Moderately  Yes 
1 2 3 4 5 
Comment: 
 
 
(3) Was the AV biofeedback system easy to 
setup? 
No  Moderately  Yes 
1 2 3 4 5 
Comment: 
 
 
(4) Was the AV biofeedback system easy to 
operate? 
No  Moderately  Yes 
1 2 3 4 5 
Comment: 
 
 
(5) Would you recommend the AV No  Moderately  Yes 
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biofeedback guidance to your colleagues at 
other centres to implement in similar 
treatment? 
 
1 2 3 4 5 
Comment: 
 
 
(6) Do you have any comments or suggestions on your experience or how we can 
improve the AV Biofeedback system? 
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 Department of Radiation Oncology, Royal Prince Alfred Hospital  
 
Investigation of liver tumour respiratory motion for SBRT cancer patients 
using audiovisual biofeedback 
 
INFORMATION FOR PARTICIPANTS 
 
Introduction 
 
You are invited to participate in this study because you have liver cancer and will be 
receiving a course of standard radiotherapy. 
 
The aim of your cancer treatment is to deliver the radiation as precisely as possible 
to the liver and to spare the surrounding organs such as the parts of the liver 
unaffected by the cancer and kidneys. However, even when are lying still, the liver 
and surrounding organs will move when you breathe.  In order to compensate for the 
liver movement, we need to treat a “margin” around the liver to be certain that all of 
the cancer is being treated every day. If we can help you to visualise and regulate 
your breathing using an audio-visual device, we may be able to reduce the 
movement and make this margin smaller, allowing more accurate targeting of the 
radiation beam to the tumour and, reducing the side effects and, importantly, the 
radiation dose to the surrounding normal organs. 
 
This Information Sheet gives detailed information about the research study, which 
your Doctor will discuss with you. Its purpose is to explain to you as openly and 
clearly as possible all the procedures involved in this project before you decide 
whether or not to take part. Participating in the study is voluntary. Please take the 
time to read the information sheet carefully, and discuss it with family, friends and/or 
your GP if you wish.  Please ask if there is anything you do not understand or if you 
would like more information.  Once you understand the study, you will be asked to 
sign the Consent Form if you wish to participate. You will have a copy to keep as a 
record. 
 
The study is being conducted by: 
 
Dr Regina Tse (Department of Radiation Oncology, Chris O’Brien Lifehouse) 
 
Dr Robin Hill (Department of Radiation Oncology, Chris O’Brien Lifehouse) 
 
Gwi Cho (Department of Radiation Oncology, Chris O’Brien Lifehouse) 
 
Darren Martin (Department of Radiation Oncology, Chris O’Brien Lifehouse) 
 
Professor Paul Keall (Radiation Physics Laboratory, Sydney Medical School, 
University of Sydney) 
 
Sean Pollock (PhD student, Radiation Physics Laboratory, Sydney Medical School, 
University of Sydney) 
 
Danny Lee (PhD student, Radiation Physics Laboratory, Sydney Medical School, 
University of Sydney) 
 
Sean Pollock is conducting this study as a part of the requirements for the degree of 
Doctor of Philosophy in Medicine under the supervision of Professor Paul Keall.   
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It is planned that thirty (30) patients will be recruited from the  Chris O’Brien 
Lifehouse into this study.  
 
What is the purpose of this study? 
The aim of the study is to evaluate whether the Audio Visual (AV) Biofeedback 
system will improve the reproducibility of respiratory motion.  
 
This AV biofeedback system comprises a screen or goggles that you view in addition 
to speakers and controlling software. The goggles or screen allow you to visualize 
your respiration pattern on a graph (see illustrations below) and with this feedback, 
allow you to control and regulate your breathing.  
 
 
The goggles (left) and screen (right) displaying the AV biofeedback guiding software 
(centre). 
 
What will happen to me if I decide to take part? 
As part of your standard SBRT planning and treatment you will have 18 Cone Beam 
CT (CBCT) scans which are used to position you during radiotherapy. If you are 
participating in this study, you will have 2 extra CBCT scans done at your planning 
visit. During the CBCT scans, two breathing conditions will be tested: 
 
(1) with you using AV biofeedback and  
(2) without using AV biofeedback  (free breathing). 
 
The pattern of your breathing will be measured,- whichever method (with AV 
biofeedback or without) that produces more regular and consistent breathing patterns 
will be selected for use throughout your treatment. 
 
When you are breathing with the AV biofeedback system, you will either be wearing a 
pair of goggles or viewing a screen. The AV biofeedback system will guide you to 
produce regular breathing. 
 
You will also be asked to complete a questionnaire which will take about 2 minutes to 
do. You may also be asked to do a follow-up questionnaire later in your treatment, 
depending on the results of the initial study.  
 
Finally, the researchers would like to have access to your medical record to obtain 
information relevant to this study. 
 
What are the risks? 
All medical procedures - whether for diagnosis or treatment, routine or experimental 
– involve some risk. In addition, there may be risks associated with this study that are 
presently unknown and unforeseeable.  In spite of all precautions, you might develop 
medical complications from participating in this study. 
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The goggles that you will wear as part of the AV biofeedback are similar to a pair of 
glasses and are not expected to cause any discomfort. However, if you feel 
uncomfortable at any stage, they can be immediately taken off. 
The screen that you may view is a tablet computer that will be held a comfortable 
distance from you by a table-mounted tablet stand. 
 
The CBCT scans are similar to regular CT scans. The dose from the two (2) extra 
CBCT in this study is comparable to that received from routine diagnostic x-ray and 
nuclear medicine procedures. At this dose level, no harmful effects of radiation have 
been demonstrated and the risk is low.  
 
Please inform us if you have participated in any other research studies using 
radiation in the last five years.   
 
Please keep this form in a safe place for the next five years in case you volunteer for 
any more studies using radiation, when you should show it to the Investigator. 
 
It is important that women participating in this study are not pregnant and do not 
become pregnant during the course of the study. If you suspect that you are pregnant 
while you are receiving treatment on this study, you should advise your study doctor 
immediately. 
 
What are the benefits? 
While we intend that this research study furthers medical knowledge and may 
improve radiotherapy for liver cancer and lessen its side effects (and for treatment of 
other cancers which move as the patient breathes), we cannot guarantee that it will 
be of benefit to you.  However, if the AV biofeedback system proves successful it will 
continue to be used in your treatment plan. In addition, the images obtained in this 
study will be used for your treatment plan.  
 
What are the alternatives? 
This study is purely voluntary and if you choose not to participate in this study, you 
will be offered the standard SBRT for your liver cancer in this hospital. Your decision 
will not affect your treatment, follow-up or relationship with any of the medical staff 
involved in your care. 
 
Costs 
Participation in this study will not cost you anything, nor will you be paid.   
 
Compensation for injuries or complications 
If you suffer any injuries or complications as a result of this study, you should contact 
the study doctor as soon as possible, who will assist you in arranging appropriate 
medical treatment. If you are eligible for Medicare, you can receive any medical 
treatment required to treat the injury or complication, free of charge, as a public 
patient in any Australian public hospital.   
 
In addition, you may have a right to take legal action to obtain compensation for any 
injuries or complications resulting from the study.  Compensation may be available if 
your injury or complication is sufficiently serious and is caused by unsafe drugs or 
equipment, or by the negligence of one of the parties involved in the study (for 
example, the researcher, the hospital, or the treating doctor).  You do not give up any 
legal rights to compensation by participating in this study.  
 
Voluntary Participation 
Participation in this study is entirely voluntary.  You do not have to take part in it.  If 
you do take part, you can withdraw at any time without having to give a reason.  
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Whatever your decision, please be assured that it will not affect your medical 
treatment or your relationship with the staff who are caring for you.   
 
Confidentiality 
All the information collected from you for the study will be treated confidentially, and 
only the researchers named above will have access to it.  The study results may be 
presented at a conference or in a scientific publication, but individual participants will 
not be identifiable in such a presentation. 
 
Further Information 
When you have read this information, Dr. Regina Tse will discuss it with you further 
and answer any questions you may have.  If you would like to know more at any 
stage, please feel free to contact her on (02) 9515 8057. 
 
Results of Project 
It may be a number of years before the results of this research are available. The 
results will be published in medical journals. Please ask your doctor if you want to 
know more about this. 
 
Ethics Approval and Complaints 
This study has been approved by the Ethics Review Committee (RPAH Zone) of the 
Sydney Local Health District.  Any person with concerns or complaints about the 
conduct of this study should contact the Executive Officer on 02 9515 6766 and quote 
protocol number X13-0089. 
 
Disclosure of conflict of interest 
AV biofeedback is also being developed towards commercialisation. This has led to the 
incorporation of a company, Respiratory Innovations Pty Ltd, by University of Sydney 
investigators Prof. Paul Keall, and Mr. Sean Pollock. No financial support is provided 
by Respiratory Innovations to any of the investigators or to the investigation itself; 
however, Paul Keall and Sean Pollock are shareholders in Respiratory Innovations.  
No patient data will be used for promotion for Respiratory Innovations outside of what 
is publically available, e.g. presentations or publications.   
 
This information sheet is for you to keep. 
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Summary 
Study Title:  AVIATOR: Audio-Visual Investigation Advancing ThOracic 
Radiotherapy 
Protocol version:  V5.0 
Objectives There is a clear link between irregular breathing and errors in 
medical imaging and radiation treatment. We assume that 
irregular respiration is a surrogate for clinical outcomes in 
lung cancer radiotherapy. In a prospective multi-institutional 
randomised clinical trial we will test the impact of AV 
biofeedback on clinical outcomes. 
 Primary objective: Test the hypothesis that AV biofeedback 
will significantly improve breathing regularity and reduce 
medical imaging errors for lung cancer patients undergoing 
radiotherapy.  
 Secondary objectives: Patient-specific objectives will evaluate 
the impact of AV biofeedback by: (1) Quantifying the 
proportion of patients for whom breathing is more regular 
with AV biofeedback, (2) Quantifying the variability in 
breathing motion throughout a course of treatment, (3) 
Quantifying the improvement in image quality with AV 
biofeedback, (4) Evaluating the patient experience through a 
perception of care survey, (5) Developing indications and 
contra-indications for the use of AV biofeedback, (6) 
Quantifying the differences in image-guided radiotherapy 
(IGRT) shifts during treatment, and (7) recording toxicity 
outcomes for up to 12 months after treatment has been 
completed.  
 Department-specific objectives will evaluate the impact of AV 
biofeedback on clinical testing by: (1) Quantifying any 
practice changes (e.g. margin reduction), (2) Quantifying the 
impact on workflow using the AV biofeedback device through 
time-motion studies, (3) Evaluating the operator and clinician 
confidence in the AV biofeedback device’s reliability and 
clinical efficacy through a technology-impact survey, (4) 
Quantifying the system robustness through hardware and 
software fault reporting, and (5) Performing system quality 
assurance, sharing the results through a web-based upload and 
provide feedback for QA improvement.  
Study design We will perform a comprehensive clinical evaluation of the 
AV biofeedback system, a multi-institutional study will be 
performed in the following radiation oncology departments 
in the NSW/ACT region: Canberra Hospital, Calvary Mater 
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Hospital, Nepean Cancer Centre, Northern Sydney Cancer 
Centre, Chris O’Brien Lifehouse, Westmead Hospital, and 
Gosford Hospital. Our methodological framework will be 
based on the widely used Technology Acceptance Model 
(TAM).1,2 The TAM gives qualitative scales for two 
specific variables, perceived usefulness and perceived ease 
of use, which are fundamental determinants for user 
acceptance.    
 Planned sample size  
 Across the seven departments there will be a minimum of 75 
patients (+10% dropout: 83 patients).  
 Selection criteria  
 1) Lung cancer patients 
 2) >18 years old 
 3) No gender or ethnic restrictions 
 4) An ECOG score in the range of 0 to 2 
 5) Able to give written informed consent and willingness 
to participate and comply with the study 
 6) No pregnant / lactating woman 
  
Study procedure Prior to each patient’s planning and treatment they will 
undergo a breathing session during which they will breathe 
both with and without the guidance of AV biofeedback. 
Preceding each of these breathing sessions will be an AV 
biofeedback training session to familiarise the patient with the 
system. After the breathing session has been completed, the 
most reproducible breathing condition (AV biofeedback or 
free breathing) will be determined via respiratory analysis. It 
will be the most reproducible breathing condition that will 
continue to be used throughout the rest of that particular 
patient’s planning and treatment. Each patient will then be 
monitored throughout their treatment, noting any differences 
in image quality and dose distributions as a result of their 
breathing.  The AV biofeedback system is simple and easy to 
implement; the system consists of a respiratory sensor, a 
computer with customised software and a display screen. The 
simplicity of the AV biofeedback system makes it compatible 
with a number of imaging and treatment modalities.  
 Eligible patients that have agreed to participate in the study 
and have given informed consent will breathe both with and 
without the guidance of AV biofeedback. The most 
reproducible breathing condition will then be implemented in 
their planning and treatment. Further details on study 
procedure can be found in Section 4: Study Outline.  
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 Patient Time Commitment   
 Each session will take a total of 1 hour, inclusive of setting 
and packing up the AV biofeedback system in addition to AV 
biofeedback training, but it may be completed in less time 
than this. After each session the patient will be asked to 
complete a questionnaire regarding the AV biofeedback 
system; each questionnaire is designed to only take 2 minutes 
to complete.    
 
 Data Analysis 
 For each patient the acquired respiratory sensor data will be 
analysed in order to quantify the clinical impact of AV 
biofeedback through the following measurements:  
 1) Quantify the proportion of patients for whom respiration is 
more regular with the guidance of AV biofeedback. 
 2) Quantify the variability in breathing motion throughout a 
course of treatment. Respiratory results will be evaluated 
using the root mean squared error (RMSE) method and 
compared using statistical analysis methods such as the 
Student t-test. 
 3) Quantify the differences in IGRT shifts during treatment 
 4) Quantify any practice changes, such as margin reduction 
 
Estimate the clinical benefit Successful completion of this trial and positive testing of the 
primary hypothesis will give clinicians a simple tool to 
improve breathing regularity and reduce imaging and 
treatment errors for cancer radiotherapy patients. AV 
biofeedback will enable (1) identification and delineation of 
primary tumours and positive nodes, (2) identification and 
avoiding critical structures, (3) reduction of false positives and 
false negatives during image interpretation, (4) improvement 
of rigid and deformable registration algorithm performance to 
facilitate online corrections and adaptive radiotherapy 
strategies and (5) reduction of margins, leading to lower 
toxicity. From a patient perspective, the successful 
implementation of AV biofeedback will allow patients to be 
empowered by active participation in their treatment. From a 
department perspective, it will allow them to perform system 
QA in addition to developing indications for the use of AV 
biofeedback. The clinical benefit will also be assessed by 
recording toxicities for up to 12 months after the patient’s 
treatment is complete. This will offer insight into the benefits 
of AV biofeedback to patient outcomes. Successful 
completion of this study will ensure Australia is at the 
forefront of technological developments and clinical 
improvements and pave the way for broader clinical use.  
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Statistical Considerations  Without the AV biofeedback system, it is anticipated that 
approximately 40% of patients experience regular breathing. 
Increasing this proportion to 60% using the AV biofeedback 
system would be considered clinically worthwhile and 
promising for further investigation in a larger study. Based on 
the Simon’s design, a sample size of 50 patients receiving the 
AV biofeedback system will have at least 80% power with 
95% confidence to rule out a regular rate of 40% in favour of 
a 60% rate. The proposed design will be a randomized phase 
II with a 50 patients receiving the intervention and 25 standard 
care; adding 10% (8 patients) to account for 
contamination/drop out gives a total of 83 patients.  Patients 
will be stratified by treating institution and for treatment intent 
(palliative vs. radical) to ensure similar balance in the arms 
across the sites.  
 
Duration of Study 2 years 
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1.INTRODUCTION 
Lung cancer has the highest incidence of cancer-related death in Australia,
3
 and more than 50% of lung 
cancer patients are treated with radiotherapy. However, the precision of radiotherapy can be reduced due 
to respiratory-related tumour motion, leading to increased irradiation of healthy surrounding tissues, 
resulting in a significant increase in radiation-related toxicity,4-6 this is further exacerbated when 
respiration is irregular in nature (deep/shallow breaths, baseline shifts, suspended breathing, etc.).
7,8
 A 1Gy 
increase in tumour dose results in a 4% improvement in survival,
4
 however, a 0.5cm range of tumour motion 
can cause a 4~5% variation in radiation dose
6
 which leads to an increase in mean dose to healthy surrounding 
tissues resulting in an increase in risk of pneumonitis and radiation toxicity.
5,9
  
Techniques such as respiratory gating, breath-holds and tumour tracking are clinically useful for tumour 
motion management.
7,10,11
 However, irregular respiration can reduce the efficiency of such motion 
techniques
12,13
 in addition to causing motion artefacts and anatomic errors in medical imaging.
14-19
  
Respiratory guidance is one such technique which specifically aims to produce regular patient breathing. At 
the forefront of respiratory guidance is the audiovisual (AV) biofeedback system (Figure 1), developed by 
Venkat, et al.
13
 AV biofeedback is a real-time, interactive and personalised respiratory guide designed to help 
the patient breathe regularly. AV biofeedback has demonstrated a reduction in average cycle-to-cycle 
variations in respiratory amplitude and period by up to 50% and 70% respectively,
13
 which is beneficial in 
improving motion reproducibility for respiratory-gated radiotherapy
20
 in addition to reducing blurring 
artefacts in 4D PET
21
 and CT.
22
  
 
Figure 1. AV biofeedback system (left). AV goggles and real-time position management (RPM) marker block on 
the abdomen shown (IR camera not shown, see section 5.1: Study Equipment). The visual display (right) as seen 
by the subject (sans arrows) of the AV biofeedback system shows the guiding wave (white curve) and a marker 
position (grey marker) in real time.   
 
This system is ideally to be utilized for image-guided radiotherapy (IGRT) , during which the tumour motion 
can be managed by regularising respiratory motion based on the correlation between the external abdominal 
position (location of RPM marker) and the tumour itself.
23,24
 
Despite the positive results of AV biofeedback studies to date, the participants have thus far largely been 
healthy volunteers, which are sufficient when investigating tumour surrogates. There has also not been any 
analysis of the patient perception of AV biofeedback to understand and stratify responders and non-
responders to the training. Here, we will perform clinical testing of AV biofeedback in seven radiation 
oncology departments. Our study differentiates itself from previous investigations by being multi-
institutional, randomised, with a much larger number of patients, the use of an improved AV biofeedback 
device, the inclusion of patient-reporting and a comprehensive technology assessment. 
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2.BACKGROUND 
2.1. IRREGULAR BREATHING LEADS TO MEDICAL IMAGE AND TREATMENT ERRORS 
There is a clear link between respiratory irregularity and errors in medical imaging and treatment, as shown 
in Table 1 and Table 2. Irregular breathing patterns are shown in Figure 2 and Figure 3, demonstrating 
baseline drifts and inconsistent amplitude and period. The impact of this irregularity on medical images and 
targeting are shown Table 1, and are elaborated on in Table 2. 
 
Table 1. Clinical errors in medical images due to irregular respiration. Further studies in which these errors 
have been investigated are listed in the bottom row.   
Tumour delineation errors Image artefacts (CT) Image artefacts (PET) 
 
From Persson et al. (2010)
25
 
 
From Yamamoto et al. (2008)
15
 
 
From Sureshbabu et al. (2005)
26
 
Persson
25
 and Ge
27
 
Pan,
18
 Fitzpatrick,
28
 Abdelnour,
14
 
Yamamoto
15
 and Low
29
 
Sureshbabu
26
 and Yang
21
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Figure 2.  Example of tumour motion (superior-
inferior) during radiation treatment showing the 
variation in period, baseline, magnitude and mean 
position.  Adapted from Worm.
30
  
Figure 3. Example of irregular patient breathing both 
during treatment (intrafraction) and from day-to-day 
(interfraction). 46 of 50 patients had errors with an 11mm 
average error.  From Yamamoto.
15
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Table 2 details previous studies investigating the impact of irregular respiration on radiotherapy 
planning and treatment:  
Table 2. Clinical Problems of Irregular Respiration 
Clinical Problem Author # of participants Imaging Modality Comments on clinical problem 
Tumour edge 
detection errors 
Persson
25
 19 patients 4DCT 
 Variations in delineated gross 
tumour volume (GTV) sizes of up to 
15.6 cm
3
 
 Delineation error occurred in 16 out 
of 20 tumours across 19 patients.  
Tumour edge 
detection errors 
Ge
27
  10 patients 4DCT 
 Disagreement in treatment margins 
between planning and treatment.     
(Under- and over-estimation) 
 Overestimation: 39% of the fractions 
in 7 of 10 patients. Median 
overestimation: 11.4 mm (SI), 2.5 
mm (AP), and 2.5 mm (LR) 
 Underestimation: 53% of the 
fractions in 8 of 10 patients. Median 
underestimation: 3.9 mm (SI), 3.0 
mm (AP) and 1.7 mm (LR)   
Image artefacts Yamamoto
15
  50 patients 4DCT 
 90% of patients had at least one 
artefact (other than blurring) in the 
diaphragm / heart. Mean magnitude 
of artefact: 11.6 mm 
 30% of patients had at least one 
artefact (other than blurring) in the 
lung / mediastinum 
Image artefacts Pan
18
  10 patients 4DCT 
 Image artefacts: incomplete, 
overlapping, duplicate and blurring 
artefacts.  
Image artefacts Abdelnour
14
  
Phantom 
2 patients 
4DCT 
 Incorrect/incomplete binning for 
both phase and amplitude 4D-CT 
binning. 
 Phase binning: average consistency 
error (μe ± σe) ranged from 
18%±20% to 30%±35%. 
 Amplitude binning: average 
consistency error (μe ± σe) ranged 
from 11%±14% to 20%±24%.  
Image artefacts Yang
21
  
Motion phantom 
programmed 
with patient 
breathing 
PET 
 Average increase in structure due to 
image blurring was 1.3±2.2 mm.  
 Dice coefficient (metric of overlap 
between two volumes): 0.88±0.10 
Inaccurate motion 
prediction 
Murphy
31
  9 patients 
CyberKnife infra-red 
tracking 
 Observed trend that with more 
irregular respiratory signals came a 
larger prediction error.  
Inaccurate motion 
prediction 
Pollock
32
  
15 healthy 
volunteers 
MRI 
 Inaccurate respiratory motion 
prediction for both internal and 
external surrogates 
 Prediction accuracy became 
increasingly unreliable at higher 
system latencies 
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2.2. DEVELOPMENT OF BREATHING TRAINING IN RADIATION ONCOLOGY 
To address the problem of respiratory irregularity, various methods of patient respiratory guidance 
have been applied by other groups, as summarised in Table 3.  
Table 3.  Development of breathing-guidance 
Author, year 
Breathing 
Sensor 
Subjects Developments in Breathing-Guidance 
Wang, 1995
33
  Bellows belt 6  Verbal prompts for breath-hold MRI 
Wang, 1995
34
  MR navigator 6  Visual prompts for multiple breath-hold MRIs 
Wong, 1999
10
  Flow monitor 12  Immobilizing breathing motion 
Vedam, 2003
12
  RPM 5 
 Visual motion wave with two motion limits (inhale and 
exhale limits) 
 Early respiratory-guidance biofeedback (no audio, visual 
biofeedback limited to inhale/exhale limits) 
George, 2005,
35
 
2006
20,36
  
RPM 24 
 Visual motion bar with two motion limits and verbal 
instruction (“breathe in”, “breathe out”) 
 Similar to Vedam (2003) with the addition of audio prompts 
(however, audio and visual prompts were tested separately)  
Lim, 2007
37
  Thermocouple 10 
 Visual guidance with audio prompt.   
 Baseline drift not detected using the thermocouple 
Locklin, 2007
38
  Bellows belt 16 
 Visual biofeedback only for breath-hold CT scans 
 Bellows belt signal is self-correcting, and any variations in 
respiratory baseline or amplitude are lost 
Venkat, 2008
13
 RPM 10 
 First generation AV biofeedback system.  
 Audio and visual prompts performed simultaneously 
 Customizable to volunteer breathing 
 Visual prompt: wave- and bar guide were tested.  
 Wave-guide found to be the more effective of the two. 
 Audio prompts: ascending and descending tones for inhale 
and exhale, respectively.  
 Healthy volunteer study 
Kim, 2012
39
 
Pollock, 2013
40
 
RPM 15 
 More developed version of AV biofeedback, continuing on 
from Venkat’s study.  
 Visual prompt: wave-guide 
 Audio prompt: music (polyphonic midi-files) that changes in 
speed if subject deviated from wave-guide.  
 Set-up compatible with MRI. 
 Healthy volunteer study 
AVIATOR  
2013-2015 
RPM 83 
 Most recent version of AV biofeedback.  
 Visual prompt: wave-guide 
 Audio prompt: music (classical music, mp3-compatible) that 
fades out should the subject deviate from the breathing 
limits.  
 Survey of clinicians and patients to be taken for 
technological assessment of AV biofeedback 
 Randomised and stratified 
 Multi-department nature of study will give strong indication 
of clinical applicability 
 Will be the first study to comprehensively assess the impact 
of respiratory-guidance on clinical oncology planning & 
treatment for both patients and clinicians  
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As shown in Table3, respiratory-guidance has developed from simple verbal instructions for breath-
holds to the interactive, customizable and real-time AV biofeedback to be tested in this study. This 
study will involve the recruitment of at least 75 participants (+10% to counter dropout: 83 
participants), which is considerably greater than the participants involved in previous respiratory 
guidance studies. Such a number of participants in this study would make it the most comprehensive 
AV biofeedback study to date. The inclusion of more participants in a randomised clinical trial would 
also produce more accurate and significant results.  
2.3. AUDIOVISUAL BIOFEEDBACK SYSTEM 
As shown in Table 3, the AV biofeedback system is the culmination of years of respiratory-guidance 
research with a real-time, interactive and personalised respiratory-guidance system. AV biofeedback 
has demonstrated to reduce average cycle-to-cycle variations in respiratory amplitude and period by 
up to 50% and 70% respectively,
13
 which has also shown to be beneficial in improving motion 
reproducibility for respiratory-gated radiotherapy
20
 in addition to reducing blurring artefacts in 4D 
PET
21
 and CT.
22
 A schematic of the AV biofeedback system is shown below in Figure 4. 
 
A RPM system tracks the motion of an external marker positioned on the patient’s abdomen, this 
respiratory-motion is used to calculate an average cycle of respiration (using a Fourier series fit from 
10 obtained respiratory cycles). This average cycle is used as the wave-guide (white curve in Figure 
4); it continually moves from right-to-left across the visual display and acts as part of the visual 
prompt for AV biofeedback. Also on the visual display is a grey marker moving vertically up-and-
down, it is the goal of the patient to match this grey marker over the white wave-guide. The grey 
marker is made to look like the RPM marker block to be used in monitoring the patient’s breathing.  
The audio component of AV biofeedback is classical music playing to the patient; the music fades out 
should they deviate from the breathing limits (blue region shown in Figures 1 & 4). AV biofeedback 
has been shown to be compatible in a number of imaging and treatment modalities,
21,39,41
 as well as 
utilising different types of visual displays;
39,41,42
 the screen-setup as shown in Figure 4 will be utilized 
here, however, if one or more departments are not equipped with these or faults occur, there are other 
options available.  
Previous AV biofeedback studies have involved the recruitment of healthy volunteers, not cancer 
patients. This study will be the first to assess the impact of AV biofeedback on clinical oncology 
planning and treatment for both patients and clinicians.   
  
Figure 4.  The University of Sydney AV biofeedback device as used for pre-treatment imaging and treatment. 
The system consists of a respiratory sensor, a computer with customised software and a patient screen. The 
patient sees a visual representation of their current breathing and tries to match this to a personalised pattern 
of more regular breathing.  
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3.STUDY OBJECTIVES AND AIMS 
3.1. OBJECTIVES 
This study aims to assess the AV biofeedback system efficacy in a clinical setting.  To test this we 
will conduct an 83 lung cancer patient clinical study across 7 departments with the following 
objectives: 
Primary objective: In a prospective multi-institutional randomised clinical trial we will test the 
hypothesis that AV biofeedback will significantly improve breathing regularity and reduce medical 
imaging errors for lung cancer patients undergoing imaging and treatment procedures during 
radiotherapy. The patients will be randomised in a 2:1 ratio, with 2/3 of the patients being recruited 
into the AV biofeedback (intervention) arm and 1/3 in the free breathing (control) arm.  
 
Secondary objectives will involve patient-specific and department-specific objectives: 
Patient-specific objectives are to evaluate the impact of AV biofeedback by: 
1)  Quantifying the proportion of patients for whom breathing is more regular with AV 
biofeedback, 
2)  Quantifying the variability in breathing motion throughout a course of treatment, 
3)  Quantifying the improvement in image quality with AV biofeedback, 
4)  Evaluating the patient experience through a perception of care survey, 
5)  Developing indications and contra-indications for the use of AV biofeedback,  
6)  Quantifying the differences in image-guided radiotherapy (IGRT) shifts during treatment, and 
7)  Recording toxicity outcomes for up to 12 months after treatment has been completed. 
Department-specific objectives are to evaluate the impact of AV biofeedback on clinical testing by: 
1)  Quantifying any practice changes (e.g. margin reduction), 
2)  Quantifying the impact on workflow using the AV biofeedback device through time-motion 
studies, 
3)  Evaluating the operator and clinician confidence in the AV biofeedback device’s reliability 
and clinical efficacy through a technology-impact survey, 
4)  Quantifying the system robustness through hardware and software fault reporting, and 
5) Performing system quality assurance, sharing the results through web-based uploads and 
provide feedback for QA improvement. 
Our methodological framework will be based on the widely used Technology Acceptance Model 
(TAM).1,2 The TAM gives qualitative scales for two specific variables, perceived usefulness and 
perceived ease of use, which are fundamental determinants for user acceptance. 
 
3.2. PARTICIPANT SECTION 
This study is aimed at patients receiving radiation therapy for their treatment of lung cancer.  Patients 
fitting the eligibility criteria (see below) will be identified and introduced to this study by their 
treating physicians, who will participate as investigators in this study.  
3.3. INCLUSION CRITERIA 
1) Lung cancer patients (no restrictions to type of radiotherapy being received) 
2) >18 years old 
3) No gender or ethnic restrictions 
4) An ECOG score in the range of 0 to 2  
5) Able to give written informed consent and willingness to participate and comply with the 
study 
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6) No pregnant / lactating woman 
 
3.4. NUMBER OF PARTICIPANTS 
A minimum of 75 lung cancer patients. Adding a 10% drop-out rate yields 83 patients; the 
explanation for this is given in Section 7: Statistical Considerations. As shown in Table 3, 83 
participants are considerably greater than the participants involved in previous respiratory guidance 
studies. Such a number of participants in this study would make it the most comprehensive respiratory 
guidance study to date. The inclusion of more participants would also produce more accurate and 
significant results. Statistical justification for 83 patients is elaborated on in Section 7: Statistical 
Consideration.  
3.5. NUMBER OF CENTRES 
This study will be conducted across 7 radiation oncology departments in the NSW/ACT region: 
Canberra Hospital, Calvary Mater Hospital, Nepean Cancer Centre, Northern Sydney Cancer Centre, 
Chris O’Brien Lifehouse, Westmead Hospital, and Gosford Hospital.  
3.6. DURATION 
The expected duration of the study is 2 years.  Estimated time of first recruitment is early 
2014. The study recruitment phase and data analysis phase will be done concurrently; 
analysis of data for each patient can commence once images have been acquired for that 
patient. Overall analysis will commence after last patient recruitment.  
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4.STUDY OUTLINE 
Prior to each patient’s planning and treatment they will undergo a breathing session during which they 
will breathe both with and without the guidance of AV biofeedback. Preceding each breathing session 
will be an AV biofeedback training session to familiarise the patient with the system. After the 
breathing session has been completed, the most reproducible breathing condition (AV biofeedback or 
free breathing) will be determined via respiratory analysis. It will be the most reproducible breathing 
condition that will continue to be used throughout the rest of that particular patient’s planning and 
treatment. Each patient will then be monitored throughout their treatment, noting any differences in 
image quality and dose distributions as a result of their breathing.  
  Once informed consent has been obtained, the principal investigator will schedule a time for the 
study. 
  
4.1. STUDY FLOW CHART 
The study flow for each department will vary slightly depending on department preferences. The 
general study flow chart is shown in Figure 5. For more details on randomisation and stratification, 
see Section 7: Statistical Considerations.  
 
Figure 5.  AVIATOR study flowchart. 
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Procedures Pre Study 
Visit 
Visit with 
Treating 
Physician   
Pre Study 
Visit 
 
Study Visit 
 
Post Study 
Visit/s 
Review 
Inclusion/Exclusion 
Criteria 
    
Medical History     
Obtain Informed 
Consent 
    
Book Scan Time     
CT sim Scans     
Study Analyses     
Review of Study 
Progression 
    
Treatment and 
Follow-up Visits 
 
    
 
4.2. STUDY PROCEDURE RISKS 
By participating in this study, the risks to the patient are extremely low: this research study involves 
the inclusion of respiratory sessions of AV biofeedback and free breathing. These study sessions 
involve the use of the RPM system and the additional equipment of a visual display (e.g. monitor, 
tablet computer), none of which are of any risk to the patient. The RPM and AV biofeedback systems 
do not involve any invasive procedures or ionising radiation and are of no risk to the patients. Any 
imaging and radiation treatment that follows are a part of the patient’s standard oncology treatments, 
which they are subject to regardless of participation in this study. The patient’s treating physician will 
be counselling them on the risk of their appropriate treatments. 
 
4.3. RECRUITMENT AND SCREENING 
Patients fitting the eligibility criteria will be identified and introduced to this study by the treating 
physicians who will participate as investigators in this study.  
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4.4. ENROLMENT PROCEDURE AND INFORMED CONSENT PROCESS 
The patients will be given ample time to completely read the informed consent form as well as ask 
any questions that they may have. The patients will be contacted by the principal investigator with 
regards to their decision in partaking in the study. Patients that agree to partake in the study will be 
asked to sign an informed consent form at their next hospital visit. 
The participant will receive a study enrolment number and this will be documented in the participant’s 
medical record and on all study documents. Patients who agree to participate will be contacted by 
principal investigator to organise times for to the study scans to be conducted.   
 
4.5. INFORMED CONSENT PROCESS 
The principal investigator will be obtaining informed consent from patients after consulting with their 
physician prior to commencing the study.  
 
4.6. RANDOMISATION PROCEDURE 
A randomised procedure will be used in this study.  
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5.SAFETY 
5.1. ADVERSE EVENT REPORTING 
5.1.1. CLINICAL TRIALS AND ADVERSE EVENT REPORTING 
The principal investigator and sub investigators will report adverse events to the Radiation Safety 
Officer on site and to the Human Research Ethics Committee and the Research Governance Officer 
within 72 hours of the event occurring unless immediate notification is required. 
 
5.1.2. ADVERSE EVENT 
The AV biofeedback system is not invasive and is not expected to cause any adverse event. The visual 
component involves viewing a display (e.g. monitor, tablet computer); for the audio component, the 
computer tablet will have built-in speakers, alternatively, the in-house speaker system could be 
utilised.  
 
5.1.3. SERIOUS ADVERSE EVENT (SAE): 
Adverse events are considered ‘serious’ if they threaten life or function. SAEs are defined as any 
adverse event which: results in death (i.e. fatal/grade 5 CTC AE); is life-threatening (i.e. grade 4 CTC 
AE); requires inpatient hospitalisation or prolongation of existing hospitalisation; results in persistent 
or significant disability/incapacity; or is a congenital anomaly/birth defect. 
Given the simple and non-invasive nature of this study’s setup, we do not anticipate any serious 
adverse events as a result of the procedures pertaining to this study. 
 
5.1.4. DEVICES EVENTS 
Standard imaging protocols and full clinical, treatment and imaging softwares will be used in the 
acquisition of imaging scans in this study.  Accidental protocol breaches will be reported to the 
hospital’s Radiation Safety Committee. 
 
5.2. SERIOUS ADVERSE EVENT REPORTING 
SAE reporting in this study will pertain only to procedures directly related to this study’s workflow; 
i.e. additional procedures undergone by patients not related to the AVIATOR trial (e.g. chemotherapy, 
surgery) that result in an SAE will not be reported for this study. This will limit the SAEs to be 
reported in this study to imaging and external-beam radiation therapy procedures. 
The principal investigator and sub investigators will report adverse events to the Radiation 
Safety Officer on site and to the Human Research Ethics Committee and the Research Governance 
Officer within 72 hours of the event occurring unless immediate notification is required. 
 
5.3. DATA SAFETY AND MONITORING BOARD 
The imaging modalities that are used in this study are approved for clinical practice, therefore this 
study we will not nominate a separate Data and Safety Monitoring Board.  
Our steering committee (investigators and sub investigators including consumer representatives) will 
meet monthly to monitor the conduct of the study and assess progress. In addition, the chief and 
majority of sub investigators will maintain weekly contact via email and face-face or teleconference 
meetings in order to facilitate implementation of the study and provide quality assurance to all aspects 
of the study. The chief investigator will be on-site to personally conduct, oversee, and supervise all of 
the activities. 
 
267
   
AVIATOR Protocol V5.0. Date: May 04, 2015 24 
5.4. EARLY TERMINATION 
We do not anticipate any reason for early termination of the study. 
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6.BLINDING AND UNBLINDING 
There is no blinding in this study.   
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7.STATISTICAL CONSIDERATIONS 
7.1. SAMPLE SIZE, POWER CALCULATION AND ANALYSIS PLAN  
The statistical considerations for this study are largely based on a previous study conducted at 
Virginia Commonwealth University (VCU) by the chief investigator, Prof Paul Keall, on 24 lung 
cancer patients.
36,42
 26 patients were recruited for the VCU study, however, 2 patients dropped out due 
to not being treated with radiotherapy or rapid worsening of disease, and so their data was not 
collected. A clinically significant different in clinical improvement due to AV biofeedback has been 
determined to be a margin calculation of less than 5 mm. Irregular breathing causes larger systematic 
errors (Σ) from motion artefacts and variations between the planned and treated anatomy as well as 
random day to day variations (σ) in the treated anatomy (see Table 1 and Figures 2 & 3).  To combine 
systematic and random errors and estimate the margin contribution due to breathing irregularity we 
will use the van Herk method
43
: margin = 2.5Σ + 0.7σ. From this calculation, there were 14/24 
patients with margins <5 mm with AV biofeedback, while only 5/24 for free breathing.  
In this proposed study, we’d like to increase the proportion of patients with reduced margins 
calculated using the van Herk method. Therefore we have designed an exploratory phase II 
randomised study examining the potential impact of an AV biofeedback system in regulating 
breathing in patients receiving radiation therapy for the treatment of lung cancer. Without this system, 
it is conservatively estimated that approximately 40% of patients experience regular breathing 
(margin component below 5mm). Increasing this proportion to 60% using the AV biofeedback system 
would be clinically worthwhile. Based on Simon’s design,44 a sample size of 50 patients receiving the 
AV biofeedback system will have at least 80% power with 95% confidence to rule out a regular rate 
of 40% in favour of a 60% rate. To minimise patient selection bias and provide an estimate of regular 
breathing from a contemporary control, the proposed design will be a randomized phase II with a 50 
patients receiving the intervention and 25 standard care. Patients will be randomised in a 2:1 ratio, 
with 2/3 of the patients being recruited into the AV biofeedback (intervention) arm and 1/3 in the free 
breathing (control) arm as shown in Figure 5. 2:1 randomisation is appropriate as within the 
interventional arm there is a screening procedure where only patients whose breathing is more regular 
with AV biofeedback use this system for their imaging and treatment procedures (Figure 5).  Patients 
will be stratified by treating institution and for treatment intent (palliative vs. radical) to ensure similar 
balance in the arms across the sites. As the study is not powered for formal comparisons between the 
groups, estimates of the proportion of patients which do not experience irregular breathing will 
provide information as to whether further investigation is warranted. 
Assuming a contamination and dropout rate of no more than 10%, this study will require that 
75+8=83 patients be recruited (the 10% value was based on the 2/26 patient drop-out rate in the VCU 
study).  The estimated patient numbers are conservative because they are derived from the 24-lung 
cancer patient VCU study which used a cruder breathing training system that what will be used in this 
study. 
Patients at each institution will be treated per department protocol with no additional 
constraints on dose, fractionation, immobilisation or image guided procedures.  Results will be 
adjusted for institution (using a fixed effect) to account for differences between institutions.  
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8.CONFIDENTIALITY AND STORAGE AND ARCHIVING OF STUDY       
DOCUMENTS 
Collected respiratory data, CT images, demographic information, and treatment data will be collected 
from the subjects at each site. At the randomisation stage of the study, patient’s will receive a trial ID, 
this is to ensure that the data saved for the trial is done so under this de-identified trial ID. However, 
patient data could be made re-identifiable to obtain additional clinical information for the data 
analysis stage of the project, but only by the chief investigator, Professor Paul Keall. De-identified 
data will be transferred from each study site (hospital) to the study sponsor (University of Sydney) for 
analysis. De-identified data will then be stored on a secure, password protected backed up database 
that will be created, much the same to what we have designed for previous University of Sydney 
studies. A separate key of the subject study number and their medical record number will be securely 
stored by the chief investigator to allow re-identification if necessary. Only the chief investigator will 
have the ability to re-identify subjects. All other investigators will only have access to the de-
identified data. De-identified data transfer from study site to study sponsor will be performed in 
accordance with each study site’s ethics and security allowances and protocols. The data will be 
stored for 15 years as per clinical trial guidelines. Data across the multiple study sites will be shared 
via an online file sharing component (e.g. Redmine). 
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Department Name, Site Name 
 
Investigating breathing training for lung cancer radiotherapy  
 
INFORMATION FOR PARTICIPANTS 
 
INTRODUCTION 
 
You are invited to participate in this study because you have lung cancer and will be 
receiving a course of standard radiotherapy.  
 
The aim of your cancer treatment is to deliver the radiation as precisely as possible 
to the lung and to spare the nearby organs such as the parts of the lung unaffected 
by the cancer, as well as the heart and liver. However, even when you are lying still, 
the lung and surrounding organs will move when you breathe.  If we can help you to 
monitor and regulate your breathing using an audio-visual guidance device, we may 
be able to more accurate target the radiation beam to the cancer.  
 
This information sheet provides detailed information about the study including its 
purpose and all the procedures involved. Your doctor will also discuss this with you. 
Its purpose is to explain to you as openly and clearly as possible all the procedures 
involved in this project before you decide whether or not to take part. Participating in 
the study is voluntary. Please take the time to read the information sheet carefully, 
and discuss it with family, friends and/or your GP if you wish.  Please ask if there is 
anything you do not understand or if you would like more information.  Once you 
understand the study, you will be asked to sign the Consent Form if you wish to 
participate. You will have a copy to keep as a record. 
 
The study is being conducted within this institution by: 
 
Dr __________ (site physician)  
 
Professor Paul Keall (Radiation Physics Laboratory, Sydney Medical School, 
University of Sydney) 
 
Dr Ricky O’Brien (Radiation Physics Laboratory, Sydney Medical School, University 
of Sydney) 
 
Sean Pollock (PhD student, Radiation Physics Laboratory, Sydney Medical School, 
University of Sydney) 
 
Sean Pollock is conducting this study as a part of the requirements for the degree of 
Doctor of Philosophy in Medicine under the supervision of Prof. Paul Keall.   
 
It is planned that eighty-three (83) patients will be recruited across the NSW and ACT 
region into this study.  
 
What is the purpose of this study? 
The aim of the study is to evaluate whether breathing training will improve the 
regularity of your breathing, and therefore, lung motion.  
 
The breathing training system is comprised of a screen, speakers and controlling 
software. The screen allows you to visualise your pattern of breathing on a graph 
(see illustrations below) and with this feedback, allow you to control and regulate 
your breathing.  
275
Participant Information Sheet, version 6, 20/02/15 
  Page 2 of 6 
 
What will happen to me if I decide to take part? 
This study will begin with testing which breathing condition will be best for you to use 
throughout the rest of the study. This will be either: (1) with breathing training, or (2) 
free breathing. We will compare the results from these two breathing conditions, and 
whichever one is deemed to yield the best results for you will be the one that will be 
selected for usage throughout your treatment. The initial test will only take 
approximately 15 minutes; the extra time needed during your treatment due to using 
breathing training will only be approximately 10 minutes.  
When you are breathing with the training system, you will be watching a screen and 
listening to music. The training system will guide you to produce regular breathing.  
You will also be asked to complete a questionnaire which will take about 2 minutes to 
do. You may also be asked to do a follow-up questionnaire later in your treatment, 
depending on the results of the initial study. In this questionnaire we want to gauge 
your opinion of the training system and suggest ways we could improve upon it.  
However, by participating in this study you may not even need to use breathing 
training; this could be due to one of two reasons: 
1) In the initial test, you performed better breathing freely, so breathing training 
is not best for you.  
2) This study is randomised. A randomised study means that the patients are 
split into two groups: a tested group and an untested group. The tested group 
will be tested with breathing training, and the untested group will have their 
treatment as per normal, with no breathing training. This is done so the 
researchers can compare their new technology the current clinical standard 
and determine how much it might improve upon it.  
Finally, the researchers would like to have access to your medical record to obtain 
information relevant to this study. 
 
What are the risks? 
All medical procedures - whether for diagnosis or treatment, routine or experimental 
– involve some risk. In addition, there may be risks associated with this study that are 
presently unknown and unforeseeable.  In spite of all precautions, you might develop 
medical complications from participating in this study. 
The visual display for breathing training will be either wearing display-goggles with a 
built-in screen or watching a computer screen held in place by a clamp to the bed. 
Such setups are not expected to cause any discomfort. However, if you feel 
uncomfortable at any stage, do not hesitate to notify staff. 
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Please inform us if you have participated in any other research studies using 
radiation (or exposed by other means, e.g. occupational) in the last five years. By 
participating in this study, you will not be exposed to any additional radiation that 
would otherwise be a part of your treatment; this study will be performed alongside 
your treatment. However, it should be noted that the prescribed imaging procedures 
do involve a small level of radiation exposure; at radiation dose level of the imaging 
procedures, no harmful effects of radiation have been demonstrated and the risk is 
low.  
Please keep this form in a safe place for the next five years in case you volunteer for 
any more studies using radiation, when you should show it to the Investigator. 
It is important that women participating in this study are not pregnant and do not 
become pregnant during the course of the study 
 
What are the benefits? 
You may not benefit from participating in this study; while we intend that this research 
study furthers medical knowledge and may improve radiotherapy for lung cancer and 
lessen its post-treatment side effects (and for treatment of other cancers which move 
as the patient breathes), we cannot guarantee that it will be of benefit to you.  
However, if breathing training proves successful it will continue to be used in your 
treatment plan. In addition, the images obtained in this study will be used for your 
treatment plan.  
 
What are the alternatives? 
This study is purely voluntary and if you choose not to participate in this study, you 
will be offered the standard radiation treatment for your lung cancer in this hospital. 
Your decision will not affect your treatment, follow-up, or relationship with any of the 
medical staff involved in your care. 
 
Costs 
Participation in this study will not cost you anything, nor will you be paid.   
 
Compensation for injuries or complications 
If you suffer any injuries or complications as a result of this study, you should contact 
the study doctor as soon as possible, who will assist you in arranging appropriate 
medical treatment. If you are eligible for Medicare, you can receive any medical 
treatment required to treat the injury or complication, free of charge, as a public 
patient in any Australian public hospital.   
In addition, you may have a right to take legal action to obtain compensation for any 
injuries or complications resulting from the study.  Compensation may be available if 
your injury or complication is sufficiently serious and is caused by unsafe drugs or 
equipment, or by the negligence of one of the parties involved in the study (for 
example, the researcher, the hospital, or the treating doctor).  You do not give up any 
legal rights to compensation by participating in this study.  
 
Voluntary Participation 
Participation in this study is entirely voluntary.  You do not have to take part in it.  If 
you do take part, you can withdraw at any time without having to give a reason. If you 
decide to withdraw from the study all the information relation to you will be destroyed.  
Whatever your decision, please be assured that it will not affect your medical 
treatment or your relationship with the staff who are caring for you.   
 
Confidentiality 
277
Participant Information Sheet, version 6, 20/02/15 
  Page 4 of 6 
All the information collected from you for the study will be treated confidentially, and 
only the researchers named above will have access to it.  The study results may be 
presented at a conference or in a scientific publication, but individual participants will 
not be identifiable in such scientific distributions. Researchers from the University of 
Sydney will be analysing the data for this study, therefore the data we obtain from 
your participation in this study will be transferred securely and confidentially from the 
hospital to the University of Sydney for analysis. 
 
Further Information 
When you have read this information, Dr __________ (site physician) will discuss it 
with you further and answer any questions you may have.  If you would like to know 
more at any stage, please feel free to contact him/her on (02) ________. 
 
Results of Project 
It may be a number of years before the results of this research are available. The 
results will be published in medical journals. Please ask your doctor if you want to 
know more about this. 
 
Ethics Approval and Complaints 
This research has been approved by the Hunter New England Human Research Ethics 
Committee of Hunter New England Local Health District, Reference  12/08/21/3.01   
Should you have concerns about your rights as a participant in this research, or you 
have a complaint about the manner in which the research is conducted, it may be 
given to the researcher, or, if an independent person is preferred, to Dr Nicole 
Gerrand, Manager Research Ethics and Governance, Hunter New England Local 
Health District, Locked Bag 1, New Lambton NSW 2305, telephone (02) 49214950, 
email HNEHREC@hnehealth.nsw.gov.au 
 
 
This information sheet is for you to keep. 
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Audio-Visual Investigation Advancing Thoracic Radiotherapy (AVIATOR) 
 
PARTICIPANT CONSENT FORM 
 
I, 
...................................................................................................................................... 
[name]  
 
of 
 
..............................................................................................................................……. 
[address]  
 
have read and understood the Information for Participants on the above named 
research study 
 
and have discussed the study with  
 
.............................................................................................. 
 
I have been made aware of the procedures involved in the study, including any 
known or expected inconvenience, risk, discomfort or potential side effect and of their 
implications as far as they are currently known by the researchers. 
 I understand that my participation in this study will allow the researchers and 
others, as described in the Information for Participants, to have access to my medical 
record, and I agree to this. 
 I freely choose to participate in this study and understand that I can withdraw at 
any time. 
 
I also understand that the research study is strictly confidential. 
 
I hereby agree to participate in this research study. 
 
NAME:   
 ........................................................................................................... 
 
 
SIGNATURE:  
 ........................................................................................................... 
 
 
DATE:   
 ........................................................................................................... 
 
 
NAME OF WITNESS: 
 .................................................................................................. 
 
 
SIGNATURE OF WITNESS:
 .................................................................................................. 
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NAME OF INVESTIGATOR: 
 .................................................................................................. 
 
 
SIGNATURE OF INVESTIGATOR:
 .................................................................................................. 
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1. Introduction 
AV biofeedback is a simple, personalised and customisable respiratory guidance system which aims 
to produce regular patient breathing. The problem that AV biofeedback is addressing is that should a 
lung cancer patient’s breathing be irregular, it can result in incorrect information presented in medical 
imaging in addition to incorrect tumour targeting in radiotherapy. This can result in an increase in 
radiation dose delivered to healthy tissue and less precise dose delivered to the tumour itself. The 
following details the software required for the implementation of this novel technique. By facilitating 
regular breathing we can improve the quality of planning images as well as the accuracy of radiation 
treatment delivery.  
The AVIATOR trial aims to assess the AV biofeedback system efficacy in a clinical setting. To test 
this we will conduct a 75 lung cancer patient clinical study across 7 departments with the following 
objectives: 
Primary objective: In a prospective multi-institutional randomised clinical trial we will test the 
hypothesis that AV biofeedback will significantly improve breathing regularity and reduce medical 
imaging errors for lung cancer patients undergoing imaging and treatment procedures during 
radiotherapy. The patients will be randomised in a 2:1 ratio, with 2/3 of the patients being recruited 
into the AV biofeedback (intervention) arm and 1/3 in the free breathing (control) arm. 
Secondary objectives will involve patient-specific and department-specific objectives: 
Patient-specific objectives are to evaluate the impact of AV biofeedback by: 
1) Quantifying the proportion of patients for whom breathing is more regular with AV 
biofeedback, 
2) Quantifying the variability in breathing motion throughout a course of treatment, 
3) Quantifying the improvement in image quality with AV biofeedback, 
4) Evaluating the patient experience through a perception of care survey, 
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 5) Developing indications and contra-indications for the use of AV biofeedback, 
6) Quantifying the differences in image-guided radiotherapy (IGRT) shifts during treatment, and 
7) Recording toxicity outcomes for up to 12 months after treatment has been completed. 
Department-specific objectives are to evaluate the impact of AV biofeedback on clinical testing by:  
1) Quantifying any practice changes (e.g. margin reduction),  
2) Quantifying the impact on workflow using the AV biofeedback device through time-motion 
studies,  
3) Evaluating the operator and clinician confidence in the AV biofeedback device’s reliability 
and clinical efficacy through a technology-impact survey,  
4) Quantifying the system robustness through hardware and software fault reporting, and  
5) Performing system quality assurance, sharing the results through web-based uploads and 
provide feedback for QA improvement.  
 
2. Physical Properties 
A software package has been written by The University of Sydney that will be used in the Clinical 
Trial to guide the patients to breathe regularly. The system is called AV biofeedback. The system, for 
approval through TGA CTN process, is illustrated in Figure 1 and detailed below. 
2.1  Alterations to Standard Treatment 
The AV biofeedback system is simple and easy to use; there will be no alterations to standard 
treatment as part from the use of AV biofeedback: the same images will be acquired and the same 
treatment will be delivered as per department protocol.  
There will be an addition of audio and visual prompts displaying the AV biofeedback interface to the 
patient as well as the controlling software in the control room. An example of the AV biofeedback 
interface as well as in-room displays is shown in Figure 1.  
After imaging and treatment it is imperative that the following data be saved: RPM files, AV 
biofeedback files, image files, questionnaires.  
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 FIGURE 1. The AV biofeedback system. The visual display (centre) as seen by the subject (sans arrows) of the 
AV biofeedback system shows the guiding wave (white curve) and a marker position (marker block) as an 
indicator of their real time breathing.  
 
2.2  AV biofeedback software 
This software for AV biofeedback is known as the Sydney University Audio-Visual biofeedback 
Experience (SUAVE). SUAVE will read the breathing signal from the RPM system and display this 
breathing signal to the patient.  The primary functionality of AV biofeedback for this clinical trial is:  
1) Compile a patient-specific guiding wave 
2) Commence breathing-guidance session 
3) Analyse breathing session 
These points are illustrated in Figure 2:  
The AV biofeedback software is operated by treatment staff. The menu items detail the necessary 
operations to complete during patient imaging/treatment. Point 1 above only needs to be performed 
once per patient to ensure consistent breathing across imaging and treatment sessions.  
 
3.  Effects in Humans 
3.1  Safety and Efficacy 
The AV biofeedback system does not result in any additional radiation dose.  
A tablet-computer screen for the breathing guidance will be held in place by a clamp to the bed. Such 
a setup is not expected to cause any discomfort or risk of injury to the patient.   
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FIGURE 2. Primary functionalities of SUAVE software. Numbers 1-3 correspond to points 1-3 in section 2.2. 
AV biofeedback software. 1) the calculation of a guiding wave using patient breathing data. 2) Patient display of 
their guiding wave and real-time breathing motion. 3) Analysis of breathing with regularity metrics in the top-
right corner of the display.  
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Audiovisual (AV) Biofeedback Toxicity Report 
 
Goal: To determine any impact on patient outcomes by identifying radiation-related toxicities and their 
severity 12 months after treatment has concluded.  
 
Introduction: To correlate the impact of such study objectives as breathing regularity, margin-
calculation, and image quality with patient outcomes. Should the primary object of the study achieve a 
positive result, then we would expect the patients in the AV biofeedback arm to have less numerous and 
less severe radiation-related toxicities.  
Toxicities listed here were taken from Common Terminology Criteria for Adverse Events (CTCAE), 
Version 4. The grading of severity here will largely remain consistent with the CTCAE document:  
 Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
 Grade 2: Moderate; minimal, local or non-invasive intervention indicated; limiting age-
appropriate instrumental ADL (Activities of Daily Living). 
 Grade 3: Severe or medcally significant but not immediately life-threatening; hospitalisation or 
prolongation of hospitalisation indicated; disabling; limiting self-care ADL 
 Grade 4: Life-threatening consequences; urgent intervention indicated. 
 Grade 5: Death related to AE. 
Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, 
managing money, etc. 
Self-care ADL refers to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, not bedridden.  
 
Timing: To be completed up to 12 months after patient treatment has concluded with each patient follow 
up. 
 
Date: 
 
Patient ID: 
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Toxicity/Outcome Severity/Grade 
Pneumonitis 
(inflammation of lung 
tissue) 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Comments: 
 
 
 
Radiation fibrosis 
(scarring of lung tissue) 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Comments: 
 
 
 
Dyspnoea 
(shortness of breath) 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Comments: 
 
 
 
Dysphagia 
(difficulty swallowing) 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Comments: 
 
 
 
Odynophagia 
(painful swallowing) 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Comments: 
 
 
 
Pleuritic pain 
(inflammation of the 
pleura) 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Comments: 
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Toxicity/Item(?) Severity/Grade 
Oesophagitis 
(inflammation of the 
oesophagus) 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Comments: 
 
 
 
Fistula 
(abnormal communication 
between anatomic 
sites/organs) 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Nature of fistula / comments: 
 
 
 
Respiratory 
failure 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Comments: 
 
 
 
Sleep Apnea 
(cessation of breathing for 
short periods during sleep) 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Comments: 
 
 
 
Fatigue 
Not present  Moderate  Severe 
1 2 3 4 5 
Comments: 
 
 
 
Stenosis 
(abnormal narrowing of 
vessel/tubular organ) 
Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Nature of stenosis / comments: 
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Toxicity/Item(?) Severity/Grade 
Lung Function 
(lung function test) 
Improved  
No 
difference 
 Worsened 
1 2 3 4 5 
Score/Comments: 
 
 
Nausea 
Not present  Moderate  Severe 
1 2 3 4 5 
Comments: 
 
 
Sexual Function 
Improved  
No 
difference 
 Worsened 
1 2 3 4 5 
Comments: 
 
 
Number of 
unscheduled visits 
since treatment’s 
end 
Number of unscheduled visits: 
Comments: 
 
 
 
Cancer 
Reoccurrence 
Yes No 
Comments: 
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ADDITIONAL 
COMMENTSS 
(and/or additional issue(s) 
not already covered) 
Comments: 
 
 
 
 
 
 
 
 
 
______________ _______________ _______________ 
Oncologist name  Signature  Date 
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Audiovisual (AV) Biofeedback Patient Survey  
 
Goal: To evaluate your experience with the audiovisual (AV) biofeedback guidance 
system and identify any areas where you feel development is needed to improve the 
AV biofeedback experience.   
 
Introduction: In medical imaging and radiotherapy, irregular breathing negatively 
impacts image quality, in addition to inaccurate tumour targeting. AV biofeedback 
provides respiratory guidance to produce consistent respiratory motion. AV 
biofeedback will help to improve the quality of imaging scans in addition to the 
accuracy of radiotherapy treatment. 
 
Timing: After initial simulation session and within last week of treatment 
 
Demographics  
 
Age range: Impeded eyesight: y / n 
Sex: Impeded hearing:  y / n  
Height: Highest level of education: 
Weight: Frequency of computer use: 
 Anxiety level: 
     1 (not at all anxious) – 10 (very anxious)  
(1) Do you feel your breathing was more 
consistent using the AV biofeedback? 
No  Moderately  Yes 
1 2 3 4 5 
Comment: 
 
 
 
(2) Was the training session that you had 
prior to this session helpful? 
No  Moderately  Yes 
1 2 3 4 5 
Comment: 
 
 
 
(3) Did you feel physically comfortable with 
the AV biofeedback system? 
No  Moderately  Yes 
1 2 3 4 5 
Comment: 
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(4) Did you feel the AV biofeedback visual 
guide (blue curve) was too slow or fast? 
Too slow  Just right  Too fast 
1 2 3 4 5 
Comment: 
 
 
 
 
(5) Did you feel the AV biofeedback visual 
guide (blue curve) was too shallow or deep? 
Too shallow  Just right  Too deep 
1 2 3 4 5 
Comment: 
 
 
 
(6) Did you like having the music? 
 
No  Moderately  Yes 
1 2 3 4 5 
Comment: 
 
 
 
(7) Did the music help you breathe more 
consistently? 
 
No  Moderately  Yes 
1 2 3 4 5 
Comment: 
 
 
 
(8) Did you feel anxious during the session? 
 
No  Moderately  Yes 
1 2 3 4 5 
Comment: 
 
 
 
 (9) Do you have any comments or suggestions either on your experience or how we 
can improve the AV Biofeedback system? 
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Audiovisual (AV) Biofeedback Radiotherapist Survey  
 
Goal: To quantify the user acceptance of audiovisual (AV) biofeedback and identify 
areas to improve the user AV biofeedback experience.   
 
Introduction: In medical imaging and radiotherapy, variations in cycle-to-cycle 
breathing results in imaging artefacts, leading to inaccurate radiation beam coverage 
and tumour targeting. AV biofeedback guides patients to produce regular respiratory 
motion using an AV device combined with a respiratory monitoring system. The AV 
biofeedback system will help to improve the quality of scans and the accuracy of 
radiotherapy treatment for patients. 
 
Timing: After initial simulation session and within last week of treatment for each 
patient 
 
Demographics  
Position: 
Years of experience: 
 
(1) Do you think that the training session was 
useful for the patient? 
No  Moderately  Yes 
1 2 3 4 5 
Comment: 
 
 
(2) Do you think the AV biofeedback system 
helped your patient to breathe more 
regularly? 
 
No  Moderately  Yes 
1 2 3 4 5 
Comment: 
 
 
(3) Was the AV biofeedback system easy to 
setup? 
No  Moderately  Yes 
1 2 3 4 5 
Comment: 
 
 
(4) Was the AV biofeedback system easy to 
operate? 
No  Moderately  Yes 
1 2 3 4 5 
Comment: 
 
 
(5) Would you recommend the AV No  Moderately  Yes 
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biofeedback guidance to your colleagues at 
other centres to implement in similar 
treatment? 
 
1 2 3 4 5 
Comment: 
 
 
(6) Do you have any comments or suggestions on your experience or how we can 
improve the AV Biofeedback system? 
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Appendix III 
 
Published Case Report of patient 1 recruited into the study detailed in 
Chapter 4. Published in The Journal of Medical Imaging and Radiation 
Oncology (2015; 59(5) 654-656) 
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Summary
This case report details a clinical trial’s ﬁrst recruited liver cancer patient who
underwent a course of stereotactic body radiation therapy treatment utilising
audiovisual biofeedback breathing guidance. Breathing motion results for both
abdominal wall motion and tumour motion are included. Patient 1 demon-
strated improved breathing motion regularity with audiovisual biofeedback. A
training effect was also observed.
Key words: abdomen; intervention; physics; radiation oncology imaging;
radiation oncology; respiratory.
Introduction
Liver tumours are highly mobile due to their proximity
to the thoracic diaphragm. When a patient’s breathing
motion is irregular, it exacerbates both systematic and
random errors which compromise the accuracy of
radiation therapy.1,2 To reduce these errors, breathing
guidance strategies have been investigated to facilitate
stable and regular breathing.3,4 This study represents a
milestone in breathing guidance investigations as it
addresses a gap in the literature by assessing the
impact of the breathing guidance system, audiovisual
biofeedback (AVB), on intra- and inter-fraction liver
tumour motion, via ﬁducial marker surrogacy, in liver
cancer patients undergoing stereotactic body radiation
therapy (SBRT). The AVB system, shown in Figure 1,
utilises audio and visual prompts to guide the patient
to breathe regularly. External breathing motion from
the Real-time Position Management (RPM) system
(Varian Medical Systems, Palo Alto, CA, USA) of the
patient’s abdominal wall is shown on the patient
display. The marker block moves up as they inhale and
down as they exhale. The patient adjusts their breath-
ing such that the marker block stays within the blue
region and traces the motion of the waveguide (white
wave in Fig. 1).
Case report
Patient 1 was a 65-year-old male with metastatic (recur-
rent) cholangiocarcinoma and received 36 Gy across 6
fractions using volumetric-modulated arc therapy-based
SBRT to a 30 mm solitary lesion in segment 8 of the liver.
Due to previous liver resection, this patient had pre-
existing surgical clips implanted into his liver, which were
utilised for image guidance. He had a number of other
bs_bs_banner
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comorbidities including bronchiectasis with impaired pul-
monary function and was of Karnofsky performance
status 1. Prior to treatment planning, a screening pro-
cedure was performed to ensure that the most regular
breathing condition (free breathing (FB) or AVB) was
utilised throughout the patient’s subsequent course of
SBRT. Breathing motion was monitored for 4 minutes for
each of the breathing conditions FB and AVB; at the
2-minute mark, cone beam CT (CBCT) images were
acquired. Determining which breathing condition would
be selected was based on the regularity of the 4 minutes
of external breathing motion (quantiﬁed by the root mean
square error (RMSE) in displacement and period); the
lower the RMSE, the more regular the breathing motion.
Decisions were made in situ using a function within the
AVB software. Patient 1’s screening procedure yielded the
decision to utilise AVB for the remainder of their course of
SBRT.
Patient 1’s treatment planning and treatment delivery
proceeded as per the currently implemented clinical liver
SBRT protocol with the addition of the AVB setup (see
Fig. 1). CBCT images were acquired prior to treatment
delivery on each day of treatment, motion of the surgical
clips was extracted from the CBCT projection images
utilising a method developed by Fledelius et al.,5 as a
surrogate for tumour motion. Figure 2 and Figure 3
demonstrate the breathing motion results across patient
1’s course of radiotherapy. It was also observed that AVB
increased the average range of tumour motion from
1.5 cm for FB, to 1.8 cm for AVB.
Discussion
This study reported on the ﬁrst patient recruited into a
clinical trial investigating the use of breathing guidance
during a course of liver SBRT planning and treatment
Fig. 1. Study setup in the linac bunker with the Real-time Position Management (RPM) marker block and patient display (left). AVB (audiovisual biofeedback)
interface (right).
Fig. 2. AVB (audiovisual biofeedback) and FB (free breathing) RMSE (root mean square error) results for Screening Procedure (left); and results for AVB across
patient 1’s course of treatment (right), for RMSE of displacement (RMSE Disp, blue circle markers) and RMSE of period (RMSE Per, purple triangle markers). External
motion shown as hollow markers/bars and dotted lines, tumour motion shown as solid markers/bars and unbroken lines.
AVB in liver cancer SBRT
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utilising an initial screening procedure. A training effect
was observed, with the patient’s breathing motion
becoming more regular inter-fractionally, plateauing at
peak regularity around Fraction 3. It was also observed
that AVB increased breathing amplitude compared with
FB. Given that the AVB waveguide peak-to-peak ampli-
tude was set at 1.5 cm and the observed external peak-
to-peak amplitude was 1.7 cm indicates that Patient 1
‘over-shot’ the AVB breathing limits. For future patients in
this study further attention will be given to managing
breathing motion amplitude and patient training.
In conclusion, the ﬁrst patient recruited into this study
yielded the decision to utilise AVB through their course of
SBRT. Patient 1 demonstrated good acceptance of the
breathing guide in addition to increasingly regular
breathing throughout their course of SBRT.
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Appendix IV 
 
Documentation provided for study site credentialing for the clinical trial 
presented in Chapter 5 
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AVIATOR Credentialing v1.2. for software version v2.3.  
AVIATOR Site Credentialing 
Prior to commencing patient recruitment patient, each site needs to complete the following 
credentialing, please tick off as completed: 
CREDENTIALING ITEM COMPLETE 
1) Perform patient Randomisation call   
2) Pass AV biofeedback Daily & Monthly QA using motion phantom in the: 
a) CT imaging room 
 
b) Treatment room  
3) Simulate CT imaging and treatment sessions with a volunteer in the: 
a) CT imaging room (complete Analysis and Decision Form as well) 
 
b) Treatment room  
4) Anonymised data transferred to University of Sydney secure storage  
 
Once the above Credentialing points have been completed and signed off by a member of the Radiation 
Physics Laboratory, that site is open to patient recruitment.  
 
Required Documentation to complete this Credentialing:  
 AV biofeedback QA (version 3 – ‘Breathe Well’) 
 Patient questionnaire 
 Staff questionnaire 
 Session information form 
 AVIATOR Randomisation document 
 
For further details and assistance on the AV biofeedback system setup, user guide, and study workflow, 
please see the following: 
 AV biofeedback User Guide (version 4.1) 
 Clinical Workflow 
 AV biofeedback system components (version 7.1)  
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AVIATOR Credentialing v1.2. for software version v2.3.  
 
Contents 
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AVIATOR Credentialing v1.2. for software version v2.3.  
Performing QA with motion phantom 
These motion phantom tests will test the completion of quality assurance (QA), setup compatibility with 
department equipment, and incorporation of AV biofeedback procedures into department protocol. In 
addition to the AV biofeedback software and hardware, you will also need a motion phantom: 
  
 
The motion phantom dry run is performed in both the CT sim room and linac room, the workflow and 
checklist needs to be completed individually for each room.  
At the start of the study, each patient will have been given a study ID number, use this number as the 
patient name in AV biofeedback software to create a New Patient, and for reference for when you load 
an Existing Patient.  
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AVIATOR Credentialing v1.2. for software version v2.3.  
CT sim room - Phantom 
Action Steps 
Success (y/n) 
If ‘no’, detail why 
AV biofeedback 
system setup 
1. Setup AV biofeedback system and motion 
phantom. 
 
2. Move couch to patient imaging position 
with motion phantom in place at the typical 
position of a patient’s abdomen. 
 
AV biofeedback 
Quality 
Assurance 
3. Complete AV biofeedback Daily QA  
 
4. Complete AV biofeedback Monthly QA 
 
Imaging with 
AV biofeedback 
5. Perform 4D-CT scan as per department 
protocol with the AV biofeedback system 
running. 
 
6. Stop Session and save data 
 
Data retrieval 
7. Save the following data to the database 
allocated by [site data manager]: 
a. RPM breathing files 
 
b. Image files  
c. AV biofeedback software breathing 
files 
 
8. University of Sydney researchers received 
saved data?  
 
 
 
______________ _______________ _______________ 
Site credentialing   Signature  Date 
name 
 
 
 
______________ _______________ _______________ 
RPL name  Signature  Date  
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AVIATOR Credentialing v1.2. for software version v2.3.  
Linac room - Phantom 
Action Steps 
Success (y/n) 
If ‘no’, detail why 
AV biofeedback 
system setup 
1. Setup AV biofeedback system and motion 
phantom. 
 
2. Move couch to patient treatment position 
with motion phantom in place at the typical 
position of a patient’s abdomen. 
 
AV biofeedback 
Quality 
Assurance 
3. Complete AV biofeedback Daily QA  
 
4. Complete AV biofeedback Monthly QA 
 
Imaging/ 
treatment with 
AV biofeedback 
5. Perform CBCT scan (if linac has OBI) as per 
department protocol with the AV biofeedback 
system running. 
a. Record start and finish times of imaging 
from AV biofeedback software. 
 
6. Stop Session and save data 
 
Data retrieval 
7. Save the following data to the database 
allocated by [site data manager]: 
a. RPM breathing files 
 
b. Image files  
c. AV biofeedback software breathing files 
 
8. University of Sydney researchers received 
saved data?  
 
 
 
 
______________ _______________ _______________ 
Site credentialing   Signature  Date 
name 
 
 
______________ _______________ _______________ 
RPL name  Signature  Date 
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AVIATOR Credentialing v1.2. for software version v2.3.  
Dry-run with a volunteer 
These volunteer tests will test the setup compatibility with department equipment, and incorporation of 
AV biofeedback procedures into department protocol as well as performing breathing session analysis 
and decision form (CT room only). 
  
 
The volunteer dry run is performed in both the CT sim room and linac room, the workflow and checklist 
needs to be completed individually for each room.  
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AVIATOR Credentialing v1.2. for software version v2.3.  
CT sim room - Volunteer 
Action Steps 
Success (y/n) 
If ‘no’, detail why 
AV biofeedback 
system setup 
1. Setup AV biofeedback system and couch for 
lung cancer patient imaging, with volunteer. 
 
2. Move couch to patient imaging position with 
volunteer positioned in accordance with 
department lung cancer patient protocol. 
 
Free breathing 
session 
3. Create a New Patient under the name “AV 
TEST” and start Free Breathing session 
 
4. After four minutes stop respiratory session 
and save session 
 
AV biofeedback 
session 
5. Acquire a new waveguide, and commence a 
new respiratory session. 
 
6. After 1 minute, ask volunteer if breathing-
guide is OK. If not modify waveguide based on 
volunteer comments (increase/decrease 
waveguide amplitude/period) and start 
respiratory session with modified waveguide. 
 
7. After loading new waveguide (or not, 
depending on volunteer comments), have 
volunteer follow AV biofeedback for four 
minutes. Stop session and save data.  
 
AV biofeedback 
Analysis and 
Decision Form 
8. Analyse and save the Free Breathing and AV 
biofeedback breathing sessions using 
‘Analyse’.  
 
9. Fill in and save Breathing Decision Form  
 
Data retrieval 
10. Save the following data to the database 
allocated by [site data manager]: 
a. RPM breathing files 
 
b. AV biofeedback software breathing 
files 
 
c. Respiratory Analysis images  
d. Decision Form  
11. University of Sydney researchers received 
saved data?  
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AVIATOR Credentialing v1.2. for software version v2.3.  
 
 
______________ _______________ _______________ 
Site credentialing   Signature  Date 
name 
 
______________ _______________ _______________ 
RPL name  Signature  Date 
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AVIATOR Credentialing v1.2. for software version v2.3.  
Linac room - Volunteer 
Action Steps 
Success (y/n) 
If ‘no’, detail why 
AV biofeedback 
system setup 
1. Setup AV biofeedback system and motion 
phantom 
 
2. Move couch to patient treatment position 
with volunteer positioned in accordance with 
department lung cancer patient protocol. 
 
AV biofeedback 
session 
3. Load existing “AV TEST” patient and load their 
waveguide. 
a. Record start and finish times of imaging 
from AV biofeedback software.  
 
4. After four minutes, end respiratory session 
and save session  
 
Data retrieval 
5. Save the following data to the database 
allocated by [site data manager]: 
a. RPM breathing files 
 
b. AV biofeedback software breathing files  
6. University of Sydney researchers received 
saved data?  
 
 
 
 
 
______________ _______________ _______________ 
Site credentialing   Signature  Date 
name 
 
______________ _______________ _______________ 
RPL name  Signature  Date 
 
Last Updated: 26th February 2015 
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AVIATOR Site Credentialing 
Prior to commencing patient recruitment patient, each site needs to complete the following 
credentialing, please tick off as completed: 
CREDENTIALING ITEM COMPLETE 
1) Pass AV biofeedback Daily & Monthly QA using motion phantom in the: 
a) CT imaging room 
 
b) Treatment room  
1) Simulate CT imaging and treatment sessions with a volunteer in the: 
c) CT imaging room (complete Analysis and Decision Form as well) 
 
d) Treatment room  
2) Anonymised data transferred to University of Sydney secure storage  
 
Once the above Credentialing points have been completed and signed off by a member of the Radiation 
Physics Laboratory, that site is open to patient recruitment.  
 
Required Documentation to complete this Credentialing:  
 AV biofeedback QA (version 3 – ‘Breathe Well’) 
 Patient questionnaire 
 Staff questionnaire 
 Session information form 
 
For further details and assistance on the AV biofeedback system setup, user guide, and study workflow, 
please see the following: 
 AV biofeedback User Guide (version 4.1) 
 Clinical Workflow 
AV biofeedback system components (version 7.1)  
309
 Contents 
AVIATOR Site Credentialing ............................................................................................................................ 1 
Simulations with motion phantom ................................................................................................................. 3 
CT sim room - Phantom .......................................................................................................................... 4 
Linac room - Phantom ............................................................................................................................. 5 
Dry-run with a volunteer ................................................................................................................................ 6 
CT sim room - Volunteer ......................................................................................................................... 7 
Linac room - Volunteer ........................................................................................................................... 9 
 
  
310
Performing QA with motion phantom 
These motion phantom tests will test the completion of quality assurance (QA), setup compatibility with 
department equipment, and incorporation of AV biofeedback procedures into department protocol. In 
addition to the AV biofeedback software and hardware, you will also need a motion phantom: 
  
 
The motion phantom dry run is performed in both the CT sim room and linac room, the workflow and 
checklist needs to be completed individually for each room.  
At the start of the study, each patient will have been given a study ID number, use this number as the 
patient name in AV biofeedback software to create a New Patient, and for reference for when you load 
an Existing Patient.  
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CT sim room - Phantom 
Action Steps 
Success (y/n) 
If ‘no’, detail why 
AV biofeedback 
system setup 
1. Setup AV biofeedback system and motion 
phantom. 
 
2. Move couch to patient imaging position 
with motion phantom in place at the 
typical position of a patient’s abdomen. 
 
3. Setup has adequate clearance of imaging 
bore? 
 
AV biofeedback 
Quality 
Assurance 
4. Complete AV biofeedback Daily QA  
 
5. Complete AV biofeedback Monthly QA 
 
Imaging with 
AV biofeedback 
6. Perform 4D-CT scan as per department 
protocol with the AV biofeedback system 
running. 
 
7. Stop Session and save data 
 
Data retrieval 
8. Save the following data to the database 
allocated by [site data manager]: 
a. RPM breathing files 
 
b. Image files  
c. AV biofeedback software breathing 
files 
 
9. University of Sydney researchers received 
saved data?  
 
 
 
______________ _______________ _______________ 
Site credentialing   Signature  Date 
name 
 
 
 
______________ _______________ _______________ 
RPL name  Signature  Date  
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Linac room - Phantom 
Action Steps 
Success (y/n) 
If ‘no’, detail why 
AV biofeedback 
system setup 
1. Setup AV biofeedback system and motion 
phantom. 
 
2. Move couch to patient treatment position 
with motion phantom in place at the typical 
position of a patient’s abdomen. 
 
3. Rotate the gantry 360° about the couch. 
Setup has adequate clearance of gantry? 
 
AV biofeedback 
Quality 
Assurance 
4. Complete AV biofeedback Daily QA  
 
5. Complete AV biofeedback Monthly QA 
 
Imaging/ 
treatment with 
AV biofeedback 
6. Perform CBCT scan (if linac has OBI) as per 
department protocol with the AV biofeedback 
system running. 
a. Record start and finish times of imaging 
from AV biofeedback software. 
 
7. Stop Session and save data 
 
Data retrieval 
8. Save the following data to the database 
allocated by [site data manager]: 
a. RPM breathing files 
 
b. Image files  
c. AV biofeedback software breathing files 
 
9. University of Sydney researchers received 
saved data? 
 
 
 
 
______________ _______________ _______________ 
Site credentialing   Signature  Date 
name 
 
 
______________ _______________ _______________ 
RPL name  Signature  Date 
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Dry-run with a volunteer 
These volunteer tests will test the setup compatibility with department equipment, and incorporation of 
AV biofeedback procedures into department protocol as well as performing breathing session analysis 
and decision form (CT room only). 
  
 
The volunteer dry run is performed in both the CT sim room and linac room, the workflow and checklist 
needs to be completed individually for each room.  
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CT sim room - Volunteer 
Action Steps 
Success (y/n) 
If ‘no’, detail why 
AV biofeedback 
system setup 
1. Setup AV biofeedback system and couch for 
lung cancer patient imaging, with volunteer. 
 
2. Move couch to patient imaging position with 
volunteer positioned in accordance with 
department lung cancer patient protocol. 
 
3. Setup has adequate clearance of imaging 
bore? 
 
Free breathing 
session 
4. Create a New Patient under the name “AV 
TEST” and start Free Breathing session. 
 
5. After four minutes stop respiratory session 
and save session 
 
AV biofeedback 
session 
6. Acquire a new waveguide, and commence a 
new respiratory session. 
 
7. After 1 minute, ask volunteer if breathing-
guide is OK.  
a. If not, edit waveguide accordingly. 
 
8. After loading new waveguide (or not, 
depending on volunteer comments), have 
volunteer follow AV biofeedback for four 
minutes. Stop session and save data 
 
AV biofeedback 
Analysis and 
Decision Form 
9. Analyse and save the Free Breathing and AV 
biofeedback breathing sessions using 
‘Analyse’ 
 
10. Fill in and save Breathing Decision Form. 
 
Data retrieval 
11. Save the following data to the database 
allocated by [site data manager]: 
a. RPM breathing files 
 
b. AV biofeedback software breathing 
files 
 
c. Respiratory Analysis images  
d. Decision Form  
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12. University of Sydney researchers received 
saved data? 
 
 
 
 
______________ _______________ _______________ 
Site credentialing   Signature  Date 
name 
 
______________ _______________ _______________ 
RPL name  Signature  Date 
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Linac room - Volunteer 
Action Steps 
Success (y/n) 
If ‘no’, detail why 
AV biofeedback 
system setup 
1. Setup AV biofeedback system and motion 
phantom 
 
2. Move couch to patient treatment position 
with volunteer positioned in accordance with 
department lung cancer patient protocol. 
 
3. Rotate the gantry 360° about the couch. 
Setup has adequate clearance of gantry? 
 
AV biofeedback 
session 
4. Load existing “AV TEST” patient and load their 
waveguide 
a. Record start and finish times of imaging 
from AV biofeedback software.  
 
5. After four minutes, end respiratory session 
and save session 
 
Data retrieval 
6. Save the following data to the database 
allocated by [site data manager]: 
a. RPM breathing files 
 
b. AV biofeedback software breathing files  
7. University of Sydney researchers received 
saved data? 
 
 
 
 
 
______________ _______________ _______________ 
Site credentialing   Signature  Date 
name 
 
______________ _______________ _______________ 
RPL name  Signature  Date 
 
Last Updated: 27th February 2015 
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AVIATOR Clinical Workflow 
1. General Workflow 
The AVIATOR study is a randomised clinical trial, as such, not all patients will be using the breathing-
guidance system: audiovisual (AV) biofeedback. Once an eligible patient has been identified, the 
Canberra Hospital data manager will contact the University of Sydney Randomisation group to know 
which study group each patient will be allocated to as well as receiving that patient’s Trial ID number.  
Below are the general workflows for two AVIATOR study groups:  
 
Intervention Group  
(Test with AV biofeedback) 
Control Group 
 (no AV biofeedback) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NB. AV Biofeedback-specific steps shown as blue; Free Breathing (no AV biofeedback) steps shown as red; General 
steps (or both AV and Free Breathing) shown as purple. 
 
What follows is an outline for each of these steps.  
For more details on AV Biofeedback see documents:  
 User Guide (Version 4-2) 
 AVIATOR Protocol (Version 5) 
 BreatheWell QA (Version 3-1) 
  
Decision Session: 
Will the patient use  
AV biofeedback? 
YES NO 
Image and Treat 
using  
AV biofeedback 
Image and Treat 
without  
AV biofeedback 
Data to collect:  
 RPM & AV Breathing 
signals 
 AV Decision Form 
 All images (CT sim & 
CBCT) 
 Surveys  
 Toxicity Reports 
Data to collect:  
 RPM Breathing signals 
 All images (CT sim & 
CBCT) 
 Toxicity Reports 
Image and Treat 
without  
AV biofeedback 
Data to collect:  
 RPM Breathing signals 
 All images (CT sim & 
CBCT) 
 Toxicity Reports 
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2. Intervention Group 
The AVIATOR trial is randomised in a 2:1 ratio meaning that for every 3 patients that are recruited into 
the study, 2 of them will be allocated to the intervention group to be tested with AV biofeedback while 1 
in 3 are allocated to the control group. The advantage of using AV biofeedback is that their breathing 
becomes more regular; however, to ensure that this is the case, each patient will undergo a Decision 
Session prior to their CT sim and treatment to determine whether AV biofeedback is the best option for 
them. Once Randomisation has been performed the patient will receive a ‘Trial ID’, use this number to 
label and save the relevant AVIATOR trial data.  
2.1. Decision Session 
There are cases where patients naturally have regular breathing, or have difficulty following the AV 
biofeedback guide, so a Decision Session will be performed to determine whether it is best to use AV 
biofeedback for each patient. The general workflow of the Decision Session is below:  
 
What follows are the details and user guide for each of the above processes.  
2.1.1 AV Biofeedback information video 
A brief (~1 minute) information video has been made to inform the patients about what AV Biofeedback 
is and what they will be required to do to follow it. Have the patient watch the video on the research 
computer before they go into the CT sim room and answer any question that they may have (video file 
should be on the research computer’s desktop).  
Setup AV Biofeedback 
System 
Record patient Free 
Breathing  
(NO AV biofeedback)  
for 4 minutes  
AV Biofeedback information 
video 
Record AV Biofeedback 
breathing for 4 minutes 
Complete Breathing Analysis 
& Decision Form 
AV Biofeedback practice  
(1 - 2 minutes) 
Modify guide if necessary  
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Screen shot from information video 
2.1.2 Setup AV Biofeedback System 
Equipment needed:  
 Research computer with AV Biofeedback software (called ‘BreatheWell) installed 
 Audio-visual (AV) display goggles 
 RPM System 
 Cabling 
Schematic of the setup is shown below: 
  
 
Open up AV Biofeedback using the ‘Breathe Well’ desktop icon on the Research computer:  
You will see the initial AV Biofeedback screen:  
320
 
 
If the Patient Display Preview reads “No preview available” (like it does above) it means that the display 
goggles are not properly connected to the AV biofeedback computer.  
The functions to perform on the Breathe Well software (in order) are:  
1) Connect to RPM  
2) Create New Patient / Load Existing Patient  
3) Create New Waveguide / Load Existing Waveguide 
4) New Respiratory Session 
5) Analyze 
6) Breathing Decision Form  
Once the patient is on the couch ensure that the RPM is both tracking AND recording the RPM marker 
block motion. In the RPM screenshot on the following page, the Record button is highlighted and a bar 
containing blue blocks is highlighted. Once the number of blue blocks on the bar is 3 or fewer, click 
‘Record’.  
If there are more than 3 blue blocks it means that the phase calculation is not performing optimally, and 
errors can occur in the Breathe Well software if the number of blue blocks exceeds 3 for an extended 
period of time.  
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Screen shot of RPM. There are fewer than 3 blue blocks present on the highlighted bar, so it’s good to Record.  
Once the RPM is recording the breathing signal, in the Breathe Well software click ‘Connect’ to start 
receiving the RPM breathing signal (if unsuccessful, try a different COM# from the dropdown menu in 
the Breathe Well software and click ‘Connect’ again).  
2.1.3. Record Patient Free Breathing 
Once connected to the RPM, click ‘New Patient’ and enter 
Trial ID (received with the Randomisation call) as their first 
name, ‘AVIATOR’ as their last name, and their Trial ID again 
as the Patient ID: 
 
Do not have the patient wear the display goggles at this point and ensure that the music is muted. It is 
important that they breathe as naturally as possible without instruction.  
 After you have created a New Patient file, click ‘New Waveguide’, this will acquire 10 breaths to 
and calculate the average of these to create the waveguide, and save it without any 
modifications.  
 Click ‘New Respiratory Session’ and once the wave appears on the screen click ‘Start’ on the 
stopwatch panel:  
 At 4 minutes click ‘Stop Session’ and save the data as ‘FB’:  
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  The functions described above are shown below, highlighted by a red rectangle.   
 
 
 After the session has been saved, click ‘Analyse’, this will analyse the session you just saved  
 In the analysis screen, click ‘Save’ and then close the analysis screen.  
 Click ‘Reset’ in the Breathe Well software 
 Stop and save in the RPM software, then re-track and record in preparation for the AV 
biofeedback session.  
 
This concludes the Free Breathing Session. 
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2.1.4. AV Biofeedback Practice 
With the RPM tracking and recording the signal, now the patient wears the display goggles and unmute 
the audio. In the Breathe Well software:  
 Connect to RPM 
 Click ‘Existing Patient’ and select the correct ‘Trial ID AVIATOR’ patient 
 Click ‘New Waveguide’, AV Biofeedback will acquire 10 breaths before displaying them to you: 
 
Blue curves:  each of the 10 acquired 
breathing cycles 
Red curve:  a selected blue curve 
Green curve: the average of the blue 
curves, which will be displayed as the 
waveguide 
The slider-bar (highlighted by the red 
rectangle) underneath the curves scrolls 
through each of the 10 cycles.  
 
 
If there are any outlier breathing cycles not representative of their “normal” breathing (e.g. 
overly-deep breaths, coughs, yawns, etc.) select them using the slider-bar and delete them: 
 
Too shallow Too deep  
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 An issue with making patients conscious of their breathing is that they tend to put more effort 
in to their breathing, inadvertently breathing slightly more deeply than they usually would.  
o To counter this, scale the waveguide’s ‘Avg Wave – Scale’ from 1.0 down to 0.9   
 
 The ‘Avg Wave Time Period’ (given in seconds) can also be modified if it exceeds the limits of 
4D-CT reconstruction (e.g. 10 breaths per minute: 6 seconds). 
 Save this waveguide 
 Next click ‘Select Waveguide’ and select the one you just saved (most recently saved files 
appear at the top of the list – time the file was created highlighted with red rectangle: 
hour:minute:second) 
 
 Click ‘New Respiratory Session’, this will commence AV biofeedback guided breathing. After a 
brief calculation of mean position the waveguide will appear and the music will begin to play. 
 Give the patient 1 minute to attempt the AV biofeedback guidance (use the sidebar stopwatch 
if necessary). Are there any issues? 
o Is the patient having difficulty staying within the blue region?  
o Is the patient having difficulty following the waveguide? (Is it too fast? Too slow?) 
 If points a) and/or b) are issues, then a modification of the waveguide may be necessary: click 
Reset → Existing Patient → Edit Waveguide and select the recently acquired Waveguide you 
wish to modify 
 This will bring up the selected waveguide and options to modify it:   
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o If patient consistently moved outside of the blue region, increase Waveguide Amplitude (it’s 
a scaling factor, so changing it from 1.0 to 1.2 will yield a waveguide with 1.2×Amplitude). 
o OR if the patient remained well within the blue region, perhaps decreasing the 
amplitude from 1.0 to 0.8 may be more appropriate  
o If patient found the waveguide to move too fast, increase Waveguide Period 
o If patient found the waveguide to move too slow, decrease Waveguide Period 
o Only minor modifications to these numbers should achieve the desired result.  
o Save modified waveguide 
 Click ‘New Respiratory Session’; after a brief moment to position the marker in the correct 
position, the breathing session will commence.  
 Once the white waveguide appears on the screen (and the music commences) click ‘Start’ on the 
sidebar stopwatch. 
 After 4 minutes ‘Stop Session’ save it as ‘AV_Decision’:  
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 After the session has been saved, click ‘Analyse’, this will analyse the session you just saved  
 In the analysis screen, click ‘Save’ and then close the analysis screen 
 
 
 Stop and save in the RPM software. 
 Aside: in the analysis form, the blue curves are each individual breath, the red curve is the 
waveguide, and the yellow curve is the average curve based on all the blue breaths 
o RMSE Disp is a measure of how much all the breaths vary from this average curve 
 
This concludes the AV Biofeedback Session 
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2.1.5. Breathing Decision Form 
 Now that both breathing sessions have been performed and both sessions have been analysed 
and saved click ‘Breathing Decision Form’  
 This will bring up the Decision Form window, select the AV biofeedback (AV) and Free Breathing 
(FB) analysis files you just saved (they will be jpegs) and fill in the rest of the patient details:  
 
Breathing Decision Form.  
Left: Unfilled. Right: Complete. 
Note: Enter the same patient name and ID information here as you did in 
creating a new patient file (Trial ID and AVIATOR).  
Decisions are made by which breathing session has the lower ‘RMSE Disp’ value.  In this instance, the AV 
biofeedback session was more regular (RMSE Disp (AV) = 0.48, less than RMSE Disp (FB) = 0.59).   
There is no threshold for how much less the RMSE value needs to be to make the decision (e.g. if RMSE 
Disp (AV) = 0.48, and RMSE Disp (FB) = 0.49, then AV would still be the decision).  
Save the Decision Form as a PDF.  
The entire Decision Session takes approximately 20-30 minutes to complete.  
 If Decision Session is being performed on a different day to the CT sim, have the patient and the 
staff member who operated the Breathe Well software complete the patient and staff surveys 
o If Decision Session and CT sim session are being performed on the same day, wait until 
the CT sim is completed to perform the surveys.   
 
This concludes the Decision Session. 
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2.2. Image and Treat Using AV Biofeedback 
Continuing on from the previous section, we will first address those patients for whom, based on the 
Decision Session, AV Biofeedback was selected to remain in their imaging and treatment.  
 
2.2.1. CT sim with AV Biofeedback 
The setup here is the same as used for the Decision Session:  
 
The purpose of AV Biofeedback is to not only facilitate regular breathing during imaging and treatment, 
but also across multiple imaging and treatment sessions, so it is important to use the same Waveguide 
as used in the 4 minute of AV biofeedback breathing in the Decision Session: 
  
 Position patient as per department protocol in preparation for their CT sim 
AV Biofeedback during  
CT sim 
AV Biofeedback during  
Treatment Delivery 
Complete Patient and 
Radiotherapist Surveys 
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 Once in position, ensure patient is wearing display goggles and imaging and sound from AV 
Biofeedback computer is clear.  
 Start a New Respiratory Session 
o Select the correct Waveguide 
 After a brief moment to position the marker in the correct position, the breathing session will 
commence.  
 Perform imaging as per department protocol. 
 After imaging is complete, click ‘Stop Session’ and save data as ‘AV_CT’: 
 
 Stop and save in the RPM software 
 Also save:  
o CT sim images (DICOM data) [file location] 
 It is important to save these files straight away, as they may be automatically deleted within 
days 
 If Decision Session was performed on the same day as CT sim, have the patient and the staff 
member who operated the Breathe Well software complete the patient and staff surveys  
 
This concludes the AV Biofeedback CT sim Session. 
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2.2.2. Treatment Delivery with AV Biofeedback 
The setup here is similar to the setup used for the Decision and CT sim Sessions: 
 
Use the same Waveguide as used in the 4 minutes of AV biofeedback breathing in the Decision Session, 
and then again in the CT sim Session.  
 
 Position patient as per department protocol in preparation for treatment. 
 Once in position, ensure patient is wearing display goggles and imaging and sound from AV 
Biofeedback PC is clear.  
 Start a New Respiratory Session and select the correct Waveguide. 
 After a brief moment to position the marker in the correct position, the breathing session will 
commence.  
 Perform treatment delivery as per department protocol – regarding any couch shifts:  
o After a couch shift, in the Breathe Well software click ‘Renormalise’, which repositions 
the marker-block at the centre of the AV biofeedback display because the couch shifts 
may have moved the marker-block off-screen 
o DO NOT click renormalise during any beam-on times 
o Renormalise will automatically save the breathing data, so after a treatment session and 
‘Renormalise’ was clicked once, there will be two breathing data files for that one 
session.  
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 Once treatment is complete, click ‘Stop Session’ and save the data as ‘AV_Treatment’: 
 
 Also save:  
o CBCT images (DICOM data) if used (if linac does not have on-board imaging, disregard 
this point) 
o RPM File [file location] 
 It is important to save these files straight away, as they may be automatically deleted within 
days.  
 
 If this is the final fraction of treatment, complete patient and staff surveys  
 
This concludes the AV Biofeedback Treatment Session 
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2.3. Image and Treat with Free Breathing 
In the event that the patient is randomised into the control arm, or in the event that ‘RMSE Disp’ for 
Free Breathing is less than the ‘RMSE Disp’ for AV Biofeedback in the Decision Session, then the AV 
Biofeedback system will not be used in their imaging and treatment, the setup will be as per department 
protocol, and it is important that the RPM system is used:  
 
While AV Biofeedback will not be used, it is still important to save the 
following data for each CT sim and treatment fraction:  
 RPM Breathing signals 
 CT sim images  
 CBCT images (if CBCTs are not acquired then disregard this point) 
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3. Control Group 
Patients in the Control Group will have been identified as an eligible patient by the Radiation Oncologist, 
and then agreed to take part in the study. However, they have been randomised into the Control Group 
and will not be using AV Biofeedback. The setup, conduct of AVIATOR in the control group as well as the 
data to save will be the same as detailed in the previous section: ‘2.3. Image and Treat with Free 
Breathing’.  
4. Post-Treatment Toxicity Report 
As noted in the Flowcharts on page 1, a Toxicity Report is required for every patient regardless of their 
allocation to intervention or control groups.  
With each patient follow-up visitation the Toxicity Report must be completed by the treating physician; 
this is done for each follow-up for up to 12 months after each patient has completed their treatment.  
The completion of this Toxicity Report marks the conclusion of the AVIATOR trial for each patient.  
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AVIATOR Clinical Workflow 
1. General Workflow 
The AVIATOR study is a randomised clinical trial, as such, not all patients will be using the breathing-
guidance system: audiovisual (AV) biofeedback. Once an eligible patient has been identified, Fiona Hegi-
Johnson will contact the University of Sydney Randomisation group to know which study group each 
patient will be allocated to as well as receiving that patient’s Trial ID number.  
Below are the general workflows for two AVIATOR study groups:  
 
Intervention Group  
(Test with AV biofeedback) 
Control Group 
 (no AV biofeedback) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NB. AV Biofeedback-specific steps shown as blue; Free Breathing (no AV biofeedback) steps shown as red; General 
steps (or both AV and Free Breathing) shown as purple. 
 
What follows is an outline for each of these steps.  
For more details on AV Biofeedback see documents:  
 User Guide (Version 4-1: Breathe Well) 
 AVIATOR Protocol  
Decision Session: 
Will the patient use  
AV biofeedback? 
YES NO 
Image and Treat 
using  
AV biofeedback 
Image and Treat 
without  
AV biofeedback 
Data to collect:  
 RPM & AV Breathing 
signals 
 AV Decision Form 
 All images (CT sim & 
CBCT) 
 Surveys  
 Toxicity Reports 
Data to collect:  
 RPM Breathing signals 
 All images (CT sim & 
CBCT) 
 Toxicity Reports 
Image and Treat 
without  
AV biofeedback 
Data to collect:  
 RPM Breathing signals 
 All images (CT sim & 
CBCT) 
 Toxicity Reports 
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2. Intervention Group 
The AVIATOR trial is randomised in a 2:1 ratio meaning that for every 3 patients that are recruited into 
the study, 2 of them will be allocated to the intervention group to be tested with AV biofeedback while 1 
in 3 are allocated to the control group. The advantage of using AV biofeedback is that their breathing 
becomes more regular; however, to ensure that this is the case, each patient will undergo a Decision 
Session prior to their CT sim and treatment to determine whether AV biofeedback is the best option for 
them. Once Randomisation has been performed the patient will receive a ‘Trial ID’, use this number to 
label and save the relevant AVIATOR trial data.  
2.1. Decision Session 
There are cases where patients naturally have regular breathing, or have difficulty following the AV 
biofeedback guide, so a Decision Session will be performed to determine whether it is best to use AV 
biofeedback for each patient. The general workflow of the Decision Session is below:  
 
What follows are the details and user guide for each of the above processes.  
2.1.1 AV Biofeedback information video 
A brief (~1 minute) information video has been made to inform the patients about what AV Biofeedback 
is and what they will be required to do to follow it. Have the patient watch the video on the research 
computer before they go into the CT sim room and answer any question that they may have (video file 
should be on the research computer’s desktop).  
Setup AV Biofeedback 
System 
Record patient Free 
Breathing  
(NO AV biofeedback)  
for 4 minutes  
AV Biofeedback information 
video 
Record AV Biofeedback 
breathing for 4 minutes 
Complete Breathing Analysis 
& Decision Form 
AV Biofeedback practice  
(1 - 2 minutes) 
Modify guide if necessary  
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Screen shot from information video 
2.1.2 Setup AV Biofeedback System 
Equipment needed:  
 Research laptop with AV Biofeedback software (called ‘BreatheWell’) installed 
 Audio-visual (AV) screen/tablet 
 RPM System 
 Cabling: 
o Serial Cable 
o USB-to-Serial Cable 
o USB 20 m extension cable 
o USB-tablet cable 
Schematic of the setup is shown below: 
  
 
 Once connected, open iDisplay software on the research laptop:  
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 Open up iDisplay on the tablet and press ‘connect via USB’, you should then see the laptop’s 
background on the tablet 
o Connecting the laptop to the tablet via iDisplay is quite sequence-sensitive. If an error 
occurs, the best solution is typically to close iDisplay on the laptop and tablet and try 
again. 
 Open up AV Biofeedback software: ‘BreatheWell’ using the Desktop icon on the Research 
laptop:   
 You will see the initial AV Biofeedback screen:  
 
 
 
 If the Patient Display Preview reads “No preview available” (like it does above) it means that the 
display goggles are not properly connected to the AV biofeedback computer.  
 The functions to perform on the Breathe Well software (in order) in the Decision Session are:  
1) Connect to RPM  
2) Create New Patient / Load Existing Patient  
3) Create New Waveguide / Load Existing Waveguide 
4) New Respiratory Session 
5) Analyze 
6) Breathing Decision Form  
 Once the patient is on the couch ensure that the RPM is both tracking AND recording the RPM 
marker block motion.  
 In the RPM screenshot on the following page, the Record button is highlighted and a bar 
containing blue blocks is highlighted. Once the number of blue blocks on the bar is 3 or fewer, 
click ‘Record’.  
 If there are more than 3 blue blocks it means that the phase calculation is not performing 
optimally, and errors can occur in the Breathe Well software if the number of blue blocks 
exceeds 3 for an extended period of time.  
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Screen shot of RPM. There are fewer than 3 blue blocks present on the highlighted bar, so it’s good to Record.  
 Once the RPM is recording the breathing signal, in the Breathe Well software click ‘Connect’ to 
start receiving the RPM breathing signal  
o If unsuccessful, try a different COM# from the dropdown menu in the Breathe Well 
software and click ‘Connect’ again 
2.1.3. Record Patient Free Breathing 
 
Once connected to the RPM, click ‘New Patient’ and 
enter Trial ID (received with the Randomisation call) as 
their first name, ‘AVIATOR’ as their last name, and their 
Trial ID again as the Patient ID: 
 
 
Turn off the tablet at this point and ensure that the music is muted. It is important that they breathe as 
naturally as possible without instruction.  
 After you have created a New Patient file, click ‘New Waveguide’, this will acquire 10 breaths to 
and calculate the average of these to create the waveguide, and save it without any 
modifications.  
 Click ‘New Respiratory Session’ and once the wave appears on the screen click ‘Start’ on the 
stopwatch panel:  
 At 4 minutes click ‘Stop Session’ and save the data as ‘FB’:  
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 The functions described above are shown below, highlighted by a red rectangle.   
 
 
 After the session has been saved, click ‘Analyse’, this will analyse the session you just saved  
 In the analysis screen, click ‘Save’ and then close the analysis screen.  
 Click ‘Reset’ in the Breathe Well software 
 Stop and save in the RPM software, then re-track and record in preparation for the AV 
biofeedback session.  
 
This concludes the Free Breathing Session. 
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2.1.4. AV Biofeedback Practice 
With the RPM tracking and recording the signal, turn on the tablet (and double-check iDisplay is still 
running properly, extending the laptop screen to the tablet) and unmute the audio. 
In the Breathe Well software:  
 Connect to RPM 
 Click ‘Existing Patient’ and select the correct ‘Trial ID AVIATOR’ patient 
 Click ‘New Waveguide’, AV Biofeedback will acquire 10 breaths before displaying them to you: 
 
Blue curves:  each of the 10 acquired breathing 
cycles 
Red curve:  a selected blue curve 
Green curve: the average of the blue curves, 
which will be displayed as the waveguide 
The slider-bar (highlighted by the red rectangle) 
underneath the curves scrolls through each of the 
10 cycles.  
 
 
If there are any outlier breathing cycles not representative of their “normal” breathing (e.g. 
overly-deep breaths, coughs, yawns, etc.) select them using the slider-bar and delete them: 
 
Too shallow Too deep  
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 An issue with making patients conscious of their breathing is that they tend to put more effort 
into their breathing, inadvertently breathing slightly more deeply than they usually would.  
o To counter this, scale the waveguide’s ‘Avg Wave – Scale’ from 1.0 down to 0.9   
 
 The ‘Avg Wave Time Period’ (shown above as 5.2177 seconds) can also be modified if it 
exceeds the limits of 4D-CT reconstruction (e.g. 10 breaths per minute: 6 seconds). 
 Save this waveguide 
 Next click ‘Select Waveguide’ and select the one you just saved (most recently saved files 
appear at the top of the list – time the file was created highlighted with red rectangle:  
hour-minute-second) 
 
 Click ‘New Respiratory Session’, this will commence AV biofeedback guided breathing. After a 
brief calculation of mean position the waveguide will appear and the music will begin to play. 
 Give the patient 1 minute to attempt the AV biofeedback guidance (use the sidebar stopwatch 
if necessary). Are there any issues? 
a) Is the patient having difficulty staying within the blue region?  
b) Is the patient having difficulty following the waveguide? (Is it too fast? Too slow?) 
 If points a) and/or b) are issues, then a modification of the waveguide may be necessary: click 
Reset → Existing Patient → Edit Waveguide and select the recently acquired Waveguide you 
wish to modify 
 This will bring up the selected waveguide and options to modify it:   
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o Avg Wave Time Period: period of the waveguide in seconds  
o Avg Wave - Scale: Amplitude of waveguide scale:  
 More than 1.0: Increasing amplitude size   
 Smaller than 1.0: Decreasing amplitude size 
o Only minor modifications to these numbers should achieve the desired result.  
o Save modified waveguide 
 Click ‘New Respiratory Session’; after a brief moment to position the marker in the correct 
position, the breathing session will commence.  
 Once the white waveguide appears on the screen (and the music commences) click ‘Start’ on the 
sidebar stopwatch. 
 After 4 minutes ‘Stop Session’ and save it as ‘AV_Decision’: 
 
 
 
 After the session has been saved, click ‘Analyse’, this will analyse the session you just saved  
343
 In the analysis screen, click ‘Save’ and then close the analysis screen 
 
 
 Stop and save in the RPM software 
 Aside: in the analysis form, the blue curves are each individual breath, the red curve is the 
waveguide, and the yellow curve is the average curve based on all the blue breaths 
o RMSE Disp is a measure of how much all the breaths vary from this average curve 
  
This concludes the AV Biofeedback Session 
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2.1.5. Breathing Decision Form 
 Now that both breathing sessions have been performed and both sessions have been analysed 
and saved click ‘Breathing Decision Form’  
 This will bring up the Decision Form window, select the AV biofeedback (AV) and Free Breathing 
(FB) analysis files you just saved (they will be jpegs) and fill in the rest of the patient details:  
 
Breathing Decision Form.  
Left: Unfilled. Right: Complete. 
Note: Enter the same patient name and ID information here as you did in 
creating a new patient file (Trial ID and AVIATOR).  
Decisions are made by which breathing session has the lower ‘RMSE Disp’ value.  In this instance, the AV 
biofeedback session was more regular (RMSE Disp (AV) = 0.48, less than RMSE Disp (FB) = 0.59).   
There is no threshold for how much less the RMSE value needs to be to make the decision (e.g. if RMSE 
Disp (AV) = 0.48, and RMSE Disp (FB) = 0.49, then AV would still be the decision).  
Save the Decision Form as a PDF.  
The entire Decision Session takes approximately 20-30 minutes to complete.  
 If Decision Session is being performed on a different day to the CT sim, have the patient and the 
staff member who operated the Breathe Well software complete the patient and staff surveys 
o If Decision Session and CT sim session are being performed on the same day, wait until 
the CT sim is completed to perform the surveys.   
 
This concludes the Decision Session. 
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2.2. Image and Treat Using AV Biofeedback 
Continuing on from the previous section, we will first address those patients for whom, based on the 
Decision Session, AV Biofeedback was selected to remain in their imaging and treatment.  
 
2.2.1. CT sim with AV Biofeedback 
The setup here is the same as used for the Decision Session:  
 
The purpose of AV Biofeedback is to not only facilitate regular breathing during imaging and treatment, 
but also across multiple imaging and treatment sessions, so it is important to use the same Waveguide 
as used in the 4 minute of AV biofeedback breathing in the Decision Session: 
AV Biofeedback during  
CT sim 
AV Biofeedback during  
Treatment Delivery 
Complete Patient and 
Radiotherapist Surveys 
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 Position patient as per department protocol in preparation for their CT sim 
 Once in position, ensure the tablet is on and iDisplay is correctly extending the laptop’s screen.  
 Select the correct patient and waveguide 
 Start a New Respiratory Session 
 After a brief moment to position the marker in the correct position, the breathing session will 
commence.  
 Perform imaging as per department protocol. 
 After imaging is complete, click ‘Stop Session’ and save data as ‘AV_CT’: 
 
 Stop and save in the RPM software 
 Also save:  
o CT sim images (DICOM data) [file location] 
 It is important to save these files straight away, as they may be automatically deleted within 
days 
 If Decision Session was performed on the same day as CT sim, have the patient and the staff 
member who operated the Breathe Well software complete the patient and staff surveys  
 
This concludes the AV Biofeedback CT sim Session. 
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2.2.2. Treatment Delivery with AV Biofeedback 
The setup here is similar to the setup used for the Decision and CT sim Sessions: 
 
Use the same Waveguide as used in the 4 minutes of AV biofeedback breathing in the Decision Session, 
and then again in the CT sim Session.  
 
 Position patient as per department protocol in preparation for treatment. 
 Once in position, ensure the tablet is on and iDisplay is correctly extending the laptop’s screen.  
 Select the correct patient and waveguide 
 Start a New Respiratory Session 
 After a brief moment to position the marker in the correct position, the breathing session will 
commence.  
 Perform treatment delivery as per department protocol – regarding any couch shifts:  
o After a couch shift, in the Breathe Well software click ‘Renormalise’, which repositions 
the marker-block at the centre of the AV biofeedback display because the couch shifts 
may have moved the marker-block off-screen 
o DO NOT click renormalise during any beam-on times 
o Renormalise will automatically save the breathing data, so after a treatment session and 
‘Renormalise’ was clicked once, there will be two breathing data files for that one 
session.  
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 Once treatment is complete, click ‘Stop Session’ and save the data as ‘AV_Treatment’: 
 
 Also save:  
o CBCT images (DICOM data) if used (if linac does not have on-board imaging, disregard 
this point) 
o RPM File [file location] 
 It is important to save these files straight away, as they may be automatically deleted within 
days.  
 If this is the final fraction of treatment, complete patient and staff surveys  
 
This concludes the AV Biofeedback Treatment Session 
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2.3. Image and Treat with Free Breathing 
In the event that the patient is randomised into the control arm, or in the event that ‘RMSE Disp’ for 
Free Breathing is less than the ‘RMSE Disp’ for AV Biofeedback in the Decision Session, then the AV 
Biofeedback system will not be used in their imaging and treatment, the setup will be as per department 
protocol, and it is important that the RPM system is used:  
 
While AV Biofeedback will not be used, it is still important to save the 
following data for each CT sim and treatment fraction:  
 RPM Breathing signals 
 CT sim images  
 CBCT images (if CBCTs are not acquired then disregard this point) 
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3. Control Group 
Patients in the Control Group will have been identified as an eligible patient by the Radiation Oncologist, 
and then agreed to take part in the study. However, they have been randomised into the Control Group 
and will not be using AV Biofeedback. The setup, conduct of AVIATOR in the control group as well as the 
data to save will be the same as detailed in the previous section: ‘2.3. Image and Treat with Free 
Breathing’.  
4. Post-Treatment Toxicity Report 
As noted in the Flowcharts on page 1, a Toxicity Report is required for every patient regardless of their 
allocation to intervention or control groups.  
With each patient follow-up visitation the Toxicity Report must be completed by the treating physician; 
this is done for each follow-up for up to 12 months after each patient has completed their treatment.  
The completion of this Toxicity Report marks the conclusion of the AVIATOR trial for each patient.  
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Audiovisual biofeedback (AV) Software 
Quality Assurance Guidelines 
1 | P a g e  
Breathe Well QA version 3 for software version 2.3.   Date: 14/01/2015 
Introduction 
 
This document describes the quality assurance tests that should be performed after any software or 
hardware change of the Audiovisual biofeedback (AV) system or before each simulation and gated 
treatment with the AV system. For background see Cui et al. Commissioning and quality assurance for a 
respiratory training system based on audiovisual biofeedback JACMP 11(4) 2010.   
The QA presented in this document is relevant for Breathe Well software version 2.3 or higher.  
 
Daily QA or prior to each simulation and treatment if used less frequently than daily 
 
1. Visual inspection of the hardware 
Is there any visible damage to the AV control computer, cables and the screen or goggles? 
 Yes (Report) 
 No 
 
2. Visual display and auditory sounding tests for the screen or video goggles 
Connect the screen or goggles to the AV computer. Play a sample video.  Is the video displayed properly 
and the sound volume comfortable and is sound coming from left and right speakers (goggles only)? 
 Yes 
 No (Report) 
Potential issue: If ‘no’ for video display:  
Goggles: go to ‘Screen Resolution’ (Control Panel\All Control Panel Items\Display\Screen Resolution) to 
ensure display is extended to the screen/goggles and that the resolution for the screen/goggles is 
correct (800 x 600).  
Tablet: Ensure that, in Settings, in Developer Options, USB debugging is ticked. If video problems persist, 
there may be an issue with the tablet drivers on the laptop not being installed.  
 
3. Initialization of the Breathe Well software 
a) Start the BreatheWell software first. Is the AV computer showing the operator interface, as 
shown in Fig. 1(a), while the screen/goggles showing the patient interface with a welcome 
instruction as in Fig. 1(b)?  
 Yes 
 No (Report) 
  
(a) (b) 
Fig. 1. (a) The operator interface 
(b) Patient display as shown on the screen/goggles 
(intentionally blank). 
b) On the operator interface, does the in-screen patient display match what is shown on patient 
screen/goggles?   
 Yes 
 No (Report) 
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Audiovisual biofeedback (AV) Software 
Quality Assurance Guidelines 
2 | P a g e  
Breathe Well QA version 3 for software version 2.3.   Date: 14/01/2015 
 
Monthly QA. Also to be performed after a software change. 
Details of test 
 
_______________ _______________   _______________ 
Centre name  Breathe Well Software Version**  RPM Software Version (Help->About)
* 
**see Breathe Well software top-bar for version number 
1. AV computer-RPM computer Connectivity 
AV computer connects to RPM computer via serial cable. Once connected, ensure RPM computer is 
tracking RPM marker block. On AV computer select correct COM# from the ‘RPM dropdown menu’ in 
Breathe Well software and click ‘Connect’. If unsuccessful, try a different COM# from the dropdown 
menu. Successful?  
  Yes 
 No (Report) 
If unsuccessful, refer to User Guide ‘Appendix A: Troubleshooting’ for further options to address AV-
RPM connectivity issues. 
 
2. Create an unmodified New Waveguide Session 
Use the RPM test phantom. In the Breathe Well software create New Patient (First Name: ‘AVQA’. Last 
Name: (the date) ‘DDMMYYYY’), then create New Waveguide. With the RPM phantom in motion acquire 
sample respiratory traces, and save it without any modification. Successful? 
 Yes 
 No (Report) 
 
3. Play a New Respiratory Session for the unmodified waveforms 
Still using the RPM test phantom. Click Load unmodified waveguide by clicking ‘Select Waveguide’ (file 
to select will be the only option available in the menu). Now click ‘New Respiratory Session. After 
calculating the mean, the audio patch should be toggled automatically and the music should sound 
synchronous and harmonious. Is the block tracing the motion magnitude, shape and time period of the 
background wave?  
Note: small variations in period may be observed, <0.1s per cycle, causing a small drift out of 
synchronisation (the phantom is not performing biofeedback!) and are acceptable.  
 Yes 
 No (Report) 
Is the exhale (bottom) period longer than the inhale (top) period on the AV screens? 
 Yes 
 No (Report) 
Stop Session. Do not save file.  
 
4. Create a modified New Waveguide Session 
Still using the RPM test phantom. Click ‘Restart’, click ‘Existing Patient’ and select the patient name you 
created in Step 2. Click ‘New Waveguide’. Remove one sample; adjust the average wave time period and 
scale. Are all of these operations successful and the modified waveforms saved? 
 Yes 
 No (Report) 
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5. Play a New Respiratory Session for the modified waveforms 
Still using the RPM test phantom. Click ‘Select Waveguide’, there should now be two files to choose 
between. Select the top one (top option is always the most recent). Begin another New Respiratory 
Session for the modified waveform. The block should be immediately out of synch with respect to the 
background waveguide. Observed successfully? 
 Yes 
 No (Report) 
Stop Session. Do not save file.  
 
6. Audio synchronization test & Randomization – Out-of-bounds respiratory pattern 
a) Still using the RPM test phantom. Load the original unmodified guiding waveform such as the 
one in Step 2 (second file option in ‘Select Waveguide’ – if you are uncertain, the timestamp is 
written into the file name - select the earlier option). Start ‘New Respiratory Session’. Once 
session is started, slightly raise the motion phantom itself (by ~2 cm) by placing something 
beneath it, producing a partially out-of-bounds respiratory pattern. When the block moves 
outside the blue region the music should fade to silence, and when the block returns within the 
blue region, the music volume should increase back to normal. Successful? 
 Yes 
 No (Report) 
Press ‘Renormalize’. After the mean had been calculated, the block should be continuously 
within the blue region and music should be playing continuously, not fading in and out.  
Stop Session. SAVE FILE. 
Successful? 
 Yes 
 No (Report) 
b) On the AV computer, open folder: ‘C:\ProgramData\UniversityofSydney\BreatheWell’ and open 
the folder with the correct patient name you created in Step 2. There should be two ‘REC files’, 
these are the breathing files. Renormalizing the data creates an additional breathing file. 
Successful? 
 Yes 
 No (Report) 
  
7. Changed range of motion function test 
Turn off RPM test phantom, and add tape (4-5 layers) to the widest point of the rotating disc. This will 
increase the range of motion of the phantom. Turn test phantom back on. It is best to slightly elevate 
the RPM test phantom for this as the added layers of tape may scrape across the couch surface.  
a) Using the original unmodified wave, begin another New Respiratory.  The block should NOT 
trace the background wave and should move above and/or below the ranges of the background 
wave. Successful?   
 Yes 
 No (Report) 
b) Then click the Renormalize button and the ball/block should still NOT trace the background 
wave. Successful? 
 Yes 
 No (Report) 
Stop Session. Do not save file. Remove tape from test phantom.  
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Attestation 
 
_______________ _______________ _______________ 
Physicist name  Signature  Date 
 
Notes 
*
There are known problems with RPM v1.7.5 3D option and a Varian Medical Device Correction Notice 
has been issued.  
 
Reporting 
Report any problems electronically to the Chief of Clinical Physics and Sean Pollock (sean.pollock@sydney.edu.au). 
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Revision History: Do not print this with QA document 
2008-09-29 PJK  Initial draft 
2008-12-08 PJK/SG/GC Modified after actual test 
2009-03-02 PJK/SG/GC Add the audio function into the feedback system and test the synchronization between  
    the audio patch and the video patch. 
2009-04-03 PJK/SG/GC Run a QA procedure and found the audio patch is still not stable. 
2009-04-07 PJK/GC  Test the video goggles. 
2009-04-08 SG/GC  Run another QA procedure and passed. Need a phantom that has an irregular breathing  
    pattern. 
2009-04-13 SG/GC  Run the QA procedure using the motorized programmable phantom and passed. 
2009-05-22 PK/GC  Test updated A/V patches, which did not work properly. Switch back to older version  
    and they worked fine, with PK and GC as volunteers simulating real clinical setting. 
2009-06-05 PK/GC/SG Test the updated A/V patches with Renormalization function. Successful. 
2009-10-08 GC  Update the QA worksheet. 
2009-12-15 GC  After redefine the session names. 
2011-06-07 PK/THK  Applied to Sydney 
2012-02-09 THK  Modified with the latest version of Breathe Well 
2012-05-25 THK  Modified with the latest version of Audiovisual biofeedback software 
2012-08-30 PJK  Modified to add larger motion 
2012-10-02 PJK/EE  Added test for sound coming from both speakers.   
2013-03-25 SP  Added resolution info for goggles (Point 2).  
2013-05-10 PK  Added directionality test based on EE/EC/JK observation from RPM  
2013-05-10 PK  Added version number for RPM due to Device Correction Notice and above observation  
2013-05-17 DL  Removed offset test from Point 3 and 4. 
2013-06-21 SP  Goggles resolution dimensions (800 x 600) added to Point 2.  
2013-06-16 PK/DL  Added allowable variation in period (<0.1s).  
2013-10-14 PK/SP  General revisions for screen and V2.0.  
2013-10-15 SP  General revisions for V2.0. Point 6 in Monthly QA separated into a) and b).  
2013-10-15 SP  ‘Potential  issue’ added in to point 2 in Daily QA and points 1 & 2 for Monthly QA to  
    counter potential problems user may come across for those steps. 
2014-04-02 SP  Amended sections pertaining to ‘music speeding up’ as this is no longer a function in  
Breathe Well v2.1.0 – Previous Step 5 (Audio synchronization test – irregular respiratory 
pattern) in Monthly QA replaced with Step 5 (Audio synchronization test – out-of- 
bounds respiratory pattern).  
2014-11-4 SP/PK  SUAVE -> Breathe Well and improved clarify in several sections.  
2015-01-14 SP  Updated for Breathe Well v2.3: 
 Screenshots updated for latest version in Daily QA. 
 New first step in Monthly QA: ‘AV computer-RPM computer Connectivity’ 
o  This negates a previous ‘Potential issue’ comment.  
 Step added for testing ‘Free Breathing’ function.  
 Out-of-bounds respiratory pattern & Renormalization steps merged into 
one 
 Step added to check whether Renormalzing created an additional .rec file. 
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audiovisual biofeedback studies 
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Sydney Regular Respiration Software 
User Guide 
This User Guide is for Breathe Well software version 2.5 
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1. Setup 
1.1 Breathe Well Software Initialization and Setup 
After Breathe Well software has been installed it will auto-save patient data to folders in the location: 
C:\ProgramData\UniversityofSydney\BreatheWell   
If this location does not show up, it means the folder is hidden; type the file location into Windows 
Explorer and you will see it there. 
IMPORTANT: Breathe Well software is compatible with a number of different motion sensor cameras, it 
is important to specify which sensor is being used in the config.txt text file located in 
C:\ProgramData\UniversityofSydney\BreatheWell:  
 If the Intel Realsense is being used, ensure the line in config.txt reads:  
Clinical,Realsense,COM4,30,1  
 If the Microsoft Kinect is being used, ensure the line in config.txt reads:  
Clinical,Kinect,COM4,30,1  
 If the Varian RPM (6-dot) is being used, ensure the line in config.txt reads:  
 Clinical,RPM-6Dot,COM4,30,1 
 If the Varian RPM (2-dot) is being used, ensure the line in config.txt reads:  
 Clinical,RPM-2Dot,COM4,25,1 
 
Start the Breathe Well software 
i. Run the BreatheWell executable file 
ii. The initial screens on the Breathe Well computer are shown below.  
Operator Display Patient Display (intentionally blank) 
 
 
Figure 1.  Screenshot of the video patch of the Breathe Well audiovisual biofeedback system for operator and 
patient displays. 
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1.2 Breathe Well Operator Bar 
As shown on the Operator Display in Figure 1, there is an options bar to the left of the screen. Various 
options will become active once certain actions are completed; this is illustrated below in Figure 2.  
ACTION 
Initial Display – 
Not connected to 
motion sensor 
Connected to 
Motion sensor – 
Perform Regular 
Breathing or Breath 
Hold 
Create New Patient 
file or select 
Existing Patient 
Waveguide options 
(Regular Breathing) 
Breathing Session 
options 
(Regular Breathing) 
OPERATOR 
BAR 
     
Figure 2.  Breathe Well options becoming activated as workflow actions are completed. 
Breathing Session 
options 
(Breath Hold) 
 
360
Breathe Well user guide version 5.0 for software version 2.5  Date: 02/12/2015 
 
2. Breathe Well Patient Session 
2.1. Audiovisual Biofeedback Session 
2.1.1 Create a Waveguide 
Setup the Breathe Well software as well as the RPM software (see Section 1.SETUP). 
Select New Patient and enter patient details (if patient has already been entered into Breathe Well, 
select Existing Patient and select correct patient). 
 
  
Figure 3.  Selecting either a New Patient or an Existing Patient. 
Select New Waveguide, the software will start obtaining ten breaths to construct the waveguide for 
the patient to follow.  
When the program has completed collecting samples, the waveforms for each sample will be 
displayed on the screen along with options to edit the waveforms (see Figure 4 below).   
 
  
Figure 4.  Screen to determine patient’s waveguide.  The blue curves are sampled from the patient (each 
individual breath).  The green curve is the average waverform for the remaining samples (to be used as the 
waveguide).  The red curve is the selected breath that can be deleted.  Move the arrow at the lower left to 
change the selected blue patient curve.  The period and scale of the average waveform can be modified 
using the options on the bottom-right.   
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Select individual curves and delete outliers if necessary. No threshold is available on when to 
delete/keep waveforms – it is up to the personal judgment of the operator as to what is an ‘outlier’ 
breath is.  
Click Save to save the waveguide.  
Select Select Waveguide and select the waveguide files created for your patient (see Figure 5).  
 
Figure 5.  Screen to select a created waveguide. If multiple waveguides have been created, the most 
recently saved waveguide will be at the top of the list. 
 
If the patient is having difficulty following the waveguide, modifying the waveguide may be necessary. 
Click Edit Waveguide and adjust the average wave time period and scale using the respective controls 
(see Figure 4).  
 
2.1.2. New Respiratory Session 
Ensure correct patient and desired waveguide have been selected.  
Select New Respiratory Session. The session will commence automatically.  
 
Figure 6.  Starting a new respiratory session. 
362
Breathe Well user guide version 5.0 for software version 2.5  Date: 02/12/2015 
 
The software will start calculating the mean marker-position to correctly position it on within the 
breathing limits (within the blue region). 
 
Figure 7.  Breathe Well software calculating marker mean position (from 4 breathing cycles) to correctly position 
marker on guiding interface. 
Once the mean marker-position has been calculated, the session will start automatically. 
The waveguide is displayed as a white wave moving from left-to-right while the real-time respiratory 
breathing of the patient is displayed as a grey marker-block. 
 
Figure 8.  Patient Display: showing their waveguide (white) and their current breathing position (block). 
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It is important that the patient uses exactly the same waveguide throughout their course of treatment 
to minimize inter-fraction breathing motion variations.  
If the couch is shifted/moved or patient shifts position, this will move the marker, potentially off-screen.  
When couch/patient shifts occur, click the ‘Renormalize’ button to renormalize the baseline of the 
marker block; it readjusts the mean position of the marker block to be in the middle of the display.  
Only click Renormalize before imaging and treatment procedures, not during beam-on time. 
Clicking Renormalize will also prompt you to save the file for the pre-renormalize data.  
 
Figure 9.  Location of Renormalize function (top), and save the file (bottom). 
N.B. By renormalizing, this will save a data file of the breathing session up until to the point Renormalize 
was clicked and then commence a new file from the point after renormalization. i.e. there will be two 
data files for the one session if Renormalization is used once. This should not discourage the use of the 
364
Breathe Well user guide version 5.0 for software version 2.5  Date: 02/12/2015 
 
Renormalize function, it is especially important to use after couch-shifts, just note that there will be 
multiple breathing data files associated with its use.   
When the session is over, click Stop Session and select Yes when you are prompted to Save 
Current Session and select the appropriate option for the session (AV_Decision, AV_CT, or 
AV_Treatment): 
 
Figure 10.  Pop-up options when you click ‘Stop Session’ for AV biofeedback sessions. 
Data will be saved automatically into that patient’s folder 
If using goggles - Discard the hygiene covers and wipe down the goggles using sani-wipes after use 
(thanks to Diana Browder’s input, 10/28/2009). 
Place the goggles/tablet carefully away in the appropriate storage place.   
 
2.1.3. Audiovisual Biofeedback Operator’s Display 
The Operator’s Display presents information pertaining to the current Respiratory Session, illustrated 
and explained below:   
 
Figure 11.  Operator’s Display with session information highlighted 
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Brown box: Breathe Well software version number  
Dark blue box: The sensor being used  
Yellow box: Patient name. 
Purple box: Stopwatch. To time length of breathing sessions in minutes and seconds if needed.  
Light blue box: Time and displacement information from the motion sensor being used.   
Red box: An in-screen display of the patient display which refreshes at a rate of 1 Hz (hence it may 
appear out of synch, but it isn’t, it’s just a slow refresh-rate). This informs the operator if the Patient 
Display is not properly connected, or not displaying the correct information.  
 
2.2. Free Breathing Session 
A Free Breathing session is performed when a Screening Procedure is required, i.e. when a decision 
needs to be made as to what the more regular breathing condition is, either (1) unguided (Free 
Breathing), or (2) guided (audiovisual biofeedback) breathing. 
Setup the Breathe Well software as per Section 1. SETUP. 
 
Important: Ensure that the patient display is turned off. 
 
Following the selection of the correct Existing Patient, select New Waveguide. Immediately save the 
waveguide without modification, click Select Waveguide and select the one you just saved (it will be at 
the top of the option list), and then click New Respiratory Session. Record the patient’s free breathing 
for 4 minutes.   
 
Click Stop Session and select Yes when you are prompted to Save Current Session and select FB from 
the options presented.  
 
Figure 12.  Pop-up options when you click ‘Stop Session’. 
Data will be saved automatically into that patient’s folder with ‘FB’ tagged at the end of the file 
name for Free Breathing.  
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3. Respiratory Analysis & Decision Form  
If a screening procedure is being utilized to determine whether or not to use the Breathe Well software 
audiovisual biofeedback guidance, then a comparison of breathing regularity between guided and 
unguided breathing will need to be performed. The Breathe Well software has a function that allows this 
decision to be made in situ. This section will only need to be performed once per patient prior to CT sim. 
3.1. Analyse Respiratory Sessions 
Once respiratory session has been saved for unguided breathing (see Section 2.2. Free Breathing 
Session) and guided breathing (see Section 2.1 Audiovisual Biofeedback Session) select Analyse, this 
will bring up the Analyse window, shown below in Figure 13:  
  
Figure 13. Analyse option and Analysis window. Blue curves: each individual breath. Yellow curve: average breath. 
Red curve: selected waveguide (later versions of the software may not display the red curve). 
The analysis for most recently saved session will automatically be brought up. However you can select 
another breathing session from the dropdown menu. Files with ‘FB’ tagged on the end is the Free 
Breathing file, the file with ‘AV_Decision’ tagged on the end of the AV biofeedback file.  
Save each analysis for these two sessions.  
N.B. Analysis window saved as a jpeg. A new jpeg is saved each time you click ‘Save’, so best not spam 
the ‘Save’ button.  
Also present on the Analyse window are metrics for measuring regular-breathing: the root-mean-
square-error (RMSE) of displacement and period.  
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3.2. Breathing Decision Form 
Bring up the Decision Form by selecting Breathing Decision Form.  
  
Figure 14. How to bring up Breathing Decision Form 
Complete the Decision Form by selecting each of the saved ‘Analyse Respiratory Session’s, by selecting 
on the Decision Form menu Select FB/AV Image. Once the Decision form has been completed, save 
and/or print the Form by selecting File  Save, and/or File  Print. The Decision Form menu options 
are shown below in Figure 15.  
 
Figure 15. Decision Form menu options. 
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Figure 16. Breathing Decision Form.  
Left: Incomplete. Right: Complete. 
Decisions are made based on which breathing session has the lower ‘RMSE Disp’ value.  In this instance, 
the audiovisual biofeedback (AV) session was more regular (RMSE Disp (AV) = 0.48 compared to RMSE 
Disp (FB) = 0.59). So for patient ‘John Smith’, audiovisual biofeedback breathing guidance with the 
Breathe Well software will remain in his treatment planning and treatment delivery utilizing THE SAME 
WAVEGUIDE as was acquired here.     
This screening procedure (if utilized) with Free Breathing, Analyse, and Decision Form will only need to 
be completed once per patient prior to their treatment planning.    
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Appendix A: Troubleshooting 
 
If the system is working at all after trying the options below the fallback position is to use no 
training and contact the developers.   
 
If audio is causing problems or not easy to understand by the patient, turn audio off using 
computer volume control.   
 
If system is not working it may be that ‘record’ on the RPM software is not depressed, or a 
loose/wrong connection.  The RPM connects to the audiovisual through a serial port.   
 
If after learn respiratory session the green line is not a smooth curve similar to the blue curves then 
reacquire the respiratory session.   
 
If necessary enable serial output in RPM program itself. View → System Configuration → General 
tab → Advanced. Check “Enable Serial Protocol” and select Format = Extended and COM port = 
COM1. (Password RespGate needed). Restart RPM 1.7 in order to make the change take effect. 
a. If serial still does not work, (in the standard RPM installation, serial protocol options are 
disabled by default)  then: close RPM, - open RPMSetup.ini in the Program 
Files\Varian\RPM 1.7 folder,  under [Misc] section change "Serial" value to 1. [Misc] 
Serial=1 
b. If serial output is still not reappearing even after updating rpmSetup.ini then may need 
to adjust regiustry.  Use regedit change My 
Computer→HKEY_LOCAL_MACHINE→SOFTWARE→Varian Medical Systems→RPM 
Respiratory Gating System→Settings: SerialComm from False to True (enable serial 
protocol) and SerialProtocolNum from 1 to 2 (IAS to extended).   
 
For the Dell desktop setup at Stanford, there is an issue with detecting the LCD screen display in 
order to have a dual-screen setup. It was only possible to clone the screen (same display on both 
screens). However, restarting the computer after connecting the monitor cables fixed the problem. 
 
Another possible issue with having different screens on the dual displays could be the cables to which 
the display monitors are connected. The Dell desktop setup at Stanford has two VGA cables coming 
from the desktop computer. The cable with the white tag attached should be connected to the 
primary monitor. The other cable should be connected to the patient display. When the computer is 
restarted, the initial boot-up screen will be displayed to the primary monitor – make sure that this is 
the operator monitor. 
 
If the Research computer is not receiving data from the serial port, make sure that the “Enable Serial 
Port output” checkbox is set in the RPM configuration screen. 
 
Patient may hear the windows ‘beeps’.  If they exist, turn off in control panel→sounds 
 
If patient has irregular phase, then ball motion will pause.  Either reduce by changing predictive 
filter?  Could also hide ball.   
 
If not using RPM, could have smoothness issues at less than 30 Hz framerate (per Diana’s 
experience).   
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Error message may appear on patient screen.   Patient/therapist should be aware of this.  Check for 
error message programs running in task bar and close. If fails close in windows task manager (ctrl-alt-
delete).     
 
You may need to adjust the resolution of the BREATHE WELL LCD screen 
i. Adjust the resolution to 800x600 before running the BREATHE WELL software. If the 
display settings are changed while the program is running, the waveforms disappear. 
ii. The following steps to change the resolution are specific to the Dell computer system 
used at Stanford: 
a) Right-click on the desktop and select NVidia Control Panel. 
b) On the left-hand navigation panel, select Set up Multiple Displays under the 
Display category. 
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Appendix B: Revision History 
Date Name Reason for Changes Version 
01/07/2009 Siddharth (sgopalan) Updated to reflect new AVFeedback version 1.1 
02/03/2009 Siddharth (sgopalan) Merged with existing AVFeedback guide 1.2 
03/17/2009 Siddharth (sgopalan) Added instructions for the audio patch 1.3 
06/16/2010 Paul Added executive instructions 1.4 
01/27/2011 Taeho Kim Instruction in Sydney 1.5 
7/5/2012 Taeho Kim Instruction for AV biofeedback _v 1.0.8.1 2.0 
10/29/2012 Taeho Kim Breath-hold guidance included 2.1 
17/05/2013 Sean Pollock Mentions of STARR changed to SUAVE 2.1 
21/06/2013 Sean Pollock Resolution info for goggles added.  2.1 
21/10/2013 Sean Pollock Modified for AV v2.0.  
Additional sections added for Display Options 
and DIBH.   
3.0 
02/04/2014 Sean Pollock Modified for SUAVE v2.1.0. 
Display options amended & Offsets description 
added.  
‘Respiratory Analysis & Decision Form’ section 
added.  
3.1 
24/07/2014 Sean Pollock Updated DIBH section for SUAVE v2.1.0.0 3.2 
13/01/2015 Sean Pollock Updated document for Breathe Well v2.3: 
- Footer added to track software and 
document versions 
- Updated interface and workflow details  
- Removed: 
o Section on customizing interface 
(colours, etc) 
o BH & DIBH (re-insert once functionality 
added back in) 
4.0 
04/02/2015 Sean Pollock Updated to include stopwatch function 4.1 
30/06/2015 Sean Pollock Updated for version 2.3.2. which included the 
option to tag saved .rec files with session name 
4.2 
02/12/2015 Sean Pollock Updated for version 2.5.  
New options, additional motion sensor options.  
V2.5 sidebar updated in Figures.  
5.0 
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1. Hardware setup 
1.1. Hardware components 
The provided hardware components for audiovisual (AV) biofeedback are as follows:  
1) 2 × aluminium rods  
2) 2 × rod connectors  
3) 1 × table clamp 
4) 1 × Intel RealSense 
5) 1 × Patient display 
6) 1 × Intel NUC computer 
7) Cabling  
The cabling should already be 
correctly connected to its 
relevant components. The 
NUC computer should already 
be fixed to one of the rods.  
 
Figure 1.  Hardware components in delivery case. 
The assembled hardware setup for the Intel Realsense AV biofeedback setup is shown below in Figure 2.  
  
Figure 2.  AV Biofeedback setup schematic (left) and hardware components (right). N.B. rods shown in Figure 2 are 
made of a different material to those shown in Figure 1. 
Required components for AV biofeedback NOT provided with the delivered package are as follows:  
1) Monitor display with VGA input  
2) Keyboard with USB connector  
3) Mouse with USB connector  
4) Display Port to VGA cable  
5) VGA extension cable 
6) 2 × USB extension cables (1 for mouse, 1 for keyboard) 
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A schematic of all the connected components is shown below in Figure 3. 
 
Figure 3. Schematic of full AV biofeedback system setup from CT/Treatment room to the operator’s room 
Where to connect the cabling to the NUC computer is shown below in Figure 4.  
 
Figure 4. Cables plugged into the NUC computer and their purpose 
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1.2. Component assembly 
1. Remove table clamp and rod with NUC computer 
attached (components 1, 2, 3, 6 from Figure  2) 
2. Attached to a table and adjust handles 
(highlighted in figure to the right) such that the 
stand is fixed upright.  
 
3. Attach the Intel RealSense to the remaining rod, 
on the opposite end to the rod connector 
4. Attached the Patient display such that the screen 
is approximately mid-way down this same rod 
 
 
5. Attach the rod with RealSense and Patient display 
to the upright rod such that the RealSense and 
display are facing downwards  
 
6. Ensure any lose caballing is connected to the NUC 
computer in accordance with Figure 4. 
7. Connect a display and keyboard to the NUC 
computer in accordance with Figure 3 and Figure 4 
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2. RealSense software 
Open “Breathing Coach” software from the Desktop:  
On initial Breathing Coach screen click 
“Patient” and select either “New” or 
“Open”. 
 
Figure 5. New or existing (Open) Patient 
options 
 
Figure 6. Breathing Coach Realsense software initial display 
2.1. New or Existing Patient 
If this is the patient’s first use of AV biofeedback, then select “New” under the Patient menu shown in 
Figure 5 and enter the patient’s name or Study ID: 
 
Figure 7. Enter name/Study ID of new patient 
If this is NOT the patient’s first 
use of AV biofeedback, then 
select “Open” under the Patient 
menu shown in Figure 5 and 
select the patient’s name or 
Study ID. This will load this 
patient’s “Breathing Coach” 
options (these options will be 
explained in the next section).   
 
Figure 8. Select name/Study ID of existing patient 
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2.2. Tracking Patient Respiratory Motion 
The “Breathing Coach” software has been optimized for patient use and may not operate optimally with 
a motion phantom. The operational distance of the Intel RealSense depth sensor is 20cm to 120 cm.  
The Breathing Coach software does not require markers. Clicking “Start” will commence the tracking of 
the patient’s respiratory motion. Figure 9 shows the Breathing Coach software under default options 
after clicking “Start”. The respiratory motion of the region being monitored is what is used as the input 
for the audiovisual biofeedback software.  
 
 Figure 9. Left: Optical image with overlaid region of interest, registered torso, and AP, LR, SI vectors. Right: 
Respiratory signal of the region of interest. Bottom: Breathing Coach options.  
Table 1 demonstrates the Breathing Coach options in detail.  
Table 1. Breathing Coach software options 
Default 
options 
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Adjust 
‘Torso 
Distance’ 
 
Move region of interest in superior or inferior direction 
Adjust  
‘Lateral Shift’ 
 
Move region of interest in left or right direction 
Adjust 
‘Scale Factor’ 
 
 
Increase or decrease size of the region of interest 
It shouldn’t be necessary to adjust the Breathing Coach options for most patients, however, for patients 
with sufficiently large or small torsos, it may be necessary to adjust some options.  
Clicking “Save” will save the Breathing Coach options (NOT the respiratory signal, that is done in the 
audiovisual biofeedback software). This is to ensure consistent positioning of the region of interest 
interfractionally.   
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Having the Breathing Coach software and audiovisual biofeedback Breathe Well software running 
simultaneously can slow the sampling-rate of the Breathing Coach software. To maximize the sampling-
rate whilst audiovisual biofeedback is also running, switch from “color” to “depth mode” and disable the 
“Enable color”, “Enable Waveform Plot”, and “Enable 3D Vectors” options. These options are shown in 
Figure 10. 
 
 
Figure 10. 
Disabling 
options to 
maximize 
sampling-rate 
of the 
Breathing 
Coach 
software. 
 
With these options disabled, the respiratory signal of the region of interest will no longer refresh, 
appearing frozen, rest assured, as long as “Start” has been clicked it is tracking the respiratory signal.    
With the motion signal tracking in the Breathing Coach software, open the AV biofeedback software: 
Breathe Well  This will open up the AV biofeedback software on both the operator’s desktop 
and on the patient display:  
Operator Display Patient Display (intentionally blank) 
  
Figure 11.  Screenshot of the initial audiovisual biofeedback display and the initial patient display (intentionally 
blank to begin with) 
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Please refer to document “AVFeedbackUserGuide_v5 Breathe Well” for further 
instructions on how to operate the AV biofeedback Breathe Well software.  
2.3. Stop Session 
AFTER saving the breathing session in the Breathe Well software, stop the session in the Breathing 
Coach software. If the Breathing Coach software is stopped before Breathe Well an error will occur in 
the Breathe Well software.  
2.4. Adjusting the Signal Axis 
Should the magnitude of respiratory signal exceed the limits of the y-axis in the Breathing Coach 
software, it can be adjusted using the scroll-wheel of the mouse. Having the signal going off axis will not 
compromise the signal input to Breathe Well software, but it may be desirable to see it nonetheless.  
 
Figure 12.  Adjusting the displacement y-axis using the mouse scroll wheel 
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Appendix A: Revision History 
Date Name Reason for Changes Version 
04/01/2016 Sean Pollock Version 1 completed 1.0 
15/01/2016 Sean Pollock Additional details for ‘Breaching Coach’ 
software added 
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Appendix VI 
 
Media reports on the audiovisual biofeedback commercialisation 
process 
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Sources of media articles:  
 “SYDNEY GENESIS: BREATHE WELL” 
o http://www.insideenterprise.org/sydney-genesis-breathe-well/ 
 “THIS STARTUP JUST LANDED $400,000 IN SEED FUNDING TO HELP CANCER TREATMENTS”  
o http://www.businessinsider.com.au/this-medtech-startup-just-landed-400000-in-seed-
funding-to-help-cancer-treatments-2015-8 
 “THE NEXT GENERATION OF MEDICAL DEVICE INNOVATORS”  
o http://atp-innovations.com.au/2015/11/next-generation-of-medical-device-innovators/ 
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Sydney Genesis: Breathe Well 
 
 
POSTED BY: MEGAN ENGARD FEBRUARY 18, 2015 
 
Sydney Genesis is the longest running entrepreneurship program at the University of 
Sydney. The program is founded on the idea that when innovative new businesses, 
technology startups, and social entrepreneurs work side by side, a truly unique 
exchange of knowledge and inspiration flourishes. Each year Genesis opens its doors to 
students and alumni from any background who are passionate about their ideas in 
business, technology or social entrepreneurship. Over the course of the program 
participants are encouraged to bring their ideas to life with the assistance of workshops, 
mentoring, networking, funding and prizes.  
Sean Pollock was a participant of the Sydney Genesis program during the first semester 
of 2014 and was one of the 8-10 finalist teams to pitch their ideas before a panel of 
industry experts at the Final Pitch Event in May. He is a current University of Sydney 
student who completed his Masters in Medical Physics in June, 2012 and is now 
working on his PhD in Medicine. Sean and his PhD supervisor Prof. Paul Keall have 
created a start-up company around a medical device at the centre of their research 
called Breathe Well, which provides breathing guidance for cancer patients for better 
quality imaging and radiotherapy. 
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How did you come up with your idea? 
The technology behind Breathe Well was actually developed by my PhD supervisor, 
Paul Keall, while he was working in the United States in 2003. I first became involved 
in the project while working on my masters here at USYD when I received an email 
inviting students to volunteer for an imaging study that was investigating the Breathe 
Well device. That was my first contact with the project and eventually led me to join 
the project as part of my Masters’ research before continuing on with a PhD. The 
business is now run by Paul Keall as the company director, myself as co-founder, two 
software developers and a company secretary. 
What prompted you to get involved with Sydney Genesis? 
Back when we started, my advisor and I were both coming from the research side of 
things. We had a research device and we had spoken to a few colleagues about 
commercialising it, but we had no real business model. We first reached out to ATP 
Innovations about possibly working on the business plan and they directed us to Sydney 
Genesis as a starting point. Genesis was great for us because we hadn’t really thought 
about things from the perspective of customers. We had a research point of view, which 
was simply “We’ve researched it, we have a great product and you should want it, too.”  
Going through the Genesis program really helped us understand the other point of view 
and how to create a business around your buyer’s needs. 
What is your business model? 
We have created two possible revenue streams with Breathe Well. The first comes from 
a larger prototype device we have developed, which would be sold to hospitals. We 
have also developed a smaller, compact version of the device that would go to patients 
to practice on before using the larger device with their doctors. A prototype of the 
smaller tablet sized device is what we used during our Genesis Final Pitch to the panel 
of judges. After doing quite a bit of research into the competitive landscape we have set 
a price of $30,000 for the direct purchase of the device as well as an additional 20% per 
year service charge which covers systems upgrades, maintenance, breakages, etc. 
Existing devices on the market monitor patient breathing but don’t provide feedback to 
the patient, and cost between $40,000 and $50,000. Our first market would most likely 
be Australia, though we have looked at the United States as well. 
What are some of the biggest challenges you’ve faced? 
For us, the biggest challenges were around learning the important business skills that 
were very different to our research mentality. The Genesis workshops were great for 
this because they are run by people who are leaders in their field. To be able to pick 
their brains during the workshop sessions and get their feedback on our ideas was 
incredible. Another challenge for us was to create a more streamlined version for the 
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product we had going in. We wanted to be able to offer this to clinicians, and luckily we 
started with a bit of wiggle room so we were able to make the adjustments we needed. 
Where to now?  
After finishing the Genesis program we applied to work with INCUBATE and we are 
now in their winter program. INCUBATE is a great follow up from Genesis; it is more 
intensive. While Genesis was more of a learning experience, INCUBATE provides 
more of a push to get things done towards regular set milestones. We formed a private 
company at the start of INCUBATE called Respiratory Innovations and are looking at 
recruiting the first patient in one of our largest clinical trials in the next few weeks, so 
things are very exciting at the moment. We are aiming to have our first sale in the next 
twelve months. That time frame allows us time for regulatory approval, clinical trials, 
etc. After Genesis, I am much more aware of the many opportunities on the business 
side of things so there are a lot of possibilities for what I can do next. I’ve been 
involved with Breathe Well for almost three years now, so I’d love to see it taken to the 
next level. 
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 This medtech startup just landed 
$400,000 in seed funding to help cancer 
treatments 
ALEX HEBER AUG 14 2015, 2:16 PM   
 
Medtech startup Breathe Well just landed a $400,000 investment from Sydney 
Seed Fund to help develop improved cancer radiotherapy treatments. 
Invented by Paul Keall, a professor in the School of Medicine at the University 
of Sydney, Breathe Well assists cancer patients in breathing predictably during 
a course of radiotherapy. 
388
 Keall came up with the idea while working in a teaching hospital at Virginia 
Commonwealth University, USA, while focusing his research and clinical 
activities on breathing motion during cancer imaging and radiation. 
One of the key technical challenges during treatment was breathing 
irregularity. 
“We could either develop complex imaging and treatment solutions to 
accommodate irregular breathing, or we could simply develop a system to help 
patients breathe more regularly,” he said. 
“Breathing guidance improves efficiency, image quality and targeting accuracy. 
What this means is that with breathing training more patients can be treated, 
with higher cure rates and a better quality of life.” 
Keall was involved in a study at Stanford University reviewing images from 50 
lung cancer patients. It found significant errors for at least one image series in 
90% (45/50) of the patients. 
“Reducing these errors has benefits to the patient’s health, but also for the 
economy as the costly burden of managing treatment side effects is reduced,” 
he said. 
By providing visual feedback of their breathing patterns, Breathe Well helps 
patients overcome the damaging consequences of irregular breathing. 
“The problem of irregular and unstable breathing motion is widespread across 
the radiology and radiation oncology, affecting some of the most common 
forms of cancer such as lung, breast, and liver cancer. Errors caused by 
respiratory-related motion have been reported to be present in up to 90% of 
medical images used to plan the patient’s radiation treatment,” PhD medical 
candidate Sean Pollock who is also on the team, told Business Insider. 
The startup secured a $588,000 grant from the National Health and Medical 
Research Council earlier this year, allowing it to conduct a series of clinical 
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 trials around Australia. It has also applied for several additional grants 
including one from the NSW Health’s Medical Device Fund. 
Keall has also recruited software engineers Kuldeep Makhija and Dr Ricky 
O’Brien, and commercialisation expert Daniel Zafir, who recently joined as 
Managing Director. 
“Apart from ground-breaking Breathe Well technology, we were impressed by 
its remarkable team led by Professor Keall,” Sydney Seed Fund partner 
Benjamin Chong said. 
Pollock says the simplicity of the design is why he joined the startup. 
“Rather than spend millions on a better treatment machine, you can improve 
the accuracy of existing facilities at a fraction of the cost by providing breathing 
guidance to the patient,” he said. 
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THE NEXT GENERATION OF
MEDICAL DEVICE INNOVATORS
  Nov 27, 2015
Health Minister Jillian Skinner tonight congratulated 12 outstanding medical
researchers as they graduated from the 2015 Medical Device Commercialisation
Training Program.
Presenting certificates at a ceremony at ATP Innovations, Eveleigh, Mrs Skinner said
the graduates represent the next generation of medical innovators. 
“These entrepreneurial graduates come from medical, biomedical engineering,
mechatronics and biological science research backgrounds,” Mrs Skinner said. 
“Their research includes a templating system to develop patient-customised implants,
a new method of heart valve repair and a home diagnostics kit for medical testing.”
The Medical Device Commercialisation Training Program (MDCTP) was set up
following a review of the first round of the NSW Government’s Medical Devices Fund.
It aims to address a gap between the skill base in the development of medical device
research and the skills required to commercialise emerging innovative technologies.
As part of the 2015 program, ATP Innovations provided a three-month intensive
training course aimed at early-to-mid-career, post-doctoral and other researchers. 
Mrs Skinner awarded four members of the graduating class with scholarships to
further develop their research: 
· Professor Stephanie Watson, Kleer-i – $50,000 in seed funding for the Kleer-i patch,
a sutureless wound sealing device for cataract surgery; 
· Dr David Yeo, Royal Prince Alfred Hospital – $25,000 in seed funding for Pivot
Sphincterotome, a procedure for the management of bile duct pathology; 
· Dr Dharmica Mistry, BCAL Diagnostics Pty Ltd – $10,000 international engagement
scholarship for higher accuracy breast imaging and screening tests; 
391
· Dr Robert Gorkin, University of Wollongong – $10,000 international engagement
scholarship for new condoms utilising an advanced hydrogel material with anti-STI
agents.
“It takes a breadth of skills to get an innovative medical research concept off the
ground and our graduating researchers are now equipped with the skills required to
bring their fantastic ideas into the marketplace,” Mrs Skinner said.
The first group of MDCTP trainees graduated in late 2014. 
For more information visit: http://www.health.nsw.gov.au/ohmr/pages/default.aspx 
Or visit the Medical Device Commercialisation Training Program page at ATP
Innovations and apply: http://atp-innovations.com.au/mdctp/
Medical Device Commercialisation Training Program 2015: Graduates 
Aiden O’Loughlin 
University of Western Sydney 
Stabilyzer: One in three people in Australia die of cardiovascular disease. The
underlying process causing the majority of these deaths is atherosclerosis.
Atherosclerosis is a disease where fatty material is deposited in sections of the wall of
the artery. Deaths occur when local atherosclerotic lesions rupture, stimulating clot
formation, leading to occlusion of the artery. These lesions are termed ‘vulnerable
plaques’. Both heart attacks and strokes can be caused by vulnerable plaques
rupturing. Recent research has shown that vulnerable plaques can be identified prior
to their rupture. The Stabilyzer device provides treatment that will prevent future
heart attacks and strokes with the development of a locally applied treatment to
stabilise these plaques.
Annabelle Chan 
University of Sydney 
Rapid Templating System: The rise in rapid prototyping technologies has presented a
unique opportunity for the creation of custom made implants. However, the logistical
shift from generic high volume production systems to individually customised
implants prevents its widespread usage. The Rapid Templating System aims to form
patient specific implants quickly and effectively. The system involves the production
of a 3D-printed guided mould, based on patient scans, to shape terminally sterilised
generic materials into patient-customised implants. The generation of custom
implants within packaged materials allow implants to be immediately ready for use,
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avoiding treatment delays due to sterilisation post production. This approach has the
capacity to significantly reduce inventory costs for medical device companies, as
abundant implant-size ranges are no longer required to accommodate all patient
cases. Further developments in regenerative medicine may allow further
customisation material properties, allowing the implant to be patient specific
anatomically as well as a biomechanically.
David Yeo 
Royal Prince Alfred Hospital 
Pivot Sphincterotome: Endoscopic retrograde cholangiopancreatography (ERCP) is an
endoscopic procedure that allows access into the biliary system and has
revolutionised the management of bile duct pathology. However, it is a notoriously
difficult procedure to learn and even in experienced hands, this procedure is
associated with complications including pancreatitis, bleeding, perforation and in rare
cases, death. Cannulation of the bile duct remains the most challenging step of the
procedure even with current sphincterotome technology. The Pivot Sphincterotome
has been developed to facilitate easier, faster and ultimately safer biliary access. The
ERCP sphincterotome US market alone is worth approximately $USD150 million and
with an increasingly elderly population requiring less invasive procedures, it is
expected to increase. Developed by an ERCP practitioner, the Pivot Sphincterotome
aims to accommodate the shortcomings of current technology making the ERCP
experience more user-friendly, efficient and safe.
Dharmica Mistry 
BCAL Diagnostics Pty Ltd (BCAL Dx) 
BCAL Diagnostics: To develop and commercialise a novel universal screening test for
the detection of breast cancer that is highly accurate, safe, cost effective, and
available to all women regardless of age, race and geographic location. 
Breast cancer is the most common cancer amongst women, therefore, the
effectiveness of the screening and diagnosis technology used is a high priority. The
current model relies on a woman being physically present at a clinic for breast
imaging which is not always convenient. While the present technologies are currently
state of the art, there is a high cost involved. There are also well known performance
limitations that result in only a small subset of women who are actually eligible for
screening. 
BCAL Diagnostics aims to shift the paradigm in breast cancer screening and diagnosis
by introducing a blood test for detection of the disease. The implication of such a
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technology could revolutionise the way breast cancer is managed by allowing a blood
sample to be taken remote from the site of analysis. This technology will allow access
to more women, anywhere in the world, who could provide a blood sample, at a time
and place convenient to them. Such a test would fit into a woman’s routine health
regime and be incorporated into their personal lifestyle. In addition, with such high
levels of accuracy, this technology would provide greater peace of mind between
annual checks. The BCAL Diagnostics technology could utilise a single blood test on
multiple levels for disease prevention, diagnostic mass screening and post-
intervention.
James Otton 
Liverpool Hospital 
SeCure Beating Heart Repair: Mitral regurgitation is a condition caused by a leaking
heart valve and affects more than four million individuals in the USA. The standard
method of fixing valves is with open heart surgery, a complex operation performed on
cardiopulmonary bypass. The operation is expensive, and recovery time from the
operation is measured in weeks or months. The SeCure Beating mitral heart repair
device enables heart valve repair while the heart is still beating, with no need for
bypass or long anaesthesia time or surgical scars. Patients can recover in hours or
days and the cost of surgery can be dramatically reduced. The heart repair can be
repeated if necessary and conventional surgery can also be performed at a later date.
With the new technology many patients who have been deemed unfit for surgery
could be given lifesaving treatment.
Robert Gorkin
University of Wollongong 
Geldom: Backed by experts at the University of Wollongong and Swinburne University
of Technology, Geldom is helping make condoms more wearable by replacing latex
with better feeling materials called tough hydrogels. These tough hydrogels are
superior to latex and can improve the experience by offering more tissue like
sensation. They also have other revolutionary benefits – no bad odours or tastes, no
latex allergies, inherent self-lubrication, and can even be embedded with anti-
sexually transmissible infections agents or stimulants. These new options have the
potential to dramatically increase condom use. The impact – not only redefining what
safe sex should feel like – but the added social benefits of improved family planning
and disease prevention. This work is geared towards disrupting the $6 billion condom
industry desperate for innovation. This patent pending work has been supported by
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the Bill & Melinda Gates Foundation and has featured on ABC’s Catalyst.
Josef Goding 
University of New South Wales 
CardioFlex: is the next generation of cardiac pacemaker leads. Conventional
pacemaker leads are comprised of a long, coiled metal wire running from the
neurostimulator to the electrode implanted in the heart. These conventional leads are
prone to infection, dislodgement and mechanical failure. They are also incompatible
with MRI because they act as antenna and generate unsafe amounts of heat in the
body under MRI. CardioFlex leads do not use metal wires but are instead fabricated
from conductive elastomers, a novel material being developed at UNSW. Conductive
elastomers allow the CardioFlex lead to be soft, flexible and totally MRI compatible.
This means recipients are less likely to require a surgical lead extraction and they do
not need to worry about their pacemaker interfering with ongoing or future medical
treatments. Other applications of conductive elastomers being investigated include
flexible electrode arrays and nerve cuffs for neural interfacing.
Sandra Ast 
AusSI Systems 
AusSI Systems: This product allows for simple medical testing remotely from home.
The home diagnostics kit consists of a small device attachable to a smartphone and
together with an app, it allows for the analysis of the same urine dipsticks that are
commonly used in the GP’s office. The medical results can then be shared with the GP
online instead of going to the doctor, when unwell or busy. This will assist in a
comprehensive assessment of the patient’s health problem currently not possible via
online consultations. This smartphone diagnostics device also features recording of
the test results over time opening up numerous additional applications, ranging from
personalised healthcare to new testing methods for diseases.As the healthcare sector
is moving towards a digital platform, these internet connected devices will be
essential in the generation of digital medical records as well as the successful
implementation of online medical services.
Sean Pollock 
Respiratory Innovations 
Breathe Well: is an interactive medical device that allows breast cancer patients to
help improve their own cancer treatment, simply by breathing. In breast cancer
radiation therapy, nearby healthy tissues like the heart and lungs are at risk of
395
receiving unnecessary, and potentially fatal, radiation damage. Breathe Well shows
patients how to hold their breath to put as much distance possible between the heart
and radiation beam to achieve the most accurate breast radiation treatment possible.
Stephanie Watson 
Save Sight Institute 
Kleer-i: One in twenty cataract surgery wounds leak, causing infection and blindness
to occur. Sutures cause scarring, are time- consuming to apply, require great skill, and
distort vision. In addition to this, patients have poor compliance with postoperative
eye drops. Cataract surgery is the most common operation and has the longest
waiting list in NSW. Eye surgery costs are rising as the population ages. Kleer-i is a
next-generation “patch”, bonded over an eye wound by a low-powered laser. It falls
off once the wound heals. Surgeons will use Kleer-i to rapidly seal eye wounds
without sutures, while simultaneously delivering drugs. Kleer-i will save 25% to 40%
of operating time and promote faster wound healing, reducing vision loss from
scarring, distortion and infection. 
Kleer-i is unique in combining drug delivery with suture-less wound closure. It avoids
the toxic side-effects and high failure rates associated with existing therapies:
sutures, histoacryl glue and fibrin sealant.
Stephen Bradford 
CSIRO/Garvan Institute of Medical Research 
MethylC&Me: Obesity is a growing global health problem with direct costs estimated
at $21 billion annually (Australian Diabetes, Obesity and Lifestyle Study). Current
therapeutic and policy intervention is not working. Evidence suggests that early
directed intervention for individuals with a predisposition to obesity and related co-
morbidities is more effective at maintaining long term positive health outcomes. This
technology measures the levels of specific modifications to a person’s DNA (DNA
methylation marks) that are associated with current or future health status. The core
IP is in panels of such DNA methylation biomarkers that could be used to identify an
individual’s risk and likely trajectory for obesity and Type 2 diabetes mellitus. This
would help direct clinicians, such as endocrinologists and dietitians, in the clinical
management of patients and identify at risk people early – reducing the health
burden of chronic disease.
Yang Chen 
Woolcock Institute 
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Scintilla Electrostatic Inhaler: Metered dose inhalers (MDI) are a commonly used
device to deliver aerosolise medications for the treatment of pulmonary diseases. The
emitted aerosols from MDI contain millions of fine particles that carry intrinsic charge
that is imparted on them during the atomisation phase. These static charges can
cause variations in particle aerosolisation and dosage. Moreover, the MDI requires
manual actuation force to operate and its efficacy relies on patient’s co-ordination
between actuation and inhalation, which can be difficult for elderly patients with
chronic obstructive pulmonary diseases (COPD). The Electrostatic Metered dose
inhalers (EMDI) is a novel electrostatic metered dose inhaler, which utilises electronic
force and electrostatic charges to generate inhalable aerosol. It will reduce the need
of excipients in the drug formulation to help with the aerosolisation process, and also
minimise the difficulties that can occur when using conventional MDIs. EMDI can
provide more efficient treatment to people with respiratory diseases, especially for
the 65 million patients who currently suffer from COPD around the world.
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Appendix VII 
 
Videos recorded and produced over the course of this thesis 
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Dropbox link to videos:  
https://www.dropbox.com/sh/8ac7ee2aumaehqq/AAC138HtW8jSA618KObiZ2Axa?dl=0 
a) Patient information video
o “AV biofeedback info video.mp4”
b) Medical Device Commercialisation Program 2015 Showcase presentation
o “MDCTP_Sean Pollock.mp4”
YouTube link to videos: 
c) Animated 3 Minute Thesis presentation: produced by 99 Scholars as a part of my runner-up
prize
o https://youtu.be/JmaSVupp2-w
d) Invited keynote Genesis final speech one year after first completing the Genesis program
o https://youtu.be/cIEFy-SUjdg
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